Föstudagur, 31. október 2014
 
TölublöðVenjuleg útgáfa

apríl, 2007

 

Jerusalem, Israel and Lund, Sweden, May 1, 2007 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated. In addition, there was a favorable trend towards reducing annual relapse rates, the number of relapse-free patients and time to first relapse compared with placebo. Treatment with a 0.3 mg dose showed no statistical significant difference compared with placebo. Contacts: +-------------------------------------------------------------------+ | Teva: | Active Biotech: | | Dan Suesskind | Sven Andréasson | | Chief Financial Officer | President & CEO | | Teva Pharmaceutical Industries Ltd. | +46 46 19 20 49 | | | | | + 972 2 589 28 40 | | | | | |-----------------------------------------------+-------------------| | George Barrett | Tomas Leanderson | | President and CEO | Chief Scientific | | Teva North America | Officer | | +1 215 591 30 30 | +46 46 19 20 95 | | | | |-----------------------------------------------+-------------------| | Liraz Kalif / Kevin Mannix | Cecilia Hofvander | | Teva Investor Relations | Manager Corporate | | +972 3 926 72 81 / +1 215 591 89 12 | Communication | | | +46 46 19 11 22 | +-------------------------------------------------------------------+ These data were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 - May 5, 2007. "Current RRMS options are effective for the treatment of the disease, but an oral therapy such as laquinimod would represent a milestone for patients as it would provide them with a completely unique, non-invasive method of drug delivery," said Giancarlo Comi, M.D., Director of Department of Neurology and Institute of Experimental Neurology, Universita Vita-Salute, San Raffaele, Milan, Italy. "Preliminary studies have already demonstrated the positive effect of laquinimod versus placebo, but these new data confirmed that a higher dose was even more effective and remained well tolerated." The 36-week study evaluated the effect of oral daily 0.3 and 0.6 mg doses of laquinimod on MRI-monitored disease activity in patients with RRMS. The majority of the patients who participated in the study continued treatment with laquinimod in an ongoing, blinded 9 month extension study. This extension study is followed by an open label study where patients will receive 0.6 mg laquinimod for an additional 24 months. "The results of this study, which once again demonstrate the efficacy and tolerability of once-daily oral laquinimod, are very exciting for the MS community - both patients and researchers," said Shlomo Yanai, President and CEO of Teva Pharmaceutical Industries Ltd. "Teva will soon initiate Phase III studies to confirm oral laquinimod's therapeutic benefits, and we expect to begin enrollment of the trial later this year." About the Study Study participants were required to have experienced one or more relapses in the year prior to entry and at least one Gd-enhancing lesion at screening. The patients (n=306) in the study were randomized to receive placebo (n=102), 0.3 mg dose of laquinimod (n=98) or 0.6 mg dose of laquinimod (n=106). At entry, active treatment and placebo groups were comparable for demographic, clinical and MRI characteristics. Patients were assessed clinically and by MRI scan at week -4, baseline, and monthly from weeks 12 to 36. The primary outcome of the study was the cumulative number of Gd-enhancing lesions at weeks 24, 28, 32 and 36. Secondary outcomes of the study included additional MRI metrics and confirmed relapse rate. The laquinimod 0.6 mg dose showed a reduction compared with placebo in the cumulative number of enhancing lesions per scan in the last four scans (mean+/-SD= 2.6+/-5.3 vs. 4.2+/-9.2, p = 0.0048); treatment with the 0.3 mg dose showed no significant difference. Significant differences in favor of the 0.6 mg dose were found for most examined secondary and exploratory MRI-based outcome measures. Trends favored the group receiving the 0.6 mg dose on measures of annual relapse rate (0.52 +/- 0.92 vs. placebo 0.77 +/- 1.25; p = 0.21), relapse-free subjects (70.8 percent vs. 62.7 percent; p = 0.33) and time to first relapse (p = 0.14). Treatment with both 0.3 and 0.6 mg doses of laquinimod were well tolerated with only some transient and dose-dependent increases in liver enzymes. About laquinimod Laquinimod is a novel once-daily, orally administered immunomodulatory compound developed as a disease modifying treatment for multiple sclerosis (MS). Active Biotech developed laquinimod and licensed it to Teva Pharmaceutical Industries, Ltd. in June 2004. A previous 24-week Phase IIa trial conducted by Active Biotech demonstrated that oral 0.3 mg laquinimod given daily was well tolerated and reduced the formation of active lesions in RRMS. To date, 460 MS patients have received laquinimod in various clinical trials. About MS Multiple Sclerosis (MS) is the leading cause of neurological disability in young adults. It is estimated that 400,000 people in the United States are affected by this disease, and that over one million people are affected worldwide. MS is a progressive, demyelinating disease of the central nervous system affecting the brain, spinal cord and optic nerves. Patients with MS may experience physical symptoms and/or cognitive impairments, including weakness, fatigue, ataxia, physical dysfunction, bladder and bowel problems, sensory effects, and visual impairment. MS also has a significant impact on the sufferers' social functioning and overall quality of life. About Teva Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system. About Active Biotech Active Biotech AB (ACTI.ST) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics International Ltd. Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra® and Neurontin®, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. ###


 

LAS VEGAS, May 1, 2007 (PRIME NEWSWIRE) -- CanAm Uranium Corp. ("CanAm" or the "Company") (OTCBB:CAUI) is pleased to announce that six holes have been completed to test the Halo property, with assay results reported for the first four. * First round of drilling on Halo confirms historical results by intercepting average grade of 0.09% (1.6 lbs) U3O8 over 8.9 meters (34 feet) * Including 0.31% U3O8 ( 6.2 lb ton over 1.52 meters) * Drill program continues on second of seven other known historical targets * Bancroft is home to four past producing mines between 1956 and 1982 * Uranium price reaches new high of $113 per lb * El Nino is the project operator Best results to date have been achieved in DDH H-4, the upper hole on the second or easternmost section drilled. Eight radioactive pegmatite dykes were intersected within an interval of 24 meters. Assays/width ranged from 0.01% U3O8 (0.2 lb/ton) / 0.11 meters to 0.31% U308 (6.2 lb/ton) / 1.52 meters. Average weighted grade of the dykes was 0.09% U3O8 (1.8 lb/ton) with a cumulative width of 8.9 meters. Anomalous amounts of certain heavy rare earth elements have been noted. In Sample 8027 from DDH H-4 18g/t Scandium was reported along with 0.10% U3O8 (2.0 lb/ton) across an interval of 1.31 meters. The objective of the phase one drill program has been achieved. We have reconfirmed historical values on the property which has not been drilled over 20 years. The non compliant 43-101 reserve estimate in 1957 on the Halo project was 472,000 tons grading 0.112% (2.24 lbs per ton U3O8). No exploration has been done on the property in the last 30 years due to low prices of uranium. The objective of the second phase of drilling will be to define reserves and resources in addition to historical estimates. Second Drill Target (ARE#2) The drill is currently being moved to the second target which is the Amalgamated Rare Earth Project (ARE#2). Between 1952 and 1957, diamond drilling and underground development identified three zones of uranium mineralization in pegmatite, and a shaft was sunk on the Main Zone to 440 feet, with a total of 5,871 feet of underground development completed at three levels. In 1957, the resource was estimated at 292,444 tons at a grade of 0.095% (1.9 lbs/ton) (non 43-101 compliant). Quality Control Mr. Tim J. Beesley, P.Eng.,a qualified person as defined in National Instrument 43-101, has reviewed the contents of this release. About Bancroft Known as "the Mineral Capital of Canada" (Bancroft & District Chamber of Commerce) due to the abundance of minerals found in the area, Bancroft was especially well known for its uranium production, once home to four past producing mines, producing a total of 14,862,653 lbs U3O8 between 1956-1982. Forward-Looking Statements Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on CanAm's website does not constitute a part of this release. About El Nino Ventures Inc. (Operator and Joint Venture Partner) El Nino Ventures is an exploration stage company whose corporate objective is to revisit former mining regions and apply the latest technologies to advanced stage exploration targets. El Nino Ventures has entered into an Option / Joint Venture Agreement with Xstrata Zinc Canada to explore the world class Bathurst Zinc / Base Metals Mining Camp in Bathurst, New Brunswick, Canada. El Nino will commence a 25,000 meter drill program on the Bathurst mining camp. El Nino continues to negotiate land positions in base metals outside of North America. About Us CanAm Uranium Corp. is a Nevada incorporated junior resource company with a corporate objective focused on the strategic acquisition and development of exploration properties in well-known prolific mining areas, especially known for Uranium, of Canada, Southern Africa, Australia and the United States. CanAm Uranium Corp has optioned over 136,825 acres of claims collectively within the Saskatchewan Athabasca Basin, Ontario and British Columbia, with significant interest in prolific Uranium mining areas. http://www.CanAmUranium.com CONTACT: CanAm Uranium Corp. David Hayes, CFO (206) 274-7598 Facsimile: (206) 299-3484 www.canamuranium.com


 

Correction to the release sent out at 4 AM this morning. In the first subhead, the first line should have read as follows : ...."Corporate Aircraft Market Forecast predicts 9,950 deliveries (...) from 2007 to 2016 ....". The corrected and complete version follows: BELFAST, NORTHERN IRELAND -- (MARKET WIRE) -- May 01, 2007 -- - 10-year baseline Corporate Aircraft Market Forecast predicts 9,950 deliveries, excluding very light jet segment, from 2007 to 2016 representing market-wide revenues of $227 billion US - 20-year Commercial Aircraft Market Forecast calls for 11,200 new deliveries in 20- to 149-seat market, worth $393 billion US Today, Bombardier Aerospace released its annual aircraft market forecasts for the business and commercial aircraft markets. Overall demand for aircraft in the segments in which Bombardier competes will remain strong. As well, there is a geographic shift towards international markets and a structural shift towards more cost-effective aircraft. Bombardier's key product families - business jets and regional aircraft - are expected to continue to generate strong interest across all markets. "With its comprehensive portfolios of innovative business and regional aircraft, with its state-of-the-art technologies and focus on customer services, Bombardier is well-positioned for continued success," said Michael McAdoo, Vice-President, Strategy and Business Development, Bombardier Aerospace. Business Aircraft Market Forecast In the 10-year period from 2007 to 2016, Bombardier's Business Aircraft Market Forecast predicts that corporate aircraft manufacturers will deliver approximately 995 business jets annually, excluding the very light jet segment, a substantial increase from the industry average of over 572 business jet deliveries annually during the 1997 to 2006 period. The total forecasted 9,950 deliveries over the 10-year period represent revenues of approximately $227 billion US for the industry. The growth in business jet deliveries is expected to continue over the next four years, continuing to improve on the record set in 2006, then remain strong for the following six years. Based on the industry's continued robust order intake and manufacturers' solid backlogs, Bombardier believes the business aircraft industry will reach this plateau two years later than it had forecasted previously. Bombardier's forecast also indicates that primary market drivers continue to be positive or stable. These include manufacturers' current average order backlog of approximately 24 months; a sustained U.S. gross domestic product growth is expected to remain at close to three per cent for the next 10 years; strong order intake from international markets, now representing approximately 50 per cent of the total market, and a number of new aircraft programs scheduled to enter service over the next two years. Commercial Aircraft Market Forecast According to Bombardier's Commercial Aircraft Market Forecast, demand for 20- to 149-seat commercial aircraft is expected to reach approximately 11,200 new aircraft in the 20-year period ranging from 2007 to 2026, an increase in demand from last year's forecast. Forecasted demand is valued at approximately $393 billion U.S. based on manufacturers' aircraft list prices. Airline capacity is expected to double over the next 20 years. The trend towards larger aircraft, coupled with sustained higher fuel prices, will reinforce operators' requirement for modern aircraft with low operating costs. The forecast reflects this shift in demand to larger commercial aircraft: - In the 20- to 59-seat aircraft segment: the forecast expects a demand of approximately 1,000 aircraft; - In the 60- to 99-seat aircraft segment: demand is expected to reach approximately 4,300 aircraft; - In the 100- to 149-seat aircraft segment: the forecast predicts a demand for approximately 5,900 aircraft. The CRJ Series and Q-Series families of airliners have enabled Bombardier to be an active player, and to continue to take advantage of growth opportunities, in the regional aircraft market. Its larger cost-efficient CRJ700/CRJ900 regional jets and the Q400 turboprop are the backbone of many airline fleets worldwide. The newly launched CRJ1000, which will seat up to 100 passengers, combines the proven platform, reliability and flexible cabin configurations of its predecessors with its closest competitor having up to 15 per cent higher trip cash operating costs. In order to address the 100-149-seat segment, Bombardier continues to refine its CSeries aircraft business plan, including optimizing the aircraft configuration to meet customers' requirements for a more economical, flexible and passenger-oriented airliner. If launched, the target date for entry into service is 2013. About Bombardier A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2007, were $14.8 billion US, and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com. Bombardier, Learjet, Challenger, Global, Flexjet, Skyjet, Skyjet International, CRJ, Q-Series, CRJ700, CRJ900, CRJ1000, Q400 and CSeries are trademarks of Bombardier Inc. or its subsidiaries. Note to editors: A PowerPoint presentation on the Bombardier Aerospace annual market forecasts for the business and commercial aircraft markets is available on the internet at the following address: www.bombardier.com FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "anticipate", "plan", "foresee", "believe" or "continue" or the negatives of these terms or variations of them or similar terminology. By their nature, forward-looking statements require Bombardier Inc. (the "Corporation") to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause the Corporation's actual results in future periods to differ materially from forecasted results. While the Corporation considers its assumptions to be reasonable and appropriate based on current information available, there is a risk that they may not be accurate. For additional information with respect to the assumptions underlying the forward-looking statements made in this press release, please refer to the respective sections of the Corporation's aerospace segment ("Aerospace") and the Corporation's transportation segment ("Transportation") in the Management's Discussion and Analysis of the 2006-2007 Annual Report on the Corporation's Web site at www.bombardier.com. Certain factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include risks associated with general economic conditions, risks associated with the Corporation's business environment (such as the financial condition of the airline industry, government policies and priorities, and competition from other businesses), operational risks (such as regulatory risks and dependence on key personnel, risks associated with doing business with partners, risks involved with developing new products and services, warranty and casualty claim losses, legal risks from legal proceedings, risks relating to the Corporation's dependence on certain key customers and key suppliers, risks resulting from fixed term commitments, human resource risks and environmental risks), financing risks (such as risks resulting from reliance on government support, risks relating to financing support provided on behalf of certain customers, risks relating to liquidity and access to capital markets, risks relating to the terms of certain restrictive debt covenants and market risks, including currency, interest rate and commodity pricing risks). For more details, please see the Risks and uncertainties section in the Management's Discussion and Analysis of the 2006-2007 Annual Report on the Corporation's Web site at www.bombardier.com. Readers are cautioned that the foregoing list of factors that may affect future growth, results and performance is not exhaustive and undue reliance should not be placed on forward-looking statements. The forward-looking statements set forth herein reflect the Corporation's expectations as at this date and are subject to change after such date. Unless otherwise required by applicable securities laws, the Corporation expressly disclaims any intention, and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts: Bombardier Aerospace Marc Duchesne 514-855-7989


 

01 May 2007 - Erik Westerink has joined the Supervisory Board of Qurius N.V. The General Meeting of Shareholders has appointed him as per 27 April 2007. Mr. Westerink is managing director of Parcom Ventures, one of the major shareholders of Qurius. As announced on 16 April 2007, Jan van Rijt has stepped down after the General Meeting of Shareholders on 27 April 2007 as member and Chairman of the Supervisory Board. The Supervisory Board will appoint as soon as possible one of its members as a chairman. Qurius N.V. Qurius provides architecture, realization and systems management of Microsoft technology based business and IT solutions, including infrastructures. Qurius has over 725 staff members; its headquarters are located in Zaltbommel, the Netherlands. Its offices in Belgium, Denmark, Germany, Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom serve over 1,700 clients. Qurius has been publicly listed on Euronext Amsterdam since 1998. On 18 December 2006, Qurius' shareholders authorized the merger with Watermark, which created Europe's largest Microsoft Dynamics partner. For further information, see www.qurius.com. Contact Qurius, Fred Hermans: telephone +31 (0)418 683 500 or fred.hermans@qurius.com.


 

Seadrill has been awarded a letter of intent by an international E & P operator for one of the newbuild deepwater units under construction in Korea/Singapore. The contract has a firm duration of five years, and estimated contract value is approximately US$970 million, including mobilization fee. Analyst contact: Jim Dåtland Vice President Investor Relations Seadrill Management AS +47 51 30 99 19 Media contact: Kjell E Jacobsen Chief Executive Officer Seadrill Management AS +47 51 30 99 19 Seadrill Limited Hamilton, Bermuda April 30, 2007


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | iSOFT Group Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 10p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 27 April 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |-------------------------------+--------------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (2) Derivatives (other than | 3,000,000 | 1.2904 | | | | options) | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | Total | 3,000,000 | 1.2904 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | CFD | LONG | 363,728 | 37.4420 | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 1st May 2007 | |---------------------------------------------------+---------------| | Contact name | James Feast | |---------------------------------------------------+---------------| | Telephone number | 0207 469 1901 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

ADDITIONAL LISTING Serabi Mining plc ("Serabi" or "the Company") announces that 246,036 options over 10 pence ordinary shares ("Ordinary Shares") in the Company have been exercised at a price of 15 pence per share. Application has been made for these new Ordinary Shares to be admitted to AIM and it is expected for trading to commence at 8.00am on the 4th May 2007. These new Ordinary Shares will, when allotted and issued fully paid, rank pari passu in all respects with the existing Ordinary Shares now in issue. The total number of Ordinary Shares in issue following the exercise of these options over Ordinary Shares will be 111,069,297. Enquiries: Serabi Mining plc Graham Roberts Tel: 020 7220 9550 Chairman Mobile: 07768 902 475 Clive Line Tel: 020 7220 9550 Finance Director Mobile: 07710 151 692 email: contact@serabimining.com Numis Securities Limited John Harrison Tel: 020 7260 1000 James Black Tel: 020 7260 1000 ---END OF MESSAGE---


 

Announcement no. 8 - 2007


 

LONDON and SEATTLE, WA -- (MARKET WIRE) -- May 01, 2007 -- University College London's (UCL) Institute of Ophthalmology, Moorfields Eye Hospital and Targeted Genetics Corporation (NASDAQ: TGEN) today announced the initiation of a Phase I/II clinical trial to test an innovative approach to treating a form of childhood blindness. The trial, funded by the UK Department of Health is the first of its kind and could have a significant impact on future treatments for eye disease. The trial involves adults and children who have a progressive deterioration in vision caused by an abnormality in the RPE65 gene. In affected individuals, this defect prevents normal function of the retina, the light-sensitive layer of cells at the back of the eye. There are currently no effective treatments for this condition. The approach being evaluated in this clinical trial utilizes an adeno-associated virus (AAV) vector to deliver a normal copy of the RPE65 gene into the cells of the retina to help them to function normally. Targeted Genetics, the leader in the development and manufacture of AAV-based product candidates, manufactured the vector that will be used in this trial. "We have been developing gene-based treatments for eye disease for almost 15 years but until now we have been evaluating the technology only in the laboratory," said Professor Ali. "Testing it for the first time in patients is very important and exciting and represents a significant step towards establishing gene therapy for the treatment of many different eye conditions." Work using animal models has demonstrated that this AAV-mediated delivery of RPE65 can improve and preserve vision. The purpose of this clinical study is to evaluate the safety and efficacy of this approach in patients. The team from UCL Institute of Ophthalmology and Moorfields Eye Hospital, led by Professor Robin Ali, includes leading eye surgeon Mr. James Bainbridge and leading retinal specialist Professor Tony Moore. "So far the operation has been performed in young adult patients who developed the condition as children," said Mr. James Bainbridge, who leads the surgical team. "The data available thus far, although preliminary, suggest that AAV-based delivery of genes to extremely fragile sites within the eye can be accomplished without significant complications." "Additional data will be needed in order to assess the outcome of this approach fully," said Professor Moore, "However we expect that the best outcomes will be observed in younger patients." About University College London UCL Institute of Ophthalmology is one of a number of specialised research centres linked to University College London and is, together with Moorfields Eye Hospital, one of the leading centres for eye research. The Institute scored a 5*A (highest point) in the last Research Assessment Exercise. The Institute is committed to a multi-disciplinary research portfolio that furthers an understanding of the eye and visual system linked with clinical investigations targeted to specific problems in the prevention and treatment of eye disease. The combination of the Institute's research resource with the resources of Moorfields Eye Hospital, which has the largest ophthalmic patient population in the Western World, opens the way for advances at the forefront of vision research. About Moorfields Eye Hospital Moorfields Eye Hospital NHS Foundation Trust is the world's oldest specialist eye hospital. It is a world-renowned centre for ophthalmic treatment, teaching and research. About Targeted Genetics Targeted Genetics Corporation is a biotechnology company committed to the development of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. Targeted Genetics' proprietary Adeno-Associated Virus (AAV) technology platform allows it to deliver genes that encode proteins to increase gene function or RNAi to decrease or silence gene function. Targeted Genetics' product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure and Huntington's disease. To learn more about Targeted Genetics, visit Targeted Genetics' website at www.targetedgenetics.com. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements regarding the data to be collected in this trial, the establishment or determination of efficacy endpoints from the data collected in the trial, the timely and complete accrual of patients in the trial and our ability to commercialize and other statements about our plans, objectives, intentions and expectations. These statements, involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Factors that could affect our actual results include, but are not limited to, our ability to obtain, maintain and protect our intellectual property, our ability to raise capital when needed, our ability to recruit and enroll suitable trial participants, the timing, nature and results of research and clinical trials, potential development of alternative technologies or more effective processes by competitors, and our ability to obtain and maintain regulatory or institutional approvals, as well as other risk factors described in Item 1A. Risk Factors in our report on Form 10-K for the year ended December 31, 2006. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations. For further information, or to arrange an interview with Professor Robin Ali, please contact Ruth Metcalfe at UCL Media Relations on: +44 (0)20 7679 9739, +44 (0)7990 675 947 (mobile) or in out of hours 44 (0)7917 271 364 Notes to editors: 1. The team is supported by funding from the Department of Health, Sir Jules Thorn Charitable Trust, The Wellcome Trust, The British RP Society, The European Union (EVI Genoret and Clinigene programmes), The Medical Research Council, Foundation Fighting Blindness USA, Fight for Sight and The Ulverscroft Foundation. 2. Robin Ali is Professor of Human Molecular Genetics at UCL Institute of Ophthalmology and Head of Division of Molecular Therapy. 3. James Bainbridge is a Wellcome Trust Advanced Fellow at UCL Institute of Ophthalmology and Consultant Ophthalmologist at Moorfields Eye Hospital 4. Tony Moore is Professor of Ophthalmology at UCL Institute of Ophthalmology and Consultant Ophthalmologist at Moorfields Eye Hospital and the Hospital for Children Great Ormond St London. Targeted Genetics' Investor and Media Contact Stacie D. Byars Director, Communications Targeted Genetics Corporation (206) 521-7392 --- End of Message --- Targeted Genetics 1100 Olive Way; Suite 100 Seattle USA WKN: A0JMQ1; ISIN: US87612M1080; ;


 

Applies for Further Exploration Licenses VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- May 01, 2007 -- Buffalo Gold Ltd. (TSX VENTURE: BUF.U)(OTCBB: BYBUF)(FRANFURT: B4K) is pleased to report assay results from its drill program at the Mt. Kare gold project, including: - 22.5 metres of 3.34 g/t gold in hole MK07-92 - Including 13.9 metres of 4.95 g/t gold - 27.5 metres of 5.40 g/t gold in hole MK07-97 - Including 11.0 metres of 12.73 g/t gold - 6.0 metres of 55.95 g/t gold in hole MK07-103 - Including 1.5 metres of 222 g/t gold So far this year Buffalo has drilled 4711 metres in nineteen holes, as part of the $11.4 million on-going exploration program at Mt. Kare to test objectives both in the vicinity of known mineralization and at existing targets. Significant results received to date are summarized below in Table 1. Hole MK07-90 targeted an untested area of the Southern Western Roscoelite Zone (SWRZ) and intersected 1.59 g/t gold reported over 74 metres including 28 metres of 2.53 g/t gold starting at a depth of 88 metres. On the eastern flank of the SWRZ, holes MK07-91 and MK07-97 encountered mainly patchy mineralization near surface but significant intersections of gold occurred at depth, most notably 27.5 metres of 5.40 g/t gold including 11 metres of 12.73 g/t gold, starting at 219 metres depth. MK07-96 also tested the eastern flank of the SWRZ and intersected significant mineralization below 123 metres, including 33.0 metres of 1.76 g/t gold. This hole was abandoned at 208 metres due to problems with the drill. Hole MK07-99 was an infill hole drilled in the southern portion of the SWRZ. Mineralization was encountered in this hole, including 17.2 metres of 0.95 g/t gold. MK06-92 is an infill hole in the southern Central Zone that intersected 22.5 metres of 3.34 g/t gold at a starting depth of just over 200 metres. The hole was stopped prematurely due to problems with the drill rig. MK07-95 lies to the east and was drilled to test the eastern extension of historical hole MK00-239. Additional infill drilling in the Northern Western Roscoelite Zone (NWRZ) included holes MK07-93, aimed at the down-dip extension of the NWRZ, and MK07-94 that intersected 53.9 metres of 1.20 g/t gold at a shallow depth of 54 metres. The eastern extension of the NWRZ was tested in hole MK07-98, down-dip from MK06-73. Mineralization was encountered at depth, including 17 metres of 1.19 g/t gold at 237 metres. Hole MK07-100 was drilled to test for a possible northern extension of the NWRZ at depth but no significant intersections were returned. A possible down-plunge extension of the Black Zone towards the C9 Zone was tested in hole MK07-101. Below 170 metres the hole intersected a sequence of strongly mineralized zones of brecciated intrusive and sandstone hosted semi massive to massive pyrite veining/disseminations, rare chalcopyrite-sphalerite-galena and antimony sulphide veins and fractures. Analysis of the hole returned 81 metres of 1.26 g/t gold and 4.68 g/t silver including 10 metres of 4.85 g/t gold and 21.12 g/t silver. Hole MK07-102 was testing the same area and encountered very high grade gold at approximately 100 metres depth, returning a 6 metre intersection of 55.95 g/t gold and 105.68 g/t silver, including 1.5 metres of 222.0 g/t gold and 385 g/t silver. ------------------------------------------------------------ Table 1. Summary of Mt. Kare Drill Hole Intersections Received from January12(th) 2007 to April 18(th) 2007 ------------------------------------------------------------ Drill Hole No. From To Intercept Gold Silver (m) (m) (m) (g/t) (g/t) ------------------------------------------------------------ MK07-90 88.0 162.0 74.0 1.59 11.52 Including 88.0 116.0 28.0 2.53 15.58 ------------------------------------------------------------ MK07-91 1.7 5.0 3.3 2.41 13.87 278.0 283.0 5.0 5.40 138.08 ------------------------------------------------------------ MK07-92 205.4 227.9 22.5 3.34 5.06 Including 214.0 227.9 13.9 4.95 6.83 ------------------------------------------------------------ MK07-93 190.0 204.0 14.0 0.71 4.26 ------------------------------------------------------------ MK07-94 54.3 108.1 53.8 1.20 39.25 Including 65.1 73.5 8.4 4.44 32.66 ------------------------------------------------------------ MK07-95 145.0 153.0 8.0 0.69 17.60 ------------------------------------------------------------ MK07-96 128.0 161.0 33.0 1.76 10.31 Including 130.0 136.0 6.0 3.35 10.87 ------------------------------------------------------------ MK07-97 22.0 28.0 6.0 2.06 15.63 130.0 133.0 3.0 2.82 40.80 219.0 246.5 27.5 5.40 31.59 225.0 236.0 11.0 12.73 72.42 Including 228.7 231.7 3.0 43.78 56.17 ------------------------------------------------------------ MK07-98 237.0 254.0 17.0 1.19 4.79 Including 245.0 254.0 9.0 1.46 4.28 ------------------------------------------------------------ MK07-99 143.0 144.0 1.0 5.63 64.90 170.8 188.0 17.2 0.95 13.43 Including 177.0 181.0 4.0 2.29 35.08 ------------------------------------------------------------ MK07-100 No significant intersections ------------------------------------------------------------ MK07-101 165.0 246.0 81.0 1.26 4.68 Including 219.0 244.0 25.0 2.37 9.46 Including 234.0 244.0 10.0 4.85 21.12 ------------------------------------------------------------ 99.5 105.5 6.0 55.95 105.68 MK07-102 102.5 104.0 1.5 222.0 385.0 ------------------------------------------------------------ MK07-103 No significant intersections ------------------------------------------------------------ All samples were analysed for gold by PT Intertek Utama Services in Jakarta, part of an internationally recognized lab testing group with ISO 17025 accreditation at the Jakarta facility. Samples were analysed using a 50g fire assay with AA finish for gold and an aqua regia digestion, ICP-OES finish for silver. "We continue to be encouraged by the results at Mt. Kare," commented Buffalo Chairman and CEO Damien Reynolds. "Based on results of our recent aeromagnetic survey and drilling we have applied for additional exploration licenses in the area." Mr. Brian McEwen, P.Geol., President and COO of Buffalo, is the qualified person for the Mt. Kare project and has approved the contents of this news release. Buffalo Gold Ltd., head-quartered in Vancouver, Canada, is actively engaged in exploring and developing gold, uranium and nickel properties in Australasia. Management is dedicated to maximizing shareholder value through growth strategies that emphasize careful opportunity assessment and vigilant project management. To find out more about Buffalo Gold Ltd. (TSX VENTURE: BUF.U), please visit the company website at www.buffalogold.ca. On behalf of the Board of Directors of Buffalo Gold Ltd. Damien Reynolds, Chair of the Board of Directors and Chief Executive Officer Cautionary Note to U.S. Investors - The United States Securities and Exchange Commission ("SEC") permits mining companies in filings with the SEC to disclose only those mineral deposits that a company can economically and legally extract or produce. The company may use certain terms in this news release, such as "inferred resource", that the SEC guidelines strictly prohibit from including in filings with the SEC. U.S. investors are urged to consider closely the disclosure contained in the company's Form 20-F Registration Statement, file no. 000- 30150. The company's filings are available on the SEC's website at http://www.sec.gov/edgar.shtml. The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy of this press release. Contacts: Buffalo Gold Ltd. Julie Hajduk Investor Relations (604) 685-5492 or Toll Free: 1-888-685-5492 (604) 685-2536 (FAX) Email: julie@buffalogold.ca Website: www.buffalogold.ca


 

Multi-Vendor Provisioning Supporting Rapid Integration to SDP Infrastructure OTTAWA -- (MARKET WIRE) -- May 01, 2007 -- Atreus Systems(TM), the leading supplier of provisioning and activation software for VoIP and user-centric IMS applications, today unveiled the latest release of its Atreus xAuthority provisioning solution. Built using a service-oriented architecture (SOA) framework, the new release is designed for rapid and seamless integration with Service Delivery Platforms (SDP), and helps providers combine atomic IMS services into composite offerings made up of complementary services. "As providers move toward the adoption of SDP-based service architectures, they need to look to vendors like Atreus for proven OSS expertise that will help them get their services to market quickly with minimal integration costs," said Lynda Starr, Senior Analyst, Frost & Sullivan. "With its expanded Service Offering application, Atreus equips providers with a powerful tool for creating profitable IMS bundles that drive competitive differentiation." Atreus' SDP-ready provisioning solution, available now and currently deployed with service providers worldwide, bolsters the core service creation and orchestration functions provided by the leading SDP offerings with critical provisioning and activation capabilities that enable the rapid operationalization of composite IMS offerings. These capabilities include: - a service offering application for creating high-value bundles that span fixed and mobile networks; - customer-proven, out-of-the-box workflows for provisioning IMS applications, including IP Centrex, SIP Trunking, Hosted Call Center, Mobile PBX, Unified Messaging, etc.; - network and application adaptors for leading IMS vendors; and - industry standard APIs that facilitate rapid integration with SDPs and critical back-office systems. By implementing key telecom standards, such as the OSS Through Java Initiative (OSS/J), Atreus accelerates the migration from a vertically integrated service delivery model to a horizontal model in which a single SDP framework can be used for the creation, bundling, and delivery of IMS applications. The Atreus solution is both flexible and extensible and gives providers many compelling service management benefits: - compatible with emerging SOA/SDP back-office architectures for inventory, ordering and billing processes; - proven interoperability with leading platforms and systems; - reusable service components; - rapid definition and deployment of service provisioning workflows at a low cost; - flexible, standards-based integration reducing time-to-market and cost-of-integration; - rapid return on network investment by simplifying and speeding service deployment. Visit Atreus at booth # 164 at TeleManagement World in Nice, France from May 21 - 24, 2007. Doug Bellinger, CTO, Atreus Systems has been enlisted by TeleManagement Forum to address, "Implementing IMS Services Using OSS/J in a SOA / SDP Environment". Conference attendees at TeleManagement World will hear expert insight in migrating from a vertically integrated service delivery model to a horizontal model that creates, bundles, and delivers high-value SIP- and IMS-based services. "The new converged communications paradigm requires provisioning solutions that are robust enough to handle the demands of dynamic user-driven applications, while also having the agility to get new and innovative services to market rapidly," said Doug Bellinger, CTO, Atreus Systems. "The enhancements we've made to the xAuthority platform specifically address the sophisticated service provider's need for IMS provisioning expertise that can be rapidly integrated into an SDP-driven back office." About Atreus Systems Atreus Systems(TM) is the leading supplier of provisioning software for VoIP and IMS-based services. As the vendor of choice for the world's most successful providers, Atreus has provided advanced activation solutions for KPN, Qwest, PCCW, Telus, Centennial, Spirit Telecom, and Bell Aliant. Atreus has formed strategic partnerships with Alcatel-Lucent, BroadSoft, Ericsson, Level 3, Oracle and Sonus, delivering carrier-class service provisioning with customer self-management. For more information, visit www.atreus-systems.com. Contacts: Atreus Systems Corporation Tony Busa tbusa@atreus-systems.com www.atreus-systems.com


 

FORM 8.1/8.3 IRISH TAKEOVER PANEL Lodge with the Irish Stock Exchange (Company Announcements Office) (which will publicise) and the Panel. Date of disclosure: 01/05/2007 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE IRISH TAKEOVER PANEL ACT 1997, (TAKEOVER) RULES, 1997 Date of dealing: 30/04/2007 Dealing in: Irish Continental (1) Class of securities (e.g. ordinary shares): Ordinary (2) Amount bought Amount sold Price per unit 829,000 20.6053 (3) Resultant total of the same class owned or controlled: 114,785 (and percentage of class): 0.49 % (4) Party making disclosure: Bank of Ireland Asset Management Compliance (5) Either (a) Name of purchaser/ vendor: (Note 1) Or (b) If dealing for discretionary Bank of Ireland client(s), name of fund management Asset Management organisation: Ltd. (6) Reason for disclosure (Note 2) (a) (i) offeror or associate of offeror (Note 3) No (ii) offeree or associate of offeree Yes Specify which category or categories E of associate ((a) to (l) page 3 /4): If category (l), explain: (b) Rule 8.3 (i.e. disclosure because of ownership or control of No 1% or more of the class of relevant securities dealt in): Signed, for and on behalf of the party named in (4) above: (Also print name of signatory): Sharon Tracey Telephone and extension number: 01-6378000 Ext. 8117 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, e.g., where an owner normally acts on instructions of a controller. Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or with an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Rule 8.7. Note 5. It may be necessary, particularly when disclosing derivative transactions, to append a sheet to this disclosure form so that all relevant information can be given. Note 6. In the case of an average price bargain, each underlying trade should be disclosed. Note 7. Unless otherwise stated, references to Rules are to Rules in Part B of the Rules. For full details of disclosure requirements, see Rule 8. If in doubt, consult the Panel. ---END OF MESSAGE---


 

The extraordinary general meeting of SimCorp A/S was held on Tuesday 1 May 2007. The shareholders unanimously passed the resolution to amend Article 8 in the company's Articles of Association as proposed by the Board of Directors.


 

SERABI MINING plc ("Serabi" or "the Company") Serabi Mining advises that it has been notified that following a purchase of shares, the BlackRock Global Metal Open Fund has increased its holding in the issued share capital of the company and now has a notifiable interest of 4,510,333 representing 4.07% of the ordinary shares in issue. Enquiries: Serabi Mining plc Graham Roberts Tel: 020 7220 9550 Chairman Mobile: 07768 902 475 Clive Line Tel: 020 7220 9550 Finance Director Mobile: 07710 151 692 email: contact@serabimining.com Numis Securities Limited John Harrison Tel: 020 7260 1000 James Black Tel: 020 7260 1000 ---END OF MESSAGE---


 

BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically. To: The FSA Date: 26th April 2007 +-------------------------------------------------------------------+ | Name of applicant: | Kenmare Resources plc | |-----------------------------------+-------------------------------| | Name of scheme: | The 2005 Blocklisting Scheme | |-----------------------------------+-------------------------------| | Period of return: | From: | 26th October | To: | 26th | | | | 2006 | | April | | | | | | 2007 | |-----------------------------------+-------------------------------| | Balance under scheme from | N/A | | previous return: | | |-----------------------------------+-------------------------------| | The amount by which the block | N/A | | scheme has been increased, if the | | | scheme has been increased since | | | the date of the last return: | | |-----------------------------------+-------------------------------| | Number of securities | 1,625,803 Ordinary Shares of | | issued/allotted under scheme | ¤0.06 each | | during period: | | |-----------------------------------+-------------------------------| | Balance under scheme not yet | 1,165,398 Ordinary Shares of | | issued/allotted at end of period | ¤0.06 each | |-----------------------------------+-------------------------------| | Number and class of securities | 15,000,000 Ordinary shares of | | originally listed and the date of | ¤0.06c each | | admission | Admission Date: 26th October | | | 2005 | |-----------------------------------+-------------------------------| | Total number of securities in | 689,576,933 Ordinary shares | | issue at the end of the period | of ¤0.06c each | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Name of contact: | Catherine Berry | |---------------------+---------------------------------------------| | Address of contact: | Kenmare Resources plc, Chatham House, | | | Chatham Street, Dublin 2, Ireland. | |---------------------+---------------------------------------------| | Telephone number of | +353 1 6710411 | | contact: | | +-------------------------------------------------------------------+ SIGNED BY __Deirdre Corcoran Director/company secretary/suitably experienced employee/duly authorised officer, for and on behalf of Kenmare Resources plc Name of applicant If you knowingly or recklessly give false or misleading information you may be liable to prosecution. ---END OF MESSAGE---


 

BELFAST, NORTHERN IRELAND -- (MARKET WIRE) -- 05/01/07 -- - 10-year baseline Corporate Aircraft Market Forecast predicts 9,950 deliveries, excluding very light jet segment, annually from 2007 to 2016 representing market-wide revenues of $227 billion US - 20-year Commercial Aircraft Market Forecast calls for 11,200 new deliveries in 20- to 149-seat market, worth $393 billion US Belfast, Northern Ireland, May 1, 2007 - Today, Bombardier Aerospace released its annual aircraft market forecasts for the business and commercial aircraft markets. Overall demand for aircraft in the segments in which Bombardier competes will remain strong. As well, there is a geographic shift towards international markets and a structural shift towards more cost-effective aircraft. Bombardier's key product families - business jets and regional aircraft - are expected to continue to generate strong interest across all markets. "With its comprehensive portfolios of innovative business and regional aircraft, with its state-of-the-art technologies and focus on customer services, Bombardier is well-positioned for continued success," said Michael McAdoo, Vice-President, Strategy and Business Development, Bombardier Aerospace. Business Aircraft Market Forecast In the 10-year period from 2007 to 2016, Bombardier's Business Aircraft Market Forecast predicts that corporate aircraft manufacturers will deliver approximately 995 business jets annually, excluding the very light jet segment, a substantial increase from the industry average of over 572 business jet deliveries annually during the 1997 to 2006 period. The total forecasted 9,950 deliveries over the 10-year period represent revenues of approximately $227 billion US for the industry. The growth in business jet deliveries is expected to continue over the next four years, continuing to improve on the record set in 2006, then remain strong for the following six years. Based on the industry's continued robust order intake and manufacturers' solid backlogs, Bombardier believes the business aircraft industry will reach this plateau two years later than it had forecasted previously. Bombardier's forecast also indicates that primary market drivers continue to be positive or stable. These include manufacturers' current average order backlog of approximately 24 months; a sustained U.S. gross domestic product growth is expected to remain at close to three per cent for the next 10 years; strong order intake from international markets, now representing approximately 50 per cent of the total market, and a number of new aircraft programs scheduled to enter service over the next two years. Commercial Aircraft Market Forecast According to Bombardier's Commercial Aircraft Market Forecast, demand for 20- to 149-seat commercial aircraft is expected to reach approximately 11,200 new aircraft in the 20-year period ranging from 2007 to 2026, an increase in demand from last year's forecast. Forecasted demand is valued at approximately $393 billion U.S. based on manufacturers' aircraft list prices. Airline capacity is expected to double over the next 20 years. The trend towards larger aircraft, coupled with sustained higher fuel prices, will reinforce operators' requirement for modern aircraft with low operating costs. The forecast reflects this shift in demand to larger commercial aircraft: - In the 20- to 59-seat aircraft segment: the forecast expects a demand of approximately 1,000 aircraft; - In the 60- to 99-seat aircraft segment: demand is expected to reach approximately 4,300 aircraft; - In the 100- to 149-seat aircraft segment: the forecast predicts a demand for approximately 5,900 aircraft. The CRJ Series and Q-Series families of airliners have enabled Bombardier to be an active player, and to continue to take advantage of growth opportunities, in the regional aircraft market. Its larger cost-efficient CRJ700/CRJ900 regional jets and the Q400 turboprop are the backbone of many airline fleets worldwide. The newly launched CRJ1000, which will seat up to 100 passengers, combines the proven platform, reliability and flexible cabin configurations of its predecessors with its closest competitor having up to 15 per cent higher trip cash operating costs. In order to address the 100-149-seat segment, Bombardier continues to refine its CSeries aircraft business plan, including optimizing the aircraft configuration to meet customers' requirements for a more economical, flexible and passenger-oriented airliner. If launched, the target date for entry into service is 2013. About Bombardier A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2007, were $14.8 billion US, and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com. Bombardier, Learjet, Challenger, Global, Flexjet, Skyjet, Skyjet International, CRJ, Q-Series, CRJ700, CRJ900, CRJ1000, Q400 and CSeries are trademarks of Bombardier Inc. or its subsidiaries. Note to editors: A PowerPoint presentation on the Bombardier Aerospace annual market forecasts for the business and commercial aircraft markets is available on the internet at the following address: www.bombardier.com FORWARD-LOOKING STATEMENTS This press release includes forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "anticipate", "plan", "foresee", "believe" or "continue" or the negatives of these terms or variations of them or similar terminology. By their nature, forward-looking statements require Bombardier Inc. (the "Corporation") to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause the Corporation's actual results in future periods to differ materially from forecasted results. While the Corporation considers its assumptions to be reasonable and appropriate based on current information available, there is a risk that they may not be accurate. For additional information with respect to the assumptions underlying the forward-looking statements made in this press release, please refer to the respective sections of the Corporation's aerospace segment ("Aerospace") and the Corporation's transportation segment ("Transportation") in the Management's Discussion and Analysis of the 2006-2007 Annual Report on the Corporation's Web site at www.bombardier.com. Certain factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include risks associated with general economic conditions, risks associated with the Corporation's business environment (such as the financial condition of the airline industry, government policies and priorities, and competition from other businesses), operational risks (such as regulatory risks and dependence on key personnel, risks associated with doing business with partners, risks involved with developing new products and services, warranty and casualty claim losses, legal risks from legal proceedings, risks relating to the Corporation's dependence on certain key customers and key suppliers, risks resulting from fixed term commitments, human resource risks and environmental risks), financing risks (such as risks resulting from reliance on government support, risks relating to financing support provided on behalf of certain customers, risks relating to liquidity and access to capital markets, risks relating to the terms of certain restrictive debt covenants and market risks, including currency, interest rate and commodity pricing risks). For more details, please see the Risks and uncertainties section in the Management's Discussion and Analysis of the 2006-2007 Annual Report on the Corporation's Web site at www.bombardier.com. Readers are cautioned that the foregoing list of factors that may affect future growth, results and performance is not exhaustive and undue reliance should not be placed on forward-looking statements. The forward-looking statements set forth herein reflect the Corporation's expectations as at this date and are subject to change after such date. Unless otherwise required by applicable securities laws, the Corporation expressly disclaims any intention, and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts: Bombardier Aerospace Marc Duchesne 514-855-7989


 

Sales in EMEA Double Year-on-Year in 2006; BlueArc Hires New Regional Vice President of Sales and Expands Team to Continue Global Momentum SAN JOSE, CA and LONDON -- (MARKET WIRE) -- May 01, 2007 -- INTERNET WORLD -- BlueArc® Corporation, a market leader in scalable, high performance unified storage, today announced the expansion of the company's operations in the European, Middle Eastern and African (EMEA) region, amid unprecedented customer adoption for BlueArc Titan 2000 storage systems throughout the geography. In the region, 2006 sales of BlueArc's high performance network storage systems and advanced software solutions doubled year over year from 2005, as the company has greatly expanded its sales and support teams to meet this demand. The announcement of an expanded presence in the EMEA markets also includes the addition of Georg Bartz as the company's new regional vice president of sales for EMEA and further builds on BlueArc's momentum worldwide. Bartz joins BlueArc from McDATA, where he led a sales team of more than 100 people and grew the company's EMEA region substantially, achieving seven consecutive years of record revenue. BlueArc's further expansion into EMEA markets complements the recent announcement of a joint five-year global OEM agreement with partner Hitachi Data Systems and worldwide reseller agreement with Cray, as the company's continued growth in the region will enable greater customer-facing resources and partnership development. In addition, BlueArc is expanding the company's value-added reseller network in the EMEA region, India and Australia to meet the dramatically increasing market requirements for high performance NAS. Over the last year, BlueArc experienced greatly accelerated demand from customers in the EMEA region, with deployments in a variety of vertical markets, including research, energy exploration, technology and manufacturing, higher education, Internet services and entertainment, as well as enterprise deployments targeting application acceleration and server consolidation. These new customer wins and increased revenues are a direct result of the company's continued innovation in both hardware performance, where the Titan 2000 system has consistently led industry benchmarks, and enterprise-class software functionality, including policy based data migration and replication, iSCSI, enhanced data protection, disaster recovery tools, a WORM file system, and a powerful virtualization framework. "Worldwide customer demand for Titan storage systems is expanding at a quickening pace, reflecting positively on our ability to deliver comprehensive, enterprise-class solutions to the market," said Mike Gustafson, president and CEO of BlueArc. "We are very pleased to be expanding our EMEA focus at this important time of growth and momentum for the company. This represents yet another step in increasing the BlueArc customer base in new geographies." About BlueArc BlueArc is the performance, scalability and simplicity leader in world-class unified storage systems and software. BlueArc solutions enable customers in all markets to accelerate applications, reduce costs and enable infrastructure consolidation through a unique, patented platform architected well beyond today's market offerings. Information about BlueArc solutions and services can be found at www.bluearc.com. Media Contacts: Louis Gray BlueArc Corporation 408-576-6684 lgray@bluearc.com Denis Roy Text 100 415-593-8436 denisr@text100.com


 

HOUSTON, May 1, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) and Encysive (UK) Limited, the Company's European operations, today announced plans to participate in three European medical conferences during 2007. The Company will also provide educational funding to two rheumatology-related organizations in order to further advance its commitment to scientific research and medical education for pulmonary arterial hypertension (PAH) and related diseases. Encysive plans to participate actively, including participation in scientific symposia, in the following upcoming European medical conferences: * European League Against Rheumatism (EULAR) June 13-16, Barcelona * European Society of Cardiology (ESC) September 1-5, Vienna * European Respiratory Society (ERS) September 15-19, Stockholm "THELIN(r)(1) has been launched in the United Kingdom, Germany, Republic of Ireland and the Netherlands, and physicians are beginning to evaluate its benefits in their patients," said Thierry A. Plouvier, M.D., Vice President of Encysive's European Operations. "EULAR, ESC and ERS are all well-recognized and respected forums for presenting scientific and clinical information. We look forward to presenting data regarding THELIN's benefits in PAH and demonstrating our commitment to exploring its therapeutic potential in diastolic heart failure and other potential indications." During 2007, Encysive will also provide educational grants to the EULAR Scleroderma Trials and Research (EUSTAR) group and the Outcome Measures in Rheumatology (OMERACT) initiative to further advance medical research and medical education. EUSTAR, www.eustar.org, aims to foster the awareness, understanding and research of scleroderma and its management throughout Europe. OMERACT, www.omeract.org, is an international network striving to improve outcome measurements for rheumatology studies through a data driven, interactive consensus process. Marco Matucci-Cerinic, M.D., Professor of Rheumatology and Medicine, University of Florence, Italy, and chairman of EUSTAR, added, "We appreciate that Encysive has demonstrated its full commitment to supporting research and educational programs that improve scleroderma patients' early diagnosis, quality of life and access to safe and effective treatments." THELIN(r) (Sitaxentan Sodium(2)) Overview THELIN is an endothelin A receptor antagonist, a small molecule that blocks the action of endothelin, a potent mediator of blood vessel constriction and growth of smooth muscle in vascular walls. Endothelin receptor antagonists may prove to be effective in the treatment of a variety of diseases where the regulation of vascular constriction is important. THELIN is 6,500-fold selective in the targeting of the endothelin A receptor versus the endothelin B receptor. Highly selective endothelin A receptor antagonism has been shown to increase blood flow and reverse vasoconstriction in human clinical pharmacology studies. In August 2006, the European Commission granted marketing authorization for THELIN 100 mg tablets in all 27 member states of the European Union. THELIN is indicated for the treatment of patients with pulmonary arterial hypertension (PAH) classified as World Health Organization (WHO) functional class III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension(3) and pulmonary hypertension associated with connective tissue disease. THELIN is the first selective endothelin A receptor antagonist, and first once daily oral treatment available for patients with PAH. In 2006, THELIN was launched in the United Kingdom and Germany, and in 2007 has been launched in the Netherlands and in Ireland. THELIN will be launched in additional EU member states as local government approval for reimbursement is obtained. For more information, please visit www.encysive.com. About PAH PAH is estimated to afflict approximately 100,000 to 200,000 people in North America and Europe. The disease is characterized by high blood pressure and structural changes in the walls of the pulmonary arteries, the blood vessels that connect the right side of the heart to the lungs. As these arteries become increasingly constricted, blood flow and oxygenation may be inadequate to meet the body's demands. Since the heart must then pump harder to overcome the resistance, patients are susceptible to heart failure. About Encysive Pharmaceuticals Encysive Pharmaceuticals Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: www.encysive.com. The Encysive Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=843 (1) THELIN is an EU registered trademark of Encysive Pharmaceuticals Inc. (2) "Sitaxentan" sodium is the spelling recognized by the World Health Organization for Encysive Pharmaceuticals' sitaxsentan sodium. (3) Primary pulmonary hypertension is also known as idiopathic pulmonary arterial hypertension. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are: our ability to raise additional capital to fund cash requirements for future operations; acceptance of Thelin in the EU by physicians and the actual rate of acceptance; the impact of reimbursement policies and governmental regulation of prices for Thelin in the EU; and our ability to obtain regulatory approvals for additional indications for Thelin in the future, as well as more specific risks, trends and uncertainties facing Encysive such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore you should not rely on any such forward-looking statements. Furthermore, Encysive undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion. CONTACT: Encysive Pharmaceuticals Investors: Ann Tanabe, VP, Investor Relations and Corporate Communications (713) 796-8822 The Trout Group Marcy Strickler (646) 378-2927 Media: BMC Communications Dan Budwick (212) 477-9007 ext. 14


 

Imtech breaks 300-million euro mark in revenues in UK Gouda - Imtech (technical service provider in Europe) announces the acquisition of British counterpart The Aqua Group Ltd. And its subsidiary companies from the current owners. With this acquisition Imtech will significantly strengthen its position in the UK. The acquisition price comes to some 24 million euro, including earn-out, and will be paid in cash. The acquisition fits in with Imtech's strategy for further growth in the UK and contributes directly to the profit per share. René van der Bruggen, Chairman of Imtech's Board of Management, is pleased about the new Imtech company: 'In addition to good returns, Aqua is a renowned multidisciplinary technical player with firm roots in the eastern UK. In economic terms, this is a rapidly growing market in which Imtech is already active. The acquisition brings Imtech, in line with its strategy, another step closer to securing a top-3 position in the technology market in the UK.' Profile of the Aqua Group The Aqua Group (established in 1968) is a renowned multidisciplinary technical service provider and maintenance provider in the fields of electrical engineering, mechanical engineering (air conditioning and climate control technology), ICT, data- and telecommunications, security and control in the growing market of utilities. With a staff of some 210 employees, annual revenue came to almost 40 million euro in 2006. From its location in Swavesy, in Cambridge, the Aqua Group counts among the stronger players in the region of east England, including the rapidly growing eastern part of the of Greater London region. The organisation consists of three business units: Mechanical and Electrical Services (multidisciplinary technical solutions), Planned Maintenance (technological management and maintenance) and Control (computerisation and building automation). With this combination of activities, the company offers complete technical service in the form of consultancy, engineering, implementation, maintenance management and maintenance services. Aqua is active in the market of offices, care, healthcare, education, recreation, apartment blocks (including luxury homes) and technological business-to-business services. This broad scope of activities enables the company to adopt a flexible stance in relation to changing market conditions, thus making a positive contribution to continuity. The company has some 80 regular larger clients for which Aqua has been active for years. More than ninety percent of the activities fall under recurring business, therefore resulting in a rapid increase in the scope of maintenance and control activities. Prominent clients include the Imperial War Museum in Duxford, the University of Cambridge, Epping Forest College and pharmaceutical UEA Zicer. Aqua distinguishes itself by its awards which include: British Safety Council National Award for 9 consecutive years and the H+V news Heating Ventilation and Air-conditioning Constructor of the Year award. Strategy The acquisition of the Aqua Group fits in well with Imtech's growth strategy. Imtech enjoys a leading market position in Belgium, Germany, the Netherlands, Luxembourg, Spain, Eastern Europe and the UK. In the UK Imtech strives towards the strategic reinforcement of its market position. Imtech is currently active in the UK in the fields of: * multidisciplinary technical service provision (electrical engineering, instrumentation, mechanical engineering, data- and telecommunication, control and automation) in Southeast England (southern and central parts of the Greater London area) and the region around Nottingham and in West Yorkshire, near Leeds; * complete technical solutions on the inframarket, in particular in the market of water- and wastewater purification (national top-5 player); * hi-tech solutions in the field of mobility: intelligent transport systems, dynamic traffic management, traffic safety and enforcement, as well as priority systems and dynamic public transport information for travellers across the whole of the UK and Ireland. Imtech is also active in the UK in the field of maritime technology via its maritime division, by means of the orders for the Royal Navy, and in the field of fire protection, parking technology and telecommunications. Imtech has a total of more than 25 branches the UK. With the acquisition of Aqua Imtech passes the milestone of 300 million euro in revenues in the UK with a broad portfolio of activities. Synergy The acquisition means a significant increase in the geographical range of activities. The entire southern region of the UK is now largely covered with respect to the market for multidisciplinary service provision. This region in particular is where the heart of Britain's healthy economy is situated and where the demand for complete technological solutions is seeing a rapid boom. Imtech continues to carry out increasingly large-scale multidisciplinary projects for a growing and broad spectrum of mainly regular clients. Aqua's activities fit in seamlessly with those of Imtech in general (electrical engineering, ICT and mechanical engineering) and those of the current British Imtech companies (Imtech Technical Services comprising the Meica Group acquired in 2003 and Goodmarriott & Hursthouse acquired in 2005, and the recently acquired Peek Traffic) in particular. With the acquisition Imtech realises its strategy to rank among the leading players on the market of multidisciplinary service provision and its current competitive position is significantly strengthened. Collaboration between all of the Imtech companies in the UK leads to a broader market penetration, greater innovation, lower overhead costs and greater management potential. Imtech will also become appealing as a party to work for in the UK labour market. Judging by the recent developments surrounding the acquisitions of the Meica Group and Goodmarriott & Hursthouse, and the recently acquired Peek Traffic, Aqua is likely to see a future characterised by healthy growth under the financially strong wing of Imtech. Continuity After acquisition the current management will be retained for a number of years for the sake of continuity. Further information Imtech N.V. M.E.J. (Mark) Salomons Company Secretary Telephone: +31 (0)182 54 35 14 E-mail: mark.salomons@imtech.eu www.imtech.eu Imtech Profile Imtech N.V. is a European technical services provider in the fields of electrical engineering, ICT (information and communication technology) and mechanical engineering. With approximately 16,000 employees, Imtech realises annual revenue of almost ¤3 billion. Imtech holds strong positions in the buildings, industry, infrastructure and telecom markets in Belgium, Germany, Luxembourg, the Netherlands, Eastern Europe, Spain and the UK and in the global maritime market. Imtech provides services to a total of 12,000 clients. Imtech offers added value in the form of integrated and multidisciplinary total solutions that lead to improved operating processes and higher yields for clients and their clients in return. Imtech also provides solutions that contribute to a sustainable, liveable society, for example in the field of energy, mobility, safety and the environment. Imtech shares are listed on the Euronext Stock Exchange (Amsterdam), where Imtech is included in the Amsterdam SmallCap Index (AScX) and the Next 150 index.


 

BOSTON, April 30, 2007 (PRIME NEWSWIRE) -- NewStar Financial, Inc. (Nasdaq:NEWS) announced today an update to the timing of its release of first quarter 2007 results and the schedule of its earnings call. NewStar will report results for the first quarter of 2007 on Thursday, May 3, 2007 after the markets close followed by a webcast/conference call to discuss the results at 5:00 pm Eastern Standard Time. The conference call was originally scheduled to take place at 10:00am (EST). All interested parties are invited to participate via telephone or webcast, which will be hosted through the Investor Relations section of our website at www.newstarfin.com. Please visit the website to register for the webcast and test your connection prior to the call. You can also access the conference call by dialing (800) 765-0709 approximately 5-10 minutes prior to the call. International callers should dial (913) 981-5564. All callers should reference "NewStar Financial Inc." For convenience, an archived replay of the call will be available through May 10, 2007 by dialing (888) 203-1112. International callers should call (719) 457-0820. For all replays, please use the passcode # 3471739. The audio replay will also be available through the Investor Relations section of our website at www.newstarfin.com. About NewStar Financial: NewStar Financial is a specialized commercial finance company focused principally on meeting the complex financing needs of customers in the middle market through our corporate, commercial real estate, and structured products groups. Our senior banking teams call directly on customers to provide advice and finance a range of strategic transactions that may require some combination of senior secured, second lien and mezzanine financing. NewStar typically works with customers with financing needs of up to $150 million and cash flow as low as $5 million. We target 'hold' positions of up to $35 million, but may also underwrite or arrange transactions up to $100 million for syndications to other lenders. We are headquartered in Boston MA, with regional offices in Darien CT, Chicago IL, San Francisco CA, San Diego CA, and Charleston SC. In December of 2006, NewStar completed an Initial Public Offering. The Company's shares trade on the NASDAQ under the ticker symbol, NEWS. Please visit our website at www.newstarfin.com for more detailed transaction and contact information. CONTACT: NewStar Financial Robert K. Brown 500 Boylston Street, Suite 1600 Boston, MA 02116 617.848.2558 Fax: 617.848.4399 rbrown@newstarfin.com


 

Company acquires Payment Solutions Company NEW YORK, NY, April 30, 2007, Great West Gold, Inc. (PINKSHEETS: GWGO) has acquired the Unitrust Capital S.A. Group, subject to the completion of certain legal formalities, the company being engaged in the issue of and the marketing of prepaid debit and credit cards. The Company is also engaged in various payment solution enterprises. Great West Gold, Inc. will be changing its name to that of Fortress Financial Group, Inc. with immediate effect and will be obtaining a new CUSIP Number and Trading Symbol. The mining exploration companies controlled by Great West Gold, Inc. will remain as Company assets until they are distributed to stockholders, in full. It is intended that these assets be placed in quoted companies under independent and experienced mining management teams. The rationale for this transaction was to create value for stockholders and as announced on previous occasions that the Company was seeking to acquire a company in a different Industry Sector. The Company will now be appointing a new Auditor, this is a condition of the acquisition of the Unitrust Capital S.A. Group. This will result in outstanding filings being brought up to date. The Company is discussing changes to its share capital structure with the stockholders of Unitrust Capital S.A. and will be announcing its decision shortly. About Great West Gold, Inc. Great West Gold, Inc., www.greatwestgold.com, a gold mining exploration stage company, engaged in the acquisition and exploration of mining properties in the United States. The Company has Gold assets through its holdings in "Bouse", "Mockingbird", "Ambassador", "Yaba", "Golden Eagle", "Bonanza", "Storm Cloud", ""Starlight", "Venezia", "Federal", "Buffalo Lime Cap", "Red Cloud", "South Copperstone" and "Gladstone Lookout" Gold Mining Projects. The Company's Copper assets are "Copper Mountain", "Swansea", "Tip Top" and "Mineral Mountain". The Company holds five of these Mining Assets through its 51% holding in Bouse Mining Holdings plc, Copperstone Mining Holdings plc, Ambassador Gold Holdings plc, and Golden Eagle Mining Holdings plc and in Sentinel Resource Holdings plc. The other Mining Exploration Projects are 100% controlled by the Company. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC. Contact:- Great West Gold, Inc. investor@greatwestgold.com Tel : + 44 845 127 4051


 

- GENEART granted German patent for: "Method for carrying out the selective evolution of proteins in vitro" - Comparable international patent application is currently pending for Europe and North America - The patent is vital to the completion of the BMBF- funded network project for the evolution of proteins Regensburg, 30th April 2007 - GENEART AG, the world's leading specialist in the production and optimization of synthetic genes, announced today that a patent for the directed evolution of proteins has been granted by the German Patent and Trademark Office ("Deutsches Patent- und Markenamt"). A comparable patent application has been submitted in the PCT phase in several countries throughout Europe and Northern America. The patent No. DE102005037351 forms an important part of a new technology platform, which is used to significantly improve the efficacy and activity of protein-based therapeutics, vaccines and industrial enzymes. This new technology is comprised of a recursive one-step procedure. In one step, protein variants are continuously synthesized and at the same time screened for improved characteristics. Through this new methodology, GENEART endeavours to yield a large pool of the target protein variants in a shorter time frame. Thus, the one-step method significantly increases the probability of finding a superior fit for the desired variant activity / affinity when compared with the scope of prior conventional multi-step techniques. The market for these services grows steadily. Today, over $3 billion per year is spent in the U.S. solely for the identification of clinically relevant protein-based therapeutics; and this only covers protein identifications via conventional multi-step procedures in preclinical drug development. This R&D project will open the market for GENEART in the medium term. Successful completion of this project will provide GENEART with the foundation for expanded service offerings in the Gene Evolution sector. The added services will build on newly established gene variants and libraries and encompass protein synthesis and screening. Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results. For further inquiries, please contact: Bernd Merkl Frank Ostermair GENEART AG Haubrok Investor Relations GmbH Josef-Engert-Str. 11 Maximilianstraße 45 D-93053 Regensburg 80538 München Tel.: +49-(0)941-942 76 - 38 Tel: +49-(0)89-21027-204 Fax: +49-(0)941-942 76 - 11 Fax: +49-(0)89-21027-298 ir@geneart.com f.ostermair@haubrok.de www.geneart.com About GENEART AG Founded in 1999, GENEART today is the globally leading specialists providing optimized gene solutions to research institutions as well as the pharma, biotech and chemical industries. GENEART offers integrated product systems based on gene synthesis for developing innovative drugs, in particular DNA- and protein-based therapeutics and vaccines, as well as for identifying improved industrial enzymes. The service portfolio ranges from the manufacturing of optimized synthetic genes in accordance with DIN EN ISO 9001:2000 and the generation of gene libraries in combinatorial biology, to the production and development of DNA-based drugs. GENEART, currently a team of more than 100 employees in Regensburg and the subsidiary in Toronto/Canada, reached break even in 2005 and is listed on the German Stock Exchange, Frankfurt, since May 2006.


 

Link to photos of Lárus Welding, new CEO, Glitnir Picture 1 Reykjavik/Oslo, 30 April 2007 - Lárus Welding has been appointed CEO of Glitnir, after Bjarni Ármannsson, who has served as the bank's CEO for the past 10 years, stepped down today. Welding has been Managing Director for Landsbanki's London Branch since 2003,. He started his career in Glitnir's (then Íslandsbanki's) Corporate Banking division in 1999. Welding takes on responsibility for Glitnir's 1,900 employee strong organisation, with offices in 10 countries. At the end of first quarter 2007, Glitnir had a market capitalisation of EUR 4.5 billion and EUR 25.3 billion in total assets. Over the next few days, Welding and Ármannsson will visit many of Glitnir's locations to meet staff, rating agencies, analysts and media. "Under Bjarni Ármannsson's decade at the helm of Glitnir, the bank has been renowned for bold leadership and a fantastic track record in shareholder value development. I feel extremely proud and honoured to be asked to take on the position as Glitnir's new CEO," said Lárus Welding. Welding said his vision for the bank is to continue building on its strong expertise in the home markets, Iceland and Norway; to further consolidate Glitnir's position in the Nordic region and the UK in capital markets, asset management, investment banking and banking operations; and to develop Glitnir's Luxembourg-based private banking operations. "Glitnir has developed well and is fast turning into a strong brand in the markets where we operate. In my opinion, the bank's core values - fast, smart and thorough - pinpoint exactly what it takes to succeed in today's marketplace. Glitnir's employees are known for their professionalism and dedication, and I look forward to being part of their strong team," commented Welding. Welding stated his support to Glitnir's niche segment strategy: "Glitnir's unique global strategy in the industry segments seafood/food, offshore service vessels and renewable/geothermal energy is a key strength for the bank in very competitive European and global markets. I hope my experience from the vital UK market will contribute to further consolidating our strong operation and position in London. With the planned opening of an office in New York this autumn, Glitnir has become a truly global operation," said Welding. Since Glitnir started expanding abroad in 2001, the group has built a strong network of subsidiaries in Norway, Sweden, Denmark and Finland, as well as banks, branches and offices in Luxembourg, London, Moscow, Shanghai and Halifax. "Glitnir's recent acquisitions of 68.1 percent of the shares in FIM, with operations in Finland and Russia, and 91 percent of Leimdörfer in Sweden and Finland, have been very well received by the market, and I look forward to making the integration of these new subsidiaries a success for shareholders, staff and customers," commented Welding. "Lárus Welding has a solid track record in banking, and the Board of Directors is extremely pleased that he has accepted the position as Glitnir's new CEO. Over the past years, Glitnir's shareholders have enjoyed a sustained period of strong performance, and we are confident that Lárus Welding will continue to grow shareholder value and broaden our international investor base in the years to come," commented Torsteinn M. Jónsson, who was elected new Chairman of Glitnir's Board of Directors today. Glitnir's new board of directors comprises Björn Ingi Sveinsson, Haukur Gudjónsson, Jón Sigurdsson, Katrín Pétursdóttir, Pétur Gudmundarson, Skarphedinn Berg Steinarsson and Torsteinn M. Jónsson (Chairman). Lárus Welding holds a degree in business administration from the University of Iceland. He is a licensed securities broker and a graduate in Corporate Finance from the UK Securities Institute. Welding joining Landsbanki in 2003 as General Manager for the Landsbanki London branch, with operations primarily in Corporate and Investment Banking. He previously worked for the accounting firm JHR ehf. (1997-1999), the Central Bank of Iceland (1998) and the Icelandic Investment Bank (FBA) hf. (1999-2003). FBA merged with Íslandsbanki, now Glitnir Bank. Lárus Welding is married and has two daughters. Bjarni Ármannsson, who steps down from his position as Glitnir's Chief Executive Officer today, has been with the bank and its predecessors since 1997. "I have enjoyed a fabulous 10 years as CEO. I am extremely proud to have been part of a team that has multiplied the bank's shareholder value more than 20-fold, and to have headed the bank through its successful transition from a local Icelandic bank to an international financial services provider. The Glitnir staff and culture have been a vital part of my life and will retain a place in my heart," said Bjarni Ármannsson. "I leave a bank that is progressing forward at full throttle, and I congratulate Lárus Welding on his position as Glitnir's new CEO. Lárus and I will work together to ensure a smooth transition and make this change a positive step forward for the bank. For further information, please contact: Thorsteinn M. Jónsson, Chairman, Glitnir, phone through +47-47 800 100 Lárus Welding, CEO of Glitnir, phone: + 354-440-4005 or through +47-47 800 100 Bjørn Richard Johansen, Managing Director, Corporate Communication, Glitnir, e-mail: brj@glitnir.no, mobile +47 47 800 100 For photos, please contact: akj@glitnir.no Presentation of Glitnir Bank's First Quarter Results + Glitnir's new CEO Lárus Welding Glitnir will host the following presentations and webcasts in relation to the publication of its first quarter results for 2007. Lárus Welding, Glitnir's new CEO will participate together with Bjarni Ármannsson. An English version of the presentation will be available on www.glitnirbank.com Presentation in London, UK - new location Bjarni Ármannsson, CEO, will present Glitnir's first quarter results for 2007 to shareholders and market participants on Tuesday, 1 May, at 4 p.m. at Great Eastern Hotel at 40 Liverpool Street, London EC2M 7QN. Lárus Welding, Glitnir's new CEO will participate together with Bjarni Ármannsson. Participants should register with Vala Pálsdóttir, Head of Investor Relations, by e-mail at ir@glitnir.is or by calling +354 440 4989. International telephone conference and web cast Glitnir will host a live presentation via webcast in English at 8.00 a.m. (10.00 a.m. CET), Wednesday 2 May. Lárus Welding, Glitnir's new CEO, will participate together with Bjarni Ármannsson. Bjarni will present the results and answer questions. Lárus will do the same. A live broadcast of the presentation can be accessed on Glitnir's web: www.glitnirbank.com You may also submit questions by telephone. Dial-in numbers are: UK + 44 (0) 208 817 9301 Norway + 47 231 629 47 Finland + 358 969 37 97 35 USA + 1 718 354 1226 Presentation in Reykjavík, Iceland Bjarni Ármannsson, CEO, will present Glitnir's first quarter results for 2007 to shareholders and market participants on Wednesday, 2 May, at 9.15 a.m. at Glitnir's headquarters at Kirkjusandur in Reykjavík. The house opens at 9 a.m. with breakfast for guests. Lárus Welding, Glitnir's new CEO will participate together with Bjarni Ármannsson. Lunch presentation in New York, USA Bjarni Ármannsson, CEO, will present Glitnir's first quarter results for 2007 on Tuesday 15 May, at 12 p.m. at 875 Third Avenue (btw 52nd & 53rd), 4th floor Stockholm Conference Room, New York, NY 10022. Lárus Welding, Glitnir's new CEO will participate together with Bjarni Ármannsson. Participants should register with Vala Pálsdóttir, Head of Investor Relations, by e-mail at ir@glitnir.is or call +354 440 4989. Media interviews bookings To book media interviews, please contact Bjørn Richard Johansen, Managing Director, Corporate Communication, by sending an e-mail message to brj@glitnir.no or by calling mobile +47 47 800 100. About Glitnir The financial group Glitnir offers universal banking and is a leading niche player in three global segments; seafood/food, sustainable energy, and offshore services vessels. Glitnir considers Iceland and Norway its home markets. Services include retail, corporate and investment banking, stock trade and capital management. Glitnir is the sole owner of a bank in Luxembourg (Glitnir Bank Luxembourg S.A) and banks and financial services companies in Norway (BNbank, Glitnir Bank ASA, Glitnir Securities, Glitnir Factoring and Glitnir Property Holding (with partners). Glitnir's subsidiary BNbank owns 45 percent of the shares in Norsk Privatøkonomi ASA, an independent financial advisory company with 14 branches in key areas of Norway). In Sweden, Glitnir owns the leading Swedish brokerage firm Glitnir AB. Glitnir Property Group recently acquired 91 % of the shares in Leimdörfer AB, the leading commercial real estate advisor in Sweden. The group also recently acquired 68.1 percent of the shares in the leading Finnish asset management company FIM, with operations around Finland and in Stockholm and Moscow. (Glitnir has made a tender offer for all shares in FIM). Glitnir operates branches in London and Copenhagen. The group has representative offices in Halifax, Canada and Shanghai, China, and plans to open an office in New York in 2007. Glitnir is listed on the Icelandic Stock Exchange. For more information: www.glitnirbank.com


 

We invite shareholders, analysts and other interested to a presentation of our 2007 1st quarter financials. The presentation will be held at Shippingklubben, Haakon VII gate 1, Friday 4 May 2007 at 11:00. A light lunch will be served. Deep Sea Supply Plc


 

As the successor of Hans Nilsson, Stulz assumes this new role on May 1st, 2007. Urs Stulz, currently Director Cargo Switzerland Swiss WorldCargo, has been selected as successor of Hans Nilsson as Managing Director Cargo Europe. Nilsson will be leaving the company to take up a new challenge externally, after building up a strong team and reaching the ambitious targets set for Swiss WorldCargo in the European market. Urs Stulz has a solid track record of achievements in various commercial functions at Swisscargo and, since 2002, at Swiss WorldCargo. In his current position, he has proved himself to be a decisive and responsible leader, increasing the Swiss WorldCargo share in the home market, and setting new record revenues in recent months thanks to improved yield and volume. This exemplary record of achievements includes the professional management of the complex relationships with the forwarders associations, the shippers' councils and the key top shippers, as well as the various authorities and suppliers. As Managing Director Cargo Europe, Urs Stulz will be charged with ensuring the business unit's further expansion and focused development. The process to select a successor as Director Cargo Switzerland and to ensure a smooth transition is underway and further announcements will follow shortly. Swiss WorldCargo is the air freight division of Swiss International Air Lines AG. With a global network of more than 150 destinations in over 80 countries and a wide range of services offered, Swiss WorldCargo generates true added value for its customers and makes a substantial contribution to the earnings power of Swiss International Air Lines Ltd. Note to editors: For further information about Swiss WorldCargo, pictures and interview requests please contact: Bernd Maresch Senior Manager Marketing PR & Strategy bernd.maresch@swiss.com Phone +41 44 564 50 50 Please visit www.swissworldcargo.com The media release can be downloaded from the following link:


 


 

2007 2006 + / - Sales (TEUR) 7,073 4,652 51.9% EBITDA (TEUR) 1,708 1,152 48.3% EBIT (TEUR) 1,234 773 59.6% EBT* (TEUR) 937 711 31.8% Net Result* (TEUR) 623 498 25.1% Earnings per Share* (EUR) 0.16 0.13 25.1% *after profit distribution to third party shareholders Both Deckert Oberflächentechnik and Impreglon UK which were included in the consolidated result for the first time, contributed to the excellent numbers of the first quarter 2007. While the Lüneburg facility was effected by one-time charges caused by the plant expansion which will have a positive effect in the second half of 2007, all other production sites contributed to the outstanding numbers. Consolidated sales rose by 51.9 % and net results from operations (EBIT) increased by 59.6 % from TEUR 773 to TEUR 1,234. Management is optimistic that the positive development will continue throughout 2007 with added potential from plant acquisitions in the field of surface technology. IMPREGLON AG Hohenhorststraße 1 21337 Lüneburg Tel. 04131 / 2260091 Fax 04131 / 882-250 investorrelations@impreglon.de www.impreglon.de --- End of Message --- Impreglon AG Hohenhorststraße 1 Lüneburg Germany WKN: A0BLCV; ISIN: DE000A0BLCV5; Listed: Entry Standard in Frankfurter Wertpapierbörse;


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | Tisbury Capital Management | | | LLP | |--------------------------------------+----------------------------| | Company dealt in | Bodycote International Plc | |--------------------------------------+----------------------------| | Class of relevant security to which | | | the dealings being disclosed relate | 10p ordinary | | (Note 2) | | |--------------------------------------+----------------------------| | Date of dealing | 27 April 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |------------------------------------+---------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |------------------------------------+--------+------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |------------------------------------+--------+------+--------+-----| | (2) Derivatives (other than | | | | | | options) | 0 | 0.00 | | | | | | | | | |------------------------------------+--------+------+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |------------------------------------+--------+------+--------+-----| | Total | 0 | 0.00 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per | | name, | (Note 6) | (Note 7) | unit (Note 5) | | e.g. CFD | | | | |----------+------------+---------------------------+---------------| | CFD | Sell | 1,250,000 | 310.7000 GBp | |----------+------------+---------------------------+---------------| | CFD | Sell | 1,250,000 | 312.8000 GBp | |----------+------------+---------------------------+---------------| | CFD | Sell | 670,000 | 316.3900 GBp | |----------+------------+---------------------------+---------------| | CFD | Sell | 584,165 | 311.9825 GBp | |----------+------------+---------------------------+---------------| | CFD | Sell | 2,000,000 | 321.3700 GBp | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ | Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | | name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| | option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | None | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 30/04/2007 | |------------------------------------------------+------------------| | Contact name | Julien Naginski | |------------------------------------------------+------------------| | Telephone number | +44 20 7070 9642 | |------------------------------------------------+------------------| | If a connected EFM, name of offeree/offeror | | | with which connected | | |------------------------------------------------+------------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Clavis Pharma ASA invites you to attend the company's 2007 Capital Markets Day, on 22 May 2007 from 08:30 until 12:00 CET, followed by lunch. The event takes place at Grand Hotel, Oslo, Norway. All of Clavis Pharma's management will be present. For registration please send an email to gunnar.manum@clavispharma.com Gunnar Manum Chief Financial Officer Clavis Pharma ASA Tlf: +47 24 11 09 50 About Clavis Pharma Clavis Pharma ASA is a public oncology focused pharmaceutical company leveraging its proprietary Lipid Vector Technology (LVT) platform to create New Chemical Entities (NCEs) by significantly improving approved drugs. The improvement is achieved by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration and, in many cases, additional modes of action. Clavis Pharma intends to develop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter strategic partnerships with established pharmaceutical or biotech companies. The company's product portfolio includes three new cancer drugs, of which the first ELACYT(TM) , is in clinical phase II, the second, CP-4126, is in clinical phase I, and the third is in the pre-clinical phase. Results indicate that ELACYT(TM) has a promising potential for several cancer indications within solid tumours and leukaemia. Clavis Pharma ASA is listed on the Oslo Stock Exchange (ticker: CLAVIS). Additional information on Clavis Pharma can be found at: www.clavispharma.com


 

Mountain View, Calif., USA - Nokia (NYSE:NOK) today announces two new IP security appliances, Nokia IP290 and Nokia IP690 security platforms, rolling out a scalable hardware platform design offering better IT investment protection and a greater choice of security software applications to address emerging threats to company networks and data. Nokia IP690 is the first new IP security appliance with a multi-core and multi-threading architecture optimized for performance and scalability, readying businesses for processor-intensive security applications. The new hardware design offers investment protection by extending product life from two years to an average of five years. Nokia hardware platforms purchased today are upgradeable when newer versions of the Nokia IPSO(TM) operating system are released, and Nokia IP690 is expandable through various interface cards and accelerated data path (ADP card) technologies. This expandable approach allows customers to retain their initial investment for longer periods of time by offering the flexibility to expand performance at their own pace. "Businesses today are looking to get as much mileage as possible from every IT dollar spent, but they simply cannot compromise on performance when it comes to protecting the security of the corporate network," said Tom Furlong, vice president, Security & Mobile Connectivity, Nokia. "By enabling our customers to boost the performance of their security appliance - when the time is right for them - we are giving them a way to protect their network while also protecting their IT investments." Nokia IP290 combines powerful network performance with a compact ¿ RU form factor, offering branch offices and extended enterprise sites a full-featured security appliance backed by Nokia global support. Expandable with an included empty PMC slot, Nokia IP290 ships with Nokia IPSO 4.2 and an updated architecture, making it a reliable platform for unified threat management (UTM) implementations. Nokia security appliances detect and block the increasingly sophisticated threats companies face as mobile device usage among workers expands, and as new network traffic patterns alter business security requirements. Nokia security solutions use deep packet inspection to uncover vulnerabilities and provide protection against application-level threats in the perimeter, core and data center. Nokia IP690 Nokia IP690 security platform is designed to meet the demanding price performance, multi-Gigabit throughput and port-density requirements of medium to large businesses and service providers. Nokia IP690 readies businesses for processor-intensive security applications by introducing multi-core and multi-threading architecture. Businesses planning to implement next generation security applications can take advantage of the native enhancements and expandability features of Nokia IP690 without costly 'forklift' upgrades. A compact 1RU (rack unit) security appliance, Nokia IP690 supports next generation ADP cards to accelerate firewall and VPN performance and delivers enhanced business continuity through features such as dual, hot-swappable power supplies and optional redundant hard disk drives. Nokia IP690 Firewall/VPN delivers up to 7 Gbps (Gigabit per second) of throughput performance and up to 16 Gigabit Ethernet ports to run Check Point® VPN-1®, Check Point Power and VPN-1 UTM suite of applications. Nokia IP690 Intrusion Prevention with Sourcefire delivers a 1 Gbps sensor and offers the unique combination of highest port density and performance in a single rack configuration. The solution is built on hardware optimized for security and offers the ease of use, reliability and rich feature set of the Nokia IPSO operating system. Nokia IP290 Nokia IP290 is a multi-purpose security platform ideal for small and branch offices, and extended enterprises that require robust, large-enterprise performance, simple remote management, and high reliability at a low total cost of ownership. Powerful yet cost-effective, the compact, ¿RU form factor design allows for side-by-side redundancy in a single 1RU pull-out tray providing a low-cost/high-availability solution with IP clustering and VRRP technologies (virtual router redundancy protocol). Nokia IP290 Firewall/VPN supports traditional firewall and next generation security applications such as Check Point VPN-1 UTM, which includes firewall, VPN, intrusion prevention, anti virus and URL filtering. Nokia IP290 Firewall combines market-leading Nokia hardware design and quality with market-leading Check Point software and the Nokia IPSO operating system for maximum security, high availability, reliability and manageability. Nokia IP290 Intrusion Prevention with Sourcefire, as part of the Nokia Intrusion Prevention (IPS) portfolio, ensures that whatever the performance requirements for a company's network, there is an intrusion prevention appliance to meet them. Nokia offers performance of 100Mbps, 250Mbps, 400Mbps and 1Gbps across the product range. Nokia IP290 also offers resellers and system integrators a lower point-of-entry for branching out beyond firewalls to deliver intrusion prevention systems. Pricing, Service and Support Nokia IP290 and Nokia IP690 are available now starting at $3,995USD and $29,995USD respectively and are backed by world-class Nokia First Call - Final Resolution global support and services. Channel partners can also take advantage of the Nokia FastTrack marketing program for added incentives on Nokia Intrusion Prevention. For more information about the new offerings and other business mobility solutions from Nokia, visit www.nokia.com/business. About Nokia Nokia is the world leader in mobility, driving the transformation and growth of the converging Internet and communications industries. Nokia makes a wide range of mobile devices and provides people with experiences in music, navigation, video, television, imaging, games and business mobility through these devices. Nokia also provides equipment, solutions and services for communications networks. Trademarks: All trademarks and registered trademarks are the property of their respective owners. Media Inquiries only: Nokia, Americas Communications Tel. +1 972 894 4573 Email: communication.corp@nokia.com Nokia, APAC Communications Tel. +65 6723 2323 Email: communications.apac@nokia.com Nokia Communications Tel. +358 7180 34900 Email: press.office@nokia.com Industry Analysts only: Nokia Industry Analyst Relations tel. +1 914 368 0511 Industry.analyst@nokia.com www.nokia.com --- End of Message --- NOKIA P.O. Box 226<br>FIN-00045 NOKIA GROUP Espoo WKN: 870737; ISIN: FI0009000681; Index: DJ STOXX Large 200, DJ STOXX 50; Listed: Nordic list (Large Cap) in THE HELSINKI STOCK EXCHANGE;


 

Wiesbaden/Munich, 30 April 2007 - The technology group The Linde Group has concluded the sale of BOC's Polish gases activities (BOC Gazy Sp. z o.o.) to Air Products and Chemicals, Inc. at a price of 370 million euro subject to certain adjustments. Following the receipt of unconditional approval from the European Commission and from the Polish Competition Authority, the transaction was completed today. BOC Gazy achieved sales of around 126 million euro and earnings before tax, interest, depreciation and amortisation (EBITDA) of around 38 million euro in the 2006 financial year. This divestiture was one of the antitrust conditions imposed by the European Commission arising from the acquisition of The BOC Group plc by Linde which became effective on 5 September 2006. The Linde Group is a world leading industrial gases and engineering company with more than 51,000 employees working in around 70 countries worldwide. Following the acquisition of The BOC Group, the company has gases and engineering sales of approximately 12 billion euro. The strategy of The Linde Group is geared towards earnings-based growth and focuses on the expansion of its international business with forward-looking products and services. For more information, please see The Linde Group online at http://www.linde.com For further information: Press Uwe Wolfinger Telephone: +49.89.35757-1320 Investor Relations Thomas Eisenlohr Telephone: +49.89.35757-1330


 

* Moma Titanium Minerals Mine now in production * Strong market demand and price growth for minerals * Expansion to annual production of 1.2 million tonnes of ilmenite plus co-products by end 2009 * Active uranium exploration programme in Mozambique 30 April 2007 Chairman's Statement Dear Shareholder, I was delighted to announce on 25th April 2007 that Kenmare had commenced mining operations at its Moma Titanium Minerals Mine and had begun to stockpile heavy minerals concentrate for further processing. While we have only been operating for a short while, the plant has been performing well and we are now looking forward to a successful ramp-up of the mine and processing plant to full production over the coming months. Demand for our products is buoyant and the Company is already developing plans for a phased expansion. Following a recent drilling programme, the mineral resources at Moma have increased by over 60%. This confirms Moma's position as one of the premier deposits of titanium minerals and zircon in the world, and provides great opportunity for Kenmare's continued growth. Kenmare expects to ramp-up initially to annual production levels of 800,000 tonnes of ilmenite (the main titanium-bearing mineral), 56,000 tonnes of zircon (a zirconium mineral used in the ceramics industry) and 21,000 tonnes of rutile (a titanium dioxide mineral). Product Market We continue to experience strong market demand for Moma minerals and have entered into a number of heads of agreements with new customers. These are presently being converted into full sales agreements, which are expected to be concluded shortly. The titanium feedstock market continues to perform well, driven by strong demand from the end-use markets, the most important of which are titanium dioxide (TiO2) pigment and titanium metal. Pigment demand growth rates of over 3% are predicted to be sustainable into the future. This growth, combined with the depletion of existing mines which are coming to the end of their resource lives, will give Moma plenty of scope for expansion. Demand for feedstock from the smaller titanium metal market is also very robust with production growth of over 20% in 2006. This strong demand from end use markets resulted in a tight market for titanium feedstocks in 2006. Despite some new sources of supply entering the market in 2007, the market for our products is expected to remain in tight supply, which will continue to put upward pressure on prices. The zircon market performed strongly in 2006 and prices increased by around 20% over the previous year. Operations The 170 km overhead power transmission line was successfully energised in January 2007 and cold commissioning of the two mining dredges followed immediately. The commissioning process was subsequently extended to the floating wet concentrator plant and, following the resolution of snags, the plant was successfully tested and a taking-over certificate for the mining component was issued by Kenmare. This represents the first step of a phased handover of the works under a contract amendment between Kenmare and the contractor in which all changes to the original contract were agreed. Mining is now taking place using one dredge on a 24 hour basis. The Kenmare operations team are continuing to fine-tune the systems for maximum efficiency. As the mining pond is widened and deepened over the coming months, the second dredge will be brought into production. Once the mineral separation plant is taken over from the contractor, the heavy minerals concentrate will be further separated into the final products prior to export. The accommodation village, roads, product storage warehouse, overland conveyor and export jetty are all substantially complete. Construction of the self-propelled, 4,000 tonne capacity product transportation barge has been completed in Singapore and sea-trials have been carried out. Drilling activities during the past year continued to examine the numerous deposits within our Moma licences. This has yielded excellent results at the Nataka deposit, where the inferred resource has increased from 49 million tonnes to 110 million tonnes of contained ilmenite, with associated increases in co-products. These results have been independently verified by SRK Consulting. This increases the total resource under licence to Kenmare by more than 60%, from 101 million tonnes to 163 million tonnes of contained ilmenite, with associated increases in co-products to 12.4 million tonnes of zircon and 3.6 million tonnes of rutile. As the Nataka orebody remains open laterally and at depth, further increased tonnage is probable. Social Responsibility The Kenmare Moma Development Association (KMAD), a not-for-profit organisation, is continuing its activities in the area surrounding the mine. The key objective of KMAD is to use the presence of the mine to generate long term sustainable opportunities for people in the local communities. Working with local and international partners, initiatives during the past year included a HIV/AIDS awareness programme, a savings and credit programme, a partnership with Worldwide Wildlife Fund on creating and promoting cooperatives of local food producers and other initiatives, and the construction of a new primary school in Topuito, a local village. The local soccer field has been upgraded and Kenmare's operations staff has pitched in very enthusiastically and have voluntarily organised sporting events. Their support in this area is most appreciated. Exploration Kenmare also has an active uranium exploration programme underway in northern Mozambique. We have been granted licences over 1,400 km2 to explore in both the Tete and Niassa provinces. Further licence applications covering 900 km2 have been submitted. Initial field work has involved ground surveying using gamma radiation meters followed by trenching and sampling. Uranium mineralisation has already been identified in both Karoo sedimentary and granitic rocks. As a result, we have increased the size of our exploration team and look forward to reporting to shareholders on our progress. Financial Results During 2006, we report a loss of US$4.3 million, arising primarily from foreign exchange losses on Euro-denominated debt and Kenmare's corporate operating costs, net of interest earned. Construction costs capitalised during the year amounted to US$78 million while deferred project development costs and mineral exploration costs deferred increased by US$36.5 million. Bank loans amounted to US$266.1 million at the year end. Board Appointment Tony Lowrie has joined the Board of Directors and it is my pleasure to recommend him for election at the Annual General Meeting. Tony commands great respect in the equity markets and brings a wealth of experience which will assist Kenmare's continued development. Now that we have commenced mining we are pushing for a rapid start up of the minerals separation plant and the first shipments to customers. We are in the fortunate position that the market for our products is strong with positive price trends throughout. This, together with the strong indications of support we have received from our customers, gives us the necessary comfort to push rapidly into a major capacity expansion which we hope will bring us to production of 1.2 million tonnes of ilmenite plus co-products by the end of 2009. We in Kenmare are extremely proud of what has been achieved so far. I would like to take this opportunity to thank everyone who has worked so hard to reach this point. I would also like to thank you, our shareholders, for your support and the Government of Mozambique for its support of Kenmare. Charles Carvill Chairman For more information: Kenmare Resources plc Michael Carvill, Managing Director Tel: + 353 1 671 0411 Mob: + 353 87 674 0110 Tony McCluskey, Financial Director Tel: + 353 1 671 0411 Mob: + 353 87 674 0346 Conduit PR Ltd Leesa Peters Tel: + 44 (0) 207 429 6600 Mob: + 44 (0) 781 215 9885 Murray Consultants Ltd Elizabeth Headon Tel: + 353 1 498 0300 Mob: + 353 87 989 7234 www.kenmareresources.com KENMARE RESOURCES PLC PRELIMINARY UNAUDITED RESULTS GROUP INCOME STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2006 2006 2005 US$'000 US$'000 Revenue - - Operating (expenses)/gains (7,255) 2,861 Operating (loss)/profit (7,255) 2,861 Finance income 2,925 1,838 (Loss)/profit before tax (4,330) 4,699 Income tax expense - - (Loss)/profit for the year (4,330) 4,699 Attributable to Equity holders (4,330) 4,699 (Loss)/earnings per share: Basic (0.63c) 0.72c (Loss)/earnings per share: Diluted (0.63c) 0.61c KENMARE RESOURCES PLC PRELIMINARY UNAUDITED RESULTS GROUP BALANCE SHEET AS AT 31 DECEMBER 2006 2006 2005 US$'000 US$'000 Assets Non-Current Assets Deferred Development Expenditure 140,751 104,228 Construction in Progress 265,718 187,721 406,469 291,949 Current Assets Receivables 810 1,787 Cash and cash equivalents 87,230 75,520 88,040 77,307 Total Assets 494,509 369,256 Equity Capital and reserves attributable to the Company's equity holders Called Up Share Capital 55,940 54,847 Share Premium 108,512 105,713 Retained Earnings (21,504) (17,174) Other Reserves 41,101 36,373 Total Equity 184,049 179,759 Liabilities Non-Current Liabilities Bank loans 266,152 164,725 Accrued liabilities and other loans - 8,616 Long-term provision 2,365 - 268,517 173,341 Current Liabilities Accrued liabilities and other loans 41,943 16,156 Total Liabilities 310,460 189,497 Total Equity and Liabilities 494,509 369,256 KENMARE RESOURCES PLC PRELIMINARY UNAUDITED RESULTS GROUP CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2006 2006 2005 US$'000 US$'000 Operating Activities Operating (loss)/profit for the year (7,255) 2,861 Adjustment for: Foreign exchange movement 1,972 2,095 Share-based payment expense 473 166 Operating cashflows (4,810) 5,122 Decrease/(increase) in receivables 977 (230) Increase in accrued liabilities and other loans 17,171 15,045 Increase in provisions 2,365 - Net cash from operating activities 15,703 19,937 Investing Activities Interest received 2,925 1,838 Addition to Deferred Development Expenditure (36,523) (42,566) Addition to Construction in Progress (77,997) (113,738) Net cash used in investing activities (111,595) (154,466) Financing Activities Issue of Share Capital 3,892 8,047 Share Option Reserve 4,255 1,495 Increase in debt 101,427 109,751 Net cash from financing activities 109,574 119,293 Net increase/(decrease) in cash and cash 13,682 (15,236) equivalents Cash and cash equivalents at beginning of the 75,520 92,851 year Effect of exchange rate changes on cash and cash (1,972) (2,095) equivalents Cash and cash equivalents at the end of the year 87,230 75,520 Additions to Deferred Development Expenditure include loan interest capitalised of US$17,971,000 (2005: US$8,118,000). NOTES TO THE PRELIMINARY RESULTS Note 1. Basis of Accounting and Preparation of Financial Information The preliminary results have been prepared in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union. The financial statements are prepared in US Dollars under the historical cost convention. The financial information presented above does not constitute statutory accounts within the meaning of the Companies Acts, 1963 to 2006. An audit report has not yet been issued on the accounts for the year ended 31 December 2006, nor have they been delivered to the Registrar of Companies. The statutory accounts for the year ended 31 December 2005 prepared under IFRS upon which the auditors have issued an unqualified opinion, have been filed with the Registrar of Companies. Note 2. Loss per share The calculation of the loss and fully diluted loss per share is based on the loss after taxation of US$4,330,000 (2005: profit US$4,699,000) and the weighted average number of shares in issue during 2006 of 679,602,594 (2005: 656,428,548 shares). The loss per share and the fully diluted loss per share are the same in 2006, as the effect of the outstanding share options is anti-dilutive. Note 3. Deferred Development Expenditure Analysed by Geographical Area Mozambique Mozambique Ireland Total Moma Titanium Uranium Minerals Project Project US$'000 US$'000 US$'000 US$'000 Opening Balance 104,192 - 36 104,228 Additions 35,801 710 12 36,523 Closing Balance 139,993 710 48 140,751 Additions include loan interest capitalised of US$17,971,000 (2005:US$8,118,000). Loan interest is net of deposit interest earned on the temporary deposit of loan balances. The recovery of deferred development expenditure is dependent upon the successful development of the Projects, which in turn is dependent on the continued availability of adequate funding for the Projects. The Directors are satisfied that deferred expenditure is worth not less than cost less any amounts written off and that the Moma Titanium Minerals Project has the potential to achieve planned mine production and positive cash flows. Note 4. Construction in Progress 2006 2005 US$'000 US$'000 Opening Balance 187,721 73,983 Additions 77,997 113,738 Closing Balance 265,718 187,721 Construction in Progress represents expenditure under a construction contract for the engineering, procurement, building, commissioning and transfer of facilities at the Moma Project in Mozambique. This contract was entered into on 7 April 2004. The Contractor is a joint venture formed for this project, between subsidiaries of Multiplex Limited and Bateman B.V.. Multiplex is a large contracting group based in Australia with operations stretching around the globe and specialises in large complex construction projects. Bateman is an international engineering group with specific mineral sands experience and experience of working in Mozambique. The recovery of Construction in Progress is dependent upon the successful development of the Moma Titanium Minerals Project, which in turn is dependent on the continued availability of adequate funding for the Project. The Directors are satisfied that Construction in Progress is worth not less than cost less any amounts written off and that the Moma Titanium Minerals Project has the potential to achieve planned mine production and positive cash flows. Note 5. Capital Commitments Group 2006 2005 US$'000 US$'000 Construction contract 67,440 107,428 The construction contract with the Multiplex-Bateman Joint Venture was amended whereby the handover of the Moma Titanium Minerals Project works will take place in sections and all changes to the original contract price were agreed. Based on this contract amendment, the total amount payable to the Contractor is estimated to be US$265 million, net of projected applicable delay penalties, of which US$67.4 million was outstanding at the year end. The Company has access to sufficient sources of funding and cash in hand to cover these capital commitments. Note 6. 2006 Annual Report and Accounts The Annual Report and Accounts will be posted to shareholders in due course. ---END OF MESSAGE---


 

Ahlstrom Corporation STOCK EXCHANGE RELEASE 30.4.2007 Ahlstrom, a global leader in high performance fiber-based materials, today announced the completion of the acquisition of Orlandi's spunlace nonwovens business in Italy. The acquisition, initially announced in February 2007, will further strengthen Ahlstrom's position one as of the leading producers of nonwoven roll goods for wipes globally. The acquisition price is approximately EUR 60 million and the transaction is expected to be EPS enhancing from 2007. The acquired business includes two plants with four production lines in Cressa and Gallarate in Northern Italy, close to Milan. The plants employ approximately 120 people. Orlandi's business expands Ahlstrom's technology portfolio with airlace technology which is used to manufacture pulp-containing wiping fabrics. The acquired business will generate annualized net sales of approximately EUR 65 million in 2007. Orlandi is currently one of the leading wiping fabrics producers in Europe, serving the personal, household and industrial wipes markets. In addition, the acquired business manufactures medical and industrial spunlace fabrics. "The deal is in line with our strategy to serve our customers globally. Currently, Ahlstrom has a strong presence in the wipes markets in the USA. This acquisition both expands our product offering of pulp-containing wiping fabrics and allows us to enter the growing European wipes markets", says Jukka Moisio, President and CEO of Ahlstrom. On March 30, 2007 Ahlstrom announced the acquisition of the consumer wipes business of Fiberweb plc with three plants in Europe and one in the USA. Following the deal, Ahlstrom will be the leading wiping fabrics producer in the world. The company anticipates to close the acquisition of Fiberweb's consumer wipes business during the second quarter of 2007. Ahlstrom is also expanding its wiping fabrics production to South America by investing in a new production line in Brazil. The new line is expected to be operational in early 2008. For further information, please contact: Jukka Moisio, President and CEO, Ahlstrom Corporation, tel. +358 10 888 4700 Claudio Ermondi, Senior Vice President, Nonwovens, tel. +39 348 8600 9883 Distribution: Helsinki Stock Exchange Main media www.ahlstrom.com Ahlstrom in brief Ahlstrom is a global leader in the development, manufacture and marketing of high performance fiber-based materials. Nonwovens and specialty papers, made by Ahlstrom, are used in a large variety of everyday products, e.g. in filters, wipes, flooring, labels, and tapes. The company has a strong market position in several business areas in which it operates, built upon the company's unique fiber expertise and innovative approach. Ahlstrom's 5,700 employees serve customers via sales offices and production facilities in more than 20 countries on six continents. In 2006, Ahlstrom's net sales amounted to EUR 1.6 billion. Ahlstrom's share is listed on the Helsinki Stock change. The company website is www.ahlstrom.com.


 

Glitnir publishes its report for the first quarter 2007 on Wednesday, May 2 before the market opens. Glitnir will host a live presentation of the report via webcasted international telephone conference at 10.00 a m CET , Wednesday 2 May. The presentation can be followed on the Internet at 10.00 am CET with comments on the report given by CEO, Bjarni Ármansson. The presentation will be in English. Please find invitation attached. Link: http://webcast.zoomvision.se/clients/glitnir/070502/


 
Ýmislegt
30. apríl 2007

Update

Focus on growth an risk diversification


 

Summary: Pharmexa-Epimmune, a wholly-owned US subsidiary of Pharmexa A/S, and Bavarian Nordic today announced the initiation of a Phase I trial testing of the two HIV vaccines EP1233 and MVA-BN Polytope in combination. Pharmexa-Epimmune and Bavarian Nordic today announced the initiation of a Phase I trial testing two HIV vaccines EP1233 and MVA-BN Polytope in combination. The clinical trial will be conducted by the HIV Vaccine Trials Network (HVTN) which is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The HVTN will enrol up to 108 uninfected volunteers in the US. Interim results are expected by the end of 2007. Marc Hertz, CEO of Pharmexa-Epimmune said: "This is an important milestone for Pharmexa as we continue our efforts to develop HIV vaccines in collaboration with the NIH. We are still searching for the best method to deliver epitopes in the HIV setting and this approach, DNA prime: MVA boost, is one of the most promising approaches in this field." The study vaccines were developed by a Pharmexa-led consortium through a contract with NIAID, which to date has provided more than USD 10.0 million to develop a broad HIV vaccine for worldwide use with a population coverage across all ethnic and racial populations. Pharmexa and Bavarian Nordic share the marketing rights for both vaccines. Hørsholm, April 30, 2007 Jakob Schmidt Chief Executive Officer Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558 Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 105 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX. Bavarian Nordic (CSE: BAVA) is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer. With operations in Denmark, Germany, the USA, and Singapore, Bavarian Nordic employs over 200 people. Bavarian Nordic's patented technology, MVA-BN®, is as been demonstrated in clinical studies, one of the world's safest, multivalent vaccine vectors for the development of vaccines against various infectious diseases such as smallpox, HIV/AIDS, as well as against breast and prostate cancer. Several MVA-BN®-based HIV and smallpox vaccines are in clinical Phase I and Phase II trials. Bavarian Nordic has ongoing development contracts with the US government to develop IMVAMUNE® as a safe third generation smallpox vaccine. Bavarian Nordic has supplied several other governments with smallpox vaccines. Bavarian Nordic's partners include Pharmexa, Impfstoffwerk Dessau-Tornau (IDT) and Vaccine Solutions in Australia. For more information please visit www.bavarian-nordic.com This study, known as HVTN 067, will be conducted at sites in Nashville, Rochester and San Francisco. The HVTN, which is funded and supported through a cooperative agreement with the National Institute of Allergy and Infectious Disease (NIAID), part of the United States National Institutes of Health (NIH), is an international collaboration of scientists and institutions whose goal is to accelerate the search for an HIV vaccine by sharing trial results and facilitating parallel, concurrent testing. The network comprises more than 24 research institutions worldwide, coordinated from its headquarters at the Fred Hutchinson Cancer Research Center in Seattle, and conducts research in 26 cities in the United States, Caribbean, South America, Africa and Asia. The HVTN is a unique hybrid that combines the depth and diversity of the academic community and the flexibility of a commercial drug company. Working with industry and government, the HVTN seeks to expedite and coordinate the trial process, advancing vaccine candidates and building a body of knowledge around HIV vaccine trials. For more information, please visit www.hvtn.org or contact Sarah Alexander (salex@hvtn.org; +1.206.667.5296).


 

ISK 7.0 Billion (EUR 78 m) Profit after Tax 20.5% Return on Equity The highlights of Glitnir Bank's financial statements for the first quarter of 2007 are as follows: * After-tax profit for the first quarter was ISK 7.0 billion, as compared to ISK 9.1 billion in Q1 2006. After-tax profit was ISK 9.3 billion in Q4 2006. * Pre-tax profit for the first quarter was ISK 8.4 billion, as compared to ISK 11.2 billion in Q1 06. Pre-tax profit for Q4 2006 was ISK 11.6 billion. * During the first three months of 2007, 42% of the Bank's pre-tax profit was generated outside Iceland, or ISK 4.8 billion. * Net interest income for Q1 was ISK 7.9 billion, as compared to ISK 7.8 billion in Q1 2006. Net interest income was ISK 8.4 billion in Q4 06. * Fees and commissions for Q1 2007 were ISK 7.3 billion, increasing from ISK 5.6 billion in Q1 2006. Fees and commissions was ISK 10.3 billion in Q4 2006. * Earnings per share for Q1 2007 amounted to ISK 0.46. * After-tax ROE in Q1 was 20.5%, as compared to 42% in Q1 2006. After-tax ROE for the quarter, excluding trading gains in equities and capital gains, was 18.5%. * Total assets grew by ISK 9.6 billion to ISK 2,256 billion over the quarter. Of this figure, loans to borrowers other than credit institutions were ISK 1,521 billion, down by ISK 85 billion, or 5.6%, including BNbank's loans at fair value. This decrease reflects the strengthening of the ISK. * The refinancing need for 2007 was EUR 2.7 billion and has been completed. Wholesale deposits in the UK which were started in October 2006 and amounted to EUR 1 billion at the end of April 2007. * Assets under management grew by 10% over Q1, bringing AUM to ISK 541 billion. Glitnir acquired 68.1% of FIM Group in February 2007 and FIM will enter the Group's consolidated accounts as of 1 April 2007. * Book equity was ISK 153 billion at the end of March, up by 5% from the beginning of the year. The CAD ratio was 14.2% with Tier 1 ratio at 11.6%. Bjarni Ármannsson, CEO: "The year starts well for Glitnir bank. The financial performance is solid and the bank is running at a strong pace. Our acquisition of FIM and the build up of Investment management services signifies our commitment to fee generating services and our continued commitment of building a true Nordic player in the financial markets. Increased cost in the first quarter both signifies more operations and focus on building the banks' infrastructure, but also investments into future growth. We are therefore optimistic as we go into the second quarter and see a healthy build up of our business model." For further information please contact: Bjarni Tómas Bjørn Richard Vala Pálsdóttir Ármannsson Kristjánsson Johansen CEO CFO MD Corporate Head of Communication Investor Relations Tel: +354 440 Tel: +354 440 Tel: + 47 47 800 Tel: +354 440 4005 4656 100 4989 brj@glitnir.no vp@glitnir.is The accounts of the Bank are available on its website: www.glitnirbank.com. *Exchange rate as at 31.03 2007: EUR/ISK 89.3 and NOK 10.9.


 

AMERICAN MARKETS OUTLOOK: U.S. stock markets are expected to open barely changed Monday, ahead of a string of economic data that could help the Dow Jones Industrial Average to build on the new high posted last week. "So far today we have seen U.S. index futures rather choppy early on, swinging from negative to positive," says Geoff Langham at CMC Markets. "We may see that change, however, this afternoon when a whole host of data is released." CMC Markets is calling the DJIA to open at 13,118, two points down from a record closing high Friday. The Nasdaq 100 is set to open down one point at 1890 and the S&P 500 unchanged at 1494.1. Data for release include March personal income and spending, March construction, April Chicago PMI, and the April Dallas Federal Reserve manufacturing production index. Hilton Hotels, Kellogg and Radioshack are among the companies reporting financial results. EUROPEAN MARKETS: European shares are mostly higher midday. In London, the FTSE 100 is up 0.7% at 6464.70, with Cable & Wireless leading gainers after a report that the company is considering breaking up its business, and oil shares also higher. In Frankfurt, the DAX is up 0.5% at 7418.17 in quiet trading ahead of a national holiday Tuesday. In Paris, the CAC is up 0.4% at 5955.34. Bunds are marginally higher after euro-zone April consumer confidence data came in unchanged from March. The June bund future is up 0.12 at 113.73, while the June gilt is up 0.21 at 106.82. In the currency market, the dollar is mostly higher, with the weekend news of Chinas latest hike in reserve requirements having limited impact on sentiment. The dollar is up at Y119.64, the euro is down at $1.3614 and the pound is down at $1.9938. =========================== TOP STORIES: TURKISH TENSIONS PRESSURE CEE EMERGING MARKETS: Turkish financial markets dropped early Monday, buffeting other emerging markets, after weekend anti-government protests accompanied by threatened military intervention increased political uncertainty. (By Christopher Emsden and Ilona Billington) TELEFONICA WINS TELECOM ITALIA STAKE, NOT CONTROL: A EUR4.1 billion deal by Telefonica SA of Spain and three Italian financial institutions that ensures control of Telecom Italia SpA remains in Italian hands is a vivid illustration of the political constraints that major European industries face as they try to consolidate. (WSJ) ENI BUYS DOMINION GULF OF MEXICO ASSETS FOR $4.8B: Eni SpA (E), Italys biggest oil and natural gas company by volume, said it has agreed to buy Dominion Resources Inc.s (D) production, development and exploration assets in the Gulf of Mexico for $4.8 billion. (By Leia Parker) EURO-ZONE APRIL INFLATION SLOWS TO 1.8% ON YEAR: Consumer-price inflation in the euro zone eased to 1.8% in April from 1.9% in March, a little below the European Central Banks target of price stability, preliminary data from the European Unions statistics office showed. (Data Snap by Ilona Billington) ============================ INSIGHT & ANALYSIS FROM DOW JONES NEWSWIRES: =FOREX FOCUS: The yen may yet get more support from Bank of Japan rate hike expectations than anticipated. (By Nicholas Hastings) =THE SKEPTIC: Greeces pension system is a mess, and it just keeps getting messier. (By Alkman Granitsas) =CHARTING EUROPE: ICE June Brent crude futures are expected to rise further, provided a daily close below Fridays $66.73-a-barrel low isnt made. (By Axel Rudolph) =========================== STILL TO COME ET/GMT COUNTRY/PERIOD 0730/1230 US Mar Personal Income 0730/1230 US Mar Personal Spending 0845/1345 US Apr Chicago PMI 0900/1400 US Mar Construction Spending 0930/1430 US Apr Dallas Fed Mfg Production Index 1200/1900 US Treasury Borrowing Needs =========================== OTHER NEWS: Money supply growth surged again in the euro zone, adding to expectations that the European Central Bank will raise interest rates imminently. (Data Snap by Monica Houston-Waesch) U.K. consumers became more confident about the economic outlook and their personal financial prospects in April, indicating that the threat of further rises in interest rates have yet to dampen their spirits. (Data Snap by Paul Hannon) U.K. mortgage lending surged in March after three months of slowing, while mortgage approvals rose to a four-month high as house buyers clamored to take up the remaining best fixed-rate mortgage deals on the market before an expected May Bank of England rate rise, the British Bankers Association said. (Data Snap by Ilona Billington) Confidence among euro-zone manufacturers hit a record high in April, despite a strengthening euro and uncertainty about the likely severity of the U.S. economic slowdown. (By Paul Hannon) German retail sales unexpectedly fell in March, down 0.7% on the month, against expectations of an increase, Federal Statistics Office data showed. (Data Snap by Emese Bartha) Telecommunications operator Cable & Wireless PLC (CW.LN) damped talk of an impending sell-off of its two business units to private equity or foreign rivals, saying such discussions were "premature". (By Dan Thomas) Erste Bank Der Oesterreichischen Sparkassen AG (EBS.VI) said its first-quarter net profit increased 25%, driven by its Central and Eastern European markets, particularly the consolidation of a Romanian unit. (By Flemming Emil Hansen) The European bank consortium seeking to top ABN Amro Holding NVs (ABN) agreed sale to Barclays PLC (BCS) has lined up many of the funding sources needed to pay for its approximately EUR72.27 billion bid, according to people familiar with the matter. (WSJ) A spokeswoman for Pirelli & C. SpA (PC.MI) said Chairman Marco Tronchetti Provera was joking when he said in an earlier newspaper interview that he will buy shares in Spanish telecommunication firm Telefonica SA (TEF) with the cash it raises by selling a stake in Telecom Italia SpAs (TI) main shareholder. 888 Holdings PLC (888.LN), the online gambling group that recently scrapped talks about a tie-up with industry heavyweight Ladbrokes PLC (LAD.LN), posted a 34% jump in annual underlying profit and was upbeat about the new financial year. (By Lilly Vitorovich) London-listed Dana Petroleum PLC (DNX.LN) posted a 35% drop in full-year net income, largely due to foreign exchange adjustments and the fall away of extraordinary gains seen in 2005. (By Kaveri Niththyananthan) Spains largest property developer Metrovacesa S.A. (MVC.MC) bought the Canary Wharf headquarters of HSBC Holdings PLC (HBC) for GBP1.09 billion, in the biggest ever single property deal in the U.K., demonstrating the continuing strength of the London property investment market. (By Molly Dover) Housebuilder Barratt Developments PLC (BDEV.LN) said its acquisition of rival Wilson Bowden PLC will achieve annualized pre-tax synergies of at least GBP45 million - but it also expects exceptional charges of GBP35 million and 400 redundancies following the integration. (By Molly Dover)


 

HOLLYWOOD, CALIFORNIA and NEW YORK, NEW YORK -- (MARKET WIRE) -- April 30, 2007 -- Hybrid Technologies, Inc. (OTCBB: HYBT) (www.hybridtechnologies.com), emerging leaders in the development and marketing of lithium-powered products worldwide, is pleased to announce that Discovery Channel has completed filming a special on Hybrid Technologies and their latest production vehicle, the lithium-powered Mini Cooper. The filming took place in Los Angeles California at a well known Hollywood icons home. The filming is part of a GREEN GADGETS series that will air in May of 2007 (expect to see Hybrid media advisory closer to air date). To see extended press release click here: http://www.hybridtechnologies.com/media.php?mediaID=070430 The success of the Mini Cooper has raised questions from notable media such as Forbes Magazine, Popular Mechanics and Wallstreet Journal as the potential of corporate buyout, as well as national and international marketing options, for the vehicle as it has become a hit not only with the media but the general public as well. The Mini Cooper L (lithium version) uses a modified propulsion system developed originally for the New York City Taxi. Therefore, a durable and highly stable motor and controller system has been introduced to the already popular Mini Cooper. The complementary technologies introduced into the Mini give it comparable, if not greater performance characteristics compared to the standard combustion engine Mini. To see footage of the all-lithium Smart Car and Mini LS on Forbes click here: www.hybridtechnologies.com/multimedia.php?typeID=V&vidID=51 To see footage of the Mini LS in Popular Mechanics click here: www.hybridtechnologies.com/multimedia.php?typeID=V&vidID=50 About Discovery Channel click here: dcs.discovery.com About Hybrid Technologies: www.hybridtechnologies.com Forward-Looking Statements This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company's current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Contacts: Hybrid Technologies, Inc. Media Contact 1-888-HYBTECH (1-888-492-8324) Email: pr@hybridtechnologies.com Hybrid Technologies, Inc. Investor Relations 1-888-669-1808 (702) 926-9508 (FAX) Email: info@hybridtechnologies.com Website: www.hybridtechnologies.com


 

BASWARE CORP. STOCK EXCHANGE RELEASE APRIL 30, 2007 BasWare has signed an agreement with a Finnish stock-listed technology company for its procurement and invoice automation solutions. The solutions will be implemented as a Software as a Service (SaaS) delivery. The service covers BasWare Purchase Management, BasWare Invoice Processing and BasWare Order Matching and BasWare Contract Matching solutions. Additionally, it includes the management and maintenance of electronic product catalogues. BasWare's solutions will be implemented globally. The service will be taken in to use at the entire customer organization. The value of the agreement is more than EUR 450 thousand. "For BasWare, this is the first SaaS agreement with a private sector company. It further strengthens our position as a global forerunner in the software as a service market," says Ilkka Sihvo, CEO, BasWare Corp. BasWare Purchase Management, BasWare Invoice Processing, BasWare Contract Matching and BasWare Order Matching and catalogue service management form the SaaS service. For more information, please contact CEO Ilkka Sihvo, BasWare Corp. Tel. +358 9 8791 7251 or +358 40 501 8251 BASWARE CORP. Ilkka Sihvo Distribution Helsinki Stock Exchange Key media www.basware.com


 

(Fornebu, 30 April 2007) Telenor will present its financial results for the first quarter 2007 on Friday 4 May 2007 at 09:00 hrs Norwegian time/CET. The presentation, which will also be broadcast live over the Internet, will be held in Auditorium A, Telenor Expo Visitor Centre at Fornebu near Oslo. The figures will be published on Telenor's website at 07:00 CET. CEO Jon Fredrik Baksaas and CFO Trond Westlie will present the results. The presentation will be held in English. Internet and mobile broadcast The press and analysts conference will be broadcast live over the Internet, and will also be available as a recording after the conference. The live service also allows for written questions to be submitted. In addition, the conference will be available live and as a recording on mobile phones with 3G, GPRS or EDGE. For more details please visit www.telenor.com/ir. Conference Call and Q&A You may also call in and listen to the presentation over the phone. This service allows you to ask questions at the Q&A session at the end of the presentation. For details, see www.telenor.com/ir. To participate in the Conference Call please register before the conference starts by calling (+47) 800 80 119 (from Norway) or (+47) 23 00 04 00 (from Norway or abroad). Material The quarterly report and English versions of the presentations will be made available on www.telenor.com/ir. Contacts: Media: Vice President Corporate Communications, Scott Engebrigtsen tel.: (+ 47) 90 04 34 84 Analysts and investors: Senior vice president IR Erling Thune, tel.: (+47) 67 89 26 56 or (+47) 909 71 969 Vice President IR Tolle Grøterud, tel.: (+47) 67 89 39 53 or (+47) 913 71 309


 

New man at the helm of Corporate Communications Hannover, 30 April 2007: Stefan Schulz (36) is to assume responsibility for Corporate Communications at Hannover Re with effect from 1 May 2007. A graduate in economics, Mr. Schulz began his professional career in 1998 as a trainee with Hannover Re. He subsequently worked as an underwriter for the East Asian market. In 2002 Mr. Schulz moved to our subsidiary in South Africa, assuming underwriting responsibility for the specialty business written there. Since 2005 he has served as Associate Director responsible for financial reinsurance business at our Irish company Hannover Re Dublin. Mr. Schulz will continue our policy of communicating actively and openly with the capital markets and the press. His predecessor Eric Schuh - who successfully led Corporate Communications for almost four years - is leaving the position to take on a fresh challenge. Your other accustomed contacts, Gabriele Bödeker for Investor Relations and Gabriele Handrick for Public Relations, remain at your disposal. For further information please contact: Press and Public Relations: Gabriele Handrick (tel. +49 / 511 / 56 04-15 02, e-mail: gabriele.handrick@hannover-re.com) Investor Relations: Gabriele Bödeker (tel. +49 / 511 / 56 04-17 36, e-mail: gabriele.boedeker@hannover-re.com) Hannover Re, with a gross premium of around 9 billion euro, is one of the leading reinsurance groups in the world. It transacts all lines of non-life and life and health reinsurance. It maintains business relations with more than 5,000 insurance companies in about 150 countries. Its worldwide network consists of more than 100 subsidiaries, branch and representative offices in around 20 countries with a total staff of roughly 2,000. The rating agencies most relevant to the insurance industry have awarded Hannover Re very strong insurer financial strength ratings (Standard & Poor's AA- "Very Strong" and A.M. Best A "Excellent"). Disclaimer: Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Hannover Re does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Hannover Re and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.


 


 

- 42 Actavis products recommended Reykjavik, Iceland, 30 April 2007 -- Actavis Group (OMX: ACT), the international generic pharmaceuticals company, today announced that its subsidiary in Germany has signed a partnership contract with the German VdAK / AEV association. The association represents seven health insurance funds in Germany that provide coverage for around 8.7 million people across the country. Under the terms of the contract, Actavis will supply a wide range of products used for the treatment of chronic and acute illnesses. The agreement follows the signing with the largest health insurance provider in Germany, Allgemeine Ortskrankenkassen ("AOK") in March, where Actavis was also selected in a preferred partnership agreement. The association has only selected Actavis for all of the 42 products, whose products will be listed and recommended for the patients of the participants. The new agreement is valid for one year. Participants will include the following: * DAK - German employee health insurance company, Hamburg * HEK - Hanseatic health insurance company, Hamburg * HMK - Hamburg Munich health insurance company, Hamburg * Hkk - Commercial health insurance company, Bremen * GEK -Gmünder private health insurance fund, Swabian Gmünd * HZK - Health insurance company for professionals in building industry and wood processing, Hamburg * KEH - Private health insurance fund - Heusenstamm Svend Andersen, Executive VP for Western Europe, the Middle-East and Africa, said: "Our agreement with the VdAK/AEV association is recognition for our business in Germany. Our growing presence, combined with a dynamic pipeline of products will benefit around 9 million German health insurance policy holders going forward and we are excited to start this new business relationship. This means that German doctors and pharmacists will be encouraged to recommend products from Actavis, supporting our sales growth in the market" About Actavis Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in over 30 countries, with 11,000 employees. The company's market capitalization is approximately EUR3 billion (US$3.8 billion) and is listed in the OMX stock exchange in Iceland. Actavis expects 2007 sales to total EUR1.6 billion, with approximately 8% of sales coming from Germany, the Group's third largest market. Over 10 new product launches are expected from Actavis in Germany in 2007. The company's German operations are located in Langenfeld. More information about Actavis can be found on www.actavis.com. Inquiries Halldor Kristmannsson Vice President of Corporate Communications & IR Tel: (+354) 535 2325 / 840 3425 E-mail: hkristmannsson@actavis.com


 

YIT CORPORATION STOCK EXCHANGE RELEASE APRIL 30, 2007 10:15 From April 2 to April 20, 2007 a total of 19,972 YIT shares were subscribed for on the basis of the Series E share options and a total of 55,616 shares on the basis of the Series F share options. The increase in the share capital as a consequence of these share subscriptions, totalling EUR 477,848, was entered in the Trade Register on April 30, 2007. Departing from prior practices, the subscription price will be used in full to increase the share capital. Following the increase, YIT's share capital is EUR 146,688,843.82 and the number of shares outstanding is 126,852,260. The new shares confer all shareholder rights as from the date of registration, April 30, 2007, and they will be accepted for public trading on Helsinki Stock Exchange together with the existing shares. The objective is that trading in the shares will commence on May 2, 2007. In 2007 YIT Corporation shares can be subscribed for on the basis of Series E and F share options issued in 2004 and Series K and L share options issued in 2006. Max. 135,948 shares can still be subscribed for with Series E share options, max. 225,504 shares with Series F share options, max. 241,800 shares with Series K share options and max. 593,460 shares with Series L share options. The subscription price with the Series E options is EUR 6.80 per share, with the Series F options EUR 6.15 per share and with Series K and L options EUR 20.53 per share. The terms and conditions of the share option programmes as a whole are presented on the company's internet site www.yitgroup.com. YIT Corporation Veikko Myllyperkiö Vice President, Corporate Communications For additional information, contact: Marja Salo, Director of Administration, tel. +358 20 433 2470, marja.salo@yit.fi Jaakko Mäkynen, Vice President, Finance, tel. +358 20 433 2307, jaakko.makynen@yit.fi Distribution: Helsinki Stock Exchange, principal media, www.yitgroup.com


 

Bengt Gustafson has been appointed Senior Vice President Chief Legal Counsel of the Securitas Group. Bengt Gustafson will be a member of Securitas AB's Group Management and will report to Securitas' President and CEO Alf Göransson. Bengt Gustafson is currently Chief Legal Officer of Metso Minerals and was previously i.a. Chief Legal Counsel of Svedala Industri AB. He has also worked as Chief Legal Counsel in France. In addition to his Swedish law degree, Bengt Gustafson has earned a Masters of Law degree from University of California, Berkeley, USA. Since 2004 he is the President of European Company Lawyers Association, which is based in Brussels. Bengt Gustafson will take up his position at Securitas during the third quarter of 2007. This press release is also available at: www.securitas.com Information: Alf Göransson, President and CEO Securitas AB +46 (0) 8 657 74 00


 

~ Oslo/Stockholm/Seattle/Cambridge - April 30, 2007 Birdstep Technology ASA has signed an agreement to acquire Finnish enterprise mobility management company Secgo Software Oy. Secgo provides seamless mobility with strong information security to enterprise and OEM. Birdstep has signed a Share Purchase Agreement to acquire Secgo Software Oy against a payment of EUR 9.2 million in Birdstep shares as well as an additional payment of maximum EUR 4.6 million in Birdstep shares based on an earn-out agreement against 2007 revenue and profitability budget. The share price for both payments is set to NOK 12, equal to the share price at market closing on Friday 27. April 2007. Secgo Software, with offices in Espoo and Tampere, Finland, and Walnut Creek, CA, USA, provides software products for seamless mobility with strong information security to the OEM and enterprise markets. In 2006, company revenue reached EUR 3.1 million with 5% EBITDA. According to IDC the enterprise mobility solution market is estimated to $ 214 million during 2006 and will grow yearly with 35%. Birdstep is now the leading provider of mobility and connectivity software to the operator, OEM and the enterprise markets. The acquisition gives evidence to Birdstep's structural growth strategy to broaden the company's eco system. -We are very pleased to invite Secgo to our journey. Secgo's secure seamless mobility solutions for enterprise is an important complement to Birdstep's seamless connectivity offering to mobile operators. We intend to derive market, customer and technology synergies through the combination of Birdstep and Secgo already this year, says Petri Markkanen, CEO of Birdstep Technology ASA. The current shareholders of Secgo Software include the management and key employees, Insta DefSec Oy, Eqvitec Partners and Capman Capital Management. Secgo provides mobility solutions to customers like Nordea, Danske Bank, Sampo a majority of the Finnish government authorities and Motorola. Thales is signed up as system integrator. Secgo is also member of WiMAX forum and Mobile Enterprise Alliance. -The acquisition is evidence of Birdstep's strategy to be a leading provider of secure seamless mobility and connectivity software across all market segments. Enterprises have growing demand for secure and mobile connectivity. Investments in mobile workforce solutions are increasing and laptop manufacturers are becoming an increasingly important player in the ecosystem as secure mobility becomes a natural part of notebook shipments to market. From day one, we now have a stronger market offering towards our target customers in Europe, USA and Asia, says Petri Markkanen, CEO of Birdstep Technology ASA. - We are proud becoming a part of Birdstep. The company has high ambitions for the development of the industry, and we believe that combining two strong organizations technologically and market-wise will create huge market opportunities for the new Birdstep organization, says Matti Mujunen, CEO of Secgo Software. For more information regarding the acquisition please join our web cast at 9 AM Monday the 30th of April 2007 at http://streamsync.qbrick.com/05768/070430/. For further information, please contact: Petri Markkanen, CEO of Birdstep Technology ASA, phone +46 70 323 33 22


 

OPRA Technologies ASA, Press release, 30 April 2007. On 27 April 2007, the Extraordinary Generel Meeting approved a private placement of 12.350.000 new shares, equal to 22 % of the existing share capital, at a subscription price of NOK 6,5 per share. Gross proceeds from the private placement amounts to NOK 80.275.000. The private placement was significantly over-subscribed and the Board of OPRA Technologies ASA is pleased with the response. The proceeds from the placement will enable OPRA to continue its growth path and expand into new markets. Upon registration of the new shares to be issued in the private placement, OPRA Technologies ASA's share capital will increase from NOK 56,074,500 to NOK 68,424,500, and the number of shares, each with a par value of NOK 1.00, will increase from 56,074,500 to 68,424,500. The private placement was managed by ABG Sundal Collier. Dated: 30 April 2007 OPRA Technologies ASA For further information contact: Fredrik Mowill, CEO, OPRA Technologies ASA Tel: +47 982 50 250 Email: f.mowill@opra.no Or Lars Husby, CFO, OPRA Technologies ASA Tel: +47 982 50 224 Email: l.husby@opra.no About OPRA Technologies ASA: OPRA Technologies ASA (OPRA) is a leading, global provider of turbine driven energy solutions in the 2 MW power range. OPRA develops, manufactures, markets and services power generation sets designed for oil and gas and industrial applications. www.opraturbines.com


 

(Oslo, 30 April 2007) SAS has entered into an agreement with EDB for applications operations and Scandinavian helpdesk services linked to its SAS Eurobonus system. The contract runs for five years, with an option to extend for a further two years, and represents total contract value of around SEK 15 million. EDB's expertise in operating and developing business-critical IT systems was the deciding factor when SAS selected EDB as its partner. EDB is one of the leading Nordic IT services companies. This agreement represents the start of a long-term partnership with EDB for IT services. "We invited competitive bidding for the applications operations needed for the SAS Eurobonus system. We awarded the contract to EDB not only because the company specialises in the Nordic IT market, but also because EDB can deliver a cost-effective long-term solution", explains Lena Boström, Director, Commercial Systems at SAS Airline IT. "We are very pleased to have won this appointment as a partner for SAS against tough competition from other suppliers. The Eurobonus system is extremely business-critical, and we have extensive and long established experience in running this kind of system for other customers who, like SAS, are dependent on 24/7 delivery", comments Thomas Parmbäck, Managing Director of EDB Business Partner Sweden. Any questions may be addressed to: Geir Remman, EVP - Corporate Communications. Tel: +47 970 55 017 About EDB EDB Business Partner is a leading stock exchange listed IT group for the Nordic region. The group has 3,800 employees, and reported turnover of NOK 5.8 billion in 2006. EDB delivers solutions that cover the entire range of business critical IT services from application services and industry-specific solutions through to IT operating services and network solutions. EDB is committed to being a close and attentive IT partner that helps its customers operate more efficiently and achieve their business objectives. EDB Business Partner is listed on Oslo Børs with the ticker code: EDBASA. For further information see www.edb.com.


 

Sinclair Pharma plc announces US Atopiclair sales reach $10m 30 April, Godalming, UK. Sinclair Pharma plc (SPH.L), the specialty pharmaceutical company, today announced that cumulative net US sales since launch of Atopiclair(TM), by its distributor Graceway Pharmaceuticals, LLC ("Graceway"), have reached $10.0m. This event triggers a milestone payment of $2.5m to Sinclair. Atopiclair is Sinclair's flagship product for atopic dermatitis (eczema). It was originally launched in the US in 2005 by Chester Valley Pharmaceuticals (CVP), with a sales force of approximately 40. However, the recent merger of CVP into Graceway, which happened with Graceway's acquisition of the 3M pharmaceutical product lines in December 2006, means that Atopiclair will now be promoted by approximately 160 Graceway medical sales representatives in the US. Outside the US, Atopiclair is at the start of its commercial life with key launches planned in many EU territories in the spring. In addition to the recent launch by Sinclair's own sales and marketing operation in France as 'Atopiclair', a co-marketing arrangement with Bayer's Intendis will see the product launched as 'Zarzenda' in key European territories. Earlier this year, Atopiclair was launched by Italfarmco in Spain as 'Dersura', where sales are showing strong performance. Dr Michael Flynn, CEO of Sinclair Pharma, commented: "Atopiclair is an efficacious product, proven to deliver symptom relief for patients, without the use of steroids. Recent positive results of a clinical study in children with atopic dermatitis have added further weight to the product. This important sales milestone reflects the positive opinions of US physicians and patients and we look forward to seeing the success repeated in Europe." For further information please contact: Sinclair Pharma plc Tel: +44 (0) 1483 410 600 Dr Michael Flynn, CEO Zoe McDougall, Director of Communications Capital MS&L Mary Clark, Halina Kukula Tel +44 (0)20 7307 5340 Notes to editors: Milestone The figure of US$10.0 m represents sales of Atopiclair, by Graceway Pharmaceuticals, into the US supply chain. The retail value of these sales will be higher. The milestone payment triggered by this event will be payable to Sinclair Pharma plc within the current financial year. Atopiclair(TM) Atopiclair(TM) is a non-steroidal cream, marketed as a medical device in the US and EU, for the management of symptoms of atopic dermatitis and contact dermatitis. It is sold through Sinclair's sales and marketing team in France and Italy, and is also sold in the US, Spain, Portugal, Turkey, Indonesia, Israel and Jordan. For further product information please visit www.atopiclair.com. Atopic dermatitis (also known as eczema) is one of the most common dermatological complaints and accounts for a large number of physician consultations. It is known to affect approximately 20% of school aged children (footnotes 1, 2, & 3). The prevalence in adults is estimated at 1-3% (footnotes 4 & 5). Other atopic dermatitis treatments The current cornerstone of atopic dermatitis therapy is topical corticosteroids. However this group of drugs may have unfavourable side effects, especially when used long-term or on sensitive areas of skin such as the face, hands, or in children. These effects vary from mild and reversible thinning, to irreversible telangiectasiae (fine blood vessels becoming visible at the surface of the skin) and striae distensae (marks similar in appearance to 'stretch marks'). Steroids' effectiveness may also become less effective with continued use, which may lead to the escalation to a more potent steroid (footnote 6). There may also be a risk of adrenal suppression in children with the use of topical steroids (footnote 7). Atopiclair does not contain corticosteroids. Another group of drugs, the topical immunomodulators (TIMs), are also used in atopic dermatitis. In January 2006, the US Food and Drug Administration (FDA) approved updated labeling for two TIMs, pimecrolimus and tacrolimus. The new labeling includes a boxed warning about a possible risk of cancer and a Medication Guide (FDA-approved patient labeling). The Medication Guide is to be distributed with each prescription to help ensure that patients using these prescription medicines are aware of this concern. The new labeling also clarifies that these drugs are recommended for use as second-line treatments. This means that other prescription topical medicines should be tried first. Use of these drugs in children under 2 years of age is not recommended by the FDA. Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 65 countries. Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors. Footnotes 1. Yura A, Shimizu T. . Trends in the prevalence of atopic dermatitis in school children: longitudinal study in Osaka Prefecture, Japan, from 1985 to 1997 Br J Dermatol 2001; 145 (6): 966-73 2. Tay YK, Kong KH, Khoo L et al. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol 2002; 146 (1): 101-6 3. Mortz CG, Lauritsen JM, Bindslev-Jensen C, Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. Br J Dermatol 2001; 144 (3): 523-32 4. Schultz-Larsen F, Hanifin JM. Epidemiology of Atopic Dermatitis. Immunol Allergy Clin North Am 2002; 22: 1-24 5. Ellis CN, Drake LA, Prendergast MM. Cost of Atopic Dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46 (3): 361-70 6. Atherton DJ, BMJ. Topical Corticosteroids in atopic dermatitis. 2003;327:942-943 7. Siklar Z, Bostanci I, Atli O, Dallar Y. Pediatr Dermatol. 2004 Sep-Oct;21(5):561-3 ---END OF MESSAGE---


 

FREMONT, Calif., April 28, 2007 (PRIME NEWSWIRE) -- NIDEK, Inc., a global leader in laser and diagnostic instrumentation for the optical and eye care industry, announced today that the U. S. Food & Drug Administration (FDA) has approved the first product of the AutoEase(tm) line called ORION, an Auto-Retinal Imaging device for use in screening patients for retinal diseases such as diabetic retinopathy and AMD. With this approval, ophthalmologists, optometrists and family physicians are able to identify retinal diseases in patients and refer them to a retinal specialist for further diagnosis and treatment. With its ease of use as an Auto-Retinal Imaging device, ORION enables patients to screen their retina without the assistance of a technician. The primary method of operation behind ORION includes a voice synthesizer. The voice prompts the patient through the screening process and captures a 7 micron, high resolution image of the patient's retina, which can be electronically sent to a retinal specialist for further diagnosis. In addition, ORION can screen both retinas of a patient in less than 2 minutes. Mr. Motoki Ozawa, Vice President, NIDEK Co., Ltd. stated, "ORION is a perfect addition to NIDEK's strong, world-class product portfolio in unsurpassed diagnostic and surgical instrumentation, optical finishing and dispensing products in vision care." About NIDEK NIDEK is a global leader in diagnostic and surgical eye care products for ophthalmology and optometry focused on developing and delivering innovative technologies that enhance the quality of human life. With diversified clinical research and continual innovative development, an array of laser and optical scanning products offered that lead the way for improved diagnosis and treatments. The relentless commitment to customer satisfaction means NIDEK will diligently strive to continually exceed expectations. The NIDEK Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=1006 CONTACT: NIDEK Corporation Lamar Chandler, Director, Global Marketing +1 800 223 9044 - ext. 726 lamar_chandler@nidek.com http://www.nidek.com/orion.html NIDEK Technologies Aldo Cocchiglia, VP and Managing Director +39 049 862 9200 aldococchiglia@nidektechnologies.it http://www.nidektechnologies.it/


 

Please find the press release in the below link.


 

Shareholders of Industrieholding Cham AG approved all the Board of Directors' proposals at the 95th Annual General Meeting held today in Cham. The Annual General Meeting authorised a CHF 5.00 per share reduction in the nominal value of the registered shares to be paid out to shareholders. They further appointed Mr. Urs Ziegler to the Board of Directors and re-elected Mr. Philipp Buhofer as member of the Board of Directors for a further term of three years. The annual report and the accounts 2006 were approved and shareholders granted discharge to the Board of Directors. 108 shareholders attended the Annual General Meeting representing 432 149 votes or 75.7% of the shares entitled to vote. For further information please contact: Thomas Regli Head of Corporate Services Industrieholding Cham E-mail: regli.thomas@iccham.com Phone: +41 41 785 18 88 You will find the PDF-File attached. --- End of Message --- Industrieholding Cham AG P.O. Box Cham Switzerland ISIN: CH0001931853; Index: SPI, SSCI, SPIEX; Listed: Main Market in SWX Swiss Exchange;


 

Wiesbaden/Munich, 27 April 2007 - The technology group The Linde Group and the worldwide industrial and medical gases company Air Liquide have concluded the realignment of their joint ventures in Asia. Linde purchased Air Liquide's interests in the gas companies Malaysian Oxygen (Malaysia) and Hong Kong Oxygen & Acetylene (Hong Kong). In return, Linde sold its interests in Singapore Oxygen (Singapore), Eastern Industrial Gases (Thailand), Vietnam Industrial Gases (Vietnam) and Brunei Oxygen (Brunei) to Air Liquide. By these transactions Linde received a net purchase price of 275 million euro. Following the receipt of unconditional approval from the European Commission, these transactions were completed today. A realignment of the shareholdings in certain joint ventures in the Asia/Pacific region was one of the conditions imposed by the European Commission when it authorised the acquisition of The BOC Group plc by Linde which became effective on 5 September 2006. The Linde Group is a world leading industrial gases and engineering company with more than 51,000 employees working in around 70 countries worldwide. Following the acquisition of The BOC Group, the company has gases and engineering sales of approximately 12 billion euro. The strategy of The Linde Group is geared towards earnings-based growth and focuses on the expansion of its international business with forward-looking products and services. For more information, please see The Linde Group online at http://www.linde.com For further information: Press Uwe Wolfinger Telephone: +49.89.35757-1320 Investor Relations Thomas Eisenlohr Telephone: +49.89.35757-1330


 

Enclosed is the notice for Renewable Energy Corporation ASA`s Annual General Meeting and the proposal from the Election Committee. All information about the Annual General Meeting is available on the REC Group's website at www.recgroup.com. For more information, please contact; Jon Andre Løkke, SVP & Investor Relation Officer, +47 67 81 52 65 About REC REC is uniquely positioned in the solar energy industry as the only company with a presence across the entire value chain. REC Silicon and REC Wafer are the world's largest producers of polysilicon and wafers for solar applications. REC Solar produces solar cells and solar modules. REC Group had revenues in 2006 of NOK 4,334 million and an operating profit of NOK 1,574 million. Please also see www.recgroup.com


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | iSOFT Group Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 10p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 25 April 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |-------------------------------+--------------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (2) Derivatives (other than | 2,491,419 | 1.0716 | | | | options) | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | Total | 2,491,419 | 1.0716 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | CFD | LONG | 90,438 | 36.5590 | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 27th April 2007 | |-------------------------------------------------+-----------------| | Contact name | James Feast | |-------------------------------------------------+-----------------| | Telephone number | 0207 469 1901 | |-------------------------------------------------+-----------------| | If a connected EFM, name of offeree/offeror | | | with which connected | | |-------------------------------------------------+-----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Stockholm, Sweden - April 27, 2007 - Tobii today announced its launch of a new generation eye tracking hardware and analysis software. Fundamental technology advances and new tools facilitate use of eye tracking and add substantial new values to usability and user experience studies. Making up a complete lab solution, the new products will be presented at CHI in San Jose CA, April 29. The new Tobii Studio(TM) analysis software and the T/X series of Tobii Eye Trackers provide a comprehensive system to efficiently collect and analyze gaze data. Offering unique insights into user experience it dramatically improves opportunities for usability professionals to deliver return on investment in terms of desired quality measures. Eye tracking for usability studies Tobii Studio offers a new toolbox of visualizations, statistics, reporting and other valuable tools. Key features like logging, remote viewing and demographical filtering have been added to create a complete platform for usability testing. Tobii Studio is ideal for evaluating interactive media such as websites, software, e-mail campaigns, on-line advertising, computer games, and interactive TV, as well as print advertising, TV commercials and physical products. "We see great opportunities in adding eye tracking to our current methodologies and services, and Tobii's products allow us to do so in a time and cost efficient way. Having tried out the new Tobii Studio software, we expect it to add substantially to our customers and our business" says Anna Carin Pålsson, CEO at Market Watch. "With its new analysis software Tobii has evolved from an eye tracking provider to a complete usability software package provider. After our initial usage we are very enthusiastic about Tobii Studio and how it can support our Post Experience Eyetracked Protocol (PEEP) methodology and daily usability research business, says Robert Stevens, CEO at Bunnyfoot. Time- and cost efficient testing New hardware characteristics such as much larger head movement allowance, higher speed and automatic optimization of bright and dark pupil tracking make it easier for user experience professionals to add eye tracking to their services and perform high quality tests in a remarkable efficient and accurate way. "We are thrilled to introduce our new line of eye tracking hardware, which will allow our customers to perform eye tracking even more easily, efficiently and accurately. Eye tracking now has a potential to make a difference on a broad scale in usability studies", says Henrik Eskilsson, CEO at Tobii Technology. The new products will be offered on a subscription and pay-per-use basis and general availability will follow the launch. For questions or comments please contact: Henrik Eskilsson, CEO and founder, Tobii Technology Direct +46-8-663 69 94 Mobile +46-737-07 16 69 Email henrik.eskilsson@tobii.com John Elvesjö, Executive Vice President and founder, Tobii Technology Mobile + +46-704-82 34 98 Email john.elvesjo@tobii.com For additional press materials, please contact: Anna Ahlbaum, Marketing Communications Manager, Tobii Technology Mobile +46-70-788 01 77 Email anna.ahlbaum@tobii.com Tobii Studio(TM) - new features Tobii Studio is completely new gaze analysis software, largely replacing the ClearView software. New features include greatly improved workflow, new and improved visualizations, built-in statistics, event logging, remote viewing over IP, improved replay tool, generation of video clips and demographical filtering. Tobii Studio also offers a much more stable platform and higher performance thanks to underlying database and new architecture. Tobii T60, T120 & X120 Eye Trackers - new features Replacing the Tobii 50 series of hardware, the new Tobii T60, T120 and X120 Eye Trackers offer major improvements in all key performance categories. For on-screen research, the Tobii T60 allows for twice as much head movement and is twice as accurate as its predecessor. It brings fundamental advances to eye tracking, such as new sensors, new ways to generate NIR reflection patterns, automatic optimization of bright and dark pupil tracking, improved eye math models with advanced drift compensation, embedded eye tracker server and much more. The Tobii T120 Eye Tracker also boasts with twice as high tracking frequency for more fine-grained data. Tobii X120, for studies of real world objects and scenes, offers the same new characteristics. It also allows for more flexible setups such as angled geometries and setups with multiple eye trackers synchronized together. Facts about Tobii Tobii Technology is the world leader in hardware and software solutions for eye tracking and eye control. Founded in 2001 Tobii has continuously shown very rapid year-to-year revenue growth. The company is based in Stockholm, Sweden, with offices in McLean, VA near Washington, DC in the US and in Frankfurt, Germany. Products are sold through resellers and partners worldwide. With eye tracking a computer knows exactly where a person is looking, enabling enhanced control interfaces and a powerful way to understand behavior. Tobii's products are widely used within the scientific community and in commercial market research and usability as well as by disabled people as a primary way to communicate. Tobii also drives integration of eye tracking technology in a large number of other application areas, offering off-the-shelf or customized eye tracking components for integration into various industry applications.


 

Appointment of Ekholm follows decision to consolidate marketing, product development, quantitative analysis, and other core business functions under single executive management. COPENHAGEN Saxo Bank has announced the appointment of Rabbe Ekholm as Chief Commercial Officer, effective May 1. A native of Helsinki, Finland, Ekholm comes to Saxo from MSCI Barra, a division of Morgan Stanley, where he led its index and risk content businesses. During the merger of MSCI and Barra, Ekholm oversaw the integration of the companies' respective sales, marketing and content business units, steering them on a path of high double-digit growth. Prior to his stint at MSCI Barra, Ekholm held a number of senior executive marketing and general management positions with Procter & Gamble, Pepsi, and International Distillers and Vintners. At Saxo Bank, Ekholm will join the bank's Senior Executive Management group, leading its marketing, product development, communications, quantitative analysis, and quality and process divisions in a newly created executive function. He will report directly to the bank's co-CEO's and co-founders Kim Fournais and Lars Seier Christensen. In announcing the appointment of Mr. Ekholm, Kim Fournais and Lars Christensen issued the following joint statement: "Rabbe Ekholm brings to bear a wealth of international business and management experience to Saxo Bank, which will stand us in good stead as our global business continues to gain momentum. Combining these functions under the supervision of a single experienced leader is a key step in enabling future growth." About Saxo Bank A/S Saxo Bank A/S is a modern investment bank specializing in online investments in the international Capital Markets. Saxo Bank enables clients to trade currencies, shares, CFD contracts, futures, options and other derivatives as well as portfolio management via our online trading platform - SaxoTrader. SaxoTrader has been internally developed by Saxo Bank and is available to today's investor directly through Saxo Bank or through one of our global partnerships as an integral part of their own infrastructure. One of Saxo Bank's significant areas of business is White Labelling, which is the development of tailored versions of the online trading platform to other banks and brokerage houses. Saxo Bank has more than 70 White Label Partners and thousands of clients in 177 countries. The bank's website www.saxobank.com has approx. 65,000 visitors every day. Saxo Bank currently employs more than 800 employees from 45 different countries. The bank is headquartered in Denmark, with operating offices in London and Singapore, and an IT development center in St. Petersburg, Russia. Further information please contact: Saxo Bank - Rebecca K. Engmann - Financial Writer e-mail: rke@saxobank.com - telephone: +45 3977 474


 

Stavanger, Norway Presentation material from today's 1st quarter 2007 presentation can be downloaded from www.ocean-rig.com and www.newsweb.no. Ocean Rig owns and operates two of the world's largest and most modern drilling rigs, built for ultra deep waters and extreme weather conditions. The units are currently operating offshore Angola and Canada. NOTE: This press release contains forward-looking statements (within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended) which reflect the Company's current views with respect to certain future events and financial performance. Actual events or results may differ materially from those projected or implied in such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or otherwise. The following important factors, among other, could cause actual results to differ materially from those projected or implied in any forward-looking statements: (i) our results of operation and financial conditions in the future; (ii) the performance of our rigs, including the sufficiency of their design and their ability to prevent discharges of hazardous materials and pollutants; (iii) our ability to generate sufficient cash-flow to meet our debt service requirements; (iv) our ability to retain existing contracts and secure future drilling contracts for our rigs at attractive day rates; (v) our ability to perform our operations in accordance with our plans; (vi) the impact of changed conditions in the oil and gas industry; (vii) the occurrence of any accidents involving the Company or its assets; (viii) changes in governmental regulations, particularly with respect to environmental matters; (ix) increased competition or the entry of new competitors into the Company's markets; and (x) unforeseen occurrences in any of the areas in which the Company may conduct its operations, such as war, expropriation, nationalization, renegotiation or nullification of existing licenses or treaties, taxation and resource development policies, foreign exchange restrictions, changing political conditions and other risks relating to foreign governmental sovereignty over certain areas in which the Company will conduct operations. Due to such uncertainties and risks, investors are cautioned not to place undue reliance upon such forward-looking statements. For further information, please contact Finance Manager Andreas Lian Kvam tel: +47 5196 9000. Stavanger, April 27, 2007 Ocean Rig ASA


 

Norgani Hotels ASA has today completed its annual general meeting, in line with the proposals set out in the notice for the meeting. The shareholders approved among other things a dividend distribution of NOK 4.00 per share and the shares of Norgani Hotels will be traded ex dividend on 30 April 2007. The dividend will be paid out 10 May 2007. Furthermore, the shareholders approved to renew the proxy to the board, to issue up to 3,934,000 new shares in the company. Following the general meeting, the board of Norgani Hotels consists of Jan Petter Storetvedt (chairman), Hege Bømark, Mats Lönnqvist, Rebekka Glasser Herlofsen and Arvid Sveen. The nomination committee will as from the general meeting consist of Martin Mæland (chairman), Tom Rathke and Ervin Auren. For further information, please contact Eva Eriksson, CEO Mob: + 46 70 644 3497 Mats Sterner, CFO Mob: +46 70 690 2009 About Norgani With a portfolio of more than 70 hotels in the Nordic region, Norgani Hotels is Europe`s fifth largest hotel property investor. Through size and specialization Norgani has a knowledge of and insight in the hotel industry, creating a unique platform for development of hotel properties and business in cooperation with operators and brands. The share is listed on the Oslo Stock Exchange. www.norgani.no


 

TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): Sinclair Pharma Plc 2. Reason for the notification (please place an X inside the appropriate bracket/s): An acquisition or disposal of voting rights: ( X ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( ) Revised due to DTR rules - see Section 13 3. Full name of person(s) subject to the notification obligation (iii): AXA S.A. , 25 Avenue Matignon, 75008 Paris, and its group of companies 4. Full name of shareholder(s) (if different from 3.) (iv): 5. Date of the transaction (and date on which the threshold is crossed or reached if different) (v): 4 April 2007 6. Date on which issuer notified: 5 April 2007 7. Threshold(s) that is/are crossed or reached: 13% 8. Notified details: ....... A: Voting rights attached to shares Class/type of shares if possible Situation previous to the Triggering using the ISIN CODE transaction (vi) Number of shares Number of voting Rights (viii) 3385674 11,939,078 11,939,078 Resulting situation after the triggering transaction (vii) Class/type of Number of Number of voting rights % of voting rights shares if shares (ix) possible using the ISIN CODE Direct Direct Indirect (xi) Direct Indirect (x) 3385674 12,189,078 13.06% B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Exercise/Conversion Number of voting % of financial Date (xiii) Period/ Date (xiv) rights that may be voting instrument acquired if the rights instrument is exercised/ converted. Total (A+B) Number of voting rights % of voting rights 12,189,078 13.06% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): Proxy Voting: 10. Name of the proxy holder: 11. Number of voting rights proxy holder will acquire to hold: 12. Date on which proxy holder will acquire to hold voting rights: 13. Additional information: 14. Contact name: Terry Marsh, AXA, 020 7003 2637 Alan Olby (Company Secretary) / Zoe McDougall (Communications), Sinclair Pharma plc 15. Contact telephone number: fil-regulatoryreporting@uk.fid-intl.com investorrelations@sinclairpharma.com Annex to Notification Of Major Interests In Shares (xvi) A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities): Fidelity International Limited (FIL) Contact address (registered office for legal entities): Pembroke Hall, 42 Crow Lane, Pembroke, HM19 Bermuda Phone number: 01737 837092 Other useful information (at least legal representative for legal persons): Company Secretary B: Identity of the notifier, if applicable (xvii) Full name: Fidelity Investments International Contact address: Windmill Court XTW2B, Millfield Lane, Lower Kingswood, Tadworth, Surrey KT20 6RB Phone number: 01737 837092 Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation): Authorised to make this filing under power of attorney C: Additional information : Notes to the Forms (i) This form is to be sent to the issuer or underlying issuer and to be filed with the competent authority. (ii) Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate. (iii) This should be the full name of (a) the shareholder; (b) the person acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all the parties to the agreement referred to in DTR5.2.1 (a), or (d) the direct or indirect holder of financial instruments entitled to acquire shares already issued to which voting rights are attached, as appropriate. In relation to the transactions referred to in points DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned: - in the circumstances foreseen in DTR5.2.1 (b), the person that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights; - in the circumstances foreseen in DTR 5.2.1 (c), the person holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and person lodging the collateral under these conditions; - in the circumstances foreseen in DTR5.2.1(d), the person who has a life interest in shares if that person is entitled to exercise the voting rights attached to the shares and the person who is disposing of the voting rights when the life interest is created; - in the circumstances foreseen in DTR5.2.1 (e), the parent undertaking and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking; - in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion; - in the circumstances foreseen in DTR5.2.1 (g), the person that controls the voting rights; - in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion. (iv) Applicable in the cases provided for in DTR 5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in DTR5.2. (v) The date of the transaction should normally be, in the case of an on exchange transaction, the date on which the matching of orders occurs; in the case of an off exchange transaction, date of the entering into an agreement. The date on which threshold is crossed should normally be the date on which the acquisition, disposal or possibility to exercise voting rights takes effect (see DTR 5.1.1R (3)). For passive crossings, the date when the corporate event took effect. (vi) Please refer to the situation disclosed in the previous notification, In case the situation previous to the triggering transaction was below 3%, please state 'below 3%'. (vii) If the holding has fallen below the minimum threshold , the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is less than 3%. For the case provided for in DTR5.2.1(a), there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an Article 9 threshold. This applies upon entering into, introducing changes to or terminating an agreement. (viii) Direct and indirect (ix) In case of combined holdings of shares with voting rights attached 'direct holding' and voting rights 'indirect holdings', please split the voting rights number and percentage into the direct and indirect columns-if there is no combined holdings, please leave the relevant box blank. (x) Voting rights to shares in respect of which the notifying party is a direct shareholder (DTR 5.1) (xi) Voting rights held by the notifying party as an indirect shareholder (DTR 5.2.1) (xii) If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%. (xiii) date of maturity / expiration of the finical instrument i.e. the date when the right to acquire shares ends. (xiv) If the financial instrument has such a period-please specify the period- for example once every three months starting from the (date) (xv) The notification should include the name(s) of the controlled undertakings through which the voting rights are held. The notification should also include the amount of voting rights and the percentage held by each controlled undertaking, insofar as individually the controlled undertaking holds 5% or more, and insofar as the notification by the parent undertaking is intended to cover the notification obligations of the controlled undertaking. (xvi ) This annex is only to be filed with the competent authority. (xvii) Whenever another person makes the notification on behalf of the shareholder or the natural person/legal entity referred to in DTR5.2 and DTR5.3 Schedule FIL Issuer name: Sinclair Pharma plc Current ownership percentage: 10.1% Total Shares Held: 9,352,556 Issued Share Capital: 93,361,219 +-------------------------------------------------------------------+ | Shares held | Nominee | Management Company | |-------------+--------------------------------+--------------------| | 88,175 | STATE STR BK AND TR CO LNDN (S | FPM | |-------------+--------------------------------+--------------------| | 153,123 | STATE STR BK AND TR CO LNDN (S | FIL | |-------------+--------------------------------+--------------------| | 322,214 | NORTHERN TRUST LONDON | FPM | |-------------+--------------------------------+--------------------| | 233,000 | JP MORGAN, BOURNEMOUTH | FPM | |-------------+--------------------------------+--------------------| | 2,506,738 | JP MORGAN, BOURNEMOUTH | FISL | |-------------+--------------------------------+--------------------| | 317,264 | JP MORGAN, BOURNEMOUTH | FIL | |-------------+--------------------------------+--------------------| | 272,661 | BROWN BROTHERS HARRIMAN AND CO | FIJ | |-------------+--------------------------------+--------------------| | 5,277,005 | BROWN BROS HARRIMN LTD LUX | FIL | |-------------+--------------------------------+--------------------| | 182,376 | BANK OF NEW YORK BRUSSELS | FPM | +-------------------------------------------------------------------+ ---END OF MESSAGE---


 

Press release Maconomy hires Claus Thorsgaard as the new VP Sales. Claus Thorsgaard obtains the global sales responsibility in Maconomy and will ensure, in cooperation with the six country managers, that Maconomy's growth plans towards 2008 are realised. Copenhagen April 27, 2007. Maconomy's new VP Sales, Claus Thorsgaard, comes from a position as Sales & Marketing director at Siemens IT Solutions and Services. In his former job he was responsible for both New Orders and P/L for all Danish customers besides The Danish Defense and Siemens Group. From 2001 - 2005 Claus Thorsgaard acted as Sales Director and CEO in Ementor Danmark. Prior to this, 1995-2000, he was a consultant and partner in Ernst & Young Management Consulting with the responsibility for the ERP service line. Claus Thorsgaard is 38 years old. He holds a Master of Science in Managerial Accounting from the Copenhagen Business School. Furthermore, Claus Thorsgaard has been acting as Expert Judge at The Copenhagen Maritime and Commercial Court. "With a background in ERP, Management Consulting and IT-Solutions and Services, Claus Thorsgaard is the perfect candidate for the job. Through the last 12 years, Claus Thorsgaard has proven that he is able to create great results within sales and business development and he is going to play an important role in the further strive to realise Maconomy's growth strategy, Hugo Dorph, CEO, in Maconomy A/S, says Claus Thorsgaard will start as VP Sales on June 1st, 2007. Download picture of Claus Thorsgaard. Further information: Hugo Dorph Claus Thorsgaard CEO VP Sales (as of June 1) Phone: +45 35 27 24 24 Phone: +45 21 24 31 29Email: ir@maconomy.com About Maconomy A/S Maconomy is a global provider of industry-specific business solutions for professional services companies and marketing communications organisations. Maconomy A/S was founded in 1989 and corporate headquarters are located in Copenhagen, Denmark. Maconomy services and supports roughly 500 customers in 50 countries through our offices in the U.S. and across Europe, and through an extensive partner network. Today, more than 90,000 users worldwide use Maconomy's business solutions. For more information, please visit www.maconomy.com This announcement has been prepared in Danish and English. The Danish version is to be considered the original version for official purpose and in case of any discrepancies between the two versions the Danish version shall prevail.


 

For further information, please contact: Åke Rosenius, President, ÅF Infrastructure Division +46 (0)70-827 91 30 Viktor Svensson, Director, Corporate Information +46 (0)70-657 20 26 ÅF, via the Group's Infrastructure Division, is increasing its stake in the Danish technical consulting company Hansen & Henneberg from 49 percent to 80 percent. The acquisition takes place against the background of several years' successful cooperation between ÅF and Hansen & Henneberg. ÅF purchased 49 percent of the shares in the Danish company in 2001. Hansen & Henneberg was established in 1947 and today has a staff of almost 60 based in the company's office in Copenhagen. The company has a reputation as one of Denmark's foremost consulting companies in the areas of electrical engineering, lighting systems, traffic control and information technology. Among its more recent assignments Hansen & Henneberg has been involved in projects to design the power supply and instrumentation for the Great Belt Bridge between the Danish islands of Zealand and Funen, the Öresund Fixed Link between Sweden and Denmark, Copenhagen Airport and the Royal Library in Copenhagen. The acquisition will bring the number of ÅF employees in Denmark to a total of approximately 100. Corporate Information AB Ångpanneföreningen The ÅF Group is a leader in technical consulting, with expertise founded on more than a century of experience. We offer highly qualified services and solutions for industrial processes, infrastructure projects and the development of products and IT systems. We are also one of the leading names in testing and inspection. Today the ÅF Group has 3,500 employees. Our base is in Europe, but our business and our clients are found all over the world.


 
Ýmislegt
27. apríl 2007

Wereldhave Belgium

Treatment judicial procedure of April 27, 2007 Wereldhave Belgium announces that, during the session of April 27, 2007, the Raadkamer / Chambre du Conseil in Brussels decided to put before a private sitting of the court the case regarding the matter of a penal dispute arising from the sale of a company in 1993, later reclassified as a cash company. The decision of the Raadkamer / Chambre du Conseil concerning the proceedings is expected on May 31, 2007. For more information please see our press release of December 5, 2006 at www.wereldhavebelgium.com Comm.VA WERELDHAVE BELGIUM SCA Limited share partnership according to Belgian Law, which has made a public appeal to the savings domain. 1800 Vilvoorde, Medialaan 30 RPR 0 412.597.022


 

FL Group today has announced that the company owns 2.99% of the share capital in Commerzbank AG. This stake is currently valued at approximately EUR 723 million and has been built up in recent weeks. FL Group's evaluation is that Commerzbank represents an exciting investment opportunity in the European banking sector. The decision to invest in the company comes after a thorough analysis of the sector and FL Group believes that the current valuation is attractive and the predicted consolidation in the industry is starting to materialize. Commerzbank is the second largest bank in Germany and one of Europes leading banks. Germany is by far the banks most important market, demonstrated by a nationwide network of some 800 branches, but it has also offices in more than 40 countries outside of Germany. Commerzbank realised a profit of EUR 1,597 million in 2006 which made last year one of the best in its history. Commerzbank has a market capitalization of EUR 24.2 billion. Hannes Smárason, CEO of FL Group said: "The investment in Commerzbank fits our investment strategy where an essential part is investments in the banking and financial services. We feel that the company's valuation in the market does not reflect the turnaround of its operations, neither in Germany nor internationally. FL Group believes that there are opportunities in the sector and is evaluating other investment opportunities." Enquiries: FL Group Hannes Smárason Kristján Kristjánsson CEO Director Corp. Communications Tel: +354 591 4400 Tel: +354 591 4400 / 354 899 9352 About FL Group FL Group is an international investment company, focusing its activities on two areas of investments. The company's Private Equity and strategic investments focus on investments in public and private companies and has a long term view. The company's Capital Markets unit oversees the company's short term trading as well as derivative and security trading related to the company's asset portfolio. With its head office in Reykjavik and offices in Copenhagen and London, FL Group invests in companies in Northern Europe, focusing primarily on the Nordics and the UK but also has investments elsewhere. FL Group is listed on the OMX Nordic Exchange in Reykjavik (OMX: FL). At the end of first quarter 2007 FL Group's total assets amounted to ISK 303 billion (EUR 3.4 billion). Its market capitalisation at the end of March 2007 was ISK 236 billion (EUR 2.7 billion). The largest shareholders of FL Group are Oddaflug BV (19.8%), owned by Hannes Smárason, CEO; Baugur Group (18.2%), Gnúpur fjárfestingafélag hf. (17.2%), Icon and Materia Invest (10.7%). The shareholding can in some cases be in the name of Icelandic financial institutions because of forward contracts. More information on www.flgroup.is


 

158% increase compared to first quarter 2006 Key financial highlights * Profit after tax increases by 158% to ISK 15.1 billion (EUR 172 million) compared to first quarter 2006 * Total assets increases by ISK 40 billion during the first quarter and were ISK 302.8 billion (EUR 3,44 billion) at the end of March 2007 * Minimal change in shareholders equity from year end 2006 despite a ISK 15 billion dividend payment * Return on equity in the quarter was 42.4% on annual basis * Financial position strong with equity ratio of 47% Key investment and operating highlights * Stake in Glitnir increased to 31.97% * Stakebuilding in Commerzbank - current shareholding 2.99% * Stake in AMR Corporation increased to 8.53% * Refresco closed three acquisitions in first quarter increasing run rate revenue to over EUR 1 billion * Sale of all shares in Kynnisferðir - net profit from the sale amounted to ISK 486 million * Capital Markets Desk created Commenting on the results, Hannes Smárason, CEO of FL Group, said: "We are delighted with a successful first quarter and a great increase in profit after tax from the previous year. This shows continued strong growth with significant liquidity and investment power across our focused investment business, following the sale of Icelandair and Sterling Airlines at the end of 2006." "We are confident that our robust business model means we are now even better placed to capitalise on opportunities going forward. " Enquiries: FL Group Hannes Smárason Kristján Kristjánsson CEO Director Corporate Communications Tel: +354 591 4400 Tel: +354 591 4427 / +354 899 9352 Sveinbjörn Indriðason CFO Tel: +354 591 4400 UK / Brunswick Group Denmark / Jöp, Ove & Myrthu LLP A/S Anita Scott, Hanna Gustafsson Lars Jörgensen Tel: +44 (0) 20 7404 5959 Tel: +45 29 78 49 32 / +45 39 27 50 50 About FL Group FL Group is a unique international investment company, focusing its activities on two areas of investments. The company's Private Equity and Strategic Investments focus on investments in public and private companies and have a long term view. The company's Capital Markets unit oversees the company's short term trading as well as derivative and security trading related to the company's asset portfolio. With its head office in Reykjavik and offices in Copenhagen and London, FL Group invests in companies in Northern Europe, focusing primarily on the Nordics and the UK but also has investments elsewhere. FL Group is listed on the OMX Nordic Exchange in Reykjavik (OMX: FL). At the end of first quarter 2007 FL Group's total assets amounted to ISK 303 billion (EUR 3.4 billion). Its market capitalisation at the end of March 2007 was ISK 236 billion (EUR 2.7 billion). The largest shareholders of FL Group are Oddaflug BV (19.8%), owned by Hannes Smárason, CEO; Baugur Group (18.2%), Gnúpur fjárfestingafélag hf. (17.2%), Icon and Materia Invest (10.7%). The shareholding can in some cases be in the name of Icelandic financial institutions because of forward contracts. More information on www.flgroup.is The full report including tables can be downloaded from the following link:


 

* Novartis leading the introduction of influenza cell culture manufacturing - the first major innovation in influenza vaccine manufacturing in more than 50 years * Optaflu® to help meet growing need for seasonal influenza vaccines, production technology has potential for quick scale-up in case of an influenza pandemic * Novartis proprietary cell culture technology offers possibility to obtain a better matched vaccine with circulating viruses than currently available technology Basel, April 27, 2007 - Novartis has received a positive opinion supporting European Union approval of its cell culture-derived seasonal influenza vaccine Optaflu®, which is aiming to become the first influenza vaccine to utilize a mammalian cell line, rather than chicken eggs, for antigen production. The Committee for Medicinal Products for Human Use (CHMP), which reviews applications for all 27 countries in the EU as well as Iceland and Norway, has recommended approval of this new vaccine. The European Commission generally follows the recommendations of the CHMP and delivers its final decision within two to three months. "Novartis Vaccines is pleased with this positive recommendation for Optaflu, the first cell culture-derived influenza vaccine and the first major innovation in influenza vaccine manufacturing in more than 50 years," said Dr. Jörg Reinhardt, CEO of Novartis Vaccines and Diagnostics. "Optaflu contributes to meeting the growing demand for seasonal influenza vaccines, and this production technology offers the potential for quick scale-up of manufacturing in the event of an influenza pandemic." A submission is anticipated in 2008 for US regulatory approval of this cell culture-derived seasonal influenza vaccine. More than 3,400 people received Optaflu during the clinical development program evaluating the vaccine's safety and immunogenicity. Data reviewed by CHMP from the clinical program showed Optaflu fulfilled all of the Committee's immunogenicity criteria. The data further showed the cell culture-derived influenza vaccine was comparable to conventional egg-based vaccines in efficacy and tolerability. Additives, such as antibiotics, are avoided in the Optaflu production process. Additionally, people allergic to eggs and egg products can benefit from receiving this vaccine since it is created without egg proteins. Like established conventional egg-based vaccines, Optaflu is administered via intramuscular injection. Data from the Phase III clincial program were presented at the Influenza Vaccines for the World Congress (IVW) meeting in October 2006. About cell culture technology and the Novartis proprietary cell line Cell culture manufacturing is the first major innovation in influenza vaccine manufacturing in more than 50 years. It represents a new approach to vaccine production whereby influenza virus is propagated in readily available mammalian cell lines rather than in chicken eggs. Virus cultivation utilizing the Novartis proprietary cell line as an exclusive host offers the possibility of more robust virus proliferation since most circulating viral strains are unable to replicate in chicken eggs. In a next generation of products, it also offers the possibility for vaccine seed strain development that more closely matches the original "wild" virus because cell culture technology eliminates the need for passage through eggs where the virus may be forced to adapt in order to replicate. As a result, the antigen included in the vaccine may express more authentically the surface of the wild type virus, potentially translating into a better immunogenic and effective response. The Novartis proprietary cell culture technology enables flexible, faster start-up of vaccine manufacturing. With the advent of this technology, Novartis Vaccines is contributing to meet the growing need for seasonal influenza vaccines and quickly respond to a potential pandemic influenza threat. About influenza and pandemic influenza Influenza can cause mild to severe illness and at times can lead to death. Worldwide, influenza epidemics result in approximately 250,000 to 500,000 deaths each year[1]. Influenza-related complications can include pneumonia and dehydration, and worsening of chronic conditions, such as congestive heart failure, asthma, or diabetes[2]. The World Health Organization (WHO) and its Global Influenza Surveillance Network recommend vaccination as the principal method for preventing influenza[1]. Increased circulation of avian influenza A/H5N1 virus has been documented in Asia and Europe. On a pandemic threat scale of one to six, the World Health Organization currently ranks the H5N1 risk at phase three. This virus is highly contagious in chickens, adding the possibility that a pandemic strain could emerge at a time when egg supplies are lower than usual due to a previous epidemic in chickens. Novartis proprietary cell culture line offers an alternative to traditional egg-derived vaccines. References 1. World Health Organization "Influenza Fact Sheet" http://www.who.int/mediacentre/factsheets/fs211/en/index.html Accessed October 10, 2006 2. Centers for Disease Control and Prevention (CDC) "Questions & Answers: The Disease" http://www.cdc.gov/flu/about/qa/disease.htm Accessed October 10, 2006 Disclaimer This release contains certain forward-looking statements, relating to the Novartis Group's business, which can be identified by the use of forward-looking terminology such as "to help," "potential," "possibility," "aiming to", "recommended", "generally follows the recommendations," "anticipated," "potentially, "can," "could," or similar expressions, or by express or implied discussions regarding potential marketing approvals or future sales of Optaflu. Such forward-looking statements reflect the current views of Novartis regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Optaflu to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Optaflu will be approved for any indications in any market or that Optaflu will reach any particular sales levels. In particular, management's expectations regarding Optaflu could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including additional analysis of existing clinical data and new clinical data; competition in general; the ability of Novartis to obtain or maintain patent or other proprietary intellectual property protection; increased government, industry, and general public pricing pressures; and other risks and factors referred to in the Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis Vaccines and Diagnostics is a division of Novartis focused on the development of preventive treatments and tools. Novartis Vaccines is the world's fifth-largest manufacturer and second-largest supplier of influenza vaccines in the US. The division's products also include meningococcal, pediatric and travel vaccines. Chiron, the blood testing and molecular diagnostics business, is dedicated to preventing the spread of infectious diseases through the development of novel blood-screening tools that protect the world's blood supply. For more information, please visit http://www.novartisvaccines.com. Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative-products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com. # # # Novartis Media Relations Corinne Hoff Novartis Global Media Relations +41-61-324-9577 (direct) +41-79-248-5717 corinne.hoff@novartis.com Eric Althoff Novartis Vaccines and Diagnostics Global Communications +1-510-923-6500 (direct) +1-510-387-7604 (US mobile) eric.althoff@novartis.com e-mail: media.relations@novartis.com or nvd.communications@novartis.com Media materials For images and video related to the Novartis Vaccines influenza products, please visit www.thenewsmarket.com/novartisvaccines. Journalists may register and download print-quality images and broadcast-standard video from this site at no charge. Novartis Investor Relations International: Ruth Metzler-Arnold +41 61 324 7944 Katharina Ambühl +41 61 324 5316 Nafida Bendali +41 61 324 3514 Jason Hannon +41 61 324 2152 Thomas Hungerbuehler +41 61 324 8425 Richard Jarvis +41 61 324 4353 North America: Ronen Tamir +1 212 830 2433 Arun Nadiga +1 212 830 2444 Jill Pozarek +1 212 830 2445 Edwin Valeriano +1 212 830 2456 e-mail: investor.relations@novartis.com --- End of Message --- Novartis International AG Posfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE; Listed: Main Market in SWX Swiss Exchange, ZLS in BX Berne eXchange;


 
Ýmislegt
27. apríl 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-----------------------------------------------+-------------------| | Company dealt in | Wilson Bowden Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-----------------------------------------------+-------------------| | Date of dealing | 26th April 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 0 | | | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 506 | 2,132p | 2,132p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +------------------------------------------------------------------+ | Date of disclosure | 27th April 2007 | |----------------------------------------------+-------------------| | Contact name | Edward Hodge | |----------------------------------------------+-------------------| | Telephone number | 0207 992 16661 | |----------------------------------------------+-------------------| | Name of offeree/offeror with which connected | Wilson Bowden Plc | |----------------------------------------------+-------------------| | Nature of connection (Note 6) | Connected Advisor | +------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

A news conference will be held today on April 27, 2007 at 1:30 p.m. in Finnish and at 3:00 p.m. in English at Metso's Corporate Office, Fabianinkatu 9 A, Helsinki, Finland. The English-language news conference can be followed on the Internet at www.metso.com. Metso's Interim Review, January 1 - March 31, 2007 Profitable growth continued Highlights of the first quarter * New orders worth EUR 1,664 million were received in January-March, i.e. 16 percent more than in the corresponding period last year (EUR 1,437 million in Q1/06). * The order backlog grew by 7 percent from the end of 2006 and was EUR 3,999 million at the end of March (EUR 3,737 million on Dec. 31, 2006). * Net sales increased by 27 percent and totaled EUR 1,366 million (EUR 1,078 million in Q1/06). * Earnings before interest, tax and amortization (EBITA) were EUR 121.9 million, i.e. 8.9 percent of net sales (EUR 99.9 million and 9.3% in Q1/06). * Operating profit (EBIT) was EUR 108.4 million, i.e. 7.9 percent of net sales (EUR 95.4 million and 8.8% in Q1/06). * Earnings per share were EUR 0.50 (EUR 0.47 in Q1/06). * Free cash flow was EUR 97 million (EUR 152 million in Q1/06). * Return on capital employed (ROCE) was 20.7 percent (20.2% in Q1/06). "Metso's January - March order intake was strong, and our order backlog has further strengthened from the record-high year-end figures. This, together with the continuing favorable market outlook, gives us confidence about the rest of the year and beyond," says Jorma Eloranta, President and CEO, Metso Corporation. Eloranta notes that Metso's financial performance was solid despite seasonal factors that are typical for the first quarter. "Our net sales grew significantly over the same period in 2006. Much of the growth is due to our expanded business scope, i.e. the acquisition of the Pulping and Power businesses, but even organically we delivered some 10 percent growth. Also our operating profit improved on the first quarter of 2006." Eloranta says that Metso's outlook for 2007 continues to be favorable. "The financial performance for the rest of the year is expected to be stronger than in the first quarter of 2007. Furthermore, we repeat our estimate that our net sales will grow by more than 20 percent on 2006 and that the operating profit will clearly improve." Short-term outlook The favorable market outlook for Metso's products and services is expected to continue for the rest of 2007. Metso Paper's market situation is estimated to continue much the same as in the year's first quarter. The demand for paper, board and tissue machines and for fiber lines is expected to be satisfactory. The demand for power plants is estimated to be good. Also the demand for Metso Paper's aftermarket services is expected to remain satisfactory. Metso Minerals' favorable market outlook is expected to continue. The demand is anticipated to remain at the first quarter's excellent level in the mining and metals recycling industries, and at a good level in the construction industry. The demand for aftermarket services is expected to remain excellent. Metso Automation's market outlook in the pulp and paper customer segment is estimated to be good. In the power, oil and gas industries, the demand is expected to be good in process automation systems and excellent in flow control systems. It is estimated that Metso's financial performance for the rest of the year will be stronger than in the first quarter. Metso's net sales in 2007 are estimated to grow by more than 20 percent on 2006, thanks to the strong order backlog, continuing favorable market situation and the expanded business scope. The operating profit in 2007 is estimated to clearly improve. It is estimated that the operating profit margin in 2007 will be slightly below Metso's target, which is over 10 percent. This is primarily due to the high first-year amortization of intangible assets, integration costs and only partially materializing synergy benefits related to the acquisition of the Pulping and Power businesses. The estimates concerning financial performance are based on Metso's current structure, order backlog and market outlook. Publication dates for Metso's Interim Reviews in 2007 Metso's Interim Review for January - June will be published on July 26, 2007, Interim Review for January - September on October 25, 2007. Metso is a global engineering and technology corporation with 2006 net sales of approximately EUR 5 billion. Its 25,500 employees in more than 50 countries serve customers in the pulp and paper industry, rock and minerals processing, the energy industry and selected other industries. www.metso.com For further information, please contact: Jorma Eloranta, President and CEO, Metso Corporation, tel. +358 204 84 3000 Olli Vaartimo, Executive Vice President and CFO, Metso Corporation, tel. +358 204 84 3010 Johanna Sintonen, Vice President, Investor Relations, Metso Corporation, tel. +358 204 84 3253 It should be noted that certain statements herein which are not historical facts, including, without limitation, those regarding expectations for general economic development and the market situation, expectations for customer industry profitability and investment willingness, expectations for company growth, development and profitability and the realization of synergy benefits and cost savings, and statements preceded by "expects", "estimates", "forecasts" or similar expressions, are forward-looking statements. These statements are based on current decisions and plans and currently known factors. They involve risks and uncertainties which may cause the actual results to materially differ from the results currently expected by the company. Such factors include, but are not limited to: (1) general economic conditions, including fluctuations in exchange rates and interest levels which influence the operating environment and profitability of customers and thereby the orders received by the company and their margins (2) the competitive situation, especially significant technological solutions developed by competitors (3) the company's own operating conditions, such as the success of production, product development and project management and their continuous development and improvement (4) the success of pending and future acquisitions and restructuring.


 

Press release April 27, 2007 Norgani Q1 2007 * Operating net NOK 143 (107) million * Net profit NOK 108 (69) million * Return on equity 14.4 (15.0) percent * Earnings per share NOK 2.70 (2.30) "The strong market development in the Nordic region continued in the beginning of 2007 with increased RevPAR as both average room rate and occupancy grew. We believe that the strong market development is set to continue. We expect occupancy levels to remain high while average room rates can increase further",comments CEO Eva Eriksson. Revenue increased to NOK 157 (122) million and operating net to NOK 143 (107) million, mainly reflecting an increased size of the property portfolio. Two properties were sold during the first quarter, resulting in a cash flow of NOK 11 million. The increase in administrative and financial costs is attributable to a larger property holding and the build up of the organization to handle key administrative and operational functions. Provisions in accordance with the termination agreement with former CEO Kjell Sagstad have also been made in the period. For further information, please contact: Eva Eriksson, CEO Mob: +46 70 644 3497 E-mail: eva@norgani.se Mats Sterner, CFO Mob: +46 70 690 2009 E-mail: mats@norgani.se About Norgani With a portfolio of more than 70 hotels in the Nordic region, Norgani Hotels is Europe's fifth largest hotel property investor. Through size, specialization and a knowledge of and insight in the hotel industry, Norgani is creating a unique platform for development of hotel properties and business in cooperation with operators and brands. The share is listed on the Oslo Stock Exchange. www.norgani.no


 

Ericsson (NASDAQ:ERIC) has been chosen by Philippine operator SMART to enhance the switching capacity of its satellite-based telephony network, called SMART Link, giving consumers greater reach and access to data services. Under the agreement, Ericsson will install its Mobile Softswitch Solution at SMART's earth station in Subic Bay, north of Manila, enabling the operator to efficiently boost capacity and accommodate new users. Mobile Softswitch Solution improves voice quality and increases network efficiency, helping operators to reduce core network opex by up to 50 percent. The expanded infrastructure will allow SMART to provide access to the newly launched Inmarsat I-4 satellite. The cooperation between SMART and the UK's Inmarsat will increase SMART Link's existing coverage area across Asia to include Europe, the Middle East and Africa. Rajendra Pangrekar, President of Ericsson Philippines, says: "This project showcases the flexibility of Ericsson's Mobile Softswitch Solution. We are very pleased to be able to help SMART enhance their network with this latest technology. We are confident that this will enable them to gain network efficiency, provide an even greater array of services to their customers, and connect them to even more parts of the world." SMART is the only company in the Philippines offering satellite-based mobile services. The SMART Link Satellite Service allows subscribers to make calls anywhere in its coverage area, whether on land or at sea. It is especially popular among Filipino seafarers, who can use the roaming service while onboard, and those who travel or live in remote areas of the Philippines. Ericsson is shaping the future of mobile and broadband internet communications through its continuous technology leadership. Providing innovative solutions in more than 140 countries, Ericsson is helping to create the most powerful communication companies in the world. Read more at www.ericsson.com FOR FURTHER INFORMATION, PLEASE CONTACT Ericsson Media Relations Phone: +4687196992 E-mail: press.relations@ericsson.com About SMART and SMART Link Smart Communications, Inc. is the Philippines' leading wireless services provider with 24.2 million subscribers on its GSM network as of end-December 2006. Of its total subscriber base, 17.2 million subscribers are served under the brands Smart Buddy, Smart Gold and Smart Infinity. Another 7 million subscribers are served through its subsidiary, Pilipino Telephone Corp., under the brand Talk 'N Text. SMART has built a reputation for innovation, having introduced world-first wireless data services, including mobile commerce services such as Smart Money, Smart Load and Smart Padala. SMART also offers a 3G service, Smart 3G, and a wireless broadband service, Smart Bro. SMART is a wholly-owned subsidiary of the Philippines' leading telecommunications carrier, the Philippine Long Distance Telephone Company. About Ericsson softswitch solutions Ericsson is the leading provider of softswitch solutions for both mobile and wireline networks. Ericsson's solutions are commercially proven and fully standards-compliant, offering an efficient and low-risk evolution of existing circuit-switched networks to a telecom-quality, IP-based service platform. Ericsson solutions use network resources in the most cost-efficient way to provide both classic telephony and next-generation services. More than 160 fixed and mobile operators worldwide have commercially launched services based on Ericsson's softswitch solutions


 

Getronics increases its service capabilities in one of the world's largest IT markets and looks to further expand its relationship with NTT Data Corporation in the Asia Pacific and Greater China Region. Getronics today announced the signing of a share purchase agreement on the sale of 70% of its shares in Getronics Japan to NTT Data Corporation, creating a new strategic partnership between Getronics and NTT Data Corporation in Japan. The new partnership enables Getronics to expand its workspace management activities in Japan and increase its international client business with NTT Data Corporation. Getronics will receive EUR 33 million from NTT Data Corporation and retains a 30% share in the new partnership. Getronics has been assisted during the transaction by KPMG Corporate Finance. Completion of the transaction is planned for May 2007. The new partnership will combine the considerable strengths of both companies in the financial services sector in Japan, drawing upon NTT Data's extensive local service network and Getronics' expertise in workspace management services. In addition, NTT Data Corporation and Getronics will also work closely together to ensure that the new partnership can benefit fully from Getronics' Global Service Delivery Model, enabling the two companies to extend their working partnership beyond Japan. Getronics and NTT Data Corporation are presently actively looking to work together in the Asia Pacific and China Region, providing services together to NTT Data Corporation's clients. Klaas Wagenaar, Getronics CEO and chairman, states, 'This partnership not only creates a powerful combination in the Japanese financial services sector, it also lays the foundations for future business opportunities globally for both Getronics and NTT Data Corporation, as major Japanese clients look for a global partner in ICT services.' About NTT Data Corporation NTT Data Corporation is a public company currently traded on the Tokyo Stock Exchange (9613 JP) and is a subsidiary of NTT Group of Japan. NTT is an abbreviation for Nippon Telegraph and Telephone Corporation of Japan. As an $8 billion system integrator with over 20,000 employees globally, NTT Data Corporation has regional offices/subsidiaries in Japan, Asia (Beijing, Shanghai, South Korea, and Kuala Lumpur), Europe (London) and North America (New York, New Jersey, Pennsylvania, Washington D.C., and California). About Getronics With some 25,000 employees in more than 25 countries and approximate revenues of EUR 2.6 billion, Getronics is a leading international provider of Information and Communication Technology (ICT) services and solutions. Applying its expertise in workspace management, applications, and consulting and transformation services, Getronics helps organisations raise their performance and increase the productivity of their people, by providing them with the ability to share information and to work together efficiently, securely and effectively, wherever and whenever they need. Getronics headquarters are in Amsterdam, with regional offices in Boston and Singapore. Getronics' shares are traded on Euronext Amsterdam ('GTN'). For further information about Getronics, visit www.getronics.com. Press Enquiries Investor Enquiries Getronics Corporate Communications Getronics Investor Relations Thurstan Robinson Simon Theeuwes Tel: +31 20 586 1581 Tel: +31 20 586 1982 media@getronics.com investor.relations@getronics.com


 

Telenor will present the Group's financial results for the 1st quarter 2007 FRIDAY 4 MAY, 0900 CET/0800 UK TIME at Telenor Expo Visitor Centre, Snarøyveien 30, Fornebu The presentation will be held in English. If you are unable to attend the presentation, we offer three other options: a) Watch the presentation live on the Internet or through your mobile phone The webcast link will be posted on our website. To watch the presentation on your mobile phone, send a sms with access word q107 to no +4799454510 (abroad) or 2229 (Norway). The live webcast allows for written questions to be submitted. b) Listen to the presentation on the phone This service also allows you to ask questions at the Q and A session at the end of the presentation. To participate in the Conference Call please register at least 10 minutes before the presentation starts, dial: +47 80080119 (from Norway) or +47 23000400 (from Norway or abroad) c) Watch and listen to the recorded presentation The presentation will be available as both recorded webcast (video) and audio after the presentation. To access the conference call replay via phone, dial +47 67894091, account no: 1155 followed by # (pound sign) press 1, conference no: 155 followed by # (pound sign) press 1 to play The Q1 report and presentation material will be available on our website from 0700 CET /0600 UK time on 4 May 2007: www.telenor.com/ir/reports/07q1 Best regards, Telenor ASA Investor Relations


 

* Sales for the first quarter amounted to 2,663 MSEK (2,951) * A sharp increase in the excise tax for snus effective January 1, 2007, resulted in exceptionally low deliveries of snus to the Swedish market during the first quarter * Operating profit for the first quarter amounted to 534 MSEK (733) * Net profit for the first quarter amounted to 332 MSEK (488) * EPS for the first quarter amounted to 1.23 SEK (1.62) Swedish Match AB (publ), SE-118 85 Stockholm Visiting address: Rosenlundsgatan 36, Telephone: +46 8 658 02 00 Corporate Identity Number: 556015-0756 www.swedishmatch.com For further information, please contact: Sven Hindrikes, President and Chief Executive Officer Office +46 8 658 02 82, Mobile +46 70 567 41 76 Lars Dahlgren, Chief Financial Officer Office +46 8 658 04 41, Mobile +46 70 958 04 41 Bo Aulin, Senior Executive Advisor & Senior Vice President Corp. Communications Office +46 8 658 03 64, Mobile +46 70 558 03 64 Emmett Harrison, Vice President, Investor Relations Office +46 8 658 01 73, Mobile +46 70 938 01 73 Richard Flaherty, COO OTP, North America Division, US Investor Relations contact Office +1 804 302 1774, Mobile +1 804 400 1774 The full report with tables can be downloaded from the following link:


 

Elcoteq SE Press Release April 27, 2007 at 10.00 am (EET) Elcoteq Wins Electronics Manufacturing Asia 2007 Innovation Award Elcoteq Asia-Pacific (APAC) has been recognized as winner of the Electronics Manufacturing (EM) Asia Innovation Award 2007 in the category of Contract Services. EM Asia is a key trade publication in APAC. The awards ceremony was held in Shanghai during NEPCON China on April 25, 2007. Elcoteq won the award in the Contract Services category, and was chosen as the winner among the ten competing companies. All contestants are providers of electronics manufacturing services to original equipment manufacturers (OEMs). Elcoteq was awarded for its global end-to-end solutions concept that includes product development, sourcing, new product introduction, supply chain management, global manufacturing, and after-sales services. The EM Asia Innovation Awards program strives to recognize and celebrate excellence in the Asian electronics industry, inspiring companies to achieve the highest standards and push the industry forward. Winners were selected by an independent panel of judges who are experts and leaders in their fields. Entrants were judged on the following criteria: innovation and achievement, quality, cost efficiency, setting challenging objectives and outstanding achievements. The award was received by Mr. Bobby Wang, Sourcing Director of Elcoteq APAC. "This award is a result of a dedicated Elcoteq team that has worked together for many years and has successfully supported our strategic customers to achieve their targets through electronics manufacturing services in Asia," said Mr. Wang. "Competition is intensifying in the communications technology market and most manufacturers are seeking solutions to cope with constantly shorter product lifecycles and declining product prices. It's imperative for us to understand our customers' needs in the longer term to maintain their competitive positions." ELCOTEQ SE Reeta Kaukiainen Director, Communications and Investors Relations About Elcoteq Elcoteq SE is a leading electronics manufacturing services (EMS) company with original design manufacturing (ODM) capabilities in the communications technology field. Elcoteq provides global end-to-end solutions consisting of design, NPI, manufacturing, supply chain management, and after-sales services for the whole lifecycle of its customers' products. These products include terminal products such as mobile phones and set-top boxes as well as communications network equipment such as base-stations, tower-top amplifiers, and microwave systems. The company operates in 16 countries on four continents and employs some 23,000 people. Elcoteq's consolidated net sales for 2006 totaled 4.3 billion euros. Elcoteq SE is listed on the Helsinki Stock Exchange. For more information visit the Elcoteq website at www.elcoteq.com.


 

Reference is made to CSG notifications dated 25 January 2007 and 26 February 2007 regarding the merger between Component Software Group ASA and Component Software ASA. The merger is accomplished and registered in Brønnøysund 27 April 2007. From the same date, the share capital has been increased with NOK 832.110 by the issuance of 277.370 shares, each with the par value of NOK 3. After the capital increase, the share capital is NOK 17.470.227 divided on 5.823.409 shares, each with the par value of NOK 3.


 

Statoil ASA (OSE: STL, NYSE: STO) and North American Oil Sands Corporation (NAOSC) announced today that they have entered into an acquisition agreement whereby Statoil will make an all-cash offer to acquire all shares of NAOSC at a price of CAD 20 per share. The total transaction value is approximately CAD 2.2 billion, equivalent to about USD 2 billion. NAOSC, a Calgary-based company, was formed in 2001. It operates 257,200 acres (1,110 square kilometres) of oil sands leases located in the Athabasca region of Alberta, north-east of Edmonton. The board of directors of NAOSC has unanimously approved the offer, recommending that its shareholders accept the offer. The three principal shareholders of NAOSC - Paramount Resources Ltd, funds managed by affiliates of ARC Financial Corporation and Ontario Teachers' Pension Plan - have agreed to tender all of their shares to the offer. They represent approximately 69% of the issued and outstanding shares on a fully diluted basis. "Today's acquisition is an important strategic move which supports our global growth ambition and increases our reserve bookings in the long term," says Helge Lund, chief executive of Statoil. "We will become operator and get access to large recoverable resources that will add to our production post 2010. We are developing our global heavy oil portfolio and strengthening our marketing position in North America." Heavy oil production is energy intensive and challenging in an environmental perspective. "We will utilise our experience in developing resources in a sustainable manner, applying technology solutions that minimise environmental impact," says Mr Lund. "We are excited to have secured this agreement and look forward to creating value by leveraging on our key competences such as improved oil recovery (IOR) and large project execution skills," says Mr Lund. It is estimated that the NAOSC leases hold approximately 2.2 billion barrels in recoverable reserves. Statoil believes that by applying its broad technological competence developed through 30 years of experience on the Norwegian continental shelf, there is a potential for increasing the recoverable reserve base. A pilot production scheme, the Leismer demonstration project, is currently in its final phase of obtaining regulatory approvals. It will have a capacity of 10,000 barrels of produced bitumen per day and first production is expected late 2009/early 2010. The first phase of the commercial project, Kai Kos Dehseh, is planned to come on stream in 2011, ramping up production to around 100,000 barrels per day in the middle of the next decade. The portfolio is expected to yield more than 200,000 barrels per day at the end of the next decade. "We are impressed by the performance and competence held by the employees in NAOSC," says Mr Lund. "Combined with Statoil's experience and commitment to prudent operations, we are well-positioned to develop the resources in a sustainable manner, creating value for Statoil and its shareholders." The offer is subject to regulatory approvals and other customary conditions contained in the formal offer documents. Full details of the offer will be included in a takeover bid circular and related documents which will be filed with securities regulators and mailed to NAOSC security holders by 15 May 2007. The transaction is expected to close by the end of the second quarter of 2007. Note to the editors: The production of unconventional oil in general and extra heavy oil (EHO) in particular is becoming an increasingly important element of the global liquid production. The Orinoco belt in Venezuela and the Athabasca region in Canada represent the world's two main resource plays for extra heavy oil. The latter is the largest of three oil sands deposits in Alberta, along with the Peace River and Cold Lake deposits. Statoil has important experience with producing EHO from Venezuela where the group has participated in building and operating upgraders of heavy oil. The development plans for the acquired NAOSC portfolio call for large scale application of the SAG-D-technology (steam assisted gravity drainage), which gives a much smaller environmental footprint than strip mining. Further information: Press Ola Morten Aanestad, vice president media relations, Statoil ASA, telephone +47 480 80 212/51 99 13 77 Rannveig S. Stangeland, public affairs manager, Statoil ASA, telephone +47 48 12 59 78/51 99 26 42 Investor relations Lars Troen Sørensen, senior vice president investor relations, Statoil, telephone +47 90 64 91 44 Geir Bjørnstad, vice president, US investor relations, Statoil, telephone +1 203 978 69 50 Conference call will be staged with CEO Helge Lund and CFO Eldar Sætre at 15:00 CET and 09:00 EST. Country Number Norway Free call 800 193 95 International Dial in +44 (0) 1452 552 510 UK Free call 0800 694 2370 USA Free call 1866 966 9444 Conference ID: 7500952 Disclaimer: This press release does not constitute an offer to exchange or sell or an offer to exchange or buy any securities. An offer of securities in the United States pursuant to a business combination transaction will only be made through a prospectus which is part of an effective registration statement filed with the US Securities and Exchange Commission. Hydro shareholders who are US persons or are located in the United States are advised to read the registration statement when and if it is declared effective by the US Securities and Exchange Commission because it will contain important information relating to the proposed transaction. You will be able to inspect and copy the registration statement relating to the proposed transaction and documents incorporated by reference at the SEC's Public Reference Room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Statoil's SEC filings are also available to the public at the SEC's web site at http://www.sec.gov. In addition Statoil will make the effective registration statement available for free to Hydro shareholders in the United States.


 

Royal DSM N.V. announces that in accordance with the share buy-back program announced on 27 September 2006 the company will today, 27 April 2007, start the second phase of this EUR 750 million program. DSM has signed a Discretionary Management Agreement with the bank that will execute the share buy-back. In 2007 DSM intends to repurchase shares for a total consideration of EUR 508 million. The repurchase price will be based on the daily VWAP (Value Weighted Average Price). Daily volumes to be repurchased will be around 10% of the daily trading volume. In accordance with the present regulations DSM will regularly inform the market via press releases about the progress made in the execution of this share buy-back program. DSM DSM is active worldwide in nutritional and pharma ingredients, performance materials and industrial chemicals. The company develops, produces and sells innovative products and services that help improve the quality of life. DSM's products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing and electrics & electronics (E&E). DSM's strategy, named Vision 2010 - Building on Strengths, focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation plus an increased presence in emerging economies. The group has annual sales of over ¤8 billion and employs some 22,000 people worldwide. DSM ranks among the global leaders in many of its fields. The company is headquartered in the Netherlands, with locations in Europe, Asia, Africa, Australia and the Americas. More information about DSM can be found at www.dsm.com. For more information: DSM Corporate Communications DSM Investor Relations Elvira Luykx Dries Ausems tel. +31 (0) 45 tel. +31 (0) 45 5782864 5782035 fax +31 (0) 45 5782595 fax +31 (0) 45 e-mail 5740680 investor.relations@dsm.com e-mail media.relations@dsm.com


 

Leiden, The Netherlands, April 27, 2007- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Novartis Vaccines and Diagnostics, Inc. today announced the extension of a non-exclusive research license agreement for PER.C6®. The license agreement allows Novartis to use Crucell's PER.C6® cell technology in manufacturing alphavirus vectors for its vaccine research programs. Financial details were not disclosed. About PER.C6® technology The PER.C6® technology is a cell line developed for the development and large- scale manufacture of biopharmaceutical products including vaccines. Compared to conventional production technologies, the strengths of the PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. These characteristics, combined with its ability to support the growth of both human and animal viruses, make PER.C6® technology the biopharmaceutical production technology of choice for Crucell's current and potential pharmaceutical and biotechnology partners. About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com. Forward-looking statements This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS). For further information please contact: Crucell N.V. For Crucell in the US: Leonard Kruimer Redington, Inc. Chief Financial Officer Thomas Redington Tel. +31-(0)71-524 8722 Tel. +1 212-926-1733 Leonard.Kruimer@crucell.com tredington@redingtoninc.com Barbara Mulder Director Corporate Communications Barbara.mulder@crucell.com Tel. +31-(0)71-524 8722


 

OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that it will host an analyst meeting on May 1. The Company invites analysts to attend the meeting in Leiden at 2:30 PM CET on Tuesday, May 1, 2007. OctoPlus' senior management will present a comprehensive overview of the Company's strategy, product development and clinical development status. Analysts who would like to attend the meeting should confirm their attendance via email to IR@octoplus.nl. Presentations from this meeting will be available from OctoPlus' website on May 2nd. For further information, please contact: Rianne Roukema, Corporate Communications: +31 (71) 524 4044 About OctoPlus OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs. OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs. OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl. This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.


 

TALENTUM OYJ STOCK EXCHANGE RELEASE APRIL 27, 2007 AT 8.30 TALENTUM'S NET SALES AND OPERATING PROFIT FOR JANUARY-MARCH EXCEED PREVIOUS YEAR'S EQUIVALENT TALENTUM JANUARY-MARCH 2007 (IFRS) January-March 2007 - Net sales: EUR 32.0 million (EUR 31.0 million) - Operating profit: EUR 4.3 million (EUR 2.3 million) - Cash flow from business operations: EUR 4.5 million (EUR 1.4 million) - Earnings per share EUR 0.07 (EUR 0.04) - Equity ratio 26.76% (30.28%) Consolidated net sales in January-March increased by 3.5% over the previous year, totalling EUR 32.0 million (EUR 31.0 million). Publishing's net sales went up by 12% to EUR 20.9 million (EUR 18.6 million). The operating profit increased to EUR 4.3 million (EUR 2.3 million). Of the increase in the operating profit EUR 0.5 million was result of the continuing strong growth by Publishing Sweden. Well over EUR 1 million of the increase in the operating profit was the result of cost savings compared with the corresponding period in the previous year. About EUR 0.4 million in non-recurring costs, which increased Group items in particular, were recorded on projects unrealized in the comparison year 2006 in the result for the first quarter of 2006. Further comparison of the quarterly results with the equivalent period in the 2006 must also take into account that the relative effect of the savings of EUR 2.5 million in personnel costs at the annual level will be the greatest in the first three quarters of the year because of seasonal variations. In comparing the equity ratio to the year end one must take into account the fact that the equity ratio is materially affected by the dividend of EUR 8.0 million on the record date, March 30, 2007 (EUR 0.18/share). CEO JUHA BLOMSTER ON THE INTERIM REPORT: MORE EFFICIENT COST STRUCTURE AND BETTER SALES BEHIND IMPROVED FINANCIAL PERFORMANCE "Talentum's net sales increased and operating profit showed a clear increase in the first quarter compared with the previous year. Publishing's operating profit was more than 15% of the net sales in the first quarter, which is extremely good for the first quarter of a year. One of the factors behind the good level of profitability is the more efficient cost structure. "The growth of the publishing business in Sweden continued to be strong and in Finland the increase in net sales that started right at the end of 2006 strengthened. The net sales of the publishing business in Finland went up by 6% in the first quarter compared with the previous year, whereas the growth in the previous quarter was around 3%. The operations in Sweden are growing by about 20%, and recruitment advertising continues to develop strongly in both Finland and Sweden. The circulation of Talentum's Ny Teknik showed an increase of 6.8%, Affärsvärlden 24.5% and Talouselämä 3.1%, which was far better than that of their competitors. The 12% growth in the whole of Talentum's publishing business and the 20% increase by Direct Marketing, which gives close support, in the first quarter compared with the equivalent period in the previous year were a good achievement. "The operating profit of the TV Content Production Group at 5% of net sales was the same as in the corresponding quarter a year earlier, even though net sales fell by a few per cent compared with that of the corresponding period. The measures taken to improve profitability at Premedia have continued in the opening months of the year. "The start to the new year has been good, especially for Publishing." TALENTUM OYJ Juha Blomster CEO FURTHER INFORMATION Juha Blomster, CEO, tel +358 (0)20 442 4444 Kai Järvikare, CFO, tel +358 (0)40 342 4210 www.talentum.com COPIES TO Helsinki Stock Exchange Key Media BRIEFING A briefing for analysts and the media will be held on April 27, 2007 at 9.30 a.m. at the Talentum head office in Annankatu 34-36 B, Kamppi, Helsinki. The interim report will be presented by CEO Juha Blomster and CFO Kai Järvikare will also be present. This interim report is published in Finnish and English. In case of doubt, the Finnish report is authoritative.


 

Zug, Switzerland - April 27, 2007 - Converium welcomes ISS, Glass Lewis and Ethos recommendations of approval of all tabled AGM proposals Converium welcomes the recommendations of Institutional Shareholder Services (ISS), which has recommended that shareholders approve all seven tabled proposals at the Company's Annual General Meeting (AGM), scheduled for May 10, 2007. All agenda items have been scheduled by Converium. Amongst the proposals to be voted on at the AGM, ISS recommends approval of a reduction of the par value of Converium's registered shares from CHF 5 to CHF 2.50, with the subsequent payment expected to be made to shareholders by mid-July 2007. ISS acknowledges the potential to return capital to shareholders and better leverage Converium's balance sheet through the issuance of USD 500 million of hybrid debt, as part of the Company's road map aimed at generating a sustainable 14% return on equity by 2009. ISS further states that none of the voting resolutions at Converium's AGM relate to SCOR's bid. The recommendation of ISS is in line with those of Glass Lewis & Co., which also endorses all seven tabled AGM proposals. ISS and Glass Lewis are independent providers of proxy voting advice to the international investment community. The leading advisor in Switzerland on sustainable development principles and corporate governance best practice in investment activities, Ethos, Swiss Foundation for Sustainable Development, equally endorses all proposals. Enquiries Beat W. Werder Marco Circelli Head of Public Relations Head of Investor Relations beat.werder@converium.com marco.circelli@converium.com Phone: +41 44 639 90 22 Phone: +41 44 639 91 31 Fax: +41 44 639 70 22 Fax: +41 44 639 71 31 Dr. Kai-Uwe Schanz Inken Ehrich Chief Communication & Corporate Investor Relations Specialist Development Officer inken.ehrich@converium.com kai-uwe.schanz@converium.com Phone: +41 44 639 90 94 Phone: +41 44 639 90 35 Fax: +41 44 639 70 94 Fax: +41 44 639 70 35 For information regarding voting at the AGM, please contact our proxy solicitors, HQB Partners Limited at + 44 (0)20 7621 1351. About Converium Converium is an independent international multi-line reinsurer known for its innovation, professionalism and service. Today Converium employs about 500 people in 15 offices around the globe and is organized into three business segments: Standard Property & Casualty Reinsurance, Specialty Lines and Life & Health Reinsurance. Converium has an "A-" ("strong") financial strength rating (outlook stable) from Standard & Poor's and a "B++" financial strength rating (outlook positive) from A.M. Best Company. Important Disclaimers This document contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. It contains forward-looking statements and information relating to the Company's financial condition, results of operations, business, strategy and plans, based on currently available information. These statements are often, but not always, made through the use of words or phrases such as 'seek to', 'expects', 'aims' 'should continue', 'believes', 'anticipates', 'estimates' and 'intends'. The specific forward-looking statements cover, among other matters, the Company's strategy and management objectives, our return on equity and our plans to use capital more efficiently and to return capital to shareholders. Such statements are inherently subject to certain risks and uncertainties. Actual future results and trends could differ materially from those set forth in such statements due to various factors. Such factors include whether we are able to secure an upgrade of our financial strength ratings; our ability to refinance our outstanding indebtedness and increase our use of hybrid capital; uncertainties of assumptions used in our reserving process; risk associated with implementing our business strategies and our capital improvement measures; cyclicality of the reinsurance industry; the occurrence of natural and man-made catastrophic events with a frequency or severity exceeding our estimates; acts of terrorism and acts of war; changes in economic conditions, including interest and currency rate conditions that could affect our investment portfolio; actions of competitors, including industry consolidation and development of competing financial products; a decrease in the level of demand for our reinsurance or increased competition in our industries or markets; our ability to expand into emerging markets; our ability to enter into strategic investment partnerships; a loss of our key employees or executive officers without suitable replacements being recruited within a suitable period of time; our ability to address material weaknesses we have identified in our internal control environment; political risks in the countries in which we operate or in which we reinsure risks; the passage of additional legislation or the promulgation of new regulation in a jurisdiction in which we or our clients operate or where our subsidiaries are organized; the effect on us and the insurance industry as a result of the investigations being carried out by the US Securities and Exchange Commission, New York's Attorney General and other governmental authorities; our ability to regain past customers following any rating upgrades and the resolution of the investigations being carried out by the US Securities and Exchange Commission, New York's Attorney General and other governmental authorities; changes in our investment results due to the changed composition of our invested assets or changes in our investment policy; failure of our retrocessional reinsurers to honor their obligations or changes in the credit worthiness of our reinsurers; our failure to prevail in any current or future arbitration or litigation; and extraordinary events affecting our clients, such as bankruptcies and liquidations, and other risks and uncertainties, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission (including, but not limited to, our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission) and the SWX Swiss Exchange. The Company does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


 

Industrieholding Cham ("IC") reported net sales of CHF 118.6 million in the first quarter of 2007, an increase of 1.5% compared with CHF 116.9 million for the same period 2006. You will find the complete PDF-File attached. --- End of Message --- Industrieholding Cham AG P.O. Box Cham Switzerland ISIN: CH0001931853; Index: SPI, SSCI, SPIEX; Listed: Main Market in SWX Swiss Exchange;


 
Ýmislegt
27. apríl 2007

Notice of EGM

27 April 2007 LSE ANNOUNCEMENT UNOTICE OF GENERAL MEETING - 28 MAY 2007 Attached are Notice of General Meeting and related documents which will be mailed to shareholders today advising of a General Meeting to be held at Oaks North Quay, 293 North Quay, Brisbane, Australia on Monday 28 May 2007 at 10.30am Brisbane time. Enquiries to: +-------------------------------------------------------------------+ | Geoffrey Moore | | |----------------------------------------------+--------------------| | Monto Minerals Ltd | +61 (0)7 3034 3100 | |----------------------------------------------+--------------------| | | | |----------------------------------------------+--------------------| | Rob Bain / Samantha Robbins / Duncan | | | McCormick | | |----------------------------------------------+--------------------| | Redleaf Communications | 020 7822 0200 | |----------------------------------------------+--------------------| | | | |----------------------------------------------+--------------------| | Richard Brown | | |----------------------------------------------+--------------------| | Ambrian Partners Limited | 020 7776 6400 | +-------------------------------------------------------------------+ For further information on Monto Minerals and recent photographs of work at the mine site please visit the Company's website at http://www.montominerals.com ---END OF MESSAGE---


 

27 APRIL 2007 LSE ANNOUNCEMENT THIRD QUARTER ACTIVITIES AND CASHFLOW REPORT 2006/2007 FOR THREE MONTHS TO 31 MARCH 2007 COUNTDOWN TO PRODUCTION... - The Goondicum project remains on schedule to commence sales in second half of calendar 2007 - Further marketing opportunities emerging for ilmenite and ground feldspar In April: - Funding restructure will finance construction, initial production and planned expansion to 2009 - Additional Mining Lease application covering all known industrial mineral resources at Goondicum Development of the Goondicum multi-product industrial minerals project in Queensland advanced during the March quarter. The project is within budget and on schedule to commence production and sales in the second half of calendar 2007. In April, Monto announced a funding restructure that will take the project through to full production, and provide for planned expansion over the next two years. Construction activities at Goondicum Construction of the processing plant proceeded during the quarter and is on schedule for completion in June 2007. The mechanical construction contractor has commenced work and contracts for erection of structural steelwork, installation of equipment, pipeworks and electrics have been awarded. Mining activities have commenced and ore will be stockpiled for commissioning of the processing plant and ongoing production. Goondicum's sand-like ore is mineable by excavator and truck and requires no drilling or blasting. Construction of the water pipeline is over 60% complete and is advancing at a rate of 500 metres per day. It is anticipated that commissioning of the pipeline will take place in June 2007 to ensure it is completed in advance of the processing plant. The water bore was completed on April 4 and testing of the expected yield will be concluded shortly. A second bore is scheduled to be constructed in 2008 prior to increasing the production rate. Upgrading of the access road to the site is near complete. The road between Goondicum and Dakiel is in a satisfactory condition for initial truck haulage. Work is continuing to ensure it remains trafficable in wet weather and to minimise dust. Construction of the feldspar washing plant facility at Dakiel continued and is on track for completion in September 2007. The site office and amenities are in place and work on concrete foundations for the plant commenced in mid March. The plant, located 25km from the Goondicum site, adjacent to the rail line to the port of Gladstone, will upgrade feldspar prior to sale. In early April Monto, in conjunction with rail and port service providers, completed a successful rail trial. This involved loading rail wagons with ilmenite and feldspar at Monto township, transportation and unloading at the port of Gladstone. Successful completion of the rail trial now allows Monto to finalise commercial arrangements with the relevant service providers. Construction of the power line is expected to commence in May and is scheduled to be completed in the September quarter 2007. The critical item for mains supply is the substation which is planned for completion in early October 2007. Landholder negotiations on easement agreements are continuing. Diesel generators will provide the power supply for the Goondicum Project for commissioning and initial production. In late April, Monto applied for a Mining Lease covering 2,900 hectares within the Company's Goondicum exploration permit area, EPM 9100. Together with the Company's existing Mining Lease (ML 80044), the lease covers all known industrial mineral resources within the Goondicum Crater. Marketing With the Goondicum Project on track to commence sales in the second half of calendar 2007, Monto Minerals is placing its focus on marketing. Monto has already successfully secured contracts and letters of intent for over 40% of its first year's production and is currently in negotiations with a number of additional customers. The Company has identified further marketing opportunities for its ilmenite in Europe and for its high-value ground feldspar product in Europe and the US. The project has the unique advantage of having five industrial mineral products to market - ilmenite, ground feldspar, glass feldspar, apatite and titanomagnetite. Ilmenite (paint, paper and plastic pigment) - Following completion of initial trial shipments, Monto expects to fully contract its planned ilmenite production to a small number of large pigment manufacturers. Monto's sulphateable ilmenite is very low in contaminants, making it particularly suited to the European and Asian markets, from where Monto is receiving increased requests for supply due to a predicted global deficit from 2008. Ground Feldspar (paint, powder coating) - Several negotiations are ongoing regarding the processing and distribution of ground feldspar in both the US and European markets. The development of ground feldspar, which commands a premium price in international markets, has been accelerated in response to increased competitive pressure affecting prices for glass feldspar in the European market. Monto's silica free feldspar is particularly suited to the US market, due to its occupational health and safety benefits. Ground feldspar has a high value application in the paint and powder coatings industries. Commercial tests of Monto's ground feldspar product by a European specialised industrial minerals producer and distributor are close to completion and the product will be International Coatings Conference, Nuremberg, in May. Feldspar (glass) - Monto is moving towards a formal supply agreement with a global glass maker with which it has a long standing conditional agreement for a 3-year domestic contract for the supply of 5,000 t/yr. Further opportunities for sales to the glass industry and other applications are being monitored. Titanomagnetite (coal washing) - Monto has entered a consultancy agreement with Mineral Innovations Pty Ltd to build on the trial work conducted to date by the Australian Coal Industry Research Laboratory (ACIRL). Whilst commercial tests have successfully established the Goondicum titanomagnetite as an effective coal washing agent, further work is planned before June to define the appropriate operating parameters and to target the most suitable coal washeries. Apatite (organic fertiliser) - The Company has contracted the whole of its production of apatite with one customer and is currently finalising the delivery schedule. Funding In April, Monto finalised a A$35 million fundraising that will take the Goondicum project through to full production, and a further A$6 million facility will provide for planned expansion over the next two years. The funding comprises a A$23 million ordinary share placement to Australian and UK investors and a A$12 million Convertible Note and will be used to restructure the finances of the Project by: - Replacement of bank infrastructure guarantees (A$15.7 million); - Replacement of third party power line construction financing (A$6.5 million); - Replacement of the pre AIM IPO Sentient funding arrangement (A$6.0 million). Sentient has shown its ongoing commitment by participating in the Australian share placement; - Replacement of leverage lease funding proposal (A$5.3 million); and - Funding working capital, including fund raising costs (A$1.5 million). A further committed A$6 million loan facility completes the package and will fund scheduled production expansions in mid 2008 and 2009. The funding is being provided by major existing institutional shareholders together with several institutions new to the Monto register. The funding commitments are subject to approval at a shareholder meeting scheduled for 28 May. Full details of the funding restructure were included in an announcement to the market earlier this month. Outlook - Mining activities are continuing with ore being stockpiled for commissioning of the processing plant and ongoing production. - Construction and commissioning of the processing plant are scheduled for completion in mid 2007. - Construction of the power line is to commence in May and is scheduled to be completed in the September quarter 2007. - Deliveries of steel for construction of the Dakiel feldspar washing plant facility will be delivered in June. Construction at Dakiel is scheduled for completion by September 2007. Attached to this announcement are photos of the mine site construction and the Appendix 5B as required by the Australian Stock Exchange. Enquiries to: +-------------------------------------------------------------------+ | Geoffrey Moore | | |----------------------------------------------+--------------------| | Monto Minerals Ltd | +61 (0)7 3034 3100 | |----------------------------------------------+--------------------| | | | |----------------------------------------------+--------------------| | Rob Bain / Samantha Robbins / Duncan | | | McCormick | | |----------------------------------------------+--------------------| | Redleaf Communications | 020 7822 0200 | |----------------------------------------------+--------------------| | | | |----------------------------------------------+--------------------| | Richard Brown | | |----------------------------------------------+--------------------| | Ambrian Partners Limited | 020 7776 6400 | +-------------------------------------------------------------------+ For further information on Monto Minerals and recent photographs of work at the mine site please visit the Company's website at http://www.montominerals.com ---END OF MESSAGE---


 

With a successful start in business year 2007, Sika increases turnover by 19.1% from CHF 829 mil. to CHF 987 mil. in comparison with the first quarter of 2006. This increase comprises 16.6% organic growth, 2.1% acquisition effect (including Protective Coatings, DuPont, Germany; Covercrete, Canada) as well as 0.4% positive currency effect. Business Divisions and Regions The Construction Division as well as the Industry Division increased net sales in Swiss francs in comparison with the previous year period. Growth in the business division Construction amounted to 20.9% while growth in the division Industry was 13.9%. All market segments in the Construction Division contributed to overall growth with double-digit growth rates. The segments Roofing, Waterproofing and Concrete developed most strongly. In the Industry Division the segments Fenestration and Marine showed the broadest increases. Viewed geographically, the European regions, in particular Eastern Europe, as well as the new region IMEA (India, Middle East, Africa) and Latin America achieved the strongest rates of growth. Especially mild weather in Europe during the first few months of the business year contributed to the strong increase in turnover. Outlook For 2007 we anticipate further favorable economic development as well as strong markets. Increases in raw material prices must continue to be reckoned with. In the event of continued strong volume growth we expect an above average increase in profit. -END- Sika AG Zugerstrasse 50 CH-6341 Baar, Switzerland www.sika.com Contact: Christin Kukan, Corporate Communications & Investor Relations Tel.: +41 41 768 68 00 Fax: +41 41 768 68 50 kukan.christin@ch.sika.com Sika AG - a corporate profile Sika AG, located in Baar, Switzerland, is a globally active company supplying the specialty chemicals markets. It is a leader in processing materials used in sealing, bonding, damping, reinforcing and protecting load-bearing structures in construction (buildings and infrastructure construction) and in industry (vehicle, building component and equipment production). Sika's product lines feature high-quality concrete admixtures, specialty mortars, sealants and adhesives, damping and reinforcing materials, structural strengthening systems, industrial flooring and membranes. Subsidiaries in more than 70 countries worldwide and approximately 11,000 employees link customers directly to Sika and guarantee the success of all of its business relationships. With this business structure Sika generates annual sales of CHF 4 billion. Visit our website at www.sika.com. The media release can be downloaded from the following link: --- End of Message --- Sika AG Zugerstrasse 50 Baar WKN: 858573; ISIN: CH0000587979; Index: SMCI, SPI, SPIEX, SMIEXP, SMIM; Listed: Main Market in SWX Swiss Exchange;


 

Bakkavör Group's Q1 results 2007 Business Highlights Q1 2007 * Turnover £349.4 million * Growth in like-for-like sales in underlying business 13.8% * Shareholders' earnings £9.6 million, up 66% * Operating profit (EBIT) £25.4 million, up 37% * EBITDA £35.1 million, up 28% * EBITDA ratio 10.0% * EBITDA ratio, net of agency sales change 10.7% * Pro-forma EBITDA up 12.3% * Cash generated from operations £38.2 million, up 36% * Free cash generated by operating activities £16.9 million, up 36% * Equity £246.9 million compared with £241.4 million at year end 2006, up 2% * Equity ratio 18.6%, up from 18.2% at year end 2006 * Earnings per share 0.45 pence, up 24% * Return on equity 16.2% compared with 18.1% in 2006 * Dividend paid on 24 April which corresponds to 50% of issued share capital * Refinancing completed in Q1 providing new £700 million banking facility on favourable terms Ágúst Gudmundsson, Chief Executive Officer, said: "We are pleased to report an encouraging start to the year. Group UK sales remain robust in the fresh prepared foods and the produce markets. As well as strengthening our operations in Continental Europe we are taking pioneering steps in product innovation in the region. We are committed to further strengthening our position as a global fresh prepared foods provider, focusing on growth in new markets. The fresh prepared foods market in Western Europe is expected to grow by 20% in the next four years and by 30% in China. We are well positioned in our target geographical markets to benefit from these opportunities." Further Information: Ásdís Pétursdóttir Investor Relations, Bakkavör Group investor.relations@bakkavor.com Tel: +354 858-9715


 

Hakon Invest AB (publ) held its Annual General Meeting in Stockholm on Thursday, April 26. About 190 shareholders participated in the Meeting, chaired by Lars Otterbeck, Chairman of the Board of Directors. At the Annual General Meeting of Hakon Invest, Board members Lars Otterbeck, Cecilia Daun Wennbrog, Anders Fredriksson, Jan-Olle Folkesson, Olle Nyberg, Jan Olofsson and Thomas Strindeborn were re-elected. Lars Otterbeck was re-elected Chairman. At the subsequent statutory Board meeting, Anders Fredriksson was re-elected Vice Chairman. The fees to the Board of Directors was set at SEK 1,800,000, of which SEK 500,000 to the Board Chairman, SEK 300,000 to the Vice Chairman and SEK 200,000 each to the other members as well as an additional SEK 250,000 to be distributed for committee work in accordance with the Meeting's decision. The Meeting approved the Board's proposal for the principles of remuneration for senior executives as well as the proposal about an incentive program for 2007 directed to company management and certain key personnel. In line with the proposal, the required transfer of own shares (treasury stock) was approved. The Meeting approved a dividend of SEK 5.50 per common share (4.50). The record date was determined as Wednesday, May 2, 2007. Hakon Invest (publ) For more information, contact: General Counsel Fredrik Hägglund tel. +46-8-553 399 08 Head of Investor Relations Pernilla Linger tel. +46-8-553 399 55 Hakon Invest, which is listed the Nordic Exchange, conducts active and long-term investment operations in retail-oriented companies in the Nordic region. Hakon Invest owns 40% of ICA AB, the Nordic region's leading retail company with focus on food. In addition have holdings in Forma Publishing Group, Kjell & Company, Hemma and Cervera. Further information about Hakon Invest is available at www.hakoninvest.se.


 

* Barry Callebaut to supply a minimum of 80,000 tons per year of chocolate and finished products to Hershey under long-term global agreement * Hershey to leverage Barry Callebaut's premium chocolate expertise, cocoa and origin know-how and extensive chocolate innovation capabilities Contacts at Hershey for investors and financial analysts: for the media: Mark Pogharian Kirk Saville The Hershey Company The Hershey Company Phone: +1 717 534 7556 Phone +1 717 534 7641 Contacts at Barry Callebaut for investors and financial for the media: analysts: Europe: Victor Balli, CFO Gaby Tschofen Barry Callebaut AG, Zurich Barry Callebaut AG, Zurich Phone: +41 43 204 04 20 Phone: +41 43 204 04 60 victor_balli@barry-callebaut.com gaby_tschofen@barry-callebaut.com North America: BlueCurrent PR Annette Rogers Phone +1 214 394 5816 annette.rogers@bluecurrentpr.com BlueCurrent PR Kyle Rose Phone +1 214 738 6176 kyle.rose@bluecurrentpr.com The news release can be downloaded from the following link: --- End of Message --- Barry Callebaut AG P.O. Box Zurich Switzerland WKN: 914661; ISIN: CH0009002962; Index: SMCI, SPI, SPIEX; Listed: Main Market in SWX Swiss Exchange;


 

Brussels, 26 April 2007 - Today, Mobistar has signed a MVNO contract with Lycamobile, European market leader in prepaid SIM cards for international telecommunications. Lycamobile is targeting principally foreigners living in Belgium who communicate frequently with friends and family in their country of origin. Mobistar Investor Relations Visit our website: http://www.mobistar.be For the full PDF version, please click here below:


 

Yfirtaka Glazer-fjölskyldunnar á Manchester United hefur leitt til 137,7 milljóna punda taps sem samsvarar til tæplega 18 milljarða króna hjá eignarhaldsfélagi fjölskyldunnar sem heitir Red Football og var stofnað í kringum kaupin. Reikningar félagsins sýna í fyrsta sinn að upphæðin sem Glazer reiddi af hendi til þess að eignast Manchester United var 809 milljónir punda, eða um 105 milljarðar króna. Vaxtagreiðslur eignarhaldsfélagsins af 598 milljóna punda skuldum námu á 14 mánaða tímabili, frá 1. maí 2005 til 30. júní 2006, 85,2 milljónum punda, um 10,7 milljörðum króna.


 

The Annual General Meeting, led by Chairman of the Board Carl Bennet, decided to: * adopt the annual accounts for 2006 * confirm the decision of the Board to distribute a dividend for 2006 of SEK 2.50 per share and that the record date for the payment of dividends be 2 May 2007 * discharge the members of the Board and the Chief Executive Officer from liability for the financial year 2007 * grant, according to the proposal in the summons to attend, the Board a remuneration of a total of SEK 1,960,000 to be divided among the members for the financial year 2007 * appoint, according to the proposal in the summons to attend, the following members to the Board until the next Annual General Meeting is held in 2008: Carl Bennet (re-election) Ingegerd Gréen (re-election) Patrick Holm (CEO) (re-election) Göran Johnsson (re-election) Hans-Olov Olsson (new election) Kerstin Paulsson (new election) Johan Stern (re-election) Tore Åberg (re-election) * appoint, according to the proposal in the summons to attend, Carl Bennet as Chairman of the Board * appoint, according to the proposal in the summons to attend, the following members to the nomination committee: Carl Bennet, Carl Bennet AB (re-election) Gustav Douglas, Investment AB Latour (re-election) Göran Erlandsson, representative for the small shareholders (re-election) Hans Hedström, HQ Funds (new election) Nils Petter Hollekim, Odin Funds (re-election) Stefan Roos, SEB Funds (re-election) Caroline af Ugglas, Skandia Liv (re-election) adopt, according to the proposal in the summons to attend, the Board's proposal for the remuneration of senior officers as well as change the articles of association so that this matter will become a point among the matters to be dealt with by the Annual General Meeting. In his speech CEO Patrick Holm assured the Annual General Meeting that Elanders' international expansion will continue and that new establishments are a possibility. The protocol from the Annual General Meeting will be available on the company homepage as soon as the minutes have been verified. After the Annual General Meeting the Board held its first meeting at which Tore Åberg was appointed Vice Chairman of the Board. Carl Bennet, (Chairman), Ingegerd Gréen, Hans-Olov Olsson and Tore Åberg were appointed to the remuneration committee and Tore Åberg (Chairman), Göran Johnsson, Kerstin Paulsson, and Johan Stern were appointed to the auditing committee. The Board of Directors Carl Bennet Patrick Holm Chairman of the Board President and CEO Elanders AB Elanders AB Tel. +46 300 500 00 Tel. +46 31 750 00 00 Mbl +46 708 210 410 The press release can be downloaded from the following link:


 

 Penninn hefur ákveðið að innleiða birgðastýringarkerfið AGR Innkaup. Tilgangur kerfisins er að lækka birgðakostnað, koma í veg fyrir vantanir og auka alla sjálfvirkni í innkaupaferlinu að því er segir í frétt félagsins. AGR Innkaup tengist viðskiptakerfi Pennans og sækir þangað söguleg gögn. Kerfið framkvæmir söluspár fram í tímann á öllum vörunúmerum en kerfið velur sjálfvirkt þá spáaðferð sem hentar best fyrir hverja vörutegund. Kerfið birtir síðan innkaupatillögur byggðar á söluspánum sem lágmarka birgðahaldskostnað og vöntun. Penninn bætist því í hóp fjölmargra fyrirtækja sem nota AGR Innkaup við gerð innkaupatillagna en yfir 40 fyrirtæki hafa fjárfest í hugbúnaðinum Þar á meðal eru fyrirtæki eins og Aðföng, ÁTVR, Egill Árnason, Fríhöfnin, Húsasmiðjan, Johan Rönning, Jóhann Ólafsson&Co., Karl K. Karlsson, MS, N1, Nathan&Olsen, Oddi, Olís, SS, Stilling og Vistor.


 

Cees Maas, ING Group's former Chief Financial Officer, was appointed as Officer in the Order of Orange-Nassau by Her Majesty The Queen of The Netherlands. The royal decoration was presented today by the Dutch Minister of Finance, Wouter Bos. Cees Maas receives the royal decoration because of his contribution to ING Group's worldwide growth, his internationally acknowledged banking expertise and the fact that he is recognized as an authority in the international financial and monetary world. Furthermore, he was honoured because of his engagement in cultural institutions and organisations. On 24 April 2007 Cees Maas retired from ING Group. He had joined the Executive Board in 1992 and was appointed Chief Financial Officer in 1996. Download images Pictures from Cees Maas receiving the royal decoration * Picture 1 * Picture 2 +----------------------------------------------------------------+ | Press enquiries: | | Debbie Brand, ING Group, +31 20 541 6526, debbie.brand@ing.com | +----------------------------------------------------------------+ ING is a global financial institution of Dutch origin offering banking, insurance and asset management to over 60 million private, corporate and institutional clients in more than 50 countries. With a diverse workforce of about 120,000 people, ING comprises a broad spectrum of prominent companies that increasingly serve their clients under the ING brand.


 

Operator Statoil (OSE:STL, NYSE:STO), with support from the licensees in the Kvitebjørn field in the North Sea, have decided to temporarily cease production of gas and condensate from Kvitebjørn. Production from the field has been reduced since December 2006 to ensure justifiable drilling of the remaining wells. The operation's complexity and adaptation of necessary new technology has led to an extension of the drilling programme and resulted in further pressure fall in the reservoir. In order to prevent an additional fall in pressure and thereby maintain safe operations, and to facilitate the drilling of more wells to secure reserves and the future production level, the operator has decided to shut down the field as of 1 May. It is expected that production will commence during the fourth quarter of 2007. Statoil will meet its commitments to its gas customers during this period. Production capacity at Kvitebjørn is 190,000 barrels of oil equivalent per day. The Kvitebjørn licensees are Statoil (43.55%), Petoro (30%), Hydro (15%), Shell (6.45%) and total (5%). The temporary shut-down at Kvitebjørn means that Statoil will not reach its previously communicated production target for 2007. The company will announce a new production forecast during the week commencing 7 May. Contacts: Media: Jone Stangeland, vice president for public affairs, Exploration & Production Norway: +47 91 56 68 69 (mobile), +47 51 99 34 70 (office) Ola Morten Aanestad, vice president media relations: + 47 48 08 02 12 (mobile), +47 51 99 13 77 (office) Investor relations: Lars Troan Sørensen, senior vice president for IR: + 47 90 64 91 44 (mobile), +47 51 99 77 90 (office) Geir Bjørnstad, vice president, US investor relations, + 1 203 978 6950 Disclaimer: This press release does not constitute an offer to exchange or sell or an offer to exchange or buy any securities. An offer of securities in the United States pursuant to a business combination transaction will only be made through a prospectus which is part of an effective registration statement filed with the US Securities and Exchange Commission. Hydro shareholders who are US persons or are located in the United States are advised to read the registration statement when and if it is declared effective by the US Securities and Exchange Commission because it will contain important information relating to the proposed transaction. You will be able to inspect and copy the registration statement relating to the proposed transaction and documents incorporated by reference at the SEC's Public Reference Room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Statoil's SEC filings are also available to the public at the SEC's web site at http://www.sec.gov. In addition Statoil will make the effective registration statement available for free to Hydro shareholders in the United States.


 

Highlights during the quarter: o Strong increase in sales, up MNOK 104 (+ 19 per cent) to MNOK 663 o Sales up 48 per cent in Sweden/Denmark o Positive EBIT: MNOK 2.3 for consumer financing o Contribution margin ratio 13.7 per cent o Warehouse and IT projects on schedule, but increased 1Q expenses o EBIT of MNOK 20.0 (-7 per cent) o Acquisition of InWarehouse AB in Sweden for MSEK 173 o Web shop opened in France in January 2007 The Report including financial tables and presentation can be downloaded from the following links:


 

` FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | DEEPHAVEN CAPITAL | | | MANAGEMENT LLC | |-----------------------------------------------+-------------------| | Company dealt in | iSOFT Group Plc | |-----------------------------------------------+-------------------| | Class of relevant security to which the | 10p Ordinary | | dealings being disclosed relate (Note 2) | | |-----------------------------------------------+-------------------| | Date of dealing | 24 April 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |-------------------------------+--------------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (2) Derivatives (other than | 2,400,981 | 1.0327 | | | | options) | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------+-----------+--------+--------+-----| | Total | 2,400,981 | 1.0327 | | | | | | | | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | CFD | LONG | 170,754 | 36.1930 | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 26th April 2007 | |-------------------------------------------------+-----------------| | Contact name | James Feast | |-------------------------------------------------+-----------------| | Telephone number | 0207 469 1901 | |-------------------------------------------------+-----------------| | If a connected EFM, name of offeree/offeror | | | with which connected | | |-------------------------------------------------+-----------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

(Lysaker, Norway, 26 April 2007) Today, Navamedic ASA's subsidiary ChitiNor AS has started the commercial production of chitin at the chitin factory at Senjahopen. Navamedic's 100%-owned subsidiary ChitiNor AS has constructed a chitin factory adjacent to Nergård Reker AS at Senjahopen. The construction process has been finalized within budget, and total investments are less than NOK 10 million. ChitiNor AS will receive grants of NOK 2 million and an additional loan of NOK 2 million from Innovation Norway. Navamedic will not make internal use of its chitin production from the start. In March 2006 a letter of intent (LOI) was signed with Lytone Enterprise Inc. in Taiwan, for the sale of the first full year' chitin production. The LOI has a value of approximately NOK 7 million based on the USD/NOK rate at the time of signature. For further information, please contact: Øyvind W. Brekke, CEO Navamedic ASA E-mail: oyvind.brekke@navamedic.com Office: +47 67 11 25 40 Mobile: +47 91 19 81 64 Bernt-Olav Røttingsnes, CFO/IRO Navamedic ASA E-mail: bor@navamedic.com Office: +47 67 11 25 44 Mobile: +47 91 34 70 21 About Navamedic ASA: Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world`s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. Navamedic`s product Glucomed/Flexove has been approved across 25 EU/EEA states by European Medicines Agency (EMEA), as the first and only glucosamine based medicine against osteoarthritis. The company`s products are sold through a network of sales, marketing and distribution partners. For more information, please see www.navamedic.com


 

Wärtsilä Corporation Press release 26 April 2007 The European Commission's competition authorities have cleared the joint venture being formed by Wärtsilä, China Shipbuilding Industry Corporation (CSIC) and Mitsubishi Heavy Industries (MHI). The joint venture will manufacture large low-speed marine engines in China. CSIC's ownership in the the joint venture will be 50%, Wärtsilä's 27% and MHI's 23%. The production is expected to start in the fourth quarter of 2008. For further information please contact Ms Eeva Kainulainen, VP, Corporate Communications, Wärtsilä, phone +358 10 709 5235. www.wartsila.com


 

"Targeting Uranium and Gold" NEWS RELEASE CROSSHAIR WRAPS UP WINTER DRILL CAMPAIGN - C-ZONE URANIUM DEPOSIT CONTINUES TO EXPAND Dated: April 26, 2007 TSX-V: CXX Crosshair Exploration and Mining Corp. (TSX-V: CXX) (the "Company") is pleased to announce the completion of a highly successful 2007 winter exploration program in the Central Mineral Belt, Labrador. The Company completed over 9,400 meters of drilling focused on uranium mineralization in the Upper and Lower C Zones and targets along strike. Final assays are pending, but all drill holes have been tested with a radiometric probe that has highlighted the following: * The Upper C Zone has been extended in all directions, including northeast of the emerging high-grade zone outlined in 2006; * The Lower C drilling has encountered mineralized intercepts up to 40 meters thick, suggesting the presence of a wider zone that remains open for expansion; and * Drilling at Area 1 and Armstrong has established a zone at Area 1 with a minimum strike length of 600 meters and open for expansion. The mineralization is similar to that of the Upper C Zone and evidence continues to suggest that both zones may be part of the same system. Company geologists believe that the C Zone is part of a 4.5 kilometre long uranium bearing shear zone and that the C Zone, Area 1 and Armstrong targets are part of the same system. A drill plan is available on the Company website at: http://www.crosshairexploration.com/s/Addenda.asp?ReportID=183047. All core samples have now been split and sent for analysis; final assay results are expected from Activation Labs in May. The updated 43-101 report, as well as an updated resource estimate for the Upper C Zone, is expected in late May once all assays have been received and the report finalized. Although the 2007 winter campaign is now complete, ground geophysical work is continuing through winter break-up. Further details and assay results from this drilling will be released in the coming weeks. Approximately 35,000 metres of drilling is being planned for the 2007 summer campaign, scheduled to start in early June. Ground and Airborne Geophysical Surveys In addition to drilling, a ground EM survey and a 4,718 line kilometre helicopter-borne EM survey were also carried out. These surveys will help to delineate graphitic horizons at or near the important Aphebian-Helikian unconformity, which is known to host significant zones of uranium mineralization at the C Zone. Preliminary results show a series of previously unrecognized conductors spatially associated with the unconformity. The association of uranium with conductors at or near the Aphebian-Helikian unconformity is directly analogous to environments in the Athabasca Basin. The survey data will also help identify potential massive sulphide targets on the property, which are known to occur in the Croteau Lake area where zinc rich (3.7% Zn) massive sulphide zones were discovered by Noranda in the 1990's. Ground programs are continuing at Moran with two gravity units currently completing surveys at the C Zone and the B Zone to help define IOCG targets that will be drill tested later in 2007. The Company has also started baseline environmental studies along the Area 1, C Zone, B Zone corridor, and samples of mineralized drill core from the C Zone are currently being selected for preliminary leach tests by Saskatchewan Research Council laboratories (SRC) in Saskatoon to establish recovery parameters for both uranium and vanadium. Crosshair's 2007 summer drilling program will begin in mid-June with two rigs turning at the C Zone, while a third drill will be mobilized to the property to test regional targets. All exploration work on the Central Mineral Belt uranium property is supervised by Timothy Froude, P.Geo., a member of the Professional Engineers and Geoscientists of Newfoundland and Labrador, the Senior Vice President Exploration of the Company and a Qualified Person as defined in NI 43-101. About Crosshair Crosshair is an aggressive uranium and gold exploration and development Company with select projects in Newfoundland and Labrador. The Company has developed into a dominant player in the exploration for uranium in the Central Mineral Belt of Labrador. The 711 sq km Moran Lake Uranium / IOCG Project is host to potentially three significant types of uranium mineralization - Iron Oxide Copper Gold (IOCG - Olympic Dam), structurally controlled, shear zone ("Michelin") and unconformity types of mineralization. In addition, through option agreements with Paragon Minerals Corporation, Crosshair has secured a position in one of the most prospective massive sulphide districts in Canada as well as a promising early stage high grade gold property at South Golden Promise and Golden Promise. For more information of the Company and its properties, please visit the website at www.crosshairexploration.com. ON BEHALF OF THE BOARD "Mark J Morabito" President and CEO Crosshair Exploration & Mining Corp. - Vancouver T: 604-681-8030 F: 604-681-8039 E: dan@crosshairexploration.com www.crosshairexploration.com The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of the content of this News Release. Cautionary Note Regarding Forward-Looking Information Information set forth in this news release may involve forward-looking statements. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address a company's expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: the risks associated with outstanding litigation, if any; risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in uranium, gold and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the potential for conflicts of interest among certain officers, directors or promoters with certain other projects; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to U.S. Shareholders. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.


 

Bayer AG will be publishing its First Quarter 2007 results on May 8, 2007 at 7:30 a.m. CEST (5:30 a.m. GMT). Starting at around 2:00 p.m. CEST (12:00 noon GMT) live on the Internet, Bayer AG will be broadcasting the speech and discussion of the Investor Conference Call. With Werner Wenning, CEO of Bayer AG, and Klaus Kühn, CFO of Bayer AG. A recording of the conference call will be available as from May 9 at 9:00 a.m. CEST (7:00 a.m. GMT). The audio transmission and recording can be accessed on these sites: English: http://www.investor.bayer.com German: http://www.investor.bayer.de Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com If you have any questions, please contact: Dr. Alexander Rosar (+49-214-30-81013) Dr. Juergen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Ilia Kürten (+49-214-30-35426) Ute Menke (+49-214-30-33021) Judith Nestmann (+49-214-30-66836) Dr. Olaf Weber (+49-214-30-33567) --- End of Message --- Bayer AG Gebäude W 11 Leverkusen WKN: 575200; ISIN: DE0005752000; Index: CDAX, DAX, HDAX, Prime All Share; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Börse Berlin Bremen, Amtlicher Markt in Börse Düsseldorf, Amtlicher Markt in Hanseatische Wertpapierbörse zu Hamburg, Amtlicher Markt in Niedersächsische Börse zu Hannover, Amtlicher Markt in Bayerische Börse München, Amtlicher Markt in Börse Stuttgart;


 

* Valuation in excess of EUR 80 million significantly improves balance sheet ratios * Focus on chemical-pharmaceutical specialty products intensified * Activities to be integrated into a leading explosives group Salzbergen, April 26, 2007: H&R WASAG AG has sold its Explosives Division to the Spanish-Italian Explosives group Maxam/Pravisani. The share purchase agreement was signed today and entails the immediate transfer of shares in the Group companies Westspreng GmbH and WANO Schwarzpulver GmbH. The purchase price is based upon an enterprise value in excess of EUR 80 million. The specialty chemicals group based in Salzbergen can look forward to a substantial improvement in its balance sheet ratios as a result of the sale. The equity ratio in particular will undergo a sustained uplift, and the level of net debt will undergo a major reduction. The explosives and plastics divisions with their earnings and cashflows have in the past formed key pillars of the Group's risk strategy by balancing the impact of the crude oil price on the refinery business, and thereby stabilizing the Group's overall earnings base. The activities of the Chemical-Pharmaceutical Raw Materials Division, which are characterized by a high degree of dependence on the development of the crude oil price, have in the meantime reached a volume that effectively provides a hedge against the effects of a volatile oil market within the division. This allows peripheral activities to be sold, leading to a reduction in the complexity of the specialty chemicals group, and a more defined corporate profile. The two Group companies that have been sold, Westspreng GmbH and WANO Schwarzpulver GmbH, together generated 2006 revenue of EUR 73.3 million, equivalent to a 9% share of the consolidated total. The Group company Sythengrund, which has until now been allocated to the Explosives Division, will remain within the H&R WASAG Group. The company has extensive land assets from which the Group intends in future to extract high-quality silica sand. In acquiring this explosives division Maxam/Pravisani consolidates its leadership position in the major European core markets and is also ideally placed to benefit from growth in numerous regions of Eastern Europe. "This acquisition represents a historic step for the European explosives market, and have facilitated the emergence of our group as Europe's leading supplier of civil explosives," were the comments of José F. Sánchez-Junco, Chairman and CEO of Maxam Group. The integration of H&R WASAG's activities will help create an enterprise with a promising future as a leader in modern explosives, and their related production and application technologies. Not only will the Group enjoy growth in new markets, it will also add to its market share in existing regions with the introduction of new products. The synergies deriving from the acquisition are to be found above all in the complementary product portfolios and regional presence of the companies concerned. "For us this disposal represents an important step forward in our drive to concentrate on our high-growth chemical-pharmaceutical core business," commented Dr. Horst Hollstein, CEO of H&R WASAG AG. The specialty chemicals group will use the added financial flexibility to undertake targeted development at its chemical-pharmaceutical raw materials division. The main emphasis will be on increasing refinery capacities and expanding overseas, particularly in Asia. The Group is currently pursuing various projects in both fields, which promise to yield a substantial increase in sales and results in coming years. Important steps are to be implemented already this year. Contact: H&R WASAG AG Investor Relations / Communications Mr. Oliver König Neuenkirchener Str. 8 48499 Salzbergen Germany Tel: +49-(0)5976-945-300 Fax: +49-(0)5976-945-308 E-mail: oliver.koenig@hur-wasag.de www.hur-wasag.com Additional information on H&R WASAG AG H&R WASAG AG is an SDAX-listed specialty chemicals company engaged in the development and manufacture of crude oil-based chemical-pharmaceutical specialty products and in the production of precision plastic components. The Group companies which comprise the individual divisions enjoy excellent positions as market and/or technology leaders. According to provisional figures, in financial year 2006 the Group recorded consolidated sales of EUR 817 million and achieved pre-tax profits of EUR 75 million. --- End of Message --- H&R WASAG AG Neuenkirchener Str. 8 Salzbergen Germany WKN: 775700; ISIN: DE0007757007; Index: SDAX; Listed: Amtlicher Markt in Börse Düsseldorf, Amtlicher Markt in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Stuttgart, Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Bayerische Börse München;


 

BOSTON, April 26, 2007 (PRIME NEWSWIRE) -- NewStar Financial, Inc. (Nasdaq:NEWS) announced today that it will report results for the first quarter of 2007 on Thursday, May 3, 2007 before the markets open. NewStar will also host a webcast/conference call to discuss the results on Thursday, May 3, 2007 at 10:00 am Eastern Standard Time. All interested parties are invited to participate via telephone or webcast, which will be hosted through the Investor Relations section of our website at www.newstarfin.com. Please visit the website to register for the webcast and test your connection prior to the call. You can also access the conference call by dialing (800) 765-0709 approximately 5-10 minutes prior to the call. International callers should dial (913) 981-5564. All callers should reference "NewStar Financial Inc." For convenience, an archived replay of the call will be available through May 10, 2007 by dialing (888) 203-1112. International callers should call (719) 457-0820. For all replays, please use the passcode # 3471739. The audio replay will also be available through the Investor Relations section of our website at www.newstarfin.com. About NewStar Financial: NewStar Financial is a specialized commercial finance company focused principally on meeting the complex financing needs of customers in the middle market through our corporate, commercial real estate, and structured products groups. Our senior banking teams call directly on customers to provide advice and finance a range of strategic transactions that may require some combination of senior secured, second lien and mezzanine financing. NewStar typically works with customers with financing needs of up to $150 million and cash flow as low as $5 million. We target 'hold' positions of up to $35 million, but may also underwrite or arrange transactions up to $100 million for syndications to other lenders. We are headquartered in Boston MA, with regional offices in Darien CT, Chicago IL, San Francisco CA, San Diego CA, and Charleston SC. In December of 2006, NewStar completed an Initial Public Offering. The Company's shares trade on the NASDAQ under the ticker symbol, NEWS. Please visit our website at www.newstarfin.com for more detailed transaction and contact information. CONTACT: NewStar Financial Robert K. Brown +1 617-848-2558 Fax: +1 617-848-4399 rbrown@newstarfin.com 500 Boylston Street, Suite 1600 Boston, MA 02116


 
Ýmislegt
26. apríl 2007

Total voting rights

26 April 2007 PayPoint plc (the "Company") - Total Voting Rights In conformity with the Transparency Directive the Company hereby notifies the market of the following: The Company's capital consists of 67,678,720 ordinary shares with voting rights. The Company does not hold any shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules. - Ends - ---END OF MESSAGE---


 

SPOKANE, Wash., April 26, 2007 (PRIME NEWSWIRE) -- Dujour Products, Inc. (OTCBB:DJRP) ("Dujour") and Endeavor Energy Corporation ("Endeavor") of Calgary, Alberta, Canada are pleased to announce the execution of a letter of intent setting forth an agreement in principal for Dujour to purchase 100% of the common shares of Endeavor for a purchase price of $8 million USD. Endeavor is an operating oil and gas production company with operating assets consisting of 31 sections of land under direct ownership and 80 sections held under farm-in agreements with six producing gas wells together with pipeline and infrastructure collection facilities. Endeavor holds a 40% interest in the "Warner" project consisting of 17.5 sections and 5 producing natural gas wells, 100% interest in 11 sections of the "Arneson" gas project, 50% interest in three sections in the "Diamond" Barons gas play and 50% in "Taber" with one producing gas well. Endeavor's farm-in agreements cover another 80 sections in Alberta and Saskatchewan, which are targeting shallow Viking gas plays and deeper Nisku oil reservoirs. Consideration for the purchase will consist of cash and Dujour's restricted common shares, and was determined by a valuation of Endeavor interests based upon a geological reserve report prepared by an independent third party. The cash portion of the purchase price will be used by Endeavor to satisfy certain outstanding secured debt obligations. The letter of intent and proposed purchase is subject to the completion of due diligence, board and shareholder approvals, the availability of sufficient financing, the satisfaction/release of any security interests held in Endeavor's interests to be conveyed, and the execution of definitive agreements. Finally, it is anticipated that Cameron King, the current President of Endeavor, will be joining Dujour as an officer and director upon closing of the transaction. ABOUT ENDEAVOR ENERGY CORPORATION Endeavor Energy is successfully exploring and developing reserves that enhance our shareholder's value as well as contributing to a reliable ongoing rate of growth. In early 2006, Endeavor was established as an asset purchase from a mid-tier energy producer giving Endeavor a start with 13,000 acres and nominal production. Since inception Endeavor was focused increasing land position and production. Today, Endeavor holds approximately 100,000 net acres within Alberta and Saskatchewan, partnering with industry leaders to develop prospective reserves in the Canadian prairies proving our expertise and growth model. Worldwide demand for energy increases incessantly, that's why the world needs more companies like Endeavor who are committed to exploring for more oil and natural gas. Notice Regarding Forward-Looking Statements This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release, which are not purely historical, are forward-looking statements. They include, but are not limited to, any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the completion of the purchase and sale of the interests in Endeavor Energy, the satisfaction of the various conditions precedent for the acquisition, and any further drilling on or production from Endeavor Energy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with oil and gas exploration; changes in reserve estimates if any; the potential productivity of Endeavor's properties; changes in the operating costs and changes in economic conditions and conditions in oil and gas exploration. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-KSB for the 2006 fiscal year, our quarterly reports on Form 10-QSB and other periodic reports filed from time-to-time with the Securities and Exchange Commission. ON BEHALF OF THE BOARD Dujour Products, Inc. Adrian Crimeni - President CONTACT: Dujour Products, Inc. Douglas Brown +1 778-231-5210


 

2007-04-26 Stockholm - The following decisions were made at the Annual General Meeting in Net Insight AB on 26 April 2007. The board of directors' complete proposals has previously been published and is available at the company's homepage, www.netinsight.net. Determination of the annual report, allocation of result and discharge from liability The Annual General Meeting of Net Insight decided to determine the Income Statement and Balance Sheet, Consolidated Income Statement and Balance Sheet for 2006. Furthermore it was decided that the deficit is applied against the reserve fund. The AGM decided to discharge the Board Members and CEO from liability. Number of board members and deputy board members The AGM decided the number of Board Members, appointed by the shareholders' meeting, to be six members without deputies. Lars Berg was re-elected as Chairman of the board, board members Clifford H. Friedman, Birgitta Stymne Göransson and Bernt Magnusson, Ragnar Bäck and Marco Limena were re-elected. The AGM decided that the remuneration to the Board should amount to SEK 925,000 to be allocated with SEK 300,000 to the chairman of the board of directors and SEK 125,000 to each other member of the board of directors. Öhrlings PricewaterhouseCoopers AB was re-elected as auditor of the company and remuneration to the auditors will be at current account. Amendment of the articles of association The AGM resolved to amend the articles of association according to the board of director's proposal. § 5 is amended with a new second section were shares of class A may upon request of the owner of such shares be converted into shares of class B. Guidelines for remuneration and other terms of employment for the group management The AGM resolved to approve the board of directors' proposal regarding guidelines for remuneration and other terms of employment for the group management. Adoption of the employee stock option plan 2007/2011 and the issuance of warrants to subscribe for new shares, and approval of disposal of the warrants issued under the employee stock option plan The AGM resolved to approve the board of directors' proposal. Employee stock options (call options) with the right to acquire not more than 7,500,000 shares of series B in the company may be issued under the plan. Allocation shall be made during the period from the tenth banking day following the announcement of the quarterly report for the first quarter 2007 up to the annual general meeting 2008. The employee stock options shall be issued free of charge. To secure that the company can meet its obligations, including payment of any social charges, to the holders of employee stock options at the time of exercise of the employee stock options the annual general meeting also resolved to issue 9,900,000 warrants with the right to subscribe for new shares to the wholly-owned subsidiary Net Insight Consulting AB. The annual general meeting approved that Net Insight Consulting AB disposes of the warrants to meet the company's obligations according to the employee stock options issued under the employee stock option plan. For more information, please contact: Lars Berg, Chairman of the Board, Net Insight AB Phone: +46 8 685 04 69, e-mail lars.berg@netinsight.net Fredrik Trägårdh, CEO, Net Insight AB. Phone: +46 8 685 04 00, e-mail: fredrik.tragardh@netinsight.net About Net Insight Net Insight delivers the world's most efficient and scaleable optical transport solution for Broadcast and Media, Digital Terrestrial TV, Mobile TV and IPTV/CATV networks. Net Insight products truly deliver 100 percent Quality of Service with three times improvement in utilization of bandwidth for a converged transport infrastructure. Net Insight's Nimbra(TM) platform is the industry solution for video, voice and data, reducing operational costs by 50 percent and enhancing competitiveness in delivery of existing and new media services. World class customers run mission critical video services over Net Insight products for more than 100 million people in more than 20 countries. Net Insight is quoted on the Stockholm Stock Exchange. For more information, visit www.netinsight.net


 

(Consolidated figures. Figures in parenthesis refer to last year's first quarter unless otherwise stated) SpareBank 1 Midt-Norge achieved a profit of NOK 176 million after tax in the first quarter 2007 (215m), equivalent to a return on equity of 18.2% (24.7%). The profit measured 1.10% (1.61%) of average total assets. The strong growth seen in 2006 continued into 2007. Overall lending growth of 18% over the last 12 months and matching deposit growth of 17% indicate that the Bank is continuing to take market shares. The last 12 months' growth in "other savings products" was 15% while the insurance portfolio has grown by as much as 43%. The good growth is attributable to continued satisfactory market conditions, a solid effort by a competent staff and the Bank's market and operating concept which is enabling the Bank to strengthen its position as the leading bank in Central Norway for businesses and private individuals. Net profit is NOK 39 million down compared with the first quarter 2006 when the Bank recorded larger loss recoveries as well as substantial gains on disposal of real estate, mainly in Molde. The good performance is due mainly to: * Strong growth in lending (18%) and deposits (17%), thereby maintaining net interest income at last year's level despite a continued market-related fall in the interest margin * A strong increase in commission income on sales of savings products, capital market products and estate agency services. Commission income rose by a total of NOK 31 million or 23% compared with the first quarter 2006. * A strong result for SpareBank 1 Gruppen AS. A projected result of NOK 241 million is the best quarterly performance ever. The income side shows: * A reduced net interest margin of 1.58% (1.88%) is due to lower lending margins in both the corporate and retail market. This is attributable both to intense competition and to the fact that the lower risk profile established in the Bank's loan portfolio is driving down margins. The reduction is in line with the Bank's plans and has produced the expected lending growth and more robust earnings. * Net interest income and other operating income rose by 23% to NOK 163 million. The increase is mainly on sales and portfolio commission, savings and capital market products and on estate agency. * SpareBank 1 Gruppen AS has a projected quarterly result of NOK 241 million after tax. With its 19.5% stake in SpareBank 1 Gruppen, the Bank's share of SpareBank 1 Gruppen's result is NOK 48 million. * Overall the Bank's subsidiaries increased their income. This is particularly true of EiendomsMegler 1 which carried through a strategy of expansion in 2006. * Capital gains on securities and gains on currency trading and financial instruments totalled NOK 29 million (83 million). The cost side shows: * Operating expenses of NOK 263 million (242m). Cost growth at the parent bank was limited to NOK 4 million. The growth in costs is thus largely a consequence of the push forward by the Bank's subsidiaries - especially EiendomsMegler 1 Midt-Norge. The most significant cost-side elements are: o higher staff costs at the parent bank, resulting mainly from wage growth and partly from the focus on the occupational pensions market o an offensive expansion on the part of the subsidiaries - particularly EiendomsMegler 1 Midt-Norge * The Group's cost-income ratio was 57% (59%) exc. capital gains. Low losses and reduced defaults * Net recovery of losses in the first quarter came to NOK 9 million (net recovery of NOK 22m) * The corporate area recorded a net recovery of NOK 11 million (net recovery of NOK 26m) and the retail area a net loss of NOK 2 million (NOK 4m) * Individual impairments amounted to NOK 148 million at end-March (202 million). The reduction of NOK 54 million over the last 12 months is mainly due to write-backs of losses on individual exposures and write-off of previous periods' impairment provisions. * Defaults in both the corporate market and the retail market are falling, particularly in the corporate market. Of defaults in excess of 90 days totalling NOK 176 million (326 million), 18% (25%) are loss provisioned. Other doubtful exposures total NOK 294 million (261 million), of which 39% (45%) are loss provisioned. Total problem loans (defaulted and doubtful) have fallen by NOK 117 million over the last 12 months * Collective impairments at end-March total NOK 184 million, having fallen by NOK 94 million since the first quarter 2006. The bank's assets totalled NOK 64.2 billion at end-March 2007, NOK 10.1 billion higher than 12 months previously. Total outstanding loans came to NOK 54.7 billion at end-March, having risen by NOK 8.3 billion over the previous 12 months. Customer deposits totalled NOK 31.0 billion, an increase of NOK 4.5 billion on the figure 12 months previously. In line with a resolution adopted at a meeting of the Supervisory Board on 21 March, a dividend issue was carried out whereby the Bank's PCC holders, instead of receiving a cash dividend of NOK 6 per PCC, could opt to receive dividend certificates denominated at NOK 66. As much as 71% of the Bank's PCC capital participated in the dividend issue. The ample subscription confirms that the dividend issue is viewed as attractive. Commenting, CEO Finn Haugan states that he is very pleased with the trend in operations in the first quarter 2007, as previously. Sound growth in lending and deposits along with continuing excellent sales of savings and insurance products indicate that the Bank is gaining market shares across the entire region. "It is also gratifying to note that the Bank's dividend issue has proved highly successful with an acceptance rate as high as 71%", he continues. "With intense competition is pushing down interest margins, it is important for the Bank to maintain the level of income generated by lending and deposits,. The good volume trend and the good sales of other products confirm that a solid job is still being done by the Bank's many highly competent staff. I am also very pleased with the solid performance posted by SpareBank 1 Gruppen AS and can, as Board Chairman, note with satisfaction that we have been quick to replace Gunn Wærstad as managing director at SpareBank 1 Gruppen AS. SpareBank 1 Gruppen's new managing director, Eldar Mathisen, will take up duties as early as in June this year," says Finn Haugan in conclusion. Trondheim, 26 April 2007 SpareBank 1 Midt-Norge Please direct any queries to: CEO Finn Haugan on + 47 900 41 002 Executive Director Kjell Fordal on + 47 905 41 672 About us SpareBank 1 Midt-Norge is the region's foremost financial services provider. We are the market leader in retail and corporate banking, with a presence in 71 localities across the region. Our aim is to be the recommended bank for customers in Central Norway, and as a local, independent bank we feel a particular responsibility for stimulating growth and prosperity in the region. We build our business on closeness to the customer, easy accessibility, a full product range and integrated financial advice. Headquartered in Trondheim, the Group has some 800 staff and includes the following subsidiaries: SpareBank 1 Finans Midt-Norge AS, EiendomsMegler 1 Midt-Norge AS, Allegro Finans ASA and Midt-Norge Regnskap AS. SpareBank 1 Midt-Norge is one of six owners of SpareBank 1 Gruppen AS. For further information, visit our website at http://www.smn.no The report and the presentation can be downloaded from the following links:


 

Strong operating profit improvement driven by Fine Paper and Wood Products; challenging quarters ahead Stora Enso Oyj Stock Exchange Release 26 April 2007 at 10.00 GMT Summary of First Quarter Results (compared with Q1/2006) Sales were EUR 3 855.4 (EUR 3 607.7) million. Operating profit was EUR 307.3 (EUR 247.0) million excluding non-recurring items. Operating profit was EUR 339.3 (EUR 223.8) million including non-recurring items. Profit before tax was EUR 274.8 (EUR 210.9) million excluding non-recurring items. Profit before tax was EUR 306.8 (EUR 317.7) million including non-recurring items. Net profit excluding non-recurring items was EUR 207.2 (EUR 158.3) million. Net profit including non-recurring items was EUR 222.5 (EUR 226.4) million. Earnings per share were EUR 0.26 (EUR 0.20) excluding non-recurring items. Cash earnings per share were EUR 0.59 (EUR 0.54) excluding non-recurring items. Earnings per share including non-recurring items were EUR 0.28 (EUR 0.29). ROCE excluding non-recurring items was 10.8% (8.5%). Message from CEO Jouko Karvinen: Group earnings strongly improved, but challenging quarters ahead "We are delighted to report strong earnings improvements in Fine Paper and Wood Products, and a good performance by Packaging Boards. There was a slight decline in Publication Paper's profitability in very challenging market conditions for magazine paper. However, in the next few months we are planning to curtail production at some of our Finnish pulp mills owing to wood supply constraints resulting from an unusually short winter harvesting season in Baltic Sea region and in Russia, and uncertainties around the Russian wood export tax. These stoppages, together with increased wood costs and a higher level of seasonal holiday and maintenance stoppages will negatively impact earnings in the second quarter, although earnings should remain higher than a year earlier. We are working rigorously to increase wood supply around the Baltic Sea basin and to solve the issues concerning Russian wood export tax in good co-operation with our stakeholders. Overall market situation is relatively good, with a few exceptions "The overall market situation and outlook are relatively healthy. Conditions do vary, however, between customer segments and regions. Currently, two of the biggest challenges in our industry are weak magazine paper prices worldwide and the uncertain trend in demand for printing and writing papers and newsprint in North America. On a positive note, prospects for our Fine Paper, Newsprint and Wood Products divisions in Europe are good, and Packaging Boards continues to perform well" "Cost inflation remains a real issue for our industry, particularly for wood. The additional export duties on roundwood announced by Russia, the European Union's drive to increase the utilisation of wood fibre as biofuel and the pressure from Non-Governmental Organisations with environmental concerns about wood harvesting in certain areas are all contributing to concerns over wood supply. We are convinced that all stakeholders, not least in Finland and Russia, understand the seriousness of the situation and will work with us to find positive solutions to these challenges acceptable to all parties concerned in the coming months and years. Group's ROCE target of 13% over the cycle remains "As we stated at our Annual General Meeting, we remain committed to our target of achieving a ROCE of 13% over the cycle. Our business and geographical portfolio review is progressing well. As stated before, we do not intend to announce a single multi-year plan or lists of businesses under scrutiny. Rather we will announce key decisions and actions when appropriate. The result will be a more focused Group, with businesses that all contribute to our financial improvement and strategic goals. "Another imperative is continual cost improvement to be realised primarily through structural simplification and choices. We will also be building upon our successful strategy in new growth markets, such as further development of our Latin American operations. "We will also emphasise our customer-driven product innovations, such as media packaging solutions and the positive results from the never-ending drive for operational excellence evidenced by the world speed record in production at our Kvarnsveden SC Paper Machine 12 in the first quarter. "Even with some short-term challenges and lots of decisions and choices to make, we are convinced that we will find our way to long-term, sustainable value creation. Based on track record of 2006 and the first quarter of 2007, even in a challenging environment, our goal in the future is to stay on the year-on-year improvement path. Near-term market outlook "In Europe the positive economic outlook is expected to support the consumption of advertising-driven paper grades. Stable prices for newsprint are anticipated but in magazine paper price pressure persists in non-contractual business. The outlook for fine paper remains healthy and prices are forecast to rise. Demand for packaging boards is expected to remain firm with prices rising in some business segments. Good, stable demand for wood products should keep the outlook for prices relatively steady. "In North America the demand outlook for publication paper grades and coated fine paper is uncertain. Prices may remain under pressure. "In Latin America demand for coated magazine paper is predicted to strengthen, but competition is expected to remain intense. In China a slight improvement in demand for coated fine paper is anticipated, keeping prices stable." Stora Enso Interim Review January-March 2007 Markets Compared with Q1/06 In Europe market demand was stable for newsprint but improved for magazine paper, fine paper, packaging boards and wood products. Prices were higher than a year ago in newsprint and lower in magazine paper. Prices were unchanged in coated fine paper, but higher in uncoated fine paper. Prices for most packaging boards and wood products were higher. In North America market demand for newsprint was clearly weaker than a year ago, but virtually unchanged for coated magazine paper and stronger for uncoated magazine paper. Prices declined in newsprint and magazine paper markets. Demand for coated fine paper weakened slightly during the year and prices were lower. In Latin America demand for coated magazine paper increased, whereas prices decreased. In China demand for coated fine paper also increased, but prices decreased. Compared with Q4/06 In Europe market demand was somewhat stronger than in the previous quarter in fine paper, packaging boards and wood products, but seasonally weaker in publication paper. Prices rose in newsprint, uncoated fine paper, some packaging grades and wood products. Coated fine paper prices were stable, but magazine paper prices declined. In North America demand for all publication papers weakened and prices declined. In coated fine paper demand increased slightly, mainly for seasonal reasons, but prices decreased. In Latin America market demand for coated magazine paper weakened slightly, but prices remained unchanged. In China demand for coated fine paper was stable, but prices declined slightly. Stora Enso Deliveries and Inventories Changes Q4-2006 Q1-2006 Q1-2007 Q1/07-Q1/06 Q1/07-Q4/06 Paper and Board deliveries (1 000 tonnes) 3 735 3 619 3 790 171 55 Wood Products deliveries (1 000 m3) 1 670 1 563 1 666 103 -4 Paper and Board Production (1 000 tonnes) 3 740 3 751 3 833 82 93 January-March 2007 Results (compared with Q1/2006) Sales at EUR 3 855.4 million were 6.9% higher than in the first quarter of 2006, mainly due to higher average prices for fine paper and wood products, and increased deliveries of publication paper, packaging boards and wood products. The net impact on sales of the acquisition of Arapoti Mill in Brazil together with the divestment of Pankakoski, Celbi and Grycksbo mills was EUR -42.7 million. Operating profit excluding non-recurring items increased by EUR 60.3 million to EUR 307.3 million, which is 8.0% of sales. Profitability was higher in all segments except Publication Paper. Prices rose in wood products and uncoated fine paper. In Publication Paper, operating profit decreased as higher newsprint prices only partly offset lower magazine paper prices. Wood and energy costs were materially higher in the first quarter of 2007 than a year earlier. Key Figures Change % Change % EUR million 2005 2006 Q4/06 Q1/06 Q1/07 Q1/07-Q1/06 Q1/07-Q4/06 13 14 3 3 3 Sales 187.5 593.9 731.8 607.7 855.4 6.9 3.3 EBITDA excluding non-recurring 1 1 items 501.1 872.8 472.4 516.2 568.9 10.2 20.4 Operating profit excluding non-recurring items 371.2 782.1 187.6 247.0 307.3 24.4 63.8 Non-recurring items (operational) -417.3 -133.7 60.0 -23.2 32.0 n/a -46.7 Operating margin excluding non-recurring items, % 2.8 5.4 5.0 6.8 8.0 17.6 60.0 Operating profit -46.1 648.4 247.6 223.8 339.3 51.6 37.0 Net financial items1) -165.3 -104.0 -38.6 62.3 -56.7 n/a -46.9 Profit before tax and minority interests excluding non-recurring items 273.1 602.5 141.4 210.9 274.8 30.3 94.3 Profit before tax and minority interests -144.2 631.8 234.4 317.7 306.8 -3.4 30.9 Net profit for the period excluding non-recurring items 230.3 439.4 101.4 158.3 207.2 30.9 104.3 Net profit for the period -107.4 589.2 264.8 226.4 222.5 -1.7 -16.0 EPS excluding non-recurring items, Basic, EUR 0.28 0.55 0.13 0.20 0.26 30.0 100.0 EPS, Basic, EUR -0.14 0.74 0.33 0.29 0.28 -3.4 -15.2 CEPS excluding non-recurring items, EUR 1.70 1.94 0.49 0.54 0.59 9.3 20.4 ROCE excluding non-recurring items, % 3.4 6.8 6.7 8.5 10.8 27.1 61.2 1) Includes capital gains of EUR 130.0 million (sale of Sampo shares) in Q1/2006, EUR 33.0 million (sale of Finnlines shares) in Q4/2006 totalling to EUR 163.0 million in 2006. CEPS = (Net profit for the period + depreciation and amortisation)/average number of shares Non-recurring items are exceptional transactions that are not related to normal business operations. The most common non-recurring items are capital gains, additional write-downs, restructuring provisions and penalties. Non-recurring items are normally specified individually if they exceed one cent per share. Deliveries of wood to the Group's mills in Europe and Brazil totalled 11.1 million cubic metres, which is similar to the first quarter of 2006 and up 8% on the previous quarter. A storm at the beginning of the quarter improved wood supplies and wood prices turned down in Continental Europe. In the Nordic countries market prices rose and market supplies increased. However, decreasing imports from Russia and a very short and warm winter weakened the overall delivery balance. Operating profit includes a positive non-operational effect of EUR 15.7 million (positive EUR 35.3 million), comprising a positive EUR 19.4 million net due to EUR -12.0 million and EUR 31.4 million respectively from the accounting of share-based compensation and Total Return Swaps (TRS), and a charge of EUR 3.7 million from the reduced value of government grants related to CO2 emission rights. These non-operational items include a non-cash impact of EUR 2.4 million and they are reported in the segment Other. TRS instruments, which are only partially hedging cash settled synthetic options, do not qualify for hedge accounting under IFRS criteria, and therefore all periodic changes to their fair value are recorded in the Income Statement; they were previously presented in other financial items. From the first quarter of 2007 onwards, the TRS-related gains and losses, the fair value changes and cash flows, are presented in operating profit under personnel expenses and the comparative years have been reclassified accordingly; the reclassification improved operating profit by EUR 31.4 million (EUR 52.9 million) and increased financial expenses correspondingly. There were two non-recurring items with a net positive impact of EUR 32.0 million (negative EUR 23.2 million) on operating profit: the new labour agreements in North America had a positive impact of EUR 44.0 (USD 57.7 million) million and closure of Sauga Sawmill in Estonia had a negative impact of EUR 12.0 million. The share of associated company results amounted to EUR 24.2 (EUR 31.6) million; the main contributions were from Bergvik Skog, Tornator and Veracel. Net financial items were EUR -56.7 million (positive EUR 62.3 million). Net interest expenses increased to EUR 60.7 (EUR 52.8) million and net foreign exchange gains on borrowings, currency derivatives and bank accounts were EUR 3.6 (losses of EUR 7.0) million. Other financial items totalled positive EUR 0.4 (positive EUR 122.1) million, the decrease being mainly due to a non-recurring capital gain of EUR 130.0 million from the sale of shares in Sampo Oyj during the first quarter of 2006. Profit before taxes and minority interests excluding non-recurring items increased by EUR 63.9 million to EUR 274.8 million and profit before tax amounted to EUR 306.8 (EUR 317.7) million including non-recurring items. Net taxes totalled EUR -84.3 (EUR -91.3) million, leaving a net profit for the quarter of EUR 222.5 (EUR 226.4) million. The cumulative tax-rate for the first three months was 27.5%. The profit attributable to minority shareholders was EUR 3.3 (EUR 1.4) million, so the profit attributable to Company shareholders was EUR 219.2 (EUR 225.0) million. Earnings per share excluding non-recurring items increased by EUR 0.06 to EUR 0.26. Earnings per share including non-recurring items were EUR 0.28 (EUR 0.29). Cash earnings per share were EUR 0.59 (EUR 0.54) excluding non-recurring items. The return on capital employed was 10.8% (8.5%) excluding non-recurring items. Capital employed was EUR 11 478.5 million on 31 March 2007, approximately the same as a year earlier. First Quarter Results (compared with Q4/2006) Sales at EUR 3 855.4 million were 3.3% higher than the previous quarter's EUR 3 731.8 million. Deliveries increased in fine paper and packaging boards and decreased in publication paper. Prices increased in newsprint, uncoated fine paper, wood products and somewhat in packaging boards, but decreased in magazine paper. Operating profit excluding non-recurring items increased by EUR 119.7 million to EUR 307.3 (EUR 187.6) million, which is 8.0% of sales. Operating profit increased in all product segments except Publication Paper. Strong demand and higher prices increased operating profit in Fine Paper and Wood Products. Operating profit in Packaging Boards increased mainly due to seasonally higher production and delivery volumes. Publication Paper operating profit decreased, mainly because decreases in magazine paper prices were only partly offset by increases in newsprint prices. Wood costs were higher than in the previous quarter. Profit before tax amounted to EUR 274.8 (EUR 141.4) million excluding non-recurring items and EUR 306.8 (EUR 234.4) million including non-recurring items. Earnings per share were EUR 0.26 (EUR 0.13) excluding non-recurring items. Earnings per share including non-recurring items were EUR 0.28 (EUR 0.33). Cash earnings per share were EUR 0.59 (EUR 0.49) excluding non-recurring items. The return on capital employed was 10.8% (6.7%) excluding non-recurring items. Capital employed was EUR 11 478.5 million on 31 March 2007, a net increase of EUR 146.7 million due to increased working capital partly offset by low capital expenditure. Capital Structure Change % Change % 31 Mar 07 31 Mar 07 31 Mar 31 Mar - 31 Mar - 31 Dec EUR million 31 Dec 06 06 07 06 06 Fixed assets 11 234.7 11 454.3 11 029.2 -3.7 -1.8 Operative working capital 2 174.5 2 509.6 2 388.3 -4.8 9.8 Non-current interest-free items, net -1 204.0 -1 312.1 -1 050.7 -19.9 -12.7 Operating Capital Total 12 205.2 12 651.8 12 366.8 -2.3 1.3 Net tax liabilities -873.4 -1 125.5 -888.3 -21.1 1.7 Capital Employed 11 331.8 11 526.3 11 478.5 -0.4 1.3 Associated companies 805.2 754.7 868.3 15.1 7.8 Total 12 137.0 12 281.0 12 346.8 0.5 1.7 Equity attributable to Company shareholders 7 799.6 7 072.4 7 642.0 8.1 -2.0 Minority interests 103.5 93.0 106.2 14.2 2.6 Net interest-bearing liabilities 4 233.9 5 115.6 4 598.6 -10.1 8.6 Financing Total 12 137.0 12 281.0 12 346.8 0.5 1.7 Financing Cash flow from operations was EUR 210.2 (EUR 603.9) million and cash flow after investing activities EUR 101.3 (EUR 424.2) million compared with the fourth quarter of 2006. Cash flow decreased due to increased working capital. At the end of the period, interest-bearing net liabilities were EUR 4 598.6 million, an increase of EUR 364.7 million due to the EUR 354.9 million dividend for 2006 being deducted from equity and entered into current interest-bearing liabilities for payment on 17 April 2007. Unutilised credit facilities and cash and cash-equivalent reserves totalled EUR 2.2 billion. Shareholders' equity amounted to EUR 7 642.0 million or EUR 9.69 (EUR 9.89) per share, compared with the market capitalisation on the Helsinki Stock Exchange on 30 March 2007 of EUR 10.2 billion. The debt/equity ratio at 30 March 2007 was 0.60 (0.54). The currency effect on equity was EUR -45.2 million net of the hedging of equity translation risks. Cash Flow Change % Change % Q1/07 - Q1/07 - EUR million 2006 Q1/06 Q4/06 Q1/07 Q1/06 Q4/06 Operating profit 648.4 223.8 247.6 339.3 51.6 37.0 Adjustments* 1 060.9 265.9 297.0 256.2 -3.6 -13.7 Change in working capital 199.1 -189.9 59.3 -385.3 -102.9 n/m Cash Flow from Operations 1 908.4 299.8 603.9 210.2 -29.9 -65.2 Capital expenditure -583.4 -167.7 -179.7 -108.9 35.1 39.4 Cash Flow after Investing Activities 1 325.0 132.1 424.2 101.3 -23.3 -76.1 *) Adjustments include depreciations, other non-cash income and expenses and capital gains and losses which are included in proceeds from the sale of fixed assets and shares. Capital Expenditure for the First Quarter of 2007 Capital expenditure for the first quarter totalled EUR 108.9 million, which is 42% of scheduled depreciation and 3% of sales. The Group's capital expenditure for 2007 is expected to be about EUR 900 million. The main projects during the first three months were the plantation projects at Guangxi, China (EUR 9.2 million) and in South America (EUR 6.1 million) and paper machine 3 at Varkaus Mill in Finland (EUR 6.7 million). Asset Performance Review (APR) The schedule for closing Berghuizer Mill in the Netherlands has been finalised, with paper machine PM 7 permanently ceasing production on 16 April 2007 and PM 8 on 31 October 2007. These machines had a total capacity of 245 000 tonnes of uncoated fine paper per year. Approximately 80 000 tonnes of Berghuizer Mill's annual production is expected to be transferred to Stora Enso's Nymölla Mill in Sweden. The annual capacity of Nymölla Mill will remain unchanged at 485 000 tonnes, but the mill has upgraded some of its assets to supply higher quality products with better margins and to improve its customer service. Short-term risks and uncertainties The availability and cost of pulpwood and increasing recovered fibre prices are near-term business uncertainties. The company is taking actions to mitigate these risks. Near-term market outlook In Europe the positive economic outlook is expected to support the consumption of advertising-driven paper grades. Stable prices for newsprint are anticipated but in magazine paper price pressure persists in non-contractual business. The outlook for fine paper remains healthy and prices are forecast to rise. Demand for packaging boards is expected to remain firm with prices rising in some business segments. Good, stable demand for wood products should keep the outlook for prices relatively steady. In North America the demand outlook for publication paper grades and coated fine paper is uncertain. Prices may remain under pressure. In Latin America demand for coated magazine paper is predicted to strengthen, but competition is expected to remain intense. In China a slight improvement in demand for coated fine paper is anticipated, keeping prices stable. First Quarter Events January Stora Enso signed a loan agreement with the European Investment Bank (EIB) for a EUR 140 million loan facility to finance part of Stora Enso's investment in research and development in Finland and Sweden for the next five years. The facility, which is expected to be fully drawn, is the result of good long-term co-operation between EIB and Stora Enso. March Stora Enso announced that it will expand its corrugated packaging business in Eastern Europe and Russia by constructing new plants at Balabanovo in Russia and Komarom in Hungary, and by expanding the existing plant at Lodz in Poland. The corrugated packaging markets in Eastern Europe and Russia are developing rapidly. Stora Enso's expansions are targeted at meeting customers' growing demand for value-added corrugated packaging. These developments are in line with Stora Enso's strategy of growing its packaging business and its operations in new growth markets. Stora Enso also announced that it plans to close down Sauga Sawmill in Estonia in June 2007 owing to a continuing shortage of raw material, resulting in higher costs and unprofitable operations. The closure will not have a material impact on Stora Enso's annual sales, but it is expected to have a slightly positive impact on the Group's full year 2007 operating profit. The Company has recorded a write-down and restructuring provision totalling about EUR 12 million as non-recurring items in the first quarter of 2007. Stora Enso signed an agreement with Neste Oil to join forces to develop technology for producing new-generation biofuels from wood residues to replace fossil fuels in transportation and thus cut greenhouse gases. The first step will be to design and build a full scale test plant at Stora Enso's Varkaus Mill in Finland. This plant, which will be owned on a 50/50 basis by the parties, is expected to start up in 2008. Inspections by Competition Authorities Concluding an investigation initiated in 2004, the US Antitrust authorities announced on 13 December 2006 that Stora Enso North America Corp. had been indicted for its alleged anticompetitive conduct in connection with the sale of coated magazine paper in the USA from autumn 2002 until spring 2003. No Stora Enso employee was charged individually. Stora Enso denies any wrongdoing and has entered a plea of not guilty in response to the indictment. The Group expects the trial to occur in 2007. Coincident with this investigation, Stora Enso has been named in a number of class action lawsuits filed in the USA. On 21 December 2006 Stora Enso announced that the Finnish Competition Authority, as a result of an investigation initiated in 2004, had proposed to the Finnish Market Court that a fine of EUR 30 million be imposed on Stora Enso for violating competition laws in the purchasing of wood in Finland in the period from 1997 to 2004. Stora Enso considers the proposal groundless. No provision has been made in Stora Enso's accounts for the above-mentioned investigations and lawsuits. Changes in the Group Management As announced on 17 October 2006, Stora Enso's Board of Directors appointed Jouko Karvinen, M.Sc. (Eng.), as the new CEO of Stora Enso. He joined the company on 1 January 2007 and took up the position of CEO following the Annual General Meeting (AGM) on 29 March 2007. Jukka Härmälä left the position of CEO at the AGM on 29 March 2007. He will continue to undertake special assignments specified by the Board of Directors of Stora Enso until the end of August 2007. On 29 March Stora Enso's Board of Directors appointed Hannu Ryöppönen as Deputy CEO in addition to his existing role as CFO. Certain Group-wide functional responsibilities will also be added to his responsibilities in the future. Divisions continue to report to the CEO, Jouko Karvinen. On 20 March Stora Enso announced that Pekka Laaksonen, Senior Executive Vice President, Fine Paper and member of the Executive Management Group (EMG), had accepted the position of CEO with Valio Ltd. He will relinquish his current duties with Stora Enso by 15 August 2007. Share Capital During the quarter 450 A shares were converted into R shares. The conversion was recorded in the Finnish Trade Register on 15 February 2007. During the quarter the Company allocated 10 901 repurchased R shares under the terms of the Stora Enso North America Option Plan. On 31 March 2007 Stora Enso had 178 102 667 A shares and 611 435 832 R shares in issue, of which the Company held no A shares and 941 726 R shares with a nominal value of EUR 1.6 million. The holding represents 0.12% of the Company's share capital and 0.04% of the voting rights. Decisions of the Annual General Meeting on 29 March 2007 The proposed dividend of EUR 0.45 per share was approved. The AGM approved a proposal that the Board of Directors shall have nine members and that of the present members Gunnar Brock, Lee A. Chaden, Claes Dahlbäck, Dominique Hériard Dubreuil, Birgitta Kantola, Ilkka Niemi, Jan Sjöqvist, Matti Vuoria and Marcus Wallenberg be re-elected to continue in office. The AGM also approved a proposal to appoint a Nomination Committee to prepare proposals concerning (a) the number of members of the Board of Directors, (b) the members of the Board of Directors, (c) the remuneration for the Chairman, Vice Chairman and members of the Board of Directors and (d) the remuneration for the Chairman and members of the committees of the Board of Directors. Decisions by Board of Directors At its meeting held after the AGM, the Stora Enso Board of Directors elected from among its members Claes Dahlbäck as its Chairman and Ilkka Niemi as Vice Chairman. Jan Sjöqvist (chairman), Lee A. Chaden, Claes Dahlbäck, Birgitta Kantola and Ilkka Niemi will continue as members of the Financial and Audit Committee. Claes Dahlbäck (chairman), Dominique Hériard Dubreuil, Ilkka Niemi and Matti Vuoria will continue as members of the Compensation Committee. This report is unaudited. Helsinki, 26 April 2007 Stora Enso Oyj Board of Directors Segments Publication Paper EUR million Change % Change % Q4/06 Q1/06 Q1/07 Q1/07-Q1/06 Q1/07-Q4/06 Sales 1 1 230.5 1 171.0 240.5 5.9 0.8 Operating profit* 69.0 70.3 63.5 -9.7 -8.0 % of sales 5.6 6.0 5.1 -15.0 -8.9 ROOC, %** 7.0 6.8 6.5 -4.4 -7.1 Deliveries, 1 1 860 1 666 1 824 000 t 9.5 -1.9 Production, 1 000 t 1 843 1 717 1 882 9.6 2.1 * Excluding non-recurring items ** ROOC = 100% x Operating profit/Operating capital Publication Paper sales were EUR 1 240.5 million, 5.9% up on the first quarter of 2006 due to increased deliveries. Operating profit was lower than in the first quarter of 2006 at EUR 63.5 million as magazine paper prices decreased, and energy and wood costs increased. In Europe the annual newsprint contract negotiations were successfully concluded with price increases averaging 5% agreed for 2007. Publication Paper has improved its average asset structure by divesting Wolfsheck Mill and closing down Corbehem PM 3 and PM 4, and cost reductions from the major restructuring at Summa, Reisholz, Norrsundet and Skutskär will enhance future competitiveness. Resumption of operations at Port Hawkesbury Mill will strengthen our position in North American markets again. Nevertheless, results are unsatisfactory, so further profit improvements are needed. Compared with Q1/2006 In Europe newsprint demand was unchanged, but magazine paper demand improved significantly. Producer inventories increased in newsprint and uncoated magazine paper, but decreased in coated magazine paper. Prices were higher for newsprint and lower for magazine paper. In North America demand was clearly weaker for newsprint, stronger in uncoated magazine paper and fairly stable in coated magazine paper. Inventories increased considerably and prices were lower in all product segments. In Latin America demand for coated magazine paper improved, but prices deteriorated. Compared with Q4/2006 In Europe demand for all publication paper grades was seasonally weaker than in the previous quarter and producer inventories increased. Prices were higher for newsprint and lower for magazine paper. In North America demand for all publication paper grades was weaker and inventories increased. Prices were lower in all product segments. In Latin America market demand for coated magazine was slightly weaker, but prices remained unchanged. Fine Paper EUR million Change % Change % Q4/06 Q1/06 Q1/07 Q1/07-Q1/06 Q1/07-Q4/06 Sales 718.3 776.3 738.6 -4.9 2.8 Operating profit* 34.6 52.7 61.5 16.7 77.7 % of sales 4.8 6.8 8.3 22.1 72.9 ROOC, %** 6.4 8.2 11.4 39.0 78.1 Deliveries, 1 966 000 t 946 994 -2.8 2.1 Production, 1 000 t 947 1 029 951 -7.6 0.4 * Excluding non-recurring items ** ROOC = 100% x Operating profit/Operating capital Fine paper sales were EUR 738.6 million, down 4.9% on the first quarter of 2006 mainly due to the sale of Grycksbo Mill and closure of Varkaus PM 1 during 2006, and lower coated fine paper prices. Operating profit was EUR 61.5 million, up 16.7% on the first quarter of 2006 as increased sales, higher production efficiency and improved cost efficiency more than offset the effects of lower sales prices, divestments and closures. In the first quarter of 2006 operating profit included Celbi pulp mill's operating profit of EUR 13.1 million. The operational improvement in operating profit excluding the Celbi mill effect in the first quarter of 2006 was 55.3%. Compared with Q1/2006 In Europe coated fine paper demand was stronger than a year ago driven by solid economic growth in Europe, but prices were almost unchanged. Industry and Stora Enso coated fine paper inventories decreased. Uncoated fine paper demand was slightly stronger than a year ago due to steady economic growth, and uncoated fine paper prices rose. Industry and Stora Enso uncoated fine paper inventories were lower than a year ago. In North America coated fine paper demand weakened slightly as the economy slowed and prices were lower than a year ago. Industry and Stora Enso coated fine paper inventories were lower than a year ago. In China coated fine paper demand was stronger, but prices lower than a year ago. Compared with Q4/2006 In Europe coated fine paper demand was slightly stronger than in the previous quarter, stimulated by economic growth, and prices were stable. Industry and Stora Enso coated fine paper inventories decreased to normal levels. Uncoated fine paper demand was clearly stronger than in the previous quarter due to seasonal factors and economic growth, and prices continued to rise. Industry and Stora Enso uncoated fine paper inventories continued to fall to extremely low levels. In North America coated fine paper demand was slightly stronger, mainly for seasonal reasons, but prices for reels decreased. Industry and Stora Enso coated fine paper inventories increased slightly, but were still normal. In China coated fine paper demand continued to grow, but prices declined slightly. Merchants Sales were EUR 532.9 million, up 7.3% on the first quarter of 2006 mainly due to increased sales volumes. Operating profit was EUR 16.6 million, up 72.9% on the first quarter of 2006 due to successful integration of acquired operations. Integration of recent acquisitions is proceeding well according to plan. Structural cost savings have been achieved and internal efficiency improved. Customers have been retained and sales have continued to increase during these internal changes. Packaging Boards EUR million Change % Change % Q4/06 Q1/06 Q1/07 Q1/07-Q1/06 Q1/07-Q4/06 Sales 871.7 869.0 919.8 5.8 5.5 Operating profit* 59.4 99.5 106.5 7.0 79.3 % of sales 6.8 11.4 11.6 1.8 70.6 ROOC, %** 8.6 13.9 15.4 10.8 79.1 Deliveries, 1 1 000 000 t 929 959 4.3 7.6 Production, 1 000 t 950 1 005 1 000 -0.5 5.3 *)Excluding non-recurring items ** ROOC = 100% x Operating profit/Operating capital Packaging board sales were EUR 919.8 million, up 5.8% on the first quarter of 2006 mainly due to increased deliveries. The impacts of divestment of Pankakoski Mill and closure of PM 31 at Stevens Point were offset by several improvement actions. Operating profit was EUR 106.5 million, up 7.0% on the first quarter of 2006, mainly due to increased sales volumes and improved sales mix. In addition to the successful implementation of Profit 2007 improvement initiatives, major energy efficiency improvement projects at Skoghall and Fors started to contribute to results. Demand for consumer boards was generally good with volumes higher than in the previous quarter and similar to a year ago. Prices improved slightly. Demand for industrial packaging was good with volumes and prices higher than in the previous quarter and a year ago. Wood Products EUR million Change % Change % Q4/06 Q1/06 Q1/07 Q1/07-Q1/06 Q1/07-Q4/06 Sales 443.0 377.1 479.8 27.2 8.3 Operating profit* 19.0 3.8 53.7 n/m 182.6 % of sales 4.3 1.0 11.2 n/m 160.5 ROOC, %** 11.6 2.3 32.9 n/m 183.6 Deliveries, 1 000 m3 1 670 1 563 1 666 6.6 -0.2 * Excluding non-recurring items **ROOC = 100% x Operating profit/Operating capital Wood product sales were EUR 479.8 million, up 27.2% on the first quarter of 2006 mainly due to higher sales prices. Operating profit was EUR 53.7 million, up EUR 49.9 million on the first quarter of 2006 due to higher sales prices, internal restructuring measures and successful actions to improve product and sales mix. Compared with Q1/2006 Market demand improved except in the USA, where the housing market was booming a year ago. The slowdown in the US housing market has reduced sawnwood demand and prices have fallen in the USA. In all other markets good demand, low stock levels and rapid raw material cost escalation supported sharp rises in market prices. Compared with Q4/2006 Demand remained strong in most product categories in Europe, Asia, North Africa and the Middle East, and prices continued to rise. North American markets remained depressed with weak demand and low prices, but they accounted for only a small proportion of sales. Financials Key Ratios Change % Change % 2005 2006 Q4/06 Q1/06 Q1/07 Q1/07-Q1/06 Q1/07-Q4/06 Earnings per share (basic), EUR -0.14 0.74 0.33 0.29 0.28 -3.4 -15.2 Earnings per share excl. non-recurring items, EUR 0.28 0.55 0.13 0.20 0.26 30.0 100.0 Cash earnings per share (CEPS), EUR 1.65 2.34 0.73 0.63 0.62 -1.6 -15.1 CEPS excl. non-recurring items, EUR 1.70 1.94 0.49 0.54 0.59 9.3 20.4 Return on capital employed (ROCE), % -0.4 5.6 8.9 7.7 11.9 54.5 33.7 ROCE excl. non-recurring items, % 3.4 6.8 6.7 8.5 10.8 27.1 61.2 Return on equity (ROE), % -1.4 7.7 14.0 12.5 11.4 -8.8 -18.6 Debt/equity ratio 0.70 0.54 0.54 0.72 0.60 -16.7 11.1 Equity per share, EUR 9.16 9.89 9.89 8.97 9.69 8.0 -2.0 Equity ratio, % 41.0 45.3 45.3 40.2 44.1 9.7 -2.6 Operating profit, % of sales -0.3 4.4 6.6 6.2 8.8 41.9 33.3 Operating profit excl. non-recurring items, % of sales 2.8 5.4 5.0 6.8 8.0 17.6 60.0 Capital expenditure, EUR 1 million 145.3 583.4 179.7 167.7 108.9 -35.1 -39.4 Capital expenditure, % of sales 8.7 4.0 4.8 4.6 2.8 -39.1 -41.7 Capital employed, EUR 11 11 11 11 11 million 678 332 332 526 478 -0.4 1.3 Interest-bearing net liabilities, EUR million 5 084 4 234 4 234 5 116 4 599 -10.1 8.6 Average number 46 45 45 46 43 of employees 166 631 631 056 504 -5.5 -4.7 Average number of shares (million) periodic 798.7 788.6 788.6 788.6 788.6 cumulative 798.7 788.6 788.6 788.6 788.6 cumulative, diluted 799.2 788.9 788.9 789.1 788.9 Key Exchange Rates for the Euro One Euro is Closing Rate Average Rate 31 Dec 06 31 Mar 07 31 Dec 06 31 Mar 07 SEK 9.0404 9.3462 9.2517 9.1892 USD 1.3170 1.3318 1.2563 1.3112 GBP 0.6715 0.6798 0.6819 0.6707 CAD 1.5281 1.5366 1.4247 1.5363 Transaction Risk and Hedges in Main Currencies as at 31 March 2007 EUR million USD GBP SEK JPY Estimated annual net operating cash flow exposure 1 450 600 -1 000 300 Transaction hedges as at 31 Mar. 360 255 -556 48 Hedging percentage as at 31 Mar. for the next 12 months 25 % 43 % 56 % 16 % Condensed Consolidated Income Statement 2006 Q1/2006 Q1/2007 Change % EUR million Q1/07-Q1/06 Sales 14 593.9 3 607.7 3 855.4 6.9 Other operating income 364.9 50.2 16.7 -66.7 Materials and services -8 111.5 -1 987.7 -2 160.0 -8.7 Freight and sales -1 751.4 -392.7 -430.7 -9.7 commissions Personnel expenses -2 200.9 -544.4 -483.7 11.1 Other operating expenses -988.9 -240.1 -185.0 22.9 Depreciation and impairment -1 257.7 -269.2 -273.4 -1.6 Operating Profit / (Loss) 648.4 223.8 339.3 51.6 Share of results of 87.4 31.6 24.2 -23.4 associated companies Net financial items -104.0 62.3 -56.7 n/a Profit / (Loss) before Tax 631.8 317.7 306.8 -3.4 Income tax -42.6 -91.3 -84.3 7.7 Net Profit / (Loss) for the 589.2 226.4 222.5 -1.7 Period Attributable to: Equity holders of the Parent 585.0 225.0 219.2 -2.6 Company Minority interests 4.2 1.4 3.3 135.7 589.2 226.4 222.5 -1.7 Earnings per share Basic earnings per share, 0.74 0.29 0.28 -3.4 EUR Diluted earnings per share, 0.74 0.29 0.28 -3.4 EUR Consolidated Statement of Recognised Income & Expense EUR million 2006 Q1/2006 Q1/2007 Defined benefit plan actuarial gains / (losses) 135.1 - - Tax on actuarial movements -46.6 - - Aggregate fair value movements in 251.6 -103.7 51.1 Available-for-Sale assets Currency and commodity hedges -45.3 88.7 -37.5 Associate hedges 11.1 3.5 -0.1 Tax on Other Comprehensive Income Movements 50.2 2.1 10.2 (OCI) Currency translation movements on equity net -86.4 -39.9 -69.0 investments (CTA) Equity net investment hedges 118.0 38.6 32.1 Tax on equity hedges -30.7 -10.1 -8.3 Net Income & Expense Recognised directly in 357.0 -20.8 -21.5 Equity Net profit / (loss) for the period 589.2 226.4 222.5 Total Recognised Income & Expense for the 946.2 205.6 201.0 Period Attributable to: Equity holders of the Parent Company 942.0 204.2 197.7 Minority interests 4.2 1.4 3.3 Total Recognised Income & Expense for the 946.2 205.6 201.0 Period Condensed Consolidated Cash Flow Statement EUR million 2006 Q1/2006 Q1/2007 Cash Flow from Operating Activities Operating profit 648.4 223.8 339.3 Adjustments 1 060.9 265.9 256.2 Change in net working capital 199.1 -189.9 -385.3 Change in short-term interest-bearing receivables 89.9 32.2 49.0 Cash Flow Generated by Operations 1 998.3 332.0 259.2 Net financial items -335.4 -45.1 -41.3 Income taxes paid -215.4 -10.3 -45.0 Net Cash Provided by Operating Activities 1 447.5 276.6 172.9 Cash Flow from Investing Activities Acquisitions of subsidiaries -329.8 -7.4 -0.4 Acquisitions of associated companies -19.4 0.0 -65.9 Proceeds from sale of fixed assets and shares 700.8 206.3 7.1 Capital expenditure -583.4 -167.7 -108.9 Proceeds from (payment of) the non-current receivables, net -21.4 -14.6 18.9 Net Cash Used in Investing Activities -253.2 16.6 -149.2 Cash Flow from Financing Activities Change in long-term liabilities -11.6 97.8 113.1 Change in short-term borrowings -623.5 -586.1 20.3 Dividends paid -354.9 0.0 0.0 Minority equity injections less dividends 6.6 -0.5 0.4 Options exercised -2.0 -1.3 -0.5 Repurchase / Sale of own shares 0.2 0.0 0.1 Net Cash Used in Financing Activities -985.2 -490.1 133.4 Net Increase (Decrease) in Cash and Cash Equivalents 209.1 -196.9 157.1 Cash and bank in acquired companies 1.6 0.7 0.0 Cash and bank in sold companies -20.2 -0.6 0.0 Translation adjustment -30.4 -3.8 -0.3 Net cash and cash equivalents at the beginning of period 149.5 351.4 309.6 Net Cash and Cash Equivalents at Period End 309.6 150.8 466.4 Cash and Cash Equivalents at Period End 609.0 352.7 525.5 Bank Overdraft at Period End -299.4 -201.9 -59.1 Net Cash and Cash Equivalents at Period End 309.6 150.8 466.4 Acquisitions of Subsidiary Companies Cash and cash equivalents 1.6 0.7 - Working capital 47.2 -1.2 - Operating fixed assets 281.1 1.8 0.3 Interest-bearing assets 0.0 - - Tax liabilities 1.2 0.3 - Interest-bearing liabilities -4.4 -0.6 - Non-cash share exchange - - - Minority interests 1.1 -0.2 0.1 Fair Value of Net Assets 327.8 0.8 0.4 Goodwill 2.0 6.6 Total Purchase Consideration 329.8 7.4 0.4 Disposal of Subsidiary Companies Cash and cash equivalents 20.2 0.6 - Working capital 59.5 6.5 - Operating fixed assets 217.9 44.1 - Interest-bearing assets 1.2 0.9 - Tax liabilities -18.0 -13.5 - Interest-bearing liabilities -12.0 -1.5 - Minority interests -0.2 - - Net Assets in Divested Companies 268.6 37.1 0.0 Income Statement capital gain (goodwill realised) 197.9 - - Total Disposal Consideration 466.5 37.1 0.0 Property, Plant and Equipment, Intangible Assets and Goodwill EUR million 2006 Q1/2006 Q1/2007 Carrying value at 1 January 11 213.2 11 213.2 10 440.4 Acquisition of subsidiary companies 283.1 8.4 0.3 Additions 559.1 165.1 96.7 Additions in biological assets 24.3 2.6 12.2 Change in emission rights 54.4 80.2 4.2 Disposals -237.3 -61.0 -6.4 Depreciation, amortisation and impairment -1 257.7 -269.2 -273.4 Translation difference and other -198.7 -87.9 -90.0 Balance Sheet Total 10 440.4 11 051.4 10 184.0 Borrowings EUR million 2006 Q1/2006 Q1/2007 Non-current borrowings 4 081.0 4 392.1 4 141.0 Current borrowings 1 166.5 1 667.5 1 350.2 5 247.5 6 059.6 5 491.2 Carrying value at 1 January 6 083.9 6 083.9 5 247.5 Debt acquired with new subsidiaries 4.4 0.6 - Debt disposed with sold subsidiaries -12.0 -4.3 - Proceeds from / payments of borrowings (net) -692.4 -327.9 -95.9 Translation difference and other*) -136.4 307.3 339.6 Total Borrowings 5 247.5 6 059.6 5 491.2 *) includes dividend liability of EUR 354.9 million in Q1/2007 and in Q1/2006. Condensed Consolidated Balance Sheet EUR million Change % Change % 31 Mar 31 Mar 31 Dec 31 Mar 31 Mar 07 - 31 07 - 31 06 06 07 Mar 06 Dec 06 Assets Fixed Assets and Other Non-current Investments Fixed assets O 10 230.8 10 850.0 9 957.5 -8.2 % -2.7 % Biological assets O 111.5 77.5 124.2 60.3 % 11.4 % Emission rights O 98.1 123.9 102.3 -17.4 % 4.3 % Investment in associated companies A 805.2 754.7 868.3 15.1 % 7.8 % Available-for-sale: Listed securities I 41.2 83.5 42.6 -49.0 % 3.4 % Available-for-sale: Unlisted shares O 794.3 402.9 845.2 109.8 % 6.4 % Non-current loan receivables I 149.2 141.8 127.0 -10.4 % -14.9 % Deferred tax assets T 53.5 65.2 60.0 -8.0 % 12.1 % Other non-current assets O 61.1 16.1 58.2 261.5 % -4.7 % 12 12 344.9 12 515.6 185.3 -2.6 % -1.3 % Current Assets Inventories O 2 019.5 2 210.6 2 126.9 -3.8 % 5.3 % Tax receivables T 124.8 112.6 118.4 5.2 % -5.1 % Operative receivables O 2 127.9 2 260.8 2 403.5 6.3 % 13.0 % Interest-bearing 214.2 365.8 197.5 receivables I -46.0 % -7.8 % Cash and cash 609.0 352.9 525.5 equivalents I 48.9 % -13.7 % 5 095.4 5 302.7 5 371.8 1.3 % 5.4 % Total Assets 17 17 440.3 17 818.3 557.1 -1.5 % 0.7 % Equity and Liabilities Equity attributable 7 799.6 7 072.4 7 642.0 to Company shareholders 8.1 % -2.0 % Minority interests 103.5 93.0 106.2 14.2 % 2.6 % Total Equity 7 903.1 7 165.4 7 748.2 8.1 % -2.0 % Non-current Liabilities Post-employment 763.1 886.6 697.8 benefit provisions O -21.3 % -8.6 % Other provisions O 308.3 138.0 209.9 52.1 % -31.9 % Deferred tax 793.0 919.4 795.7 liabilities T -13.5 % 0.3 % Non-current debt I 4 081.0 4 392.1 4 141.0 -5.7 % 1.5 % Other non-current 193.7 303.6 201.2 operative liabilities O -33.7 % 3.9 % 6 139.1 6 639.7 6 045.6 -8.9 % -1.5 % Current Liabilities Current portion of 630.2 159.5 650.6 long-term debt I 307.9 % 3.2 % Interest-bearing 536.3 1 508.0 699.6 liabilities I -53.6 % 30.4 % Operative liabilities O 1 972.9 1 961.8 2 142.1 9.2 % 8.6 % Tax liabilities T 258.7 383.9 271.0 -29.4 % 4.8 % 3 398.1 4 013.2 3 763.3 -6.2 % 10.7 % Total Liabilities 9 537.2 10 652.9 9 808.9 -7.9 % 2.8 % Total Equity and 17 818.3 17 Liabilities 17 440.3 557.1 -1.5 % 0.7 % Items designated with "O" comprise Operating Capital Items designated with "I" comprise Interest-bearing Net Liabilities Items designated with "T" comprise Net Tax Liabilities Items designated with "A" comprise Associate Companies Changes in Group Shareholders' Equity Share Capital Treasury Retained EUR million Capital Reserves Shares OCI CTA Earnings Total Balance at 31 7 December 2004 1 423.3 1 009.2 -180.8 67.6 -218.9 5 525.0 625.4 Repurchase of Stora Enso Oyj shares - - -344.7 - - - -344.7 Cancellation of Stora Enso Oyj shares -41.2 -224.4 265.6 - - - 0.0 Dividend (EUR 0.45 per share) - - - - - -365.3 -365.3 Buy-out of minority interests - - - - - -43.2 -43.2 Net profit for the period - - - - 0.2 -111.1 -110.9 Net expense recognised directly to equity - - - 400.4 91.6 -33.2 458.8 Balance at 31 7 December 2005 1 382.1 784.8 -259.9 468.0 -127.1 4 972.2 220.1 Cancellation of Stora Enso Oyj shares -39.9 -15.9 249.1 - - -193.3 0.0 Dividend (EUR 0.45 per share) - - - - - -354.9 -354.9 Options exercised - - - - - - 0.0 Buy-out of minority interests - - - - - - 0.0 Net profit for the period - - - - 4.2 225.0 229.2 Net expense recognised directly to equity - - - -9.4 -11.4 - -20.8 Balance at 31 7 March 2006 1 342.2 768.9 -10.8 458.6 -134.3 4 649.0 073.6 Cancellation of Stora Enso Oyj shares - - - - - - 0.0 Dividend (EUR 0.45 per share) - - - - - - 0.0 Options exercised - -2.0 0.3 - - - -1.7 Buy-out of minority interests - - - - - -0.1 -0.1 Net profit for the period - - - - -10.0 360.0 350.0 Net expense recognised directly to equity - - - 277.0 12.3 88.5 377.8 Balance at 31 7 December 2006 1 342.2 766.9 -10.5 735.6 -132.0 5 097.4 799.6 Cancellation of Stora Enso Oyj shares - - - - - - 0.0 Dividend (EUR 0.45 per share) - - - - - -354.9 -354.9 Options exercised - -0.5 0.1 - - - -0.4 Buy-out of minority interests - - - - - - 0.0 Net profit for the period - - - - - 219.2 219.2 Net expense recognised directly to equity - - - 23.7 -45.2 - -21.5 Balance at 31 7 March 2007 1 342.2 766.4 -10.4 759.3 -177.2 4 961.7 642.0 CTA = Cumulative Translation Adjustment OCI = Other Comprehensive Income Commitments and Contingencies EUR million 31 Dec 06 31 Mar 06 31 Mar 07 On Own Behalf Pledges given 1.0 1.1 0.8 Mortgages 146.8 211.9 137.0 On Behalf of Associated Companies Mortgages 0.8 0.8 0.0 Guarantees 343.0 369.0 281.2 On Behalf of Others Guarantees 9.5 11.7 10.3 Other Commitments, Own Leasing commitments, in next 12 33.0 months 38.4 30.5 Leasing commitments, after next 12 143.0 months 130.3 123.4 Pension liabilities 0.2 0.5 0.2 Other commitments 17.1 90.7 18.6 Total 687.1 861.7 602.0 Pledges given 1.0 1.1 0.8 Mortgages 147.6 212.7 137.0 Guarantees 352.5 380.7 291.5 Leasing commitments 168.7 176.0 153.9 Pension liabilities 0.2 0.5 0.2 Other commitments 17.1 90.7 18.6 Total 687.1 861.7 602.0 Purchase Agreement Commitments EUR million Scheduled Contract Payments Type of Supply Contract Total 2007 2008-9 2010-11 2012+ 2 Fibre 361 200 447 424 1 290 Energy 810 258 341 211 - Logistics 727 128 169 109 321 Other Production costs 139 126 6 3 4 4 037 712 963 747 1 615 Capital Expenditure 173 145 27 1 - Total Contractual 4 Commitments 210 857 990 748 1 615 Net Fair Values of Derivative Financial Instruments EUR million 31 Dec 06 31 Mar 06 31 Mar 07 Net Net Positive Negative Net Fair Fair Fair Fair Fair Values Values Values Values Values Interest rate swaps 48.1 43.9 86.4 -28.4 58.0 Interest rate options -1.8 -7.6 0.6 -1.6 -1.0 Cross-currency swaps -1.2 -5.9 0.0 -1.0 -1.0 Forward contracts 28.2 2.5 5.5 -4.4 1.1 FX options 5.9 1.6 6.8 -1.5 5.3 Commodity contracts 63.2 210.8 48.7 -11.7 37.0 Equity swaps 7.0 39.7 38.5 -13.0 25.5 Total 149.4 285.0 186.5 -61.6 124.9 Nominal Values of Derivative Financial Instruments EUR million 31 Dec 06 31 Mar 06 31 Mar 07 Interest Rate Derivatives Interest rate swaps Maturity under 1 year 177.4 0.0 83.0 Maturity 2-5 years 2 152.1 1 038.6 1 758.3 Maturity 6-10 years 2 490.5 1 788.4 948.5 Maturity over 10 years - - 300.3 4 820.0 2 827.0 3 090.1 Interest rate options 318.0 1 753.6 659.9 Total 5 138.0 4 580.6 3 750.0 Foreign Exchange Derivatives Cross-currency swap agreements 6.9 70.7 6.8 Forward contracts 1 778.4 2 129.0 - 4.4 FX Options 662.8 833.2 1 351.8 Total 2 448.1 3 032.9 1 354.2 Commodity Derivatives Commodity contracts 635.8 414.9 568.8 Total 635.8 414.9 568.8 Equity swaps Equity swaps 328.6 400.9 270.9 Total 328.6 400.9 270.9 Sales by Segment EUR million Q1/06 Q2/06 Q3/06 Q4/06 2006 Q1/07 Publication Paper 1 171.0 1 145.2 1 226.7 1 230.5 4 773.4 1 240.5 Fine Paper 776.3 738.9 722.8 718.3 2 956.3 738.6 Merchants 496.3 452.6 450.1 508.2 1 907.2 532.9 Packaging Boards 869.0 881.8 909.0 871.7 3 531.5 919.8 Wood Products 377.1 437.8 418.5 443.0 1 676.4 479.8 Wood Supply 674.8 651.3 633.9 687.2 2 647.2 778.6 Other -756.8 -691.3 -722.9 -727.1 -2 898.1 -834.8 Total Sales 3 607.7 3 616.3 3 638.1 3 731.8 14 593.9 3 855.4 Operating Profit by Segment excluding Non-recurring items EUR million Q1/06 Q2/06 Q3/06 Q4/06 2006 Q1/07 Publication Paper 70.3 55.3 57.0 69.0 251.6 63.5 Fine Paper 52.7 46.3 32.4 34.6 166.0 61.5 Merchants 9.6 2.9 7.7 12.5 32.7 16.6 Packaging Boards 99.5 70.8 93.7 59.4 323.4 106.5 Wood Products 3.8 14.9 21.4 19.0 59.1 53.7 Wood Supply 8.9 1.3 5.0 -12.4 2.8 12.2 Other 2.2 -73.3 12.1 5.5 -53.5 -6.7 Operating Profit excl. Non-recurring Items 247.0 118.2 229.3 187.6 782.1 307.3 Non-recurring items -23.2 6.7 -177.2 60.0 -133.7 32.0 Operating Profit (IFRS) 223.8 124.9 52.1 247.6 648.4 339.3 Net financial items 62.3 -85.2 -42.5 -38.6 -104.0 -56.7 Associated companies 31.6 20.2 10.2 25.4 87.4 24.2 Profit before Tax and Minority Interests 317.7 59.9 19.8 234.4 631.8 306.8 Income tax expense -91.3 -19.0 37.3 30.4 -42.6 -84.3 Net Profit 226.4 40.9 57.1 264.8 589.2 222.5 Non-recurring Items by Segment EUR million Q1/06 Q2/06 Q3/06 Q4/06 2006 Q1/07 Publication Paper -2.9 4.4 -225.2 11.4 -212.3 13.3 Fine Paper -22.0 3.8 72.0 8.5 62.3 19.2 Merchants - - - 0.4 0.4 Packaging Boards - -5.5 - 4.3 -1.2 4.3 Wood Products 1.7 1.2 -24.0 0.4 -20.7 -12.0 Wood Supply - 1.5 - 0.7 2.2 Other - 1.3 - 34.3 35.6 7.2 Total Non-recurring Items -23.2 6.7 -177.2 60.0 -133.7 32.0 - Operating Profit by Segment EUR million Q1/06 Q2/06 Q3/06 Q4/06 2006 Q1/07 Publication Paper 67.4 59.7 -168.2 80.4 39.3 76.8 Fine Paper 30.7 50.1 104.4 43.1 228.3 80.7 Merchants 9.6 2.9 7.7 12.9 33.1 16.6 Packaging Boards 99.5 65.3 93.7 63.7 322.2 110.8 Wood Products 5.5 16.1 -2.6 19.4 38.4 41.7 Wood Supply 8.9 2.8 5.0 -11.7 5.0 12.2 Other 2.2 -72.0 12.1 39.8 -17.9 0.5 Operating Profit 223.8 124.9 52.1 247.6 648.4 339.3 Net financial items 62.3 -85.2 -42.5 -38.6 -104.0 -56.7 Associated companies 31.6 20.2 10.2 25.4 87.4 24.2 Profit before Tax and Minority Interests 317.7 59.9 19.8 234.4 631.8 306.8 Income tax expense -91.3 -19.0 37.3 30.4 -42.6 -84.3 Net Profit 226.4 40.9 57.1 264.8 589.2 222.5 Stora Enso Shares Closing Price Helsinki, EUR Stockholm, SEK New York, USD A share R share A share R share ADRs January 12.71 12.77 115.50 115.50 16.74 February 12.40 12.47 115.25 115.25 16.42 March 12.91 13.00 122.00 120.75 17.27 Trading Volume Helsinki Stockholm New York A share R share A share R share ADRs January 93 402 107 866 499 118 480 19 169 929 2 044 400 February 71 650 111 174 276 110 544 17 875 014 1 772 500 March 104 004 102 984 571 137 834 14 498 405 1 895 700 Total 269 056 322 025 346 366 858 51 543 348 5 712 600 Basis of Preparation This unaudited interim financial report has been prepared in accordance with the accounting policies set out in International Accounting Standard 34 on Interim Financial Reporting and in the Group's Annual Report for 2006. The Group has adopted IFRS 7, Financial Instruments: Disclosures, and the complementary Amendment to IAS 1, Presentation of Financial Statements - Capital Disclosures which is mandatory for the Group's accounting periods beginning on or after 1 January 2007. The adoption of this standard and amendment will result in additional disclosures relating to financial instruments and how an entity manages its capital in the Group's Annual Report. Reclassification in 2006 Operating profit for 2006 has been reclassified. Total Return Swaps (TRS) which are partially hedging cash settled synthetic option programmes for Management, previously reported in other financial items, are now reported in operating profit under personnel expenses, with an effect of income of EUR 52.9 million and EUR 24.6 million in Q1/2006 and Q1-Q4/2006, respectively. TRS instruments do not qualify for hedge accounting and therefore all periodic changes to their fair value are recorded in the Income Statement. Calculation of Key Figures Return on capital employed, ROCE (%) 100 x Operating profit____ Capital employed 1) 2) Return on operating capital, 100 x Operating profit____ ROOC (%) Operatin


 

Today the financial services group Exista hf. published its reviewed interim financial statements for the first three months of the year 2007. In accordance with the announcements made by the Group in its last report of operating results, dated 8 February 2007, the following changes have been made in Exista's accounting methods as of the beginning of the calendar year: * Strategic investments in financial companies - that is, in Sampo Group and Kaupthing Bank - will henceforth be accounted for by equity method. * The Board of Directors of Exista has decided to utilise an authorisation to present its financial statements in euros beginning with the first quarter of 2007. According to the interim financial statements for the first quarter of 2007, the primary results for the period are as follows: * Profit EUR 641 million after tax * Earnings per share EUR 0.06 * Annualised return on equity 112.8% * Operating profit from investment businesses EUR 467 million after tax * Operating profit from operating businesses EUR 174 million after tax * Total assets EUR 6.76 billion at the end of March 2007, an increase of 54% during the period * Equity EUR 2.64 billion at the end of March, an increase of 39% since the beginning of the year * Funding in the first quarter totalled EUR 1.67 billion * Equity ratio 39.1% as of 31 March 2007 Lýdur Gudmundsson, Executive Chairman: "Exista's performance was extremely sound during the first quarter. In some ways, today's report marks a turning point for the Group. Recording our long-term holdings in Kaupthing Bank and Sampo using the equity method further highlights the importance of financial services in our revenue generation and strengthens our revenue base. It is also a logical step for us to carry out our accounting in euros, as Exista operates in international markets. The overall operation of the Group is going well, and the outlook is generally positive for our strategic holdings. We will continue to build on our solid foundations, with the aim of securing strong long-term returns for our shareholders." For further information on the Group's interim accounts, please contact: Sigurdur Nordal Managing Director of Group Communications tel: +354 550 8620 (ir@exista.com)


 

The Annual General Meeting of Consorte Group ASA was held at 10:00 CET on 26 April 2007 at Felix Konferansesenter, Bryggetorget 3 in Oslo. Please find enclosed the complete minutes translated to English on: www.newsweb.no or at www.hugin.no For further information please contact: CEO Eivind Hauglie-Hanssen Email adress: eivind.hauglie-hanssen@consorte.com Consorte Group ASA Tel + 47 03050


 

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | AXA Investment Managers UK | | | Limited/AXA Framlington | | | Investment Management Limited | |-----------------------------------+-------------------------------| | Company dealt in | Taylor Woodrow | |-----------------------------------+-------------------------------| | Class of relevant security to | Ordinary shares | | which the dealings being | | | disclosed relate (Note 2) | | |-----------------------------------+-------------------------------| | Date of dealing | 25/04/2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------------------------------+ | | Long | Short | | | | | |---------------+--------------------------+------------------------------------------------| | |Number |Number | | | (%) | (%) | |---------------+--------------------------+------------------------------------------------| |(1) Relevant |9,058,672 (1.56%) | | |securities | | | | | | | |---------------+--------------------------+------------------------------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+--------------------------+------------------------------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+--------------------------+------------------------------------------------| |Total |9,058,672 (1.56%) | | | | | | +-------------------------------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +--------------------------------------------------------------------------+ |Class of | Long | Short | |relevant | | | |security: | | | | | | | |---------------+----------------------------+-----------------------------| | |Number |Number | | | (%) | (%) | |---------------+----------------------------+-----------------------------| |(1) Relevant | | | |securities | | | | | | | |---------------+----------------------------+-----------------------------| |(2) Derivatives| | | |(other than | | | |options) | | | | | | | |---------------+----------------------------+-----------------------------| |(3) Options and| | | |agreements to | | | |purchase/sell | | | | | | | |---------------+----------------------------+-----------------------------| |Total | | | | | | | +--------------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | Sale | 834,928 | 5.00p | | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short (Note | Number of securities | Price per | | name, | 6) | (Note 7) | unit (Note | | e.g. CFD | | | 5) | |----------+------------------+------------------------+------------| | | | | | | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ |Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | |name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| |option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) NO +-------------------------------------------------------------------+ | Date of disclosure | 26/04/2007 | |---------------------------------------------------+---------------| | Contact name | Jetin Vithal | |---------------------------------------------------+---------------| | Telephone number | 0207 003 2813 | |---------------------------------------------------+---------------| | If a connected EFM, name of offeree/offeror with | N/A | | which connected | | |---------------------------------------------------+---------------| | If a connected EFM, state nature of connection | N/A | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 
Ýmislegt
26. apríl 2007

CSG - New Contract

Component Software Group ASA is chosen as supplier to NAV for delivery of consulting services related to building the data warehouse and business intelligence solution for the Pension program. The Pension program's purpose is to make all necessary preparations for the pension reform that will take effect on January 1st 2010. The delivery will take place in the period May 2007 to December 2008 with options to extend the project. Estimated contract value is minimum NOK 10 million over the period described above. The agreement is subject to a notice period which ends May 9th. This contract is a confirmation of Component Software's solid competency and ability to deliver business intelligence and data warehouse solutions. Investor relations: CEO Åge Lønning tel. +47 40 20 10 00, a.lonning@componentsoftware.no CFO Inge Larsen tel. +47 40 20 36 75, i.larsen@componentsoftware.no


 

The Annual General Meeting 2007 of Bank Austria Creditanstalt AG will take place on 3 May 2006. Starting at 09.30 a.m. (Vienna time) Bank Austria Creditanstalt will transmit the speech by Erich Hampel, Chairman of the Managing Board, live on Internet. To participate in the Annual General Meeting, you can use the following link: http://www.tv1.de/irplayer/cms/_v/bankaustria/hv2007/english Contact for enquiries: BA-CA Investor Relations Tel.: +43 (0)5 05 05 58853 Fax: +43 (0)5 05 05 58808 mailto:IR@ba-ca.com --- End of Message --- Bank Austria Creditanstalt AG Vordere Zollamtsstraße 13 Wien Austria WKN: 813030; ISIN: AT0000995006; Listed: Freiverkehr in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Stuttgart;


 

Straumur-Burdaras Investment Bank ("Straumur-Burdaras") Results for the first three months of 2007 TRANSITION TO EURO SUCCESSFUL DELIVERING ON STRATEGY CONTINUED INCREASE IN FEES AND COMMISSIONS Fridrik Jóhannsson, CEO: "We are extremely pleased to announce our first results in Euros which is a very important milestone towards our goal of becoming an international investment bank. The transition has been a successful one. We continue to increase our fees and commissions and our results in the first three months are in line with our strategy and objectives: stable income sources and further diversification in our operations. Straumur-Burdaras currently has operations in four countries, but we have begun to prepare for the opening of a branch in Stockholm, Sweden. Key personnel have been recruited there and will begin to operate in the months to come. We intend to grow this year: in the Nordic region, in the UK, and in mainland Europe if some promising opportunities arise." Results according to objectives * After-tax profit for the first quarter 2007 totalled EUR 69.16 million, as opposed to EUR 217.51 million during the same period last year when the Bank sold its 21.05% share in Glitnir, then Íslandsbanki. * Net income from operations in the first quarter amounted to EUR 92.52 million, compared with EUR 276.02 million for the same period in 2006. * Return on equity (ROE) was 4.6% for the first three months, which corresponds to 19.9% annualised ROE. This is in keeping with the Bank's plans. * The cost-income ratio was 13.2% for the first three months of 2007, whereas it was 8.0% in the first three months in 2006. The Bank will continue to invest in further growth in core markets. Continued increase in fees and commissions * Net commission income amounted to EUR 30.29 million for the first three months 2007, as against EUR 26.98 million for the same period in 2006, an increase of 12% year-on-year. * Net interest income in the first three months 2007 was EUR 11.16 million, while it was EUR 5.53 million for the same period in 2006. Strong Balance Sheet * The Bank's total assets at EUR 5,191.56 million at the end of the first quarter, compared with EUR 4,357.76 million at year-end 2006, have increased by 19% since the beginning of the year. * The Bank's CAD ratio was 32,8%, with a Tier 1 capital ratio of 30,3%. In comparison, at year-end 2006 the CAD ratio was 37.59% and the Tier 1 capital ratio 35.20%. * Shareholders' equity amounted to EUR 102.18 million at the end of the first quarter, after the deduction of own shares. Executing strategy in Balance Sheet composition * Straumur-Burdaras' loan portfolio increased from EUR 1,352.07 million at the beginning of 2007 to EUR 1,706.90 million at the end of the first quarter, an increase of 26% year-on-year. * The ratio of interest-bearing assets in the Balance Sheet has risen by four percentage points from the year 2006: from 59% to 63%.


 

- New name completes successful integration process - Additional investment expected to build platform for future growth Reykjavik, Iceland, 26 April 2007 -- Actavis Group (ICEX: ACT), the international generic pharmaceuticals company, today announced that Sindan, the leading European generic pharmaceutical company specializing in the manufacturing and distribution of oncology products, will be rebranded as Actavis with immediate effect. This follows Actavis' acquisition of Sindan in March 2006 and the completed integration of the business. Since its acquisition by Actavis, Sindan has continued to experience strong growth. The business generated revenues of EUR95 million in 2006 and expectations for 2007 are for sales of EUR115 million. Actavis is committed to extending its business in Romania and its capabilities in the field of oncology to take further advantage of the fast growing domestic and international market. To achieve that the Group will continue to invest in the oncology business and initial plans are in place to expand Actavis' oncology facilities either through acquisition or new development and build a platform for future growth and create further opportunities for employees. Actavis has one of the strongest pipelines in the generic industry, with over 355 projects under development, covering all key therapeutic classes. The Company has successfully introduced a number of products from its international portfolio into the Romanian market and had seven product launches in 2006. During 2006, 376 product and market launches were made (163 molecules), out of which 54 were first to market for the Group as a whole. This year, 17 new Actavis products will enter the Romanian market in the retail segment, covering central nervous system, cardiovascular and anti-infective therapeutic classes and OTC products. The Romanian division is expecting a 30% growth in exports by the end of 2007, which represents the Group's strong oncology portfolio. The name Actavis is derived from two Latin words "acta" meaning action and "vis" meaning strength. The name reflects Actavis commitment to being a dynamic, fast growing company with a global reach and one of the broadest product pipelines. Sindan will become formally known as Actavis Romania and the existing management team, led by Laurentiu Scheusan, will continue to be actively involved in the business. At a formal launch ceremony held in Bucharest, Romania, Robert Wessman, President and CEO of Actavis, Jonas Tryggvason, Executive Vice President of Central-Eastern Europe and Asia (CEEA), Sales & Marketing Division and Laurentiu Scheusan, Country Manager, Romania were present. Commenting, Robert Wessman, President and CEO of Actavis said: "Our acquisition of Sindan has been a huge success. The formal introduction of the Actavis name into the Romanian market is the final step in the integration process but just the beginning of the next stage in our development and investment in this exciting environment. We have a solid platform from which to achieve further growth and take our Romanian business to the next stage. " For further information, please contact: Halldor Kristmannsson VP of Corporate Communications & IR Tel: +354 535 7400 / + 354 8403425 About Sindan Founded in 1992, Sindan is headquartered in Bucharest, Romania, and currently employs 280 people across the country. The Company is one of Europe's leading manufacturers of generic oncology pharmaceuticals and the largest hospital distributor in the country. Sindan develops, manufactures and distributes a wide range of solid-dose and injectable generic drugs and is successfully entering a growing number of export markets through its offices in the UK, Poland and Switzerland. Key export markets for Sindan's own developed products currently include the UK, US, Japan, Germany, Italy and Spain. In addition, the Company has traditionally had a leading position in many Central and Eastern European markets and generates sales in Bulgaria, Hungary, Poland, the Czech Republic, Slovakia and Russia. About Actavis Group Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in more than 30 countries, with over 11,000 employees. The Company's market cap is approximately EUR3.0bn (US$3.8 billion) and it's listed on the OMX Exchange in Iceland. For further information, please visit www.actavis.com. Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


 

The Annual General Meeting in Photocure ASA took place on 25 April 2007. The General Meeting approved the Directors' Report and the Annual Accounts, as well as the Board of Directors' proposed distribution of for 2006. Erik Engebretsen, Jon Hindar, Lars Lindegren and Birgit Stattin Norinder were re-elected for as a members of the Board of Directors. In addition, Kari E. Krogstad was elected as a new director of the Board. All were elected for a period of one year. The new Board of Directors of Photocure ASA consists of: Erik Engebretsen, Chairman of the Board Jon Hindar, Board member Kari E. Krogstad, Board member Lars Lindegren, Board member Birgit Stattin Norinder, Board member The Nomination Committee was elected for a period of one year. The Nomination Committee consists of: Jónas Einarsson Tharald Brøvig Jon Ringvold In accordance with the proposals of the Board of Directors, the General Meeting also resolved to grant authority to the Board to increase the share capital and to change the articles of association. For further information, please contact: President and CEO Kjetil Hestdal E-mail: kh@photocure.no Mobile: +47 913 19 535 CFO Christian Fekete E-mail: cf@photocure.no Mobile: +47 916 42 938 www.photocure.com Photocure ASA is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of different types of cancer. Photocure has three products on the market: Metvix® cream combined with the Aktilite® lamp for the treatment of sun-damaged skin and certain types of skin cancer, and Hexvix® for the diagnosis of bladder cancer. In addition, the company has several follow-on products and technologies in the pipeline.


 

Gouda, 26 April 2007 - Imtech N.V. (European technical services provider) announces that the intended acquisition of Peek Traffic Holdings Ltd. (Peek Traffic), a technical service provider and system integrator specialising in total mobility solutions in the fields of Intelligent Transport Systems, dynamic traffic management, traffic safety, traffic enforcement, the environment and public transport, is definitive. The acquisition has been approved by the German Bundeskartellamt (German Federal Cartel Office). With this acquisition Imtech gains a strong position in the infrastructure market in Western Europe and secures entry position in Eastern Europe. The acquisition price, excluding debts, is approximately 80 million euro and will be paid in cash. The acquisition fits the Imtech strategy of further international growth in the European infra-market and directly contributes to the earnings per share. The synergy between the activities of Imtech and Peek Traffic is as follows: * The activities complement each other splendidly in the expanding mobility market partly due to the strong market position of both (combined revenues of approximately 265 million euro with 2,200 infra specialists). * A strong position for the development and execution of integral (total) projects in Europe * The ideal combination for advanced project management, intelligent mobility solutions, ICT and delivery capacity in large-scale maintenance projects, in PPP collaboration and with Asset Management contracts. * An attractive party as a partner for various joint ventures for national governments by offering high-tech total solutions. Further information Imtech N.V. M.E.J. (Mark) Salomons Company Secretary Telephone: +31 (0)182 54 35 14 E-mail: mark.salomons@imtech.eu www.imtech.eu Imtech Profile Imtech N.V. is a European technical services provider in the fields of electrical engineering, ICT (information and communication technology) and mechanical engineering. With approximately 16,000 employees, Imtech realises annual revenue of almost ¤3 billion. Imtech holds strong positions in the buildings, industry, infrastructure and telecom markets in Belgium, Germany, Luxembourg, the Netherlands, Eastern Europe, Spain and the UK and in the global maritime market. Imtech provides services to a total of 12,000 clients. Imtech offers added value in the form of integrated and multidisciplinary total solutions that lead to improved operating processes and higher yields for clients and their clients in return. Imtech also provides solutions that contribute to a sustainable, liveable society, for example in the field of energy, mobility, safety and the environment. Imtech shares are listed on the Euronext Stock Exchange (Amsterdam), where Imtech is included in the Amsterdam SmallCap Index (AScX) and the Next 150 index.


 

Evox Rifa Group Oyj Stock Exchange Release on April 26, 2007 * Net sales of the first quarter of 2007 were EUR 23.6 million (EUR 21.6 million in 2006). Net sales increased by 9.3% compared to the previous year. * Operating profit was 0.2 million (loss EUR 0.5 million). Operating profit includes EUR 0.9 million of costs related to the public tender offer made by KEMET for Evox Rifa Group Oyj's shares (restructuring costs in the corresponding period in 2006 were EUR 0.3 million). * Loss before taxes was EUR 0.2 million (loss EUR 1.0 million). * Earnings per share were EUR -0.004 (EUR -0.007). * Order backlog on March 31, 2007 was EUR 21.5 million (EUR 20.4 million). ECONOMIC DEVELOPMENT Net Sales Net sales of the Group totalled EUR 23.6 million (EUR 21.6 million in 2006). In the first quarter of 2007 demand remained at a satisfactory level, but price competition was hard in all market areas. Profit Operating profit of the Group was EUR 0.2 million (loss EUR 0.5 million) and loss before taxes was EUR 0.2 million (loss EUR 1.0 million). The operating profit includes EUR 0.9 million of costs related to the public tender offer made by KEMET Corporation, through its wholly owned subsidiary, KEMET Electronics Corporation, for Evox Rifa's shares. Ín the corresponding period last year, the costs related to restructuring were EUR 0.3 million. Earnings per share were EUR -0.004 (EUR -0.007) and shareholders' equity per share was EUR 0.031 (EUR 0.034). Order backlog The order backlog of the Group was EUR 21.5 million at the end of the first quarter of 2007 (EUR 20.4 million at the end of the corresponding period of 2006). FINANCIAL STATUS AND CAPITAL EXPENDITURE Liquid assets of the Group were EUR 1.4 million (EUR 0.6 million) and the equity ratio was 11.4% (11.8%) at the end of the period. If the convertible capital loan is counted as shareholders' equity, the equity ratio is 21.7%. Investments in manufacturing equipment were EUR 0.4 million (EUR 0.3 million). SHARES AND SHARE CAPITAL The number of shares of Evox Rifa Group Oyj was 178.156.018 on March 31, 2007 and the share capital was EUR 8.908.400,90. ANNUAL GENERAL MEETING The Annual General Meeting on April 23, 2007 decided, according to the proposal by the Board of Directors, not to pay a dividend for the fiscal period ended on December 31, 2006. Mr. Per-Olof Loof, Mr. David E. Gable, Mr. Marc Kotelon, Mr. Kirk D. Shockley and Mr. Michael W. Boone were elected as Members of the Board. The Board of Directors has elected Per-Olof Loof as Chairman of the Board. KPMG Oy Ab was re-appointed auditors of the company. The General Meeting also decided on the amendment of the Articles of Association to comply with the new Companies Act. The Annual General Meeting on 20 April 2006 had authorised the Board of Directors for one year following the AGM to decide on one or more new share issues and/or convertible loans so that the increase of the share capital, based on new issues and/or convertible loans, could be a maximum EUR 1.772.210. The authorization has expired and it was not used. PERSONNEL The average number of personnel in Evox Rifa Group was 1376 during the first quarter of 2007 (1343 in the same period in 2006). BUSINESS DEVELOPMENT Net sales of the electrolytic capacitors product group were EUR 13.2 million in the first quarter of 2007 (EUR 11.6 million in 2006). Profitability of the product group continued at a good level. Net sales of the film capacitors product group were EUR 10.4 million (EUR 10.1 million in 2006). Profitability of the product group was still at an unsatisfactory level, primarily because of the negative result of the Suomussalmi plant. MATERIAL RISKS AND UNCERTAINTIES IN THE NEAR FUTURE The capacitor industry market has become increasingly global, which has eliminated geographical market differences. A visible impact of this has been the harmonization of prices and logistics requirements. Major customers tend to concentrate their purchases with fewer suppliers, keeping just one or two suppliers instead of three or four. Half a dozen global suppliers dominate competition in certain product areas. Evox Rifa Group's customers compete in areas in which technologies change rapidly and products have a short life cycle. Product development is exceptionally fast in the telecommunications market, as new technologies weaken the competitiveness of existing technologies or render them obsolete. The Group continuously evaluates benefits and profitability of new production processes and technologies. Evox Rifa Group has received product reclamations that are still being processed. The Group's management believes that the provisions contained in the consolidated balance sheet are sufficient to cover potential currently known compensation risks. EVENTS AFTER THE END OF THE FIRST QUARTER OF 2007 On 12 March 2007, KEMET Corporation through its wholly owned subsidiary, KEMET Electronics Corporation, launched a public tender offer for all shares of Evox Rifa Group Oyj and for all loan notes of the convertible capital loan. The offer period expired on 12 April 2007. KEMET Electronics Corporation acquired the tendered shares and convertible capital loan notes on 24 April 2007, after which it owned 92.7% of Evox Rifa Group Oyj's shares and 95.7% of the convertible capital loan notes. KEMET's total holding in Evox Rifa Group Oyj amounts to 94.1% of all shares and the loan notes, if all loan notes were converted into new shares. Following the settlement of the completion trades relating to KEMET's tender offer, Evox Rifa Group Oyj has on 24 April 2007 become a subsidiary of KEMET Electronics Corporation. As KEMET's ownership in Evox Rifa Group Oyj exceeds 90 %, it has under the Finnish Companies Act, the right and obligation to redeem at a fair price the remainder of Evox Rifa's issued and outstanding shares. KEMET Electronics Corporation has on 24 April 2007 notified Evox Rifa Group Oyj of its decision to exercise the redemption right and presented its redemption claim for the remaining shares in Evox Rifa Group Oyj under the Finnish Companies Act. The Board of Directors of Evox Rifa has on 24 April 2007 decided, subject to Trade Register approval, to appoint Kirk D. Shockley as Managing Director of Evox Rifa after former Managing Director Tuula Ylhäinen having notified the company of her decision to leave the company and move towards new challenges. Kirk Shockley will also be leading the new Electrolytic and Film Business Group within the KEMET group of companies. OUTLOOK FOR THE YEAR 2007 KEMET Electronics Corporation, the majority owner of Evox Rifa Group Oyj, has announced its intention to integrate the business of Evox Rifa Group into KEMET's global organization of business units and sales region units. The planning and implementation of such activites will start in the second quarter of 2007. During the course of completing the compulsory redemption proceedings under the Companies Act, it is expected that the company's shares will be delisted from the Helsinki Stock Exchange. INCOME STATEMENT OF EVOX RIFA GROUP 1.1.- 1.1.- 1.1.- 31.3.07 31.3.06 31.12.06 1000 EUR 1000 EUR 1000 EUR NET SALES 23 578 21 635 89 787 Operating expenses -22 754 -21 484 -85 220 Depreciation and amortisation expenses -673 -657 -2 702 OPERATING PROFIT (LOSS) 151 -506 1 865 Financial income and expenses -379 -502 -2 090 PROFIT (LOSS) BEFORE TAXES -228 -1 008 -225 Income Taxes -385 -163 -716 NET PROFIT (LOSS) FOR THE PERIOD -613 -1 171 -941 Attributable to: Shareholders of the parent -625 -1 152 -948 Minority interest 12 -19 7 -613 -1 171 -941 Earnings per share (EUR) -0.004 -0.007 -0.005 Earnings per share (EUR), diluted -0.004 -0.007 -0.005 BALANCE SHEET OF EVOX RIFA GROUP 31.3.07 31.3.06 31.12.06 ASSETS 1000 EUR 1000 EUR 1000 EUR NON-CURRENT ASSETS Property, plant and equipment 12 471 15 314 12 821 Intangible assets 1 288 1 295 1 266 Other receivables 275 363 285 CURRENT ASSETS Inventories 17 321 15 472 16 615 Trade and other receivables 17 390 18 822 17 109 Cash and cash equivalents 1 403 578 1 313 TOTAL ASSETS 50 148 51 844 49 409 EQUITY AND LIABILITIES Share capital 8 909 8 861 8 909 Other restricted equity 2 611 2 603 2 611 Retained earnings -5 957 -5 465 -5 276 Minority interest 145 114 133 TOTAL EQUITY 5 708 6 113 6 377 LIABILITIES Deferred tax liabilities 496 712 515 Convertible capital loan 5 158 5 038 5 125 Pension obligations 1 645 2 220 1 904 Non-current liabilities 7 530 9 137 7 557 Current liabilities 29 611 28 624 27 931 TOTAL EQUITY AND LIABILITIES 50 148 51 844 49 409 STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY 1.1. - 31.3.2007 Share Other Transl. Retained Minority Total capital reserves difference earnings interest Shareholders' equity on 8 909 2 611 -1 589 -3 687 133 6 377 31.12.2006 Movements: Translation difference -56 -56 Loss for the period -625 12 -613 Shareholders' equity on 31.3.2007 8 909 2 611 -1 645 -4 312 145 5 708 STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY 1.1. - 31.3.2006 Share Other Transl. Retained Minority Total capital reserves difference earnings interest Shareholders' equity on 8 861 2 603 -1 481 -2 739 142 7 386 31.12.2005 Movements: Translation difference -93 -9 -102 Loss for the period -1 152 -19 -1 171 Shareholders' equity on 31.3.2006 8 861 2 603 -1 574 -3 891 114 6 113 EVOX RIFA GROUP CASH FLOW STATEMENT 1.1.- 1.1.- 1.1.- 31.3.07 31.3.06 31.12.06 1000 EUR 1000 EUR 1000 EUR Net cash flow from operating activities 330 -3 846 -1 765 CASH FLOWS FROM INVESTING ACTIVITIES Acquisition of property, plant and -266 7 -738 equipment* Acquisition of intangible assets -27 -10 -16 Proceeds from sale of property, plant and 28 4 106 5 952 equipment Net cash from investing activities -265 4 103 5 198 CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from borrowings 500 458 658 Repayment of borrowings -759 -2 024 -5 169 Payment of finance lease liabilities -32 -37 -141 Proceeds from the issue of shares 56 Net cash from financing activities -291 -1 603 -4 595 Net change in cash and cash equivalents -226 -1 346 -1 163 Cash and cash equivalents at the beginning of the period -5 183 -3 883 -3 883 Translation difference -1 137 Cash and cash equivalents at the end of -5 409 -5 228 -5 183 the period Cash and cash equivalents: Cash in bank and in hand 1 403 578 1 313 Bank overdrafts -6 812 -5 806 -6 496 Total -5 409 -5 228 -5 183 * New investment grant of 151 thousand euros has been deducted (Q1/2006 and year 2006 260 thousand euros). The figures in the Group cash flow statement cannot be directly traced from the balance sheet due to translation differences and elimination of non-cash items. EVOX RIFA GROUP KEY FIGURES 31.3.07 31.3.06 31.12.06 Return on equity %, ROE -40,6 % -69,4 % -13,7 % Return on investment %, ROI 2,6 % -5,9 % 5,6 % Equity ratio % 11,4 % 11,8 % 12,9 % Equity ratio %*) 21,7 % 21,5 % 23,3 % Gross investments in fixed assets, TEUR 444 263 1 021 % of net sales 1,9 % 1,2 % 1,1 % Earnings per share (EUR) -0,004 -0,007 -0,005 Equity of parent shareholders/ share (EUR) 0,031 0,034 0,036 Order backlog, (MEUR) 21,5 20,4 23,2 Average number of personnel 1 376 1 343 1 391 *) The convertible capital loan is included in the shareholders' equity. The figures of this Financial Report are unaudited. This Financial Report is in compliance with the IFRS accounting standards, but all requirements under IAS 34 have not been fulfilled. In Espoo on April 26, 2007 EVOX RIFA GROUP OYJ Board of Directors For further information please contact: Evox Rifa Group Oyj, Juhani Pöhö, Chief Financial Officer, tel. +358 9 5406 5011 DISTRIBUTION: Helsinki Stock Exchange, Main Media The full report including tables can be downloaded from the following link:


 

Please find notice of Annual General Meeting in Algeta ASA enclosed. The Annual General Meeting will be held on May 10 at 18:30 hours in Oslo Konserthus, Lille Sal, Munkedamsveien 14 Oslo. Please use main entrance from Johan Svendsens plass / Ruseløkkveien Oslo, Norway. Printed edition of the notice is this week being sent by mail to Algeta's shareholders. ### For further information, please contact Dr Thomas Ramdahl, CEO +47 23 00 79 90 / +47 913 91 458 (mob) post@algeta.com Geir Christian Melen, CFO +47 23 00 79 84 / +47 913 02 965 (mob) post@algeta.com About Algeta Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing new targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use. Algeta's lead product candidate, Alpharadin, is expected to enter Phase III clinical trials in hormone refractory prostate cancer based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers. Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA). Alpharadin and Algeta are trademarks of Algeta ASA.


 

- Net sales amounted to SEK 102.8 (102.1) million. - Operating income amounted to SEK -82.1 (-16.0) million. - Earnings per share amounted to SEK -1.92 (-0.75). - Inflow of orders amounted to SEK 185.0 (57.9) million. - In February, the Company received its single largest order ever, valued at SEK 85 million from leading fixed line network operators. - The result was charged with SEK 30 million attributable to expenses for projects commitments. - Action plan under implementation. President's comments The quarter showed a large loss sustained as a result of commitments to three major delivery projects, a more conservative approach to capitalisation as well as provisions being made for these projects. The projects also entailed increased expenses during the quarter in the form of increased consultants expenses. Implementation of Action Plan The new Board of Directors has, together with management, decided to launch an action plan to review business logic, expenses, procedures and capitalisation. Work has already commenced and any results will be reported in the coming quarters. In the first few months of the year, a new organisational structure was implemented. The main purpose of this is to improve the different business areas product sales, service and solution sales and, thereby, clarify responsibility for profitability regarding the respective transactions. Sales trends In terms of the inflow of orders, the first quarter of 2007 has been the strongest in the Company's history. The inflow of orders is based on a couple of large orders from leading carriers in Europe, as well as a number of customers placing additional orders to supplement existing system solutions. The strong inflow of orders during the quarter has not significantly affected income for Q1. In February, a leading fixed operator appointed Teligent as a supplier of platforms and services for the carrier's large scale migration to IP telephony. The income generated from the deal amounted to a record breaking SEK 85 million. During the same period, the Company also received a major order for delivery of the Teligent Application Server to another leading European operator for SEK 30 million. Teligent also received its first order for Mobile Office based on the Teligent Application Server, an important milestone in the integration of Teligent and Trio. These transactions have been made possible by the new platform offer, Teligent Application Server, and demonstrate the strength of the Company's product portfolio. During the current quarter, the Company has also delivered system upgrades to TeliaSonera, Deutsche Telekom, Maroc Telecom and others. The subsidiary, Trio Enterprise, which develops presence and customer service systems for the business market, has continued to develop according to plan. The operations have so far been focused on the Nordic region and Trio Enterprise is now planning a major effort in the Northern European market through our partners. The Company has successfully carried out a new share issue during the quarter. Questions regarding this interim report may be directed to: Tomas Duffy, President and CEO, +46-(0)8-410 172 76 or Jan Bengtsson, CFO, + 46-(0)8-410 171 52


 

Data Respons achieved a record start to the year. Operating revenues for the 1st quarter showed a 76 percent growth compared to the previous year, whereof 30 percent is organic. At the same time EBITDA is up by 148 percent. - The progress confirms how well we are positioned in the market. We have a sought after concept that combines local competence and services with international products and solutions. In addition, our employees are doing a fantastic job, says Kenneth Ragnvaldsen, CEO of Data Respons ASA. Considerable growth outside of Norway Most of the top line growth in the first quarter comes from outside of Norway. - So now, it is not just the Norwegian operations that are pulling the load. Revenue growth has also provided improved profitability in both Sweden and Denmark, says Ragnvaldsen. Continued strong order intake The order intake for the quarter was NOK 187 million - an increase of 56 percent when compared to the same period last year providing a growth of 51 % of the groups order reserves to NOK 321 million, and the ninth consecutive quarter with growth in order reserves. New chief executive in Sweden - Data Respons has employed Anders Due-Boje as the new managing director for Data Respons Sweden starting May 7th, says Ragnvaldsen. Due-Boje has had several central executive positions in international companies and is the right man to develop Data Respons in an exciting and comprehensive growth period in Sweden. For further information please contact: Kenneth Ragnvaldsen, CEO, Data Respons ASA, phone: +47 67 11 20 00 Mob: +47 913 90 918. About Data Respons Data Respons` vision is to become leading in Europe within 2010 on Embedded Solutions in the industrial market. Embedded Solutions can be described as being the brains of a machine, system or industrial end product. Data Respons supplies Embedded Solutions to leading OEM companies, system integrators and vertical product suppliers in a range of market segments such as defence, offshore, automation, medical equipment, surveillance, transport, telecommunications and other industries. Data Respons` customers include Ericsson, Nera, ABB, Brüel & Kjær, Tandberg, Anritsu and Saab. Data Respons ASA is listed on the Oslo Stock Exchange (Ticker: DAT), and is part of the information technology index. The company has offices in Denmark, Finland, Norway, Sweden and Germany. At the close of the 1st quarter 2007 the company had a total of 259 employees. More information on Data Respons ASA can be found on our website: www.datarespons.com


 

ACQUISITION REPRESENTS PLATFORM FOR STRATEGIC EXPANSION OF MILESTONE'S FINANCIAL SERVICES ACTIVITIES OUTSIDE OF ICELAND STOCKHOLM, 26 April 2007 - A Swedish subsidiary of Milestone ehf. today announces a cash tender offer to acquire Invik & Co. AB (publ) ("Invik") for SEK 253 per Class A share, SEK 230 per Class B share and SEK 153.20 per warrant subject to the offer. The offer values Invik at SEK 7,424 million. Milestone ehf.'s Swedish subsidiary has today, immediately prior to the announcement of the offer, entered into agreements with Investment AB Kinnevik (publ), Emesco AB and certain other sellers (the "Sellers") regarding indirect and direct purchases of shares in Invik representing in the aggregate 63.1% of the voting rights and 25.9% of the share capital in Invik. Invik's board of directors unanimously recommends that holders of shares and warrants in Invik accept the offer. Invik brings to Milestone several niche non-life insurance platforms, a growing unit-linked life operation and an established presence in retail and institutional funds management. It also brings a private banking business with operations in Luxembourg and Sweden, focused on traditional private banking services, credit card programs and treasury outsourcing. The combined company will be privately owned by the brothers Karl Wernersson and Steingrímur Wernersson. The company will have key presences in insurance in Sweden and Iceland, where Milestone owns Sjóvá, one of Iceland's largest insurance companies, and banking with Milestone's Askar Capital complementing Banque Invik. Anders Fällman, CEO of Invik, and the management team will continue in their present positions after fulfillment of the offer. Karl Wernersson, Chairman of Milestone, said: "We are delighted to begin a new chapter in the development of the Milestone group. Invik is a major strategic step in our expansion outside of Iceland, and brings some of the best talent in Nordic financial services with it. We believe the acquisition of Invik will fuel our expansion within the Nordic region and position Milestone as a growing participant in the Nordic financial services arena." Gudmundur Ólason, CEO of Milestone, said: "With Invik, we are creating a business that will be able to continue to provide attractive products for its customers as well as first-class customer service. We look forward to completing the acquisition and working with Anders Fällman and his team to create a strong competitor in Nordic financial services and continue Invik's impressive track record in delivering growth and profitability." Anders Fällman, CEO of Invik, said: "We remain assured that Invik will continue to be a strong independent financial group. We share Milestone's entrepreneurial philosophy in the development of financial services businesses and, like them, we have seized opportunities both organically and through acquisition. We believe that the cultural fit is strong and are looking forward to work with our new partners to further develop our combined businesses." Recommended Cash Offer of SEK 253 per Class A Share and SEK 230 per Class B Share in Invik Goldcup D 2811 AB, a Swedish subsidiary of Milestone ehf. ("Milestone"), with a proposed change of name to Racon Holdings AB ("Milestone Sweden"), today announces a public cash offer to the holders of all issued and outstanding shares and warrants (other than warrants held by Invik or any of its subsidiaries[1]) of Invik to tender all Invik shares and warrants to Milestone Sweden (the "Offer"). Invik's Class B shares are listed on the Stockholm Stock Exchange (Sw. Stockholmsbörsen) (the "SSE"). Summary * Milestone Sweden is offering SEK 253 and SEK 230 per Class A and Class B share, respectively, in Invik. * Milestone Sweden is also offering SEK 153.20 for each outstanding warrant.[2] * The offer price for each Class B share represents a premium of 35.3% relative to the average closing prices of the Invik Class B shares on the SSE for the three month period prior to 26 April 2007 and a premium of 23.0% relative to the Invik Class B share closing price on the SSE of SEK 187 on 25 April 2007, the last trading day before the announcement of the Offer. * The offer price for each Class A share (carrying 10 times the votes of a Class B share) is 10% higher than the offer price for each Class B share. * The consideration offered is made for the shares after separation of the proposed dividend of SEK 4 per share. * The Offer values Invik at SEK 7,424 million. * Invik's board of directors unanimously recommends the Offer. * Milestone Sweden has, immediately prior to the announcement of the Offer, entered into agreements with the Sellers regarding indirect and direct purchases of shares in Invik representing in the aggregate 63.1% of the voting rights and 25.9% of the share capital in Invik. For this reason, the Offer complies with the provisions on mandatory offers of the SSE's Rules regarding Public Takeover Offers on the Stock Market (the "Takeover Rules"). * The acceptance period for the Offer is expected to run from the week of 21 May 2007 to the week of 11 June 2007. Settlement of the Offer is expected to begin approximately a week after the end of the acceptance period.[3] Background and Reasons for the Offer Milestone is an Icelandic, privately held investment company with a diversified portfolio of businesses and assets and whose bonds are listed on the OMX Icelandic Stock Exchange in Reykjavík. The company is regulated by the Icelandic Financial Supervisory Authority due to its holdings in Sjóvá, Glitnir Bank and Askar Capital and is required to publish its semi-annual accounts on the Icelandic Stock Exchange. Milestone is wholly owned by the brothers Karl Wernersson and Steingrímur Wernersson. The Milestone group's portfolio is comprised of holdings in insurance, financial services, pharmaceuticals, pharmacies and real estate in Europe, Asia and North America. Milestone has placed insurance at the forefront of its future growth segments within the Nordic region. The acquisition of Invik marks a new era for Milestone and will play a pivotal role in the transformation of the Milestone group. The acquisition will give Milestone the opportunity to use its resources and experience within banking and insurance to expand in the Nordic financial market and provide an enhanced platform for expansion of the banking operations of the Milestone group. Milestone believes that the acquisition of Invik represents an excellent fit with its existing financial services investments, and would add strong niche presences in selected areas of the Nordic financial services market. In particular, Milestone's ownership of Sjóvá, one of Iceland's largest insurance companies with EUR 99 million in net insurance premium for 2006, and its controlling stake in Askar Capital are potential cross-border synergies with Invik's operations. Milestone foresees significant synergies between the Milestone group and the Invik group in relation to operations, investments and future expansion in the Nordic region. Milestone's actions demonstrate that, like Invik, it is willing to start up businesses where this is the most appropriate growth strategy and rely on management's local expertise in growing the Invik platform. Milestone prides itself on working closely with management and fully expects to create synergies with the current management team of the Invik group based on the experience Milestone has gained in closely running a similarly sized insurance business in Iceland. The Offer Milestone Sweden is offering SEK 253 and SEK 230 in cash for each Invik Class A share and each Invik Class B share, respectively, and SEK 153.20 in cash for each Invik warrant. Pursuant to an exemption received from the Swedish Securities Council (Ruling 2007:14), the Offer is not being made in respect of any warrants currently held by Invik or any of its subsidiaries. The consideration offered is made for the shares after separation of the proposed dividend of SEK 4 per share. The offer prices for the Invik shares and warrants are subject to adjustment should Invik pay any dividend or make any other value transfer (Sw. värdeöverföring) prior to the settlement of the Offer other than the scheduled dividend of SEK 4. No commission will be charged to holders of Invik shares and warrants in the Offer. The offer price for each Class B share represents a premium of 35.3% relative to the average closing prices of the Invik Class B shares on the SSE for the three month period prior to 26 April 2007, a premium of 26.1% relative to the average closing prices of the Invik Class B shares on the SSE for the twenty trading-day period prior to 26 April 2007 and a premium of 23.0% relative to the Invik Class B share closing price on the SSE of SEK 187 on 25 April 2007, the last trading day before the announcement of the Offer. The offer price for each Class A share (each carrying 10 times the votes of a Class B share) is 10% higher than the offer price for each Class B share. The Offer values Invik at SEK 7,424 million (based on 6,990,376 Class A shares and 24,279,547 Class B shares outstanding and 467,500 outstanding warrants). Purchase Agreements with the Sellers Milestone Sweden has on this 26 April 2007, immediately prior to the announcement of the Offer, entered into agreements with the Sellers regarding indirect and direct purchases of in the aggregate 5,700,774 Class A shares and 2,387,520 Class B shares in Invik representing in the aggregate 63.1% of the voting rights and 25.9% of the share capital in Invik. If Milestone Sweden were to increase the prices in the Offer, the purchase agreements entitle the Sellers to be compensated for the difference. Furthermore, in the event that Milestone Sweden sells the purchased shares in a competing offer, the Sellers are entitled to receive 80% of Milestone Sweden's gain in such transaction. In such case, the prices in the Offer will be increased accordingly. Completion of these purchases is conditional upon approval by relevant financial supervisory authorities. Milestone Sweden's Holding of Invik Shares Except for the shares referred to under Purchase Agreements with the Sellers above, neither Milestone nor Milestone Sweden owns or otherwise controls shares in Invik. Mandatory Offer The Offer complies with the provisions applicable to mandatory offers of the SSE's Takeover Rules. Upon completion of the purchases from the Sellers referred to above, Milestone Sweden's holding of voting rights in Invik will exceed the mandatory offer threshold under the Swedish Act on Public Takeover Offers on the Stock Market (Sw. lag (2006:451) om offentliga uppköpserbjudanden på aktiemarknaden) (the "Takeover Act"). When the mandatory offer requirement is triggered, the Offer will be converted into a mandatory offer. Recommendation from Invik's Board of Directors The board of directors of Invik unanimously recommends that holders of Invik shares and warrants accept the Offer. Support from Invik In a letter to Milestone Sweden dated 26 April 2007, Invik's board of directors informs that it will recommend the Offer to the holders of Invik shares and warrants and assist Milestone Sweden in the preparation of the offer document relating to the Offer and in obtaining approvals from relevant financial supervisory authorities. The support from Invik's board of directors in this respect is however subject to, inter alia, that the Offer is completed within 20 weeks from announcement, that the Offer does not lapse or is not withdrawn, that the terms and conditions of the Offer are not changed and that no third party offer is made for Invik which corresponds to an offer value exceeding the value of the Offer. Condition to the Offer Completion of the Offer is conditional upon the relevant financial supervisory authorities' approval to Milestone Sweden's acquisition of Invik. Milestone Sweden reserves the right to withdraw the Offer in the event that it is clear that the above condition is not fulfilled or cannot be fulfilled. Withdrawal will however only be made if the defective fulfillment of the above condition is of material importance to Milestone Sweden's acquisition of shares and warrants in Invik. Description of Milestone and Milestone Sweden Milestone is an Icelandic investment company, wholly-owned by the brothers Karl Wernersson and Steingrímur Wernersson. The Milestone group's portfolio comprises holdings in insurance, financial services, pharmaceuticals, pharmacies and real estate in Europe, Asia and North America. As per 28 February 2007, Milestone had, on a consolidated basis, total assets of EUR 2,275 million and a total equity of EUR 712 million. Milestone Sweden is a wholly owned subsidiary of Milestone. Milestone Sweden's corporate registration number is 556726-9732, its registered office is in the municipality of Stockholm and its address is Box 5747, 114 87 Stockholm, Sweden. The company was registered with the Swedish Companies Registration Office (Sw. Bolagsverket) on 23 March 2007. Milestone Sweden has never conducted and at present does not conduct any business and its sole purpose is to make the Offer and take all actions to complete the Offer and operate as a parent company of Invik. About Invik Invik is a financial group with a broad product profile focusing on insurance, banking and fund management. Invik is active in a number of carefully selected industry segments in which the Invik group can create high growth and build long-term, successful companies, while consistently focusing on profitability. Invik group companies are distinguished by their constant efforts to seek new avenues for growth in profitable niches in the financial sector. Invik comprises five business areas: Modern Insurances Non-life, with its direct insurance operations focusing on individuals and small companies; Modern Insurances Life, which offers life, pension and endowment insurance; Assuransinvest manages the remaining run-off portfolio; Banque Invik, a private bank based in Luxemburg with operations in asset management, card operations and corporate services; Invik Funds, pursuing fund operations in Aktie-Ansvar and Modern Funds. The Invik Class B share is listed on the Stockholm Stock Exchange in the Mid Cap segment and is traded under the symbol INVKB. Financing for the Offer Milestone has irrevocably and unconditionally committed to provide Milestone Sweden with acquisition financing in the amount of EUR 557 million to finance the purchases of Invik shares from the Sellers and Invik shares and warrants under this Offer. Additional funds necessary to finance purchases of shares and warrants under the Offer will be provided through a EUR 250 million credit facility. Drawdown pursuant to the credit facility is subject to the condition to the Offer being satisfied. Besides the foregoing, the credit facility does not include any conditions relating to Invik or its business and is otherwise subject to conditions which Milestone Sweden and Milestone in practice control, and to other limited conditions (such as not becoming illegal for the lender to provide funding and the loan documentation remaining legal and binding), which are customary for a credit of this kind. The conditions to drawdown, which Milestone Sweden and Milestone in practice control are essentially that: - Milestone Sweden is capitalized by Milestone as agreed and that Milestone continues to control Milestone Sweden; - Milestone Sweden acts in compliance with the Offer and laws and regulations relating to the Offer; - Milestone Sweden provides agreed security, including a pledge over the shares acquired in Invik; and - Milestone Sweden is not in breach of certain limited key representations and undertakings, and certain limited key events of default under the loan documentation not having occurred. Management and Employees Milestone has high regard for Invik's management team and employees and intends to continue the excellent employee relations that it believes exist at Invik. Indicative Timetable Offer document made public Week of 21 May 2007 Acceptance period Week of 21 May 2007 to week of 11 June 2007 Estimated date for payment Week of 18 June 2007[4] Milestone Sweden reserves the right to extend the acceptance period. An extension of the acceptance period will, however, not affect the settlement date for those holders of Invik shares and warrants who have already accepted the Offer.[5] The Offer document will be distributed to the holders of Invik shares and warrants in connection with it being made public. The acquisition of Invik requires clearance from relevant financial supervisory authorities. The necessary clearances are expected to be received by the end of the acceptance period and the Offer is expected to be completed in June 2007. Compulsory Acquisition If Milestone Sweden acquires shares representing more than 90 percent of the shares in Invik, Milestone Sweden may call for compulsory acquisition of the then outstanding minority shares. De-listing Milestone Sweden intends to have the Invik Class B shares de-listed from the SSE provided that such de-listing can be made in accordance with applicable rules and regulations. Applicable Law and Disputes The Offer shall be governed by and construed in accordance with the laws of Sweden. Milestone Sweden has, in accordance with the Takeover Act, undertaken in relation to the SSE, and hereby undertakes in relation to the holders of Invik shares and warrants, to comply with the Takeover Rules and the Swedish Securities Council's (Sw. Aktiemarknadsnämnden) rulings regarding interpretation and application of the Takeover Rules,[6] and to submit to the sanctions that may be imposed by the SSE upon breach of the Takeover Rules. The courts of Sweden shall have exclusive jurisdiction over any dispute arising out of or in connection with the Offer and the City Court of Stockholm (Sw. Stockholms Tingsrätt) shall be the court of first instance. This Offer is not being made (nor will any tender of shares or warrants be accepted from or on behalf of holders) in any jurisdiction in which the making of the Offer or the acceptance of any tender of shares therein would not be made in compliance with the laws of such jurisdiction. The Offer is not being made, directly or indirectly, in or into Australia, Canada, Japan, South Africa or the United States of America. The press release has been published in Swedish and English. In the event that there are any differences between the language versions, the English language version shall prevail. Advisors Bear, Stearns International Limited and Morgan Stanley & Co. Limited are acting as financial advisors and Gernandt & Danielsson Advokatbyrå is acting as legal advisor to Milestone and Milestone Sweden in connection with the Offer. Stockholm, 26 April 2007 Racon Holdings AB[7] The board of directors Further Information For further information, see Invik's separate press release. Relevant material is to be published on Milestone's website (www.milestone.is). For further information, please contact: Gudmundur Ólason, CEO Milestone +46 (0) 8 696 12 10 Forward-looking Statements This press release may contain forward-looking statements. These statements are not guarantees of future performance and are subject to inherent risks and uncertainties. Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as "may," "will," "expects," "believes," "anticipates," "plans," "intends," "estimates," "projects," "targets," "forecasts," "seeks," "could," or the negative of such terms, and other variations on such terms or comparable terminology. Forward-looking statements include, but are not limited to, statements about the expected future business of Invik resulting from and following the Offer. These statements reflect Milestone Sweden's current expectations, based upon information currently available to it and are subject to various assumptions, as well as risks and uncertainties that may be outside of their control. Actual results could differ materially from those expressed or implied in such forward-looking statements. Any such forward-looking statements speak only as of the date on which they are made and Milestone Sweden is under no obligation to (and expressly disclaims any such obligation to) update or alter such forward-looking statements whether as a result of new information, future events or otherwise. [1] Pursuant to an exemption received from the Swedish Securities Council (Ruling 2007:14) the Offer is not being made in respect of such unallocated warrants. [2] The offer price for each warrant represents the difference between the offer price for each Class B share and the strike price of the warrants being SEK 76.80. [3] Provided that necessary approvals have been obtained from relevant financial supervisory authorities. [4] Provided that necessary approvals have been obtained from relevant financial supervisory authorities. [5] However, settlement will not commence until necessary approvals have been obtained from relevant financial supervisory authorities. [6] This includes its former rulings with respect to the rules on public offers for the acquisition of shares issued by the Swedish Industry and Commerce Stock Exchange Committee, where applicable. [7] The company name, Racon Holdings AB, will be registered as promptly as possible with the Swedish Companies Registration Office.


 

Elcoteq SE Stock Exchange Release April 26, 2007, at 9.00 am (EET) ELCOTEQ SE'S INTERIM REPORT JANUARY-MARCH 2007 (UNAUDITED) Elcoteq SE's net sales between January and March totaled 952.5 million euros (981.1 in January-March 2006). Operating income was -52.4 million euros (8.3) and excluding restructuring costs -22.3 million euros. * Net sales 952.5 million euros (981.1) * Operating income -52.4 million euros (8.3) * Operating income includes 30.1 million euros in one-time restructuring costs. An additional 5 million euros in restructuring costs in 2007 will be recognized later. * Operating income excluding restructuring costs -22.3 million euros (8.3) * Income before taxes -59.0 million euros (2.9) * Earnings per share (EPS) -1.49 euros (0.07) * Cash flow after investing activities -40.9 million euros (14.2) * Rolling 12-month return on capital employed -2.9% (16.0%) * Gearing 0.7 (0.3) This interim report has been prepared using IFRS recognition and measuring principles. The tables have been prepared in compliance with the IAS 34 requirements approved by the EU. Net Sales and Result Elcoteq recorded net sales of 952.5 million euros (981.1) between January and March. Operating income, -52.4 million euros (8.3), included restructuring costs totaling 30.1 million euros related to the company's action plan to restore its profitability and competitiveness. The weak operating income is due to low production volumes, price pressure experienced by the Communications Networks business area, and production problems in Mexico. The Group's net financial expenses were 6.4 million euros (5.1). Income before taxes was -59.0 million euros (2.9) and net income totaled -46.9 million euros (2.1). Earnings per share (EPS) were -1.49 euros (0.07). The Group's gross capital expenditures on fixed assets between January and March were 11.2 million euros (16.0) or 1.2% of net sales. Depreciation amounted to 20.1 million euros (18.9). Financing and Cash Flow Cash flow after investing activities was -40.9 million euros (14.2). Cash flow was burdened, in addition to the weak result, by a deterioration in turnover of net working capital compared to the end of 2006, caused by the timing and customer breakdown of deliveries and by changes to certain agreements. Furthermore, the cash flow received by the Group from sold accounts receivable decreased by 17.4 million euros from the end of 2006 (187.7 million euros) to a total of 170.3 million euros at the end of March. The solvency ratio was 22.5% (23.5%) and gearing was 0.7 (0.3). At the end of March Elcoteq has unused but immediately available credit limits totaling 294.9 million euros (293.8 million euros at the end of 2006), which included a syndicated loan with a committed credit limit of 230 million euros. Commercial papers issued by the Group had a total nominal value of 30.0 million euros on March 31, 2007. Business Areas Elcoteq has two business areas: Terminal Products and Communications Networks. In the first quarter Terminal Products contributed 81% (82%) and Communications Networks 19% (18%) to the Group's net sales. Elcoteq's sales to companies within the Ericsson and Nokia groups during the first quarter decreased by roughly 20% compared to the same period last year and the aggregate contribution of these companies to Elcoteq's consolidated net sales amounted to 58.5% (72.0%). These figures do not include business activities with Sony Ericsson. Net sales from customers not belonging to the Nokia and Ericsson groups, in contrast, increased by more than 40% from the comparison period and Research in Motion (RIM) rose to become Elcoteq's second largest customer. Net sales of the Terminal Products business area were slightly lower in the first quarter than one year earlier, standing at 767.2 million euros (808.0). The segment's operating income was -36.9 million euros (15.9), or -4.8% of its net sales. Operating income excluding restructuring costs was -8.6 million euros. Operating income was weakened by lower production volumes, lower prices and production problems in Mexico. Net sales of the Communications Networks business area increased by roughly 7% on last year's first quarter to 185.3 million euros (173.1). The segment's operating income was -4.7 million euros (4.6), or -2.5% of its net sales and, excluding the restructuring costs, -3.3 million euros. Underlying the weaker operating income were heavy pressure on prices, especially in Europe, and lower than forecast production volumes from new customers acquired during the second half of 2006. In March Elcoteq signed a multi-year manufacturing services contract with Redline Communications. Elcoteq is Redline's primary EMS provider of manufacturing services for WiMAX Forum Certified base station and end-user devices as well as its RedCONNEX backhaul products. Geographical Areas Elcoteq has three geographical areas: Europe, Asia-Pacific and Americas. Elcoteq's first-quarter net sales were derived from these areas as follows: Europe 507.6 million euros (530.5), Asia-Pacific 231.2 million euros (253.8) and Americas 213.6 million euros (196.8). Personnel At the end of March the Elcoteq Group employed 23,452 people (21,842): 666 (881) in Finland and 22,786 (20,961) elsewhere. The geographical distribution of the workforce was as follows: Europe 10,822 (10,568), Asia-Pacific 7,459 (7,403) and Americas 5,171 (3,871). The average number of Elcoteq employees on the company's direct payroll between January and March was 19,065 (15,748). Progress in Action Plan The action plan initiated in order to restore Elcoteq's cost-efficiency, profitability and competitiveness has proceeded according to plan. The aim of the plan, which particularly concerns the company's operations in Europe and Americas, is to achieve annual savings in the region of 20 million euros. The actions taken in Europe include, among other things, personnel negotiations concerning the Lohja manufacturing plant and the NPI organization in Finland, which have resulted in 242 redundancies on production and economic grounds and the closure of the Lohja plant by the end of August. The personnel negotiations in Finland also applied to the Group's corporate office and product development organization and have resulted in 84 redundancies on production and economic grounds. At the same time the company decided to close the Elcoteq Design Center in Turku and move this unit's operations to Salo. In Americas, Elcoteq has decided to close the Juarez plant in Mexico by the end of the year. The plant's production will be moved mainly to China and partly also to the Monterrey plant in Mexico. The Juarez plant had 2,335 employees at the end of March. Additionally, the company's Americas office in Dallas, USA, will be moved to the premises occupied by the Dallas NPI Center. The action plan will induce one-time restructuring costs totaling roughly 35 million euros, 30.1 million euros of which has been entered in the first-quarter result. The Lohja plant accounts for almost 5 million euros of the restructuring costs, the Juarez plant for approximately 9 million euros, the product development organization for about 6 million euros, and the writedowns of the design-related Cellon holding and receivables for around 14 million euros. The costs arising at the Lohja and Juarez plants relate mainly to redundancies, rent commitments, writedowns of fixed assets and production transfers. Of these items, certain costs related to the termination of employment contracts and to production transfers were not entered in the first-quarter result but will be recognized under restructuring costs as they occur during the current year. These costs amount to approximately 5 million euros. The restructuring costs arising from Elcoteq's own product development organization are mainly attributable to a 3.4 million euro writedown of goodwill, as well as writedowns of the balance sheet carrying values of certain projects, and the termination of employee and rental contracts. The value of the Cellon holding has been based primarily on the value in use of the EMS services made available to Elcoteq through Cellon. Owing to the changes in Elcoteq's own product development organization and to Cellon's financial and structural situation, utilizing this partnership in the originally intended manner no longer seems possible and the entire holding has been written down. Cellon International is a wireless terminal products design company in which Elcoteq has held a minority stake since the co-operation agreement was signed in 2003. Approximately 12 million euros of the 35 million euro restructuring costs affect the company's cash flow. The cash flow items will mostly be recognized during 2007, although it is possible that items related to lease commitments could also be paid during 2008 and 2009. In addition to the action plan, Elcoteq is also undertaking other streamlining measures including a global program to raise production efficiency at all the company's manufacturing plants and the adoption of a new contract and invoicing model in Europe. Short-Term Risks and Uncertainty Factors The most important short-term challenges with respect to Elcoteq's business operations concern the company's ability to improve its cost structure and thus its profitability sufficiently fast as market conditions become increasingly tight, coupled with its ability to offer relevant service packages corresponding to customer demand and needs. Shares and Shareholders At the end of March 2007 the company had 31,539,877 shares divided into 20,962,877 Series A shares and 10,577,000 Series K shares. All the K shares are held by the company's three principal owners. Elcoteq had 11,078 shareholders on March 31, 2007. There were a total of 8,480,438 nominee-registered and foreign-registered shares, or 26.9% of the share capital and 6.7% of the votes outstanding. Altogether 550 new Elcoteq A shares were subscribed between December 14, 2006 and January 26, 2007 under Elcoteq SE's 2001 stock option scheme. The share subscription price was 6.53 euros as stipulated in the option scheme's conditions. Elcoteq's share capital rose by altogether 220 euros as a result of these subscriptions to 12,615,950.80 euros. The share subscription period ends on April 30, 2007. Decisions of the Annual General Meeting Elcoteq SE's Annual General Meeting took place in Helsinki, Finland, on March 22, 2007. The Meeting approved the Board's proposal to distribute a dividend of 0.20 euros per share on the financial year 2006. The Meeting decided that the company's domicile will be transferred from the city of Lohja in Finland to the Grand Duchy of Luxembourg. The transfer is currently expected to take place on January 1, 2008. The Meeting also authorized the Board of Directors to issue Series A shares and/or to issue specific rights entitling to shares pursuant to Chapter 10 §1 of the Finnish Companies Act, in the total amount of 15,527,573 Series A shares, as well as to purchase the company's own Series A shares. The authorization to issue shares includes the right to disapply the pre-emptive subscription right of the shareholders. The authorization to issue shares is in effect for five years and the authorization to purchase the company's own Series A shares 18 months from the Meeting's decision. Both authorizations, however, become void on transfer of the company's domicile, which is currently expected to take place on January 1, 2008. The Meeting elected seven members to the Board of Directors. The composition of the Board remained unchanged. The following persons were re-elected: President Martti Ahtisaari; Mr Heikki Horstia, Vice President, Treasurer, Wärtsilä Corporation; Dr Eero Kasanen, Rector of the Helsinki School of Economics; Mr Antti Piippo, principal owner and founder-shareholder of Elcoteq SE; Mr Henry Sjöman, founder-shareholder of Elcoteq SE; Mr Juha Toivola, MSc, and Mr Jorma Vanhanen, founder-shareholder of Elcoteq SE. The terms of office of the Board members extend until the end of the following Annual General Meeting. Ahtisaari, Horstia, Kasanen and Toivola are independent Board members, and they represent more than half of the Board's members. At its constitutive meeting after the AGM, the Board of Directors elected Antti Piippo as its chairman and Juha Toivola as its deputy chairman. Antti Piippo was elected chairman of the Nomination Committee and the Working Committee and Henry Sjöman, Jorma Vanhanen and Juha Toivola as the other members of these committees. Juha Toivola was elected chairman of the Compensation Committee and Audit Committee and Martti Ahtisaari, Heikki Horstia and Eero Kasanen as the other members of these committees. The Meeting decided that the firm of authorized public accountants KPMG Oy Ab under the supervision of principal auditor Mr Mauri Palvi (APA) will continue as the company's auditors. From the transfer of domicile, which is currently expected to take place on January 1, 2008, the auditors will be KPMG Audit S.à.r.l. until the end of the following Annual General Meeting. Prospects Elcoteq forecasts that its full-year net sales will increase only slightly on last year's and that its operating income excluding restructuring costs will be on a break-even level. Net sales in the second quarter of 2007 are expected to be slightly higher than in the first quarter. Operating income excluding restructuring costs is forecast to improve on the first quarter but still to be negative. Elcoteq's forecasts are based on the company's view of market growth and on the project-specific forecasts of its customers, based on which Elcoteq makes its own forecasts of the realization of agreed and planned new projects. Elcoteq's Board of Directors has approved a plan that will significantly increase and broaden Elcoteq's current service offering (EMS) into integrated electronics manufacturing services (IEMS). The change includes development of existing operating models, as well as M&A arrangements and various forms of collaboration with other companies operating in the same field. Espoo, Finland April 25, 2007 Board of Directors Further information: Jouni Hartikainen, President and CEO, +358 10 413 11 Teo Ottola, CFO, tel. +358 10 413 1240 Reeta Kaukiainen, Director, Communications and IR, tel. +358 10 413 1742 or +358 50 522 0924 Press Conference and Webcast Elcoteq will hold a combined press conference, conference call and webcast in English at 2.30 pm (EET) on Thursday April 26, in the Akseli Gallen-Kallela Room of Hotel Kämp (address: Pohjoisesplanadi 29, Helsinki, Finland). To participate by phone, please call 5 - 10 minutes before the start of the conference on +44 20 7162 0025 (Europe) or +1 334 323 6201 (the USA), code Elcoteq. The press conference can also be followed as a live webcast or later as a recording via Elcoteq's website www.elcoteq.com. The presentation material used at the press conference (pdf file) will be available on the company's website www.elcoteq.com from approximately 11.00 am (EET) on April 26. Elcoteq will publish its second-quarter interim report at 9.00 am (EET) on Wednesday, July 25, 2007. Enclosures: 1 Income statement 2 Balance sheet 3 Cash flow statement 4 Calculation of changes in shareholders' equity 5 Calculation of key figures 6 Key figures 7 Writedowns of non-current assets 8 Business areas 9 Assets pledged and contingent liabilities 10 Quarterly figures


 

* EBIT Q1 5% higher: ¤ 25 mln (Q1 2006: ¤ 24 mln) * Net result Q1 2% higher: ¤ 19 mln, eps: ¤ 0.62 (Q1 2006: ¤ 18 mln, eps: ¤ 0.57) * Turnover 4% higher: ¤ 497 mln (Q1 06: ¤ 479 mln) * Orders received up by 8%: ¤ 550 mln (Q1 06: ¤ 508 mln) * Order book up by 9%: ¤ 1,153 mln (Q1 06: ¤ 1,053) * Technical Services and Prints performed well, Food Systems broadly good, but Aerospace result strongly reduced; Aerospace Industries will make negative contribution to result for 2007 * Risks NH90 programme still considerable CEO Sjoerd Vollebregt: "Turnover and orders for our activities increased once again, both autonomously and through acquisitions. Technical Services and Prints performed well; Food Systems broadly good. Aerospace result strongly reduced. For Aerospace Industries, the dark clouds have certainly not yet cleared away. Given the situation with the Airbus A380 and the NH90 helicopter, Aerospace Industries is set to make a negative contribution to the results for 2007. Only in the course of 2008 but more likely in 2009 will this situation improve markedly, once these programmes are back up to speed. For Stork as a whole, the World Class Performance programme will contribute over the coming years to continuous improvement of results. The first projects have been launched and are showing clear improvement potential." Press information: Stork N.V. Dick Kors Tel: +31 (0)35 - 695 75 75 or +31 (0)6 - 51 98 40 54 Please open link below for the complete Press Release including tables


 

MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) today reported financial results according to IFRS for its first quarter ended March 31, 2007. The MorphoSys Group achieved revenues of EUR 14.1 million (Q1 2006: EUR 14.8 million), a profit from operations of EUR 1.3 million (Q1 2006: EUR 4.7 million), and a net profit of EUR 0.6 million (Q1 2006: 4.9 million). MorphoSys's cash position amounted to EUR 72.0 million at the end of the first quarter of 2007 (December 31, 2006: EUR 66.0 million). Highlights of the First Quarter 2007: * Formation of an antibody partnership with Astellas, MorphoSys's third alliance with a Japanese pharmaceutical company. Under the terms of the agreement, MorphoSys grants Astellas access to its HuCAL GOLD antibody library for use in its internal pharmaceutical drug discovery programs. * Existing partnered therapeutic antibody pipeline currently comprises 43 programs in total, of which currently two are in phase 1 clinical development, 16 in pre-clinical development, and 25 in research. * Significant expansion of AbD Serotec's license agreement with the U.K. Medical Research Council (MRC). The agreement, which provides AbD Serotec with access to a broad range of hybridoma cell lines as a source of research antibodies, is extended for a further five years, and includes additional products which will be implemented in AbD Serotec's offering. * Formation of a research alliance involving MorphoSys's Tokyo-based partner GeneFrontier Corporation together with a renowned Japanese research organization. The expanded collaboration now also covers the generation of HuCAL-derived fully human antibodies for proteome research and target validation as well as commercialization of resulting antibody products. "MorphoSys continues to increase its market presence in both operating segments, as evidenced by the addition of yet another top 20 pharmaceutical company and a leading research institute in Asia, to our partner roster" commented Dave Lemus, Chief Financial Officer of MorphoSys AG. "Moreover, we expect to remain on track to hit this year's operational and financial targets." Financial Review of the First Quarter 2007 (IFRS): Revenues in the first three months of 2007 slightly decreased in comparison to the same period of the former year by 5% to EUR 14.1 million (Q1 2006: EUR 14.8 million). Reasons for the decrease were in large part attributable to unusually high levels of success-based payments received in the first quarter of 2006. Revenues arising from the Therapeutic Antibodies segment amounted to EUR 8.8 million or 62% of total revenues, which included success-based payments in the amount of EUR 1.6 million. The AbD segment contributed EUR 5.3 million or 38% to total revenues. Total operating expenses for the first three months of 2007 amounted to EUR 12.8 million, compared to EUR 10.2 million in the same period of 2006. Cost of goods sold amounted to EUR 2.7 million (Q1 2006: EUR 2.1 million), representing cost of sales for goods sold by the AbD segment. Research and development costs increased to EUR 4.9 million from EUR 3.8 million; sales, general & administrative expenses amounted to EUR 5.2 million compared to EUR 4.2 million in the previous year. Stock-based compensation, reported as components within COGS, R&D and S,G&A expenses, amounted to EUR 0.4 million (Q1 2006: EUR 0.3 million). Operating profit for the first three months of 2007 reached EUR 1.3 million (Q1 2006: EUR 4.7 million). Non-operating expenses, including taxes, amounted in the first three months of 2007 to EUR 0.7 million (Q1 2006: non-operating income of EUR 0.2 million). Earnings before interest and taxes (EBIT) amounted to EUR 1.5 million, compared to an EBIT of EUR 4.9 million in the same period of the previous year. In the first quarter of 2007, MorphoSys achieved a net income of EUR 0.6 million, compared to a net income of EUR 4.9 million in the same period of the previous year. Diluted net income per share for the first three months of 2007 amounted to EUR 0.09 (Q1 2006: EUR 0.78). On March 31, 2007, MorphoSys had cash, cash equivalents and available-for-sale financial assets of EUR 72.0 million, compared to EUR 66.0 million at the end of 2006. The number of shares outstanding at March 31, 2007 was 6,697,678, compared 6,686,160 at December 31, 2006. Financial Outlook MorphoSys left its financial outlook for 2007 unchanged. The Company projects total revenues of EUR 60 to 65 million, and profit from operations of EUR 7 to 10 million for fiscal year 2007. For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Public Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com MorphoSys will hold a public conference call today at 10:00 am CEST to present the financial results of the first quarter 2007. Dial-in number for the Conference Call (listen-only): +49 (0)69 9897 2634 (listen-only) U.K. residents: +44 (0)20 7138 0820 (listen-only) Please dial in 10 minutes before the beginning of the conference. A replay and the manuscript of the conference call will be available on http://www.morphosys.com/conferencecalls About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Astellas (Japan), Bayer-Schering (USA/Germany), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (USA), Centocor Inc. (USA), Daiichi Sankyo & Co., Ltd. (Japan), GPC Biotech AG (Germany), Hoffmann-La Roche AG (Switzerland), ImmunoGen Inc. (USA), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Novoplant GmbH (Germany), OncoMed Pharmaceuticals, Inc. (USA), Pfizer Inc. (USA), ProChon Biotech Ltd. (Israel), Schering-Plough (USA), Shionogi & Co., Ltd. (Japan), Xoma Ltd. (USA) and others. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005 and Serotec Group in 2006. For further information please visit the corporate website at: http://www.morphosys.com/ HuCAL® and HuCAL GOLD® are registered trademarks of MorphoSys AG Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.


 

On Friday April 27, 2007, at approx. 10:15 a.m. CEST (8:15 a.m. GMT), the speech given by Werner Wenning, CEO of Bayer AG, at the Annual Stockholders' Meeting will be broadcasted live on the Internet: http://www.asm2007.bayer.com A recording of the speech will be available as from approx. 2:00 p.m. CEST (12:00 noon GMT). On the Annual Stockholders' Meeting website you can find the following information: * Invitation and agenda * Countermotions/Election Proposals * Information about ways to cast your vote * Voting results (after the meeting) * Online services for the Annual Stockholders' Meeting (dates, how to get there, downloads etc.) Bayer AG 51368 Leverkusen Germany http://www.bayer.com If you have any questions please contact: Investor Relations Peter Dahlhoff (Tel.: +49 214 30 33022, E-mail: peter.dahlhoff.pd1@bayer-ag.de) Communications - Media Relations Günter Forneck (Tel.: +49 214 30 50446, E-mail: guenter.forneck.gf@bayer-ag.de) Christian Hartel (Tel.: +49 214 30 47686, E-mail christian.hartel.ch@bayer-ag.de) Fax: +49 214 30 55156 --- End of Message --- Bayer AG Gebäude W 11 Leverkusen WKN: 575200; ISIN: DE0005752000; Index: CDAX, DAX, HDAX, Prime All Share; Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Prime Standard in Frankfurter Wertpapierbörse, Amtlicher Markt in Börse Berlin Bremen, Amtlicher Markt in Börse Düsseldorf, Amtlicher Markt in Hanseatische Wertpapierbörse zu Hamburg, Amtlicher Markt in Niedersächsische Börse zu Hannover, Amtlicher Markt in Bayerische Börse München, Amtlicher Markt in Börse Stuttgart;


 

(Lysaker, Norway, 25 April, 2007). Navamedic ASA reported an ordinary profit before taxes of NOK -3.3 million in the first quarter 2007, compared with NOK -3.4 million in the first quarter 2006. During the quarter, Navamedic has entered into marketing and distribution agreements in Germany, United Kingdom, Austria and Mexico. Navamedic will receive NOK 11 million in up-front payments from the agreements in Germany and United Kingdom. During the quarter, Glucomed was launched in Denmark. The highlights in the quarter were the marketing- and distribution agreements in United Kingdom and Germany. In United Kingdom, Navamedic has entered into an agreement with William Ransom & Son plc, the leading player in the existing nutraceutical glucosamine market. Ransom and Navamedic will in Q3/Q4 07 launch the first glucosamine product approved as a pharmaceutical in the large British market. In Germany, Navamedic has entered into an agreement with a strong undisclosed partner. The product will be launched under an undisclosed name in Q2/Q3 2007. During the quarter, Navamedic has broadened the cooperation with Grünenthal to include Austria and Mexico. Prior to these agreements, Navamedic and Grünenthal already had agreements covering 7 countries in Central and Eastern Europe. Including the new agreements, Navamedic has established a network of 14 marketing and distribution partners, covering 26 countries. In February, Glucomed was launched in Denmark through the local partner Meda. During the quarter, the company has received Marketing Authorization (MA) in 5 new countries, and by the end of the quarter, MA is received in a total of 11 countries. Please find enclosed the full interim report for the first quarter 2007. About Navamedic ASA: Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world`s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. Navamedic`s product Glucomed/Flexove has been approved across 25 EU/EEA states by European Medicines Agency (EMEA), as the first and only glucosamine based medicine against osteoarthritis. The company`s products are sold through a network of sales, marketing and distribution partners.


 

OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that it reached agreement with IsoTis, Inc. (NASDAQ: ISOT) to obtain additional rights to its PolyActive(TM) drug delivery technology, the technology used in OctoPlus' lead product Locteron(TM). Locteron is a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, currently in Phase IIa studies. Under the revised agreement, OctoPlus obtains full rights to the PolyActive technology and its intellectual property in certain strategic areas, including additional applications in orthopedics. Furthermore, the contract has financial benefits for OctoPlus as it includes an upfront license fee of ¤ 1.25 million, which will decrease future payments on OctoPlus' revenues using PolyActive. OctoPlus had gained access to PolyActive from IsoTis in 2003, when it acquired IsoTis' affiliate Chienna B.V. The license agreement covered the intellectual property rights to the technology in the areas of pharmaceuticals and medical device coatings. Under the revised agreement, OctoPlus gains control over the use and manufacturing of the technology to include all applications in controlled release pharmaceuticals, medical coatings and orthopedics, and include all intellectual property covering the technology in these areas. IsoTis retains the rights to manufacture, market and sell orthopedic plugs and cement restrictors including those related to its marketed product SynPlug(TM). Joost Holthuis, Chief Executive Officer of OctoPlus, commented: "We are happy to have taken this extra step in securing the future value of the PolyActive drug delivery technology for OctoPlus. This contract strengthens our intellectual property position for PolyActive and shows our strategic commitment to developing this technology to its full potential within our product pipeline." About PolyActive PolyActive is a polymer-based drug delivery technology for controlled release of biopharmaceuticals and small lipophilic molecules. OctoPlus uses the technology for the development of products that are more patient-friendly and that are potentially safer and more efficacious than currently marketed pharmaceuticals. The PolyActive polymer is already marketed in several FDA-approved medical devices and has a proven safety record. For further information, please contact: Rianne Roukema, Corporate Communications: +31 (71) 524 4044 About OctoPlus OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy / safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs. OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs. OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl. About IsoTis, Inc. IsoTis is a leading orthobiologics company that develops, manufactures and markets proprietary products for the treatment of musculoskeletal diseases and disorders. IsoTis' current orthobiologics producst are bone graft substitutes that promote the regeneration of bone and are used to repair natural, trauma-related and surgically-created defects common in orthopedic procedures, including spinal fusions. IsoTis' current commercial business is highlighted by its Accell line of products, which the company believes represents the next generation in bone graft substitution. This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.


 

Gouda, the Netherlands - Imtech (technical service provider in Europe) has been contracted to realise a solution that converts harmful kerosene emissions, which are currently being released into the atmosphere, into electricity. The technology not only benefits the environment but also generates electricity and heat. The first specific project will be implemented at Amsterdam Airport Schiphol. If it proves successful, Imtech will promote this innovation worldwide. At the request of Aircraft Fuel Supply (AFC) B.V., the company that supplies kerosene for all aircraft at Schiphol Airport, a joint venture of Imtech, IPCO Power and BioSoil will develop the world's first system to capture and process kerosene vapours and kerosene residues at Schiphol Airport. Imtech will be the main contractor in the joint venture. The system will be used to capture and process kerosene vapours that are released when fuel supply trucks are being loaded. During the process, reusable electricity and thermal heat will be generated for company use. The system, which was developed by IPCO Power, is called the Vapour Processing System. At Schiphol Airport, the uploading of kerosene in supply trucks is a continuous process during which an estimated 1,000,000 m3 of kerosene vapour is released into the atmosphere every year. This is a situation that AFS wants to bring to an end in order to create a cleaner environment at and near the airport as well as in the built-up areas in the immediate surroundings. In addition, the approximately 250 tons of kerosene residue left in the tanks every year will also be processed in this environmentally-friendly way. The electricity generated in this way will by be used by AFS itself, while the surplus will be sold on to third parties at Schiphol Airport or to the national grid. The same applies to the heat that is released, which will be used to heat buildings and garages. The electricity and heat generated with this innovative system will produce sufficient savings to recover the total investment in around seven years. The emission of kerosene vapours is a problem that occurs at virtually all airports. Capturing the vapours and converting them into electricity, which can in turn be used for lighting or cooling, produces major potential savings. It also provides airports with a one-stop solution to a serious environmental problem. With this project, Imtech, BioSoil and IPCO Power hope to create a worldwide spin-off to large international airports in Europe, Asia, the Middle East and the USA in the short term, with Imtech playing a leading role. Further information Imtech N.V. Mark Salomons Company Secretary Telephone: +31 182 54 35 14 E-mail: mark.salomons@imtech.eu www.imtech.eu Imtech Profile Imtech N.V. is a European technical services provider in the fields of electrical engineering, ICT (information and communication technology) and mechanical engineering. With approximately 16,000 employees, Imtech realises annual revenue of almost ¤3 billion. Imtech holds strong positions in the buildings, industry, infrastructure and telecom markets in Belgium, Germany, Luxembourg, the Netherlands, Eastern Europe, Spain and the UK and in the global maritime market. Imtech provides services to a total of 12,000 clients. Imtech offers added value in the form of integrated and multidisciplinary total solutions that lead to improved operating processes and higher yields for clients and their clients in return. Imtech also provides solutions that contribute to a sustainable, liveable society, for example in the field of energy, mobility, safety and the environment. Imtech shares are listed on the Euronext Stock Exchange (Amsterdam), where Imtech is included in the Amsterdam SmallCap Index (AScX) and the Next 150 index. Profile BioSoil BioSoil's main activity is soil decontamination, for which the company prefers to use sustainable technologies based on the organic breakdown of pollutant compounds. Through its ten or so subsidiaries, BioSoil is also working on a better environment in other ways. For this project, BioSoil provided the basic idea for using kerosene vapours to power generators and contributes to project management. For more information: www.biosoil.com Profile IPCO Power IPCO Power has been a producer of vapour processing systems in the petrochemical industry for over ten years. This application is now being used worldwide to generate electricity and heat in an environmentally-friendly way. IPCO Power not only contributes know-how to this project, but also the Vapour Processing System. This system captures the kerosene vapours released when fuel supply trucks are being loaded and processes those vapours into a fuel for combined heat and power systems. For more information: www.ipcopower.com


 

Basel, Switzerland, April 25, 2007 - Basilea Pharmaceutica Ltd. (SWX:BSLN) reported today phase III study results showing that patients with severe chronic hand eczema can benefit from re-treatment with alitretinoin. In two previous randomized clinical trials, alitretinoin was found to be effective in treating severe chronic hand eczema in patients refractory to topical treatments. This pivotal trial demonstrated that patients responsive to initial treatment with alitretinoin can also benefit from additional treatment courses after eventual disease recurrence. The safety profile of alitretinoin observed in this study was consistent with that seen in previous trials. These positive data will be integrated into regulatory submissions planned for later this year. Severe refractory Chronic Hand Eczema (CHE) is a relapsing disorder for which no approved treatment currently exists. This debilitating disease prevents patients from using their hands normally and requires frequent treatment interventions over time. The objective of this re-treatment study was to describe the safety and efficacy of a second treatment course of alitretinoin in patients who achieved clear or almost clear hands after a previous initial treatment course. This study included 117 patients who eventually had disease recurrence, and 243 patients who had incomplete response after the initial treatment trial. Patients who had disease recurrence were randomized in double blind manner to receive another 12 to 24 weeks treatment with either placebo or their previous dose of alitretinoin. Response rates were 80% for the alitretinoin 30mg group (Placebo 8.3%) and 48% for the 10mg group (Placebo 10%). These results indicate that alitretinoin is effective in treating severe refractory CHE in subsequent treatment courses. Those patients who had either no or an incomplete response in the previous study received 30mg alitretinoin in an open-label fashion for another 12 to 24 weeks. Forty-seven percent (47%) achieved a response as defined by clear or almost clear hands. These results further confirm the efficacy of alitretinoin in patients with CHE refractory to topical therapy. Alitretinoin was generally well tolerated with a safety profile similar to that reported in previous phase II and phase III clinical studies. The most frequent adverse events were headache and blood lipid elevations. Dr. Anthony Man, CEO of Basilea said, "Because of the relapsing nature of Chronic Hand Eczema it was important for patients and treating physicians that we further characterize the safety and efficacy of more than one treatment course of alitretinoin. These trial results confirm that alitretinoin is an effective treatment for severe refractory Chronic Hand Eczema. Alitretinoin has the potential to be integrated into pragmatic re-treatment algorithms for these chronically affected patients who have limited treatment options." About Chronic Hand Eczema (CHE) Hand eczema is a common skin disease and is often chronic and relapsing. It is estimated to affect up to 10% of the general population. The more severe, chronic form of the condition is thought to affect up to 7% of these patients, many of whom do not respond, or no longer respond to topical corticosteroids. Basilea estimates there are at least one million patients in Europe and North America with refractory severe CHE for which currently no approved, effective pharmaceutical treatment is available. For the patient, severe CHE can be a frustrating and debilitating disease. Patients often suffer for years from erythema, blisters, vesicles, scaling and fissures which can cause chronic pain and functional impairment of the hands. Studies suggest these patients have a significantly reduced quality of life and the majority experience social or emotional distress and sleep disorders. It is reported that up to 20% of sufferers have to leave their jobs and one patient in five takes prolonged sick leave resulting in high socio-economic and individual patient burden. About Alitretinoin Alitretinoin is an investigational drug being developed in Phase III clinical trials by Basilea as a novel treatment for severe refractory Chronic Hand Eczema (CHE), a complex disease for which no effective treatment options are currently available. Alitretinoin has been shown to be effective in Phase II and Phase III clinical studies in patients with severe refractory CHE. In a phase II double-blind international multi-center placebo controlled trial of 319 patients with moderate and severe chronic hand eczema refractory to topical treatment, alitretinoin was clinically effective in 29% to 53 % of patients depending on the dose administered. Alitretinoin was generally well tolerated with dose dependent headache observed as the most common side effect. Basilea's first pivotal phase III international multi-center placebo-controlled BACH trial (Benefit of Alitretinoin in Chronic Hand eczema) showed that alitretinoin was effective in patients suffering from severe refractory CHE, as determined by the endpoint of clear and almost clear hands. This randomized double-blind phase III pivotal study was the largest therapeutic trial ever performed in chronic hand eczema with 1,032 patients whose severe chronic disease was unresponsive to topical steroids. The patients were randomized either to a once-daily dose of 30mg or 10mg of alitretinoin, or placebo for a treatment duration of up to 24 weeks. Alitretinoin's efficacy was significantly superior to placebo in both the high and the low dose regimen. In the 30mg group 48% of patients and in the 10 mg group 28% of patients reached the primary endpoint. In this study alitretinoin was again generally well tolerated with dose dependent headache and blood lipid elevations as the most commonly observed side effects. Alitretinoin is a teratogen and therefore pregnancy prevention measures must be in place for all women of child-bearing potential who receive alitretinoin. Within days after discontinuation of therapy, alitretinoin levels return to endogenous levels. In clinical studies the post-treatment contraceptive period was four weeks. About Basilea Basilea Pharmaceutica Ltd. is an independent biopharmaceutical company headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange (SWX:BSLN). Basilea's fully integrated research and development operations are currently focused on new antibacterial and antifungal agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including three investigational phase III drugs of which two have shown positive pivotal phase III results. The company is integrating commercialization into its organization, in a first step through co-promoting ceftobiprole with its partner Cilag GmbH International, a Johnson & Johnson company, in North America and major European countries. Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: +-------------------------------------------------------------------+ | General Information | Investor Relations | |------------------------------+------------------------------------| | information@basilea.com | Dr. Barbara Zink | | | investor_relations@basilea.com | +-------------------------------------------------------------------+ This press release can be downloaded from www.basilea.com The press release can also be downloaded from the following link:


 

As the global technology leader in fineblanking and forming, Feintool traditionally carries out its research in conjunction with leading international universities. This year's Feintool university colloquium once again yielded rapidly implementable customer benefits, most notably in the form of new, environmentally compatible chlorine-free lubricants. Feintool's success as the technology leader in fineblanking and forming derives firstly from the pioneering spirit of company founder Fritz Boesch and secondly from the research and development collaboration with specialist departments at universities in Switzerland, Germany, China and the United States. This collaboration is not just restricted to basic research but extends to applied R&D covering the entire process chain. By bringing together specialist skills and focusing on customer-oriented solutions, the aim is to retain the leading position of this globally used technology process. New applications and technologically perfected and cost-optimized fineblanking and forming processes that open up new markets for Feintool's technology and press customers while at the same time encouraging an environmentally aware use of resources serve as both an objective and an incentive. Theory and practice provide rapidly implementable customer benefits Working with its partners in academia, Feintool is using theory and practice - in other words science coupled with top-notch technical and manufacturing performance - to further expand its competitive lead for the years ahead and provide comprehensive support for its customers. Results are presented and new goals agreed at the university colloquia that Feintool regularly organizes with its international university partners. Feintool university colloquium 2007 in Munich This year's colloquium, attended by the Chairman of the Feintool Board of Directors and Group management, took place at utg, the Technical University of Munich's Institute of Metal Forming and Casting. Prof. Hartmut Hoffmann, the Institute's head, and Professors Fritz Klocke of RWTH Aachen, Pavel Hora from ETH Zurich, Xueyu Ruan of SRI University Shanghai und Robert H. Wagoner from Ohio State University Cincinnati presented the results of their work. As project manager, the Feintool Group's Chief Technology Officer, Arthur Locher, is responsible for ensuring that Feintool's operational divisions can successfully use these results in the market place in consultation with key account customers and without infringing the universities' intellectual property rights. Feintool premieres new environmentally compatible chlorine-free fineblanking oils In an interdisciplinary consortium with reputable partners from the petroleum industry such as WISURA and coating experts such as Oerlikon Balzers, Feintool has developed and tested forward-looking chlorine-free fineblanking oils at the machine tools laboratory at RWTH Aachen. By adopting innovative approaches it has been possible to overcome earlier setbacks to develop fully fledged solutions that have yielded positive results in real-life testing with a large number of customers. The advantages offered by the new products cover the entire process, making them more cost-efficient, quality-enhancing and, above all, environmentally compatible. An improvement in the performance of selected tools in the production environment goes hand-in-hand with a reduction in oil consumption. Series-production parts and the systems on which they are manufactured are automatically protected against corrosion. The need for expensive part cleaning and anti-corrosion treatment is eliminated along with the costs of disposing of chlorine-contaminated scrap metal. Moreover, the new fineblanking oils represent a significant step forward for employee health and environmental compatibility overall. This is Feintool's good news for its customers - news that is entirely in keeping with last year's environmental certification at the Group's Lyss headquarters in Switzerland. For further information, please contact: Arthur Locher, Chief Technology Officer Dr. Rolf-A. Schmidt, Head of Technology Services Phone +41 (0)32 387 51 11 Feintool is a leading technology and systems provider in fineblanking/forming and assembly automation. It is also a global supplier of metal and plastic components. Feintool operates throughout the world at the company's own facilities in Switzerland (head office in Lyss), Germany, France, Italy, Great Britain, the United States, Japan, China and Thailand, where around 1800 employees are committed to customer satisfaction. Feintool International Holding Industriering 8, CH-3250 Lyss Phone +41 (0)32 387 51 11 Fax +41 (0)32 387 57 81 feintool-fim@feintool.com www.feintool.com Head of Corporate Communications Urs Feitknecht Phone +41 (0)32 387 51 63 Fax +41 (0)32 387 54 16 Mobile 079 204 41 13 urs.feitknecht@feintool.com The media release can be downloaded from the following link: --- End of Message --- Feintool International Holding Industriering 8 Lyss Schweiz WKN: 905428; ISIN: CH0009320091 ; Index: SPI, SPIEX, SSCI; Listed: Main Market in SWX Swiss Exchange;


 

Stockholm - Wednesday, April 25, 2007 - Tele2 AB ("Tele2") (OMX Nordic Exchange: TEL2 A and TEL2 B), Europe's leading alternative telecom operator, today announced its consolidated results for the first quarter 2007. - Operating revenue for Q1 2007 grew by 5 percent to SEK 12,837 (12,243) million - EBITDA in Q1 2007 increased by 22 percent to SEK 1,488 (1,221) million - Net profit/loss for Q1 2007 amounted to SEK 82 (143) million - Earnings per share, after dilution, for Q1 2007 amounted to SEK 0.28 (0.40) - Mobile revenues in Q1 2007 increased by 29 percent to SEK 5.2 billion - Continued excellent performance in Russian mobile operations with revenues and EBITDA in Q1 2007 both growing strongly. Russia now has a customer base in excess of 7.1 million - Strong broadband intake during Q1 2007, adding a total of 254,000 new broadband customers - Fixed telephony EBITDA margin improved to 14 (11) percent in Q1 2007 Lars-Johan Jarnheimer, President and CEO of Tele2 AB comments: "We are in a stage of focus. During 2007, we expect to see the majority of our revenue being generated within our own infrastructure based mobile and broadband services, as a result of our shift in focus from resold fixed line telephony to our own infrastructure based services. These services have grown to 41 percent of group sales in Q1 2007 from 32 percent in Q1 2006 and the trend will be accelerated as a result of our current strategic review. Our operational results, with EBITDA growing 22 percent year on year, show that our increased focus on mobile and broadband services continues to pay off and that our investments in infrastructure lead to higher margins for Tele2. To be able to defend higher investments, overall profitability must improve. Our mobile operations in the Baltic region and Russia continue to show healthy operational performance. Strong net customer intake, despite tough competition, is combined with good margin development. This quarter, I am especially pleased with our development in the Nordic market area, which shows that there is still growth potential in the mobile segment. Our broadband business continued to produce impressive net customer intake numbers, with 254,000 new customers in Q1. Southern Europe represents the majority of our new broadband customers, and I am particularly pleased with the continued strong intake in Italy. Scale is important, and we are getting closer to critical mass in geographies with a sound potential for growth and profitability. Fixed line EBITDA margins improved during the quarter. However, we experienced a higher level of competition from primarily mobile operators leading to a larger net customer outflow and stronger ARPU decline than expected. As we have pointed out earlier, it continues to be important for Tele2 to move into more infrastructure based operations. The recent developments highlight this rationale as we move swiftly towards mobile and broadband services based on our own infrastructure." Tele2 is Europe's leading alternative telecom operator. Tele2's mission is to provide cheap and simple telecoms for everyone in Europe. Tele2 always strives to offer the market's best prices. We have 29 million customers in 22 countries. Tele2 offers fixed and mobile telephony, broadband, data network services and cable TV. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 has been listed on the OMX Nordic Exchange since 1996. In 2006 we had operating revenue of SEK 50.3 billion and we reported a operating profit (EBITDA) of SEK 5.7 billion


 

Vancouver, April 24, 2007 - Global Developments Inc. (PINKSHEETS: GDVM) is pleased to announce that at a meeting held on April 12, 2007, the Board of Directors approved a stock dividend in one of its portfolio investments. The Board of Directors has announced that all Global shareholders of record at the close of business on April 30, 2007 will receive one share of Moto Auto Group Ltd., a wholly owned subsidiary, for every share of Global. According to Richard Crofts, the interim, non-executive Chairman of the Board, "This dividend marks a continuation of Global Developments' stated policy of working to provide value to our loyal shareholders. Moto Auto Group aims to become a leader in the distribution of Chinese vehicles throughout the world. We are very excited about the potential of Moto, and we want to share this excitement with our shareholders." The dividend will be issued on May 15, 2007. About Moto Auto Group Ltd. Moto Auto Group Ltd. is an importer of automobiles and automotive technology. In 2005, Moto Auto Group acquired ZX Auto Group Inc., a company involved in joint ventures with Chinese automobile assembly plants. Through this acquisition, Moto Auto Group became an importer of world-class Chinese automobiles, pick-up trucks and sport utility vehicles. For more information, please visit www.motoautogroup.com. About Global Developments Inc. Global Developments Inc. was formed to create a unique investment vehicle representing a growing portfolio of innovative and emerging growth-oriented companies. Global acquires its portfolio companies primarily as wholly or majority owned subsidiaries. As a result, Global maintains substantial management control, thereby giving it the ability to provide significant oversight and guidance in building value and creating liquidity events for its shareholders. Global invests in companies with solid management, operational excellence, and the potential to grow substantial revenue streams. Please visit www.globaldevelopmentsinc.com for more information. Forward-Looking Statements You should not place undue reliance on forward-looking statements in this press release. This press release contains forward-looking statements that involve risks and uncertainties. Words such as ``will,'' ``anticipates,'' ``believes,'' ``plans,'' ``goal,'' ``expects,'' ``future,'' ``intends,'' and similar expressions are used to identify these forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks we face as described in this press release. For further information about Global Developments, Inc. please refer to its Web site at http://www.globaldevelopmentsinc.com. Contact: Global Developments Inc. info@globaldevelopmentsinc.com


 

Restructuring and Adjustments Dortmund: In order to make use of market opportunities for Microsystems in a better and more effective way in the future, ELMOS Semiconductor AG has implemented recently a new board of management at its U.S. subsidiary Silicon Microstructures Inc. (SMI) in Milpitas, California. In the meantime the new management conducted a thorough investigation and identified a need for restructuring and adjustments for 2007. This has implications also for the Dutch subsidiary ELMOS Advanced Packaging B.V. (ELAP) in Nijmegen, Netherlands, because of a significantly delayed production start of SMI products, which should have been assembled in the Netherlands. As a consequence of that, the actual headcount at ELAP will be reduced by 50 people. The necessary expenses for restructuring and adjustments amount to approximately 5.6 Mio Euro for the ELMOS group. Approximately 3.9 Mio Euro of these one-time cost will impact the profit & loss statement of the first quarter 2007, the remaining portion will result in an increase of expenses for the rest of the current year. The actual guidance for sales in 2007 remains unchanged. When the above mentioned one-time effects would be neglected, the margin-guidance for standard course of operations would remain unchanged. Taken these extra cost into account will decrease the margins by approximately 3 percent points. The Management board of ELMOS Semiconductor AG will report on the situation and the measures taken during a conference call on Wednesday, April 25th 2007, at 4 pm CEST. Dial-in number: +49 (0) 30 868 71 790 ELMOS Semiconductor AG is a producer and developer of system solutions on semiconductor basis. For more than 20 years, roughly 90% of sales have been generated with chips for automotive electronics. ELMOS Semiconductor AG Mathias Kukla Heinrich-Hertz-Str. 1 44227 Dortmund Germany Phone +49 231-75 49-0 Extension -199 Fax +49 231-75 49-548 info@elmos.de www.elmos.de --- End of Message --- ELMOS Semiconductor AG Heinrich-Hertz-Strasse 1 Dortmund Deutschland WKN: 567710; ISIN: DE0005677108; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share, GEX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Börse Stuttgart, Geregelter Markt in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München;


 

In order to make use of market opportunities for Microsystems in a better and more effective way in the future, ELMOS Semiconductor AG has implemented recently a new board of management at its U.S. subsidiary Silicon Microstructures Inc. (SMI) in Milpitas, California. In the meantime the new management conducted a thorough investigation and identified a need for restructuring and adjustments for 2007. This has implications also for the Dutch subsidiary ELMOS Advanced Packaging B.V. (ELAP) in Nijmegen, Netherlands, because of a significantly delayed production start of SMI products, which should have been assembled in the Netherlands. As a consequence of that, the actual headcount at ELAP will be reduced by 50 people. The necessary expenses for restructuring and adjustments amount to approximately 5.6 Mio Euro for the ELMOS group. Approximately 3.9 Mio Euro of these one-time cost will impact the profit & loss statement of the first quarter 2007, the remaining portion will result in an increase of expenses for the rest of the current year. The actual guidance for sales in 2007 remains unchanged. When the above mentioned one-time effects would be neglected, the margin-guidance for standard course of operations would remain unchanged. Taken these extra cost into account will decrease the margins by approximately 3 percent points. Contact: ELMOS Semiconductor AG, Heinrich-Hertz-Str. 1, 44227 Dortmund, Phone: +49 (0) 231-7549-0, Direct: -287, Fax: +49 (0) 231-7549-548, eMail: info@elmos.de, www.elmos.de --- End of Message --- ELMOS Semiconductor AG Heinrich-Hertz-Strasse 1 Dortmund Deutschland WKN: 567710; ISIN: DE0005677108; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All Share, GEX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Börse Stuttgart, Geregelter Markt in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München;


 

Vancouver, April 24, 2007 - Global Developments Inc. (PINKSHEETS: GDVM) is pleased to announce that at a meeting held on April 12, 2007, the Board of Directors approved a stock dividend in one of its portfolio investments. The Board of Directors has announced that all Global shareholders of record at the close of business on April 30, 2007 will receive one share of Moto Auto Group Ltd., a wholly owned subsidiary, for every share of Global. According to Richard Crofts, the interim, non-executive Chairman of the Board, "This dividend marks a continuation of Global Developments' stated policy of working to provide value to our loyal shareholders. Moto Auto Group aims to become a leader in the distribution of Chinese vehicles throughout the world. We are very excited about the potential of Moto, and we want to share this excitement with our shareholders." The dividend will be issued on May 15, 2007. About Moto Auto Group Ltd. Moto Auto Group Ltd. is an importer of automobiles and automotive technology. In 2005, Moto Auto Group acquired ZX Auto Group Inc., a company involved in joint ventures with Chinese automobile assembly plants. Through this acquisition, Moto Auto Group became an importer of world-class Chinese automobiles, pick-up trucks and sport utility vehicles. For more information, please visit www.motoautogroup.com. About Global Developments Inc. Global Developments Inc. was formed to create a unique investment vehicle representing a growing portfolio of innovative and emerging growth-oriented companies. Global acquires its portfolio companies primarily as wholly or majority owned subsidiaries. As a result, Global maintains substantial management control, thereby giving it the ability to provide significant oversight and guidance in building value and creating liquidity events for its shareholders. Global invests in companies with solid management, operational excellence, and the potential to grow substantial revenue streams. Please visit www.globaldevelopmentsinc.com for more information. Forward-Looking Statements You should not place undue reliance on forward-looking statements in this press release. This press release contains forward-looking statements that involve risks and uncertainties. Words such as ``will,'' ``anticipates,'' ``believes,'' ``plans,'' ``goal,'' ``expects,'' ``future,'' ``intends,'' and similar expressions are used to identify these forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks we face as described in this press release. For further information about Global Developments, Inc. please refer to its Web site at http://www.globaldevelopmentsinc.com. Contact: Global Developments Inc. info@globaldevelopmentsinc.com


 

Milan/Amberg, 2007/04/24: UR Holding S.p.A., specialized in the distribution of high tech components for embedded system solutions, reinforces the finance department. Stefan Haas (born 1970) will take over the finance department as CFO. During his 15-year professional experience, Mr. Haas used to be a senior investment manager with a Berlin-based private equity company. At last, Mr. Haas worked for Credit Suisse as deputy director in the field corporate advisory. His particular focus used to be on the topics M&A, financing and strategic planning for medium-sized companies. "I am very glad about the appointment as a Chief Financial Officer at such an interesting and international focussed company like UR Holding S.p.A. Here, I have the opportunity, to bring in my know-how and my professional experience of the financial and capital market sector and to be a co-creator of the success of the company", says Stefan Haas, designated Chief Financial Officer of UR Holding. "We are very pleased about Stefan Haas joining us. In Stefan Haas we were able to gain a long-time experienced financial and capital market expert also having substantial operational expertise in transactions (M&A), for our company. With regard to our international strategy and our listing in the Entry Standard at the end of 2006, we consider the position of a CFO as fundamental", says Giovanbattista Laghezza, CEO of UR Holding. "In appointing the CFO we meet the requirements of the international capital market. As listed company having an international shareholder structure, this is a consequent step that clearly underlines our corporate strategy", says Martin Kistner, COO of UR Holding. The Management Board UR HOLDING S.p.A Company contact: Agency contact: UR Holding S.p.A. GFEI mbH Viale Edison 44 Beethovenstraße 60 I-20090 Trezzano s/N (Mi.) D-60325 Frankfurt Phone: +39-02-484-0158-0 Phone: +49-(0)-69-743-037-00 Fax: +39-02-484-0158-1 Fax: +49-(0)-69-/-743-037-06 investors@ur-home.com ir-urgroup@gfei.de www.ur-home.com www.gfei.de About UR Holding: Founded in 1996 and listed in the Entry Standard since 2006, UR Holding is a leading European sales organization for High Tech electronic components and subassemblies for embedded system solutions. UR adds critical technology know how, embedded systems expertise and resources to help its customers to define, design and manufacture embedded system applications serving their global markets and growth strategy. --- End of Message --- UR Holding Dr.-Aigner-Str. 13 Amberg Germany WKN: A0LBEG; ISIN: IT0003463772; Listed: Entry Standard in Frankfurter Wertpapierbörse, Freiverkehr in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Stuttgart;


 

Hamburg, April 24th, 2007: nextevolution AG (ISIN: DE 000 A0J C0A 2) announces the deregulation of the lock-up-agreement with Gerd Nicklisch for the realignment of the shareholder structure with acceptance of quirin bank AG. Gerd Nicklisch backs out within the transaction completely from the corporate responsibility of nextevolution in order to adress himself to a new task. Hence, the existing advisory contract with Gerd Nicklisch was cancelled with immediate effect by mutual agreement. "We thank Gerd Nicklisch for his engagement for nextevolution AG", said Nils Manegold, nextevolutions' Chief Financial Officer. The placement of 376,000 shares took place within the bookbuilding-method to international institutional investors. Contact nextevolution AG Carl Bosch Haus Hamburger Allee 26-28 60486 Frankfurt am Main Tel.: +49 69 297 287 42 Fax.: +49 69 297 287 77 www.nextevolution.de unternehmensinformation@nextevolution.de _______________________________________________________ About nextevolution AG: The offered spectrum of services from nextevolution AG is comprised of management consulting, IT consulting, system integration, and application management. This enables the company to accompany entire life cycles of customer solutions. The company's portfolio targets medium-size businesses and large corporations with emphasis on specific requirements and their own specific characteristics. They expect individual solutions for the usage of a business-management standard software. nextevolution AG develops jointly with their customers customized IT strategies and supports them during the planning, implementation and integration phase of business systems, tailored to their industry-specific and business-specific requirements. For the subsequent usage phase, nextevolution AG offers reliable service and maintenance. The company's main emphasis in their positioning is in the optimization and integration of business processes, document management and businessmanagement application systems. nextevolution co-operates with market-leading software providers, such as SAP, FileNet and Saperion and uses their standard product platforms to setup their solutions. In addition, nextevolution AG offers a series of proprietary templates, which usually originate from project development and fulfill specific market requirements. They focus in particular on the real estate business and the housing management market. nextevolution is operating across industries. Among nextevolution's customers currently are businesses named in the following: industry, trade, financial services, telecommunication, real estate industry and public service. The company's main place of business is in Hamburg with subsidiaries in Berlin, Frankfurt, Munich and Vienna (Austria). --- End of Message --- nextevolution Am Sandtorkai 74 Hamburg Germany WKN: A0JC0A; ISIN: DE000A0JC0A2; Listed: Entry Standard in Frankfurter Wertpapierbörse, Freiverkehr in Frankfurter Wertpapierbörse, Freiverkehr in Börse Stuttgart, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Berlin Bremen;


 

Summary: Karen Lykke Sørensen, Vice President, Northern Europe, Sanofi-Aventis, and Ole Steen Andersen, CFO of Danfoss, have joined the Board of Directors. The Board of Directors has elected Ole Steen Andersen as its new Chairman. Furthermore, Pharmexa has appointed Peter Nordkild as Chief Commercial Officer (CCO) In recent years, Pharmexa has refocused the company from drug discovery towards drug development and Pharmexa is now taking the final important step, under which the company will increasingly focus on commercial operations. Karen Lykke Sørensen, Vice President, Northern Europe, Sanofi-Aventis, and Ole Steen Andersen, CFO of Danfoss, complement the commercial strength already represented on the Board of Directors of Pharmexa. The Board of Directors has elected Ole Steen Andersen as its new Chairman. Ole Steen Andersen said: "Pharmexa is a good example of the importance of business building and strategy work, also in biotech companies. The company's Board of Directors and Management have very competently repositioned the company over a short number of years. As new Chairman, I will work to continue this process." Jakob Schmidt, CEO of Pharmexa said: "Karl-Olof Borg has been an excellent chairman during a difficult but also very successful period at Pharmexa. I have thoroughly enjoyed working with him, and I am pleased that he will stay on the Board even though he now, at his own request, has stepped down as chairman. I look forward to working with Ole Steen Andersen, and I look forward to benefiting from his great industrial and commercial experience." Pharmexa has appointed Peter Nordkild as Chief Commercial Officer (CCO). Peter Nordkild (51) has extensive capabilities within business development and sales and marketing of pharmaceuticals. Before joining Pharmexa, Peter Nordkild spent six years as Senior Vice President, Commercial Operations with Ferring Pharmaceuticals. His primary task was to develop Ferring's activities outside North America and Europe, with the primary focus on the Far East, Eastern Europe and the Middle East. Peter Nordkild was responsible for some 20 subsidiaries with more than 600 employees and a sales budget of around DKK 1.5 billion. Before joining Ferring, Peter Nordkild held various management positions with Novo Nordisk over a 12-year period, among them several years as Director of Diabetes Marketing, with responsibility for all Novo Nordisk diabetes marketing activities. Peter Nordkild is an orthopaedic surgeon by background and has published a large number of scientific articles in this field. At Pharmexa, Peter Nordkild will hold overall responsibility for business development, collaborative agreements, finance, administration and IT. Peter Nordkild will report to CEO Jakob Schmidt and together with Jakob Schmidt he will make up Pharmexa's new Executive Management. Hørsholm, April 24, 2007 Jakob Schmidt Chief Executive Officer Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558 Note to editors: Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, rheumatoid arthritis, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 100 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.


 

At the Annual General Meeting of Precise Biometrics, which was held today on Tuesday 24 April, it was inter alia resolved to adopt an incentive program for employees in the group and to adopt guidelines for remuneration to management. In addition, the meeting approved the proposal of the board to authorize the board to increase the company's share capital by way of new issue of shares (in kind), through which the company intends to enable acquisitions of shares or assets in other companies against payment in own shares. Election of Board members Two new board members were elected - Eva Maria Matell and Lena Widin Klasén. Eva Maria Matell is Sales and Marketing Director in XPonCard AB and Lena Widin Klasén is Technical Director and Manager of the Division of Sensor Technology at the Swedish Defense Research Agency, FOI. The new board members' experience from security issues is expected to reinforce the company's competence within the security industry. Lars Grönberg, Christer Fåhraeus, Jan T. Jørgensen, Marc Chatel and Lisa Thorsted were re-elected as members of the board, whilst Christer Bergman and Göran Jansson had declined re-election. Lars Grönberg was re-elected as chairman of the board. The meeting also resolved that remuneration to the board shall be given so that the chairman of the board receives SEK 210,000 and the other six board members receive SEK 105,000 each. Dividends It was decided that no dividends would be issued for the financial year of 2006. Guidelines for remuneration to management In accordance with the proposal of the board, the meeting resolved to adopt guidelines for management principally entailing that remuneration and terms of employment shall be competitive and in accordance with market conditions, and that the remuneration shall have a pre-determined cap. The variable remuneration shall amount to a maximum of 50 % of the fixed basic salary as regards the President, and 30 % of the fixed annual salary as regards other management employees. Remuneration may also be paid by way of warrants and other share-related incentive programs. At termination of employment, a mutual notice period of 6 months shall be applicable as regards the President, and 3-6 months for other management employees. Redundancy payment to the President may be paid by a maximum of 12 monthly salaries if the employment is terminated by the company. Other management employees shall not be entitled to redundancy payment. Pension right shall be applicable from the age of 65, whereby the pension premium shall be calculated based on age and salary and may amount to a maximum of 25 % of the fixed salary. The resolution entails a level of remuneration principally in accordance with that of the previous year. Authorization for the board to resolve upon new issue of shares (in kind) In accordance with the proposal of the board, the meeting resolved to authorize the board to decide upon an increase of the company's share capital through new issue of a maximum of 4 million shares, against payment in kind. Full exercise of the authorization entails an increase of the company share capital by SEK 1.6 million, which corresponds to a dilution of just below 4.1 % of the present share capital and votes. The purpose of the authorization is to enable the company to make company acquisitions against payment wholly or partially in own shares. Incentive program for group employees In accordance with the proposal of the board, the meeting resolved on adoption of an incentive program for the employees by way of issue of a maximum of 3.5 million warrants, entitling to subscription for the equivalent number of shares during the period from 1 January - 1 May 2010. The subscription price at subscription of shares shall be equivalent to 133 % of the average share price during the period 14 - 28 May 2007. The warrants shall be issued to two of the company's wholly-owned subsidiaries which shall, in turn, transfer the warrants (alternatively issue purchase options on corresponding conditions) to the employees of the group in Sweden and in the USA in accordance with specific conditions for allotment. The purpose of the deviation from the preferential rights of the shareholders is that the incentive program is expected to lead to an increased interest in the development of the company, and that the employee loyalty is therewith stimulated, which in turn is expected to be for the good of the company. Full subscription and full exercise of the warrants would entail an increase of the share capital by SEK 1.4 million, which is equivalent to a dilution of approximately 3.6 % of the company's present share capital and votes. For further information, please contact Lars Grönberg, Chairman of the Board, Precise Biometrics AB Phone 0707-27 54 55 E-mail lars.gronberg@precisebiometrics.com Niklas Andersson, CFO, Precise Biometrics AB Phone 046-31 11 02 eller 0730-35 67 02 E-mail niklas.andersson@precisebiometrics.com Precise Biometrics AB (publ.) is an innovative security company that supplies world-leading systems for fingerprint and smart card-based authentication. The company's solutions replace keys, PIN codes and passwords and enhance the integrity of ID cards and passports. With its Precise Match-on-Card(TM) technology, the company is a market leader within smart ID cards. The product line includes systems for access control to buildings, computers and networks and for integration into ID cards and passports. The Precise Biometrics group has subsidiaries in Sweden, Great Britain, USA and a joint venture agreement in China. The group headquarters are in Lund, Sweden. Precise Biometrics is listed on the small cap list at the Nordic Exchange in Sweden (symbol: PREC). For more information, please visit http://www.precisebiometrics.com/ The press release can be downloaded from the following link:


 

Private Equity Holding is pleased to report a total comprehensive net gain of EUR 73.6 million for the financial year ending March 31, 2007. The comprehensive net gain per share amounts to EUR 18.19 (in 2005/2006: comprehensive net loss per share of EUR 2.78). Since April 1, 2006, the fair value per share (in EUR) has risen by over 60% (65% in CHF). At the end of the financial year it stood at EUR 45.66 (CHF 74.14). At the Extraordinary General Meeting of December 7, 2006, the shareholders of Private Equity Holding elected a new Board of Directors and decided to lift the investment restrictions in order to allow the Company to pursue suitable investment opportunities. The Board of Directors and ALPHA Associates, the Company's adviser and manager, have started to implement a long-term growth strategy. The ultimate objective of the Company's modified investment strategy is to improve the quality and return potential of the portfolio and increase the fair value per share consistently. Consistent growth should, over time, result in a significant and sustainable reduction of the discount between the share price and the fair value per share. Since the end of the financial year, the bid/offer spread for the Private Equity Holding shares has narrowed and the discount has decreased to currently 26% (basis: closing price April 23, 2007). The Company aims to decrease its exposure to venture investments and increase the percentage of buyout investments. Geographically, the strategy foresees an increase of the allocation to Europe, including the fast growing region of Central & Eastern Europe. The Chairman's letter to the Company's shareholders as well as a short version of the Annual Report as of March 31, 2007 are available on our website www.peh.ch from April 24, 2007. The complete Annual Report 2006/2007 will be published at the end of May, 2007. Private Equity Holding AG (SWX: PEHN), managed by ALPHA Associates, offers investors the opportunity to invest, within a simple legal and tax optimized structure, in a broadly diversified and professionally managed private equity portfolio. For further information, please contact: Claudine Birbaum, Investor Relations, claudine.birbaum@peh.ch, phone +41 41 726 79 80 or http://www.peh.ch --- End of Message --- Private Equity Holding AG Innere Güterstrasse 4 Zug WKN: 906781; ISIN: CH0006089921; Index: IGSP; Listed: Investment Companies in SWX Swiss Exchange;


 

At the general meeting note was taken of the report by the Supervisory Board on the activities of the company during the previous year, the Annual Report was approved, and the Supervisory Board and Executive Management were discharged from liability. The general meeting approved the dividend of 1.57 per share of DKK 5 nominal value proposed by the Supervisory Board. Flemming Lindeløv, Thorleif Krarup, Peter Kürstein, Mats Pettersson and Jes Østergaard were all re-elected to the Supervisory Board. Lars Bruhn resigned from the Supervisory Board, and Per Wold-Olsen was elected as a new member. Immediately after the general meeting the Supervisory Board elected Flemming Lindeløv Chairman and Thorleif Krarup Deputy Chairman of the Supervisory Board. After having elected its Chairman and Deputy Chairman, the Supervisory Board appointed members for the Audit Committee and the Compensation Committee. Peter Kürstein, Flemming Lindeløv and Thorleif Krarup were re-elected members of the Audit Committee. Flemming Lindeløv, Mats Pettersson and Jes Østergaard were elected members of the Compensation Committee. The Supervisory Board of H. Lundbeck A/S will hereafter comprise: - Flemming Lindeløv - Thorleif Krarup - Peter Kürstein - Mats Pettersson - Per Wold-Olsen - Jes Østergaard - Birgit Bundgaard Rosenmeier (elected by the employees) - William Patrick Watson (elected by the employees) - Kim Rosenville Christensen (elected by the employees) Deloitte Statsautoriseret Revisionsaktieselskab and Grant Thornton Statsautoriseret Revisionsaktieselskab were re-elected auditors for the company. The Supervisory Board's proposed resolutions under item 6 of the agenda were adopted. Consequently, a resolution was adopted to reduce the company's share capital by reducing the company's holding of treasury shares acquired from shareholders of the company, including as part of the implementation of share buyback programmes. Article 7(1), first sentence of the Articles of Association was amended as a consequence of the Danish municipal reform so that the company's general meeting will be held in the Capital Region in the future. The Supervisory Board was further authorised to arrange for the acquisition of treasury shares by the company pursuant to s. 48 of the Danish Public Companies Act. Finally, the chairman of the general meeting was authorised to make such changes in and supplements to the resolutions adopted by the general meeting and the notification to the Danish Commerce and Companies Agency as may be requested by the Commerce and Companies Agency in connection with its registration of the amendments made. No other business was transacted at the general meeting. The Supervisory Board The content of this release will have no influence on the Lundbeck Group's financial result for 2007. Lundbeck contacts Steen Juul Jensen Vice President +45 36 43 30 06 Investors: Media: Mads Bjerregaard Pedersen Caroline Broge Investor Relations Officer Media Relations Manager +45 36 43 41 04 +45 36 43 26 38 Jacob Tolstrup Investor Relations Manager, North America +1 201 350 0187 ________________________ Stock Exchange Release No 266 - 24 April 2007 About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com


 

Waldenburg, 24 April 2007 - In light of the company's strong earnings growth in fiscal 2006 and continuing good growth prospects, the Managing and Supervisory Boards are going to propose to the annual general shareholders' meeting of R. STAHL AG to approve a dividend distribution of EUR 0.90 per share. The current dividend yield is 2.6 %. Last year, the company distributed a dividend of EUR 0.60 per share plus an additional one-off extraordinary bonus of EUR 0.20 from the Material Handling divestment. The dividend distribution represents approx. half of R. STAHL AG's 2006 net earnings. The group intends to always distribute appropriate profit shares going forward. R. STAHL AG will hold its annual general shareholders' meeting on 22 June 2007. Contact: R. STAHL AG Communication / Investor Relations Judith Schäuble Am Bahnhof 30, D-74638 Waldenburg, Germany Phone: +49 (7942) 943-1217, Fax: +49 (7942) 943-1364 e-mail: judith.schaeuble@stahl.de --- End of Message --- R. STAHL AG Am Bahnhof 30 Waldenburg WKN: 725772; ISIN: DE0007257727 ; Index: CDAX, CLASSIC All Share, Prime All Share, GEX; Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in Börse Stuttgart, Geregelter Markt in Börse Stuttgart, Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Düsseldorf;


 

Zurich/Sofia, April 24, 2007 - Swissport International, the world's leading provider of aviation services, has established a ground handling company in Sofia, Bulgaria. With the country's strong economic growth and its rapidly-rising air travel volumes, the new operation fits ideally into the Swissport strategy of gaining key footholds in promising new markets. Bulgaria is one of the fastest-growing markets in the EU. And Swissport Bulgaria will now enter this market as the first independent ground handling company at Sofia Airport. The airport handled 2.2 million passengers last year, passenger numbers are currently rising at an annual 20%, and further double-digit growth is expected in the years ahead. Under current plans, Swissport Bulgaria should handle its first flight at the airport on June 18. "We intend to establish Swissport Bulgaria as an attractive ground handling provider at Sofia Airport by offering top-quality products and services at competitive prices," says Christian Draeger, the new company's Managing Director. "And we're greatly looking forward to further developing our activities in the rapidly-growing Southeast European market following our successful market entry in Kiev one year ago." Bulgaria joined the European Union on January 1, 2007. The country has a total population of 7.75 million. Sofia, its capital, is home to more than a million people, while Varna and Burgas, the two major cities on the Black Sea, both have populations of over 230 000. Key economic data on Bulgaria +----------------------------------------+ | | 2004 | 2005 | 2006 | |-------------------+------+------+------| | GDP growth in % | 5.7 | 5.5 | 6.0 | |-------------------+------+------+------| | Inflation in % | 4.0 | 6.5 | 6.0 | |-------------------+------+------+------| | Unemployment in % | 12.0 | 10.1 | 8.8 | +----------------------------------------+ Swissport International Ltd., which is owned by Ferrovial, a leading European infrastructure and service corporation based in Spain, provides ground services for over 70 million passengers and 3.2 million tonnes of cargo a year on behalf of some 650 client companies. With its workforce of around 23 000 personnel, Swissport is active at 180 airports in 43 countries on five continents, and generated consolidated operating revenue of CHF 1 712 million (EUR 1 070 million or USD 1 370 million) in 2006. www.swissport.com / www.ferrovial.com Swissport International Ltd. Corporate Communications P.O. Box CH-8058 Zurich Airport Phone: +41 43 812 4950 Mobile: +41 79 638 9939 Fax: +41 43 321 2874 stephan.beerli@swissport.com The media release can be downloaded from the following link:


 

LONDON (Dow Jones)--Alcan Inc (AL) expects to recoup its investment made in Indias Utkal Alumina International Limited when it sells its 45% stake, the company said Tuesday. Speaking on a conference call on the companys first-quarter results, Alcan chief executive Dick Evans said around $20 million-$30 million of investment had been made by the Canadian producer. "We expect to be able to sell with some modest upside; in other words, we dont expect to take a loss," he added. Evans said discussions for its stake sale are now underway. "Id expect some news in the coming months," he added. Alcan announced it was to sell its stake in the Utkal project April 12. The joint venture was established in 1992 and involves development of a new bauxite mine and alumina refinery in the Indian state of Orissa. Hindalco, part of the Aditya Birla group, holds the remaining 55% interest in Utkal. The decision was made in part because Alcan felt the shareholders agreement for the project didnt reflect the companys investment. "The shareholder rights agreement was inappropriate for a project of this scale, and we were unable to reach agreement on share rights that would allow us to take an active role," Evans said. Other aspects of the project including community issues and environmental concerns, as well as technical and commercial factors, led to the decision to sell, he added. "Theres potential in India for plenty of low cost bauxite and alumina capacity, and theres more than just one project in India," Evans said. Other locations such as Guinea, Ghana and Madagascar all hold potential. "The real economic benefit is in developing a bauxite mine on the right terms, and in a site near a deep water port with a refinery where you can refine alumina and ship it worldwide," he added. -By Andrea Hotter, Dow Jones Newswires; +44 (0)20 7842 9413; andrea.hotter@dowjones.com (END) Dow Jones Newswires


 

The Annual General Shareholders Meeting (AGM) of ING Groep N.V. today adopted the 2006 Annual Accounts and declared a total dividend for 2005 of EUR 1.32 per (depositary receipt for an) ordinary share. The dividend, as announced on 16 February 2006, represents an increase of 12% from EUR 1.18 for 2005. Taking into account the interim dividend of EUR 0.59 made payable in August 2006, the final dividend amounts to EUR 0.73 per (depositary receipt for an) ordinary share to be paid fully in cash. ING's shares will be quoted ex-dividend as of 26 April 2007 and the final dividend will be made payable on 3 May 2007. In addition, the AGM appointed the proposed two new Executive Board members following the retirement of Cees Maas. As announced on 15 February 2007, it was decided to split the roles of Chief Financial Officer and Chief Risk Officer given the increasing complexity and importance of both the finance and risk roles within ING. John Hele will take the position of Chief Financial Officer and Koos Timmermans will take the position of Chief Risk Officer for ING Group. The AGM also appointed Henk Breukink, Peter Elverding and Piet Hoogendoorn to the Supervisory Board. The required approvals were obtained from the Dutch Central Bank at an earlier stage. In addition, Claus Dieter Hoffmann and Wim Kok were reappointed to the Supervisory Board. As announced on 20 March 2007, Paul van der Heijden retired from the Supervisory Board, having reached the end of the third and last term. As per 27 April, the Supervisory Board of ING Group consists of: Cor Herkströter, Chairman Eric Bourdais de Charbonnière, Vice-Chairman Henk Breukink Peter Elverding (as of 1 August 2007) Luella Gross Goldberg Claus Dieter Hoffmann Jan Hommen Piet Hoogendoorn (as of 1 June 2007) Piet Klaver Wim Kok Godfried van der Lugt Karel Vuursteen +-----------------------------------------------------+ | Press enquiries: ING Group | | Debbie Brand, +31 20 541 5469, debbie.brand@ing.com | +-----------------------------------------------------+ ING is a global financial institution of Dutch origin offering banking, insurance and asset management to over 60 million private, corporate and institutional clients in more than 50 countries. With a diverse workforce of about 120,000 people, ING comprises a broad spectrum of prominent companies that increasingly serve their clients under the ING brand.


 

LIMERICK, Ireland, April 24, 2007 (PRIME NEWSWIRE) -- Genesis Lease Limited (NYSE:GLS) today announced that it was presented with Airfinance Journal's "Overall Deal of the Year 2006" award for its innovative IPO and Securitization, at a ceremony last evening in New York. Airfinance Journal recognizes the most significant deals of the year. The winner is chosen based on deals that combine innovation, structuring skill and great execution. On December 19, 2006, Genesis completed its IPO with the issuance of 27,860,000 shares at a price of $23.00 per share. In conjunction with the IPO, Genesis issued 3,450,000 shares to an affiliate of General Electric Company, in a private placement at a price of $23.00 per share and issued $810 million of floating-rate aircraft lease-backed notes in a securitization transaction. The net proceeds from these three transactions were used to finance the acquisition of a portfolio of 41 aircraft from affiliates of General Electric. "Airfinance Journal awards companies for their innovation and ability to execute well -- two traits that are a hallmark of Genesis Lease. It is always gratifying to be recognized, particularly from our peers. We are delighted that such a prestigious industry periodical has recognized Genesis' deal structure in this way and, while Genesis received the award, it is also well-deserved recognition for the entire deal team from GE, Citi and the various law firms and other advisory firms that made the deal possible." Genesis Lease received the award at the 27th Annual New York Airfinance Conference held at The Pierre Hotel in New York City at a ceremony held on Monday, April 23, 2007. About Genesis Lease Limited Genesis Lease Limited is a global commercial aircraft leasing company that is headquartered in Limerick, Ireland. Genesis acquires and leases modern, operationally efficient passenger and cargo jet aircraft to a diverse group of airlines throughout the world. Genesis leverages the worldwide platform of GE Commercial Aviation Services Limited, or GECAS, to service its portfolio of leases, allowing management to focus on executing its growth strategy. Genesis's common shares, in the form of American Depositary Shares, are listed on the New York Stock Exchange under the symbol "GLS." As discussed, the following forward-looking statements disclosure may be used in non-financial releases: The Genesis Lease Limited logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3178 Certain items in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements regarding the outlook for Genesis Lease's future business and financial performance. Forward-looking statements are based on management's current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Genesis Lease can give no assurance that its expectations will be attained. There are important factors that could cause actual results, level of activity, performance or achievements to differ from the results, level of activity, performance or achievements expressed or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the future performance or events described in the forward-looking statements in this press release may not occur. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results and Genesis Lease does not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. Such forward-looking statements speak only as of the date of this press release. Genesis Lease expressly disclaims any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in its views or expectations, or otherwise. CONTACT: Genesis Lease Limited John McMahon, Chief Executive Officer +353-61633249 john.mcmahon@genesislease.com KCSA Worldwide Jeffrey Goldberger, Managing Partner 212-896-1249 jgoldberger@kcsa.com


 

Carnegie publishes its report for the first quarter 2007 on Tuesday the 24th of April. A presentation of the report will be given at a web casted telephone conference call at 16.00 CET with comments on the report given by Stig Vilhelmson, CEO of Carnegie. Host: CEO, Stig Vilhelmson Date: Tuesday, April 24 at 16.00 CET Link: http://webcast.zoomvision.se/clients/carnegie/070424/


 

The presentation of 1st quarter 2007 accounts will be held on Friday 4th May at 09:00 am. The 1st quarter results 2007 will be made public on the previous day, Thursday 3rd May, at approx. 3.00 pm. The presentation will be held at Hotel Continental, Stortingsgaten 24/26, Oslo. For registration, please contact Kim Helling: kim.helling@hafslund.no Hafslund ASA Oslo, 24 April 2007 For further information: Heidi Ulmo, Vice President Investor Relations Telephone: +47 90 91 93 25


 

More than 100 percent increase in Retail business area's sales First quarter of 2007 * Net sales rose to MSEK 101.7 (63.5) * Operating profit excluding nonrecurring costs improved to MSEK 8.9 (0.1) * Profit after taxes improved to MSEK 2.9 (loss: 0.5) * Earnings per share improved to SEK 0.03 (0.00) * Distributor agreement signed with LaSer Symag of France,Pharmatechnik of Germany and RBS of Sweden * More than 650 cash-handling systems were delivered during the period * Order worth MSEK 13 received from Brink's of Belgium * Agne Pettersson became Managing Director and Chief Executive Officer on February 22 Event after period end * The Board has today decided to focus on the Retail business area. The CIT/ATM business area will be sold or listed The report can be downloaded from the following link:


 

Trailblazing Newspaper and ISP to Bring Lightning-Fast Mobile Broadband Services to Midwestern United States CHICAGO, ILLINOIS -- (MARKET WIRE) -- April 24, 2007 -- Moline Dispatch Publishing Co. (MDPC) will use Nortel(1) (TSX: NT)(NYSE: NT) 4G WiMAX technology to deliver high-speed broadband across western Illinois and eastern Iowa through its Internet service provider (ISP), Quad-Cities Online (QCO). The new WiMAX network will allow QCO to deliver fixed and mobile wireless broadband services to its growing subscriber base of college students and business and residential users in the Quad Cities - Davenport, Bettendorf, Moline/East Moline and Rock Island. The low cost and high capacity of Nortel's WiMAX technology will assist QCO in offering a high-speed alternative to DSL and cable Internet. QCO's network will provide broadband access for a wide range of bandwidth-intensive applications such as VoIP and real-time multimedia communication. The next-generation, high-speed, high-broadband capabilities of Nortel's WiMAX technology will also help QCO to support broadband requirements in the era of hyperconnectivity, where ever-increasing numbers of devices and applications will be connected to networks. As well, the mobile capabilities of the 802.16e WiMAX solution will help QCO build a network that subscribers can access on the go. For example, high-speed mobile access may help college students to make more efficient use of study time through the ability to access on-line educational resources and communicate with friends, study partners and professors anywhere, anytime. MDPC journalists may also use the WiMAX network from the field to post news reports in real time. "WiMAX is an ideal solution for new entrants and innovative Internet service providers like Quad-Cities Online, because it requires minimal infrastructure to establish both fixed and mobile networks," said Peter MacKinnon, general manager of WiMAX, Nortel. "In the era of hyperconnectivity, anything that would benefit from being connected to the network will be connected. WiMAX makes it possible for service providers - large and small, new and established - to offer network capabilities that are up to the hyperconnectivity challenge." "Thanks to an agreement with Black Hawk College which gives us access to wireless spectrum, and Nortel's expertise in WiMAX, we will be uniquely positioned to satisfy the information and communication needs of the communities we serve for years to come," said Gerald J. Taylor, publisher, MDPC. MDPC has long been an early adopter of online services, embracing and enabling the Web experience and connecting it with its news business. The Dispatch and The Rock Island Argus were among the first newspapers in the United States to make content available through the Internet, and Quad-Cities Online was an early ISP in the Quad-Cities. Now, with the deployment of WiMAX, MDPC has the capability to change the way it reports the news, pushing the interactive multimedia news experience further through the use of technology. QCO's 802.16e WiMAX network will run over 2.5 GHz spectrum available to QCO through a long-term lease of Black Hawk College's Educational Broadcasting Service (EBS) channels. "This agreement represents an unprecedented alliance between a local educational institution and a commercial Internet service provider to utilize EBS channels for the benefit of the community as a whole," Taylor and Dr. Keith Miller, president, Black Hawk College, said in a joint statement. About Quad-Cities Online Quad-Cities Online is a service of Moline Dispatch Publishing Co. L.L.C., which also publishes daily newspapers The Dispatch and The Rock Island Argus, and The Leader, a free-circulation weekly newspaper for the Iowa Quad-Cities. Since 1994, QCO has offered local news, email, Internet access and other services. Local news stories available through Quad-Cities Online are produced by the staffs of the three newspapers and their sister publications, including The Gold Book, Radish, Showcase and MetroEast. About Black Hawk College Black Hawk College is a comprehensive community college annually serving 13,000 college-credit students and 7,000 Continuing Education and Workforce Training adults with high-quality, cost-effective lifelong learning. The Quad-Cities Campus is located in Moline, Ill., and the East Campus is near Kewanee, Ill. About Nortel Nortel is a recognized leader in delivering communications capabilities that make the promise of Business Made Simple a reality for our customers. Our next-generation technologies, for both service provider and enterprise networks, support multimedia and business-critical applications. Nortel's technologies are designed to help eliminate today's barriers to efficiency, speed and performance by simplifying networks and connecting people to the information they need, when they need it. Nortel does business in more than 150 countries around the world. For more information, visit Nortel on the Web at www.nortel.com. For the latest Nortel news, visit www.nortel.com/news. Certain statements in this press release may contain words such as "could", "expects", "may", "anticipates", "believes", "intends", "estimates", "targets", "envisions", "seeks" and other similar language and are considered forward-looking statements or information under applicable securities legislation. These statements are based on Nortel's current expectations, estimates, forecasts and projections about the operating environment, economies and markets in which Nortel operates. These statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and the actual outcome may be materially different from those contemplated in forward-looking statements. For additional information with respect to certain of these and other factors, see Nortel's Annual Report on Form10-K, Quarterly Reports on Form 10-Q and other securities filings with the SEC. Unless otherwise required by applicable securities laws, Nortel disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. (1)Nortel, the Nortel logo and the Globemark are trademarks of Nortel Networks. Contacts: Nortel Karen Monaghan (613) 763-1133 Email: kmonagha@nortel.com Website: www.nortel.com Quad-Cities Online Joe Riley (309) 757-4935 Email: jriley@qconline.com SOURCE: Nortel and Quad-Cities Online


 

Public Sector Puts Innovation at Top of the Agenda, Cisco Research Shows LONDON -- (MARKET WIRE) -- April 24, 2007 -- Public sector organizations have made technological innovation their highest priority in a bid to stay in tune as citizens increasingly use interactive online services. Cisco® (NASDAQ: CSCO) today revealed that 'increasing my organisation's ability to innovate' was rated the top priority for 2007 by 35 percent of 84 senior government executives from 17 countries across the world. The research, carried out among attendees at the Cisco Public Sector Summit in Stockholm last year, shows how government officials, far from being grey bureaucrats, are keen to embrace the so-called 'Web 2.0' generation of Web-based services that are credited with transforming society and commerce. It also reveals that the main issue holding back transformation in public sector organisations is not lack of ambition, but lack of skilled employees, which is claimed to be 'a real obstacle to change' by 23 percent of respondents. After innovation, the main preoccupations of administration officials are increasing the availability or take up of online services (cited as 'top of my agenda' by 29 percent of those questioned), reengineering processes to improve staff productivity (highlighted by 27 percent) and increasing the organisation's ability to collaborate (26 percent). Other issues preventing transformation are political uncertainty or aversion to change (a real obstacle in 16 percent of responses), senior managers blocking change in order protect their parts of the organisation (also 16 percent) and lack of money to fund projects -- even where there is a clear payback in two years (14 percent). Shared services, where resources are split across several departments to free up budgets to be invested in applications that directly benefit citizens, are being adopted by 73 percent of organisations in back-office functions such as finance or procurement. Meanwhile, 84 percent of organisations are introducing them in IT services and infrastructure and 73 percent in front-office services related to interaction with customers. But the research worryingly also shows that some executives have yet to embrace the benefits of a shared-services approach. Six percent claimed that 'exploring the potential for sharing services with others or outsourcing them' is not a priority. "This research shows how public sector organisations worldwide are keen to embrace innovation to help deliver citizen-centric services, but may be held back through factors such as a lack of skilled personnel or funding," said Le Roux. "Shared services can help overcome this problem by unlocking substantial budgets currently tied up in the duplication of efforts, and it is heartening to see that many departments are now starting to share resources. Those that do not make it a priority, however, risk lagging behind in the race to provide the best value to their citizens." The respondents to the survey, which was carried out as a precursor to a more in-depth study that Cisco will be sponsoring this year, hailed from countries as diverse as Thailand, Belgium, Canada and Russia. "Local government and regional or state agencies both highlight the front office as a critical area where they are implementing or shortly plan to implement shared services," said Yvon Le Roux, Vice-President of the Public Sector for Cisco in Europe and Emerging Markets. "Education is the only sector which highlights IT services and infrastructure as the area where they are most rapidly implementing shared services, and healthcare and central government have both cited the back office as the focus." About Cisco Cisco Systems, Inc. (NASDAQ: CSCO) is the worldwide leader in networking for the Internet. Information on Cisco can be found at http://www.cisco.com. For ongoing news, please go to http://newsroom.cisco.com. Cisco, Cisco Systems, and the Cisco Systems logo are registered trademarks of Cisco Systems, Inc. and/or its affiliates in the U.S. and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. For direct RSS Feeds of all Cisco news, please visit "News@Cisco" at the following link: http://newsroom.cisco.com/dlls/podcasts/rss.html Press Contact: Alison Stokes Cisco Systems +44 20 8824 0926 astokes@cisco.com


 

Milan, Italy, April 24, 2007 - Shareholders of BioXell S.p.A. (SWX: BXLN) unanimously approved all items proposed by the Board of Directors at today's Annual General Meeting in Zurich. These included: * the approval of the 2006 statutory financial statements of BioXell S.p.A. * the appointment of Dr. Werner Lanthaler as member of the Board of Directors * the re-election of KPMG S.p.A. as External Auditors of the company * the increase of the authorized capital reserved to the beneficiaries of the company's stock option plan * the increase of the authorized capital reserved for strategic investments up to a maximum of 50% of the existing share capital, thus granting the company the flexibility to actively pursue strategic investments and in-licensing of complementary therapeutics within its areas of focus. The Annual General Meeting was attended by Shareholders who represented 54.87% of the total share capital of the Company. Dr. Thomas Szucs, Chairman of BioXell, commented, "It's an exciting time to be a Shareholder and participate in the BioXell story, as the Company enters a new phase in its maturation, with the goal of becoming a fully integrated biopharmaceutical company and a key player in the management of urological disorders. BioXell reached key milestones in 2006 in the development of Elocalcitol for two major urological disorders, Benign Prostatic Hyperplasia and Overactive Bladder, either of which represents a potential blockbuster market for the Company's lead compound. Furthermore, Elocalcitol will be entering clinical trials for a third indication, Male Infertility, later this year, while a new compound acquired from Roche will be advanced into Phase II trials for Post-Surgical Adhesions in 2008." About BioXell BioXell (SWX: BXLN) is a biopharmaceutical company focused on the discovery and development of drugs that exploit novel mechanisms of action to treat important urological, inflammatory, and related disorders with significant unmet medical needs. The Company was founded in 2002 as a spin-out from Roche. BioXell's strategic goal is to become a fully integrated pharmaceutical company by maximizing the commercial potential of its product portfolio and leveraging existing platforms into profitable partnerships. BioXell's lead compound, Elocalcitol, derived from its proprietary VD3 (Vitamin D3) technology platform, is in Phase II clinical trials for Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB), with a third Phase II trial for Male Infertility scheduled for 2007. In addition, the Company has several follow-on programs based on both VD3 and other technological platforms. BXL746 is to enter Phase II trials for Post-Surgical Adhesions in 2008. In 2006, BioXell in-licensed from Lay Line Genomics S.p.A. a novel anti-TrkA monoclonal antibody, MNAC13, which represents an innovative new approach to the treatment of pain. BioXell also has an exclusive partnership with Merck & Co., Inc. since 2005 for the development of its TREM platform, with TREM-1 in development for the treatment of septic shock. In June 2006, BioXell listed its shares on the main segment of the SWX Swiss Exchange. BioXell currently employs 60 people and has sites in Milan, Italy and Nutley, NJ, USA. More information on BioXell can be found at: http://www.bioxell.com For further information, please contact: BioXell S.p.A. Rochat & Partners Alvise Sagramoso/Angela Evans Christophe Lamps/Jonathan Leighton Tel: +39 (0)2 210 49 51 Tel: +41 22 718 37 46 Fax: +39 (0)2 210 49 529 Fax: +41 22 786 54 58 alvise.sagramoso@bioxell.com clamps@rochat-pr.ch angela.evans@bioxell.com jleighton@rochat-pr.ch Disclaimer This press release does not constitute or form part, or all, of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of BioXell, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of BioXell, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. BioXell disclaims any obligation to update these forward-looking statements to reflect future events or developments. --- End of Message --- bioXell S.p.A via Olgettina 58 Milan Italy WKN: A0J3MW; ISIN: IT0004069933 ; Listed: Main Market in SWX Swiss Exchange;


 

Benedikt Gíslason, managing director of proprietary trading has resigned and will leave Straumur-Burdaras in October 2007. Flemming Bendsen has joined proprietary trading. Flemming has worked in London and Scandinavia for over 20 years in proprietary trading, most recently as the head of Scandinavian proprietary desk at JP Morgan in London. Fredrik Sjöstrand has joined proprietary trading. Fredrik has 20 years experience in proprietary trading, in Sweden, Luxembourg and London, and his last two roles were Head of Trading at Svenska Handelsbanken, Stockholm, and Head of Risk Management. Lars Bo has joined proprietary trading, he has over 20 years experience in mortgage bond trading and was head of trading at Nykredit, Copenhagen.


 


 

Mortsel / Belgium, April 24, 2007 - 1.00 p.m. CET At Agfa's General Meeting today, shareholders approved the payment of a gross dividend of 50 cents per outstanding share. The share will be listed ex-coupon as of April 25, 2007. Shareholders also approved the reappointment of Jo Cornu as member of the Board of Directors. He was appointed for a 3-year period, to come into effect today. Marc Olivié, Agfa's President of the Executive Committee and CEO, commented on the progress of the business since the beginning of the year: "2007 will be a milestone for Agfa-Gevaert, as it is the last year the Group will operate as a whole. During this period, day -to-day business as well as the implementation of the growth strategies are of crucial importance for the business groups. Also in 2007, all businesses will start seeing the benefits from the savings plans, but high raw material costs are expected to continue to affect results. Graphics expects industrial inkjet to break through in 2007, with increasing sales and the gradual elimination of the start-up losses in the course of the second half of the year. Prepress operates in a mature market where the continuing decline of analog products is mostly being compensated by the growth of the more profitable digital printing plates. In HealthCare, the international roll-out of the enterprise-wide IT solutions as well as the growth in other digital and IT solutions and services should more than offset the continued market driven decline of film and print sales. Specialty Products is gaining market share in its film products and is targeting additional growth with innovative products and systems." Agfa-Gevaert's first quarter results will be announced on May 3, 2007, before the stock market opens. Another major topic of interest at the meeting was the announced demerger of the Agfa-Gevaert Group into three independent, listed companies by the end of the year. CEO Marc Olivié gave an update of the project's progress: "Currently, the demerger project is in its preliminary phase in which the different legal entities are being split up; the governance structure is being defined and the prospectus is being prepared. The final prospectus with all detailed information on the three companies will be ready for approval by the CBFA in the fall, after which it will be published. We will then convene for an Extraordinary General Meeting on the occasion of which we will ask the shareholders to approve the demerger. Following the approval, shareholders will own shares in the three new companies, in stead of one Agfa-Gevaert share." (end of message) About Agfa The Agfa-Gevaert Group is one of the world's leading imaging and information technology companies. Agfa develops, manufactures and markets analogue and digital systems for the printing industry (Agfa Graphics), the healthcare sector (Agfa HealthCare) and specific industrial applications (Agfa Materials). Agfa's headquarters are in Mortsel, Belgium. The company is present in 40 countries and has agents in another 100 countries throughout the world. The Agfa-Gevaert Group achieved a turnover of 3,401 million Euro in 2006. Agfa-Gevaert Press contacts: Katia Waegemans Director Corporate Communication +32-3-444 7124 katia.waegemans@agfa.com Johan Jacobs Corporate Press Relations Manager +32-3-444 8015 johan.jacobs@agfa.com


 

Board At the annual general meeting on 24 April 2007, the board of Handelsbanken was re-elected. Mr Lars O Grönstedt was appointed chairman. At the subsequent first board meeting Hans Larsson and Anders Nyrén were appointed as vice chairmen of the board. The board members are listed below. Dividend The annual general meeting adopted the board's proposal for a dividend of SEK 8 per share. The record day for dividend is Friday, 27 April 2007. The dividend is expected to be distributed by the VPC on Thursday, 3 May 2007. Buyback of shares In accordance with the board's proposal, the annual general meeting authorised the board to resolve on purchase of the Bank's own class A and/or B shares during the period until the annual general meeting in 2008 on the following conditions: * The purchases shall be made on Stockholmsbörsen, the Stockholm stock exchange * The Bank may purchase a total of no more than 40 000 000 class A and/or B shares. * The shares must be acquired at the market price applicable at the time of purchase. At the subsequent first board meeting, the board resolved to utilise its repurchase mandate and assigned to the group chief executive to effect the repurchases when appropriate, for a maximum amount of SEK 6bn. Reduction of the share capital through cancellation of repurchased shares and bonus issue The annual general meeting resolved in accordance with the board's proposal to reduce the share capital by 92 260 960 Swedish kronor through cancellation without repayment of 20 732 800 shares held by the Bank. With the consent of the Finansinspektionen, the share capital can be reduced without the permission of a court of law, if the Bank takes measures so that the Bank's share capital does not decrease as a result of the reduction. The annual general meeting therefore resolved by means of a bonus issue to increase the Bank's share capital by 94 244 919,30 Swedish kronor by transferring this amount from its unrestricted share capital without the issuing of new shares Nomination committee The nomination committee shall have five members. Four of the members (the "Shareholders' Representatives") shall represent the Bank's four largest shareholders/shareholder groups in terms of votes, according to shareholder information as at 31 August from the VPC (the Swedish Central Securities Depository and Clearing Organisation), or which by some other means prove to be among the largest shareholders (the "Largest Shareholders") on this date; one of these members is to chair the committee. However, the nomination committee must not include representatives of companies which are significant competitors of the Bank in any of its main areas of operations. The AGM assigns the chairman of the board to contact the Largest Shareholders, which will each appoint one representative who, together with the chairman, are to constitute the nomination committee for the period until a new nomination committee is appointed by mandate from the next annual general meeting. The members of the nomination committee for the nomination of board members for 2008 shall be announced at least six months before the 2008 AGM. Members of the board 2007 PIRKKO ALITALO, Helsinki JON FREDRIK BAKSAAS, Sandvika ULRIKA BOËTHIUS, Stockholm PÄR BOMAN, Linköping Tommy Bylund, Ljusdal GÖRAN ENNERFELT, Upplands Väsby LARS O GRÖNSTEDT, Stockholm, SIGRUN HJELMQUIST, Djursholm HANS LARSSON, Stockholm FREDRIK LUNDBERG, Djursholm SVERKER MARTIN-LÖF, Stockholm ANDERS NYRÉN, Bromma BENTE RATHE, Trondheim Minutes Minutes of the Annual General Meeting will be available at the Bank's website http://www.handelsbanken.se/ireng within two weeks as of today.


 

* The group's net sales for the first quarter amounted to SEK 6.0 million (21.0). * Profit/loss for the first quarter was SEK -9.3 million (-1.8). * Profit/loss per share for the first quarter amounted to SEK -0.10 (-0.03). * Liquid assets at the end of the quarter amounted to SEK 64.8 million (42.2). Significant events after the quarter * Precise Biometrics delivers biometric solution for national ID cards in Portugal. A procurement contract in a consortium led by the partner Gemalto was won. The new so called "Citizen Card" will replace several ID documents and will become the official ID document for all Portuguese citizens. For further information Thomas Marschall, President and CEO, Precise Biometrics AB Tel. +46 (0)46 31 11 10 or +46 (0)734 35 11 10 E-mail thomas.marschall@precisebiometrics.com Precise Biometrics AB (publ.) is an innovative security company that supplies world-leading systems for fingerprint and smart card-based authentication. The company's solutions replace keys, PIN codes and passwords and enhance the integrity of ID cards and passports. With its Precise Match-on-Card(TM) technology, the company is a market leader within smart ID cards. The product line includes systems for access control to buildings, computers and networks and for integration into ID cards and passports. The Precise Biometrics group has subsidiaries in Sweden, Great Britain, USA and a joint venture agreement in China. The group headquarters are in Lund, Sweden. Precise Biometrics is listed on the small cap list at the Nordic Exchange in Sweden (symbol: PREC). For more information, please visit http://www.precisebiometrics.com/ The full report including tables can be downloaded from the following link:


 

Espoo, Finland - Nokia today revealed the Nokia N95 multimedia computer has been voted the 'Best Mobile Imaging Device in Europe 2007' by TIPA (Technical Image Press Association), the largest photo and imaging press association in Europe. "A small mobile wonder and a camera as well," the Nokia N95 multimedia computer was commended for its outstanding imaging functionality, comparing its features directly with those of stand-alone cameras. The judging panel noted features such as the autofocus lens for sharp, large prints, a real mechanical shutter to avoid distortion, the Carl Zeiss optics with Tessar lens that can focus at close range and the up to 20x digital zoom for distant subjects. The panel also commented on the device's outstanding audio, video and web capabilities and its GPS functionality. "This award reinforces Nokia's leadership and commitment to driving forward convergence in the mobile industry," said Jonas Geust, head of Nokia Nseries Players Category, Multimedia, Nokia. "We're delighted the Nokia N95 has been recognized as an outstanding imaging device and we firmly believe that by offering our customers true multimedia computers, like our Nokia Nseries range, we can confidently say we have now arrived at a time when people no longer need to carry multiple devices." The features of the Nokia N95 include: - 5 megapixel camera with Carl Zeiss optics - Possibility to capture print quality photos and DVD-like quality video clips - Unique 2-way slide concept with dedicated media keys - Support for compatible microSD memory cards of up to 2GB - Wireless LAN connectivity and HSDPA offering high download speeds - Integrated GPS, and access to maps for more than 100 countries - The option to purchase additional features such as city guides and voice-guided navigation TIPA was founded in 1991 as an independent, non-profit association of European photo and imaging magazines. At present, TIPA includes 31 member magazines from twelve countries. A full list of Nokia N95 features is available at www.nseries.com/n95 Related photos in print quality can be found at www.nokia.com/press >photos About Nokia Nseries Nokia Nseries is a range of high performance multimedia computers that delivers unparalleled mobile multimedia experiences by combining the latest technologies with stylish design and ease of use. With Nokia Nseries products, consumers can use a single device to enjoy entertainment, access information and to capture and share pictures and videos, on the go at any time. www.nseries.com About Nokia Nokia is a world leader in mobile communications, driving the growth and sustainability of the broader mobility industry. Nokia connects people to each other and the information that matters to them with easy-to-use and innovative products like mobile phones, devices and solutions for imaging, games, media and businesses. Nokia provides equipment, solutions and services for network operators and corporations. www.nokia.com Media Enquiries: Nokia Multimedia, Communications Tel. +358 7180 45667 Email: press.office@nokia.com www.nokia.com --- End of Message --- NOKIA P.O. Box 226<br>FIN-00045 NOKIA GROUP Espoo WKN: 870737; ISIN: FI0009000681; Index: DJ STOXX Large 200, DJ STOXX 50; Listed: Nordic list (Large Cap) in THE HELSINKI STOCK EXCHANGE;


 

AMERICAN MARKETS OUTLOOK: U.S. stock markets are expected to open little changed Tuesday, ahead of economic data that could push the Dow Jones Industrial Average to new highs. Geoff Langham at CMC Markets says Mondays weakness hasnt changed overall bullish sentiment. "The first potential support level on the Dow that traders are likely to be eyeing for signs of a bounce is the psychological 12,900 mark," Langham says. Data for release Tuesday include the Redbook retail sales index, the Richmond Federal Reserve manufacturing index, the Conference Board consumer confidence index and March existing home sales. "Todays earnings should provide a far better opportunity for Wall Street to gird up its loins (than Monday)," says David Buik at Cantor Index, with AT&T, DuPont, Lockheed Martin and Amazon.com among companies releasing results. Cantor Index is calling the Dow Jones Industrial Average to open down 13 points at 12,961, the Nasdaq 100 up 2.75 points at 1865.75 and the S&P 500 unchanged at 1488.50. EUROPEAN MARKETS: European shares are mostly lower. In London, the FTSE 100 is down 0.8% at 6426.70, extending losses after the Bank of England Monetary Policy Committee member Tim Besley said money supply growth is an upside risk to inflation. Inflation fears are having a knock-on effect on financial stocks. U.K. housing stocks including Hammerson and Persimmon are among the top fallers, outweighed only by Yell Group after a profit warning. In Frankfurt, the DAX is down 0.8% at 7279.64 as a sharply higher oil price weighs on the market, encouraging profit-taking. In Paris, the CAC is down 0.6% at 5881.97. Bunds are higher, boosted by losses in equity markets and strength in Treasurys. Gilts are holding on to early gains in technically-led trading. The June bund future is up 0.20 at 114.14, while the June gilt is up 0.11 at 107.20. In the currency market, the dollar is mixed to higher after disappointing Australian inflation data helped lift the yen in places as the Australian dollar headed south. The dollar is up at Y118.90, the euro is down at $1.3563 and the pound is down at $1.9996. =========================== TOP STORIES: BP 1Q NET PROFIT DOWN 17% ON LOWER OIL PRICES, OUTPUT: BP PLC (BP) posted a net profit down 17% for the first quarter, as lower oil prices and output offset higher refining margins. (By Benoit Faucon) KKR RAISES BOOTS OFFER TO 1139P AFTER STAKE BUY: Alliance Boots PLC (AB.LN) backed a revised cash offer of 1,139 pence a share from private equity group Kohlberg Kravis Roberts & Co. and Italian billionaire Stefano Pessina, leaving a rival consortium-led by U.K. financier Guy Hands out in the cold. (By Gren Manuel and Molly Dover) ALCATEL-LUCENT POSTS 1Q OPERATING LOSS, SHARES DOWN 3%: Franco-American telecommunications equipment maker Alcatel-Lucent (ALU) reported its second profit slump in as many quarters, as a weak performance in its wireless unit continued to impact the recently merged business. (By Geraldine Amiel and Daniel Thomas) DANONE 1Q SALES RISE 3.9% ON TOP BRANDS: French food and dairy company Groupe Danone (DA) said its first-quarter sales rose 3.9% to EUR3.67 billion from EUR3.53 billion a year earlier, as the Fresh Dairy divisions sales were boosted by blockbuster brands. (By Geraldine Amiel) ============================ INSIGHT & ANALYSIS FROM DOW JONES NEWSWIRES: =FOREX FOCUS: The dollar looks set to resume its weakening trend later in the week, with key U.S. economic data expected to put pressure on the currency and widely expected rate rises in the U.K. and the euro zone also weighing on the greenback. (By Ilona Billington) =CHARTING EUROPE: European equity indexes are in for at least a minor correction lower, having been capped by resistance levels these past couple of days. (By Axel Rudolph) =========================== STILL TO COME ET/GMT COUNTRY/PERIOD 0755/1255 US Apr 21 Redbook Retail Sales Index 0900/1400 US Apr Richmond Fed Mfg Index 0900/1400 US Apr Conference Board Consumer Confidence Index 0900/1400 US Mar Existing Home Sales 1030/1530 US Tsy Secy Paulson speaks with small- business owners and finance providers in Mexico 1600/2100 US Apr 13 ABC/Washington Post Consumer Confidence Index =========================== OTHER NEWS: The cementing of low inflation in the U.K. is an "ongoing challenge," but so far the Bank of England is managing to keep price increases under control, said Tim Besley, a member of the banks Monetary Policy Committee. (By Natasha Brereton and Paul Hannon) Euro-zone factory orders fell unexpectedly in February as French orders plummeted. (By Paul Hannon) Technology conglomerate OC Oerlikon Corp AG (OERL.VX) said first-quarter sales more than tripled, due to the acquisition of Saurer in the fall, and reiterated its full year guidance. (By Hans Schoemaker) Telecommunications operator TeliaSonera AB (TLSN.SK) said first-quarter net profit rose 7.7% as it recorded less non-recurring items for restructuring compared to a year ago. (By Magnus Hansson) U.K. leisure group Whitbread PLC (WTB.LN) posted a 25% rise in underlying full-year profit and pledged to return further cash to shareholders after reviewing its balance sheet. (By Michael Carolan) Akzo Nobel NV (AKZOY) reported a 1.2% drop in first-quarter net profit, but said the operating performance of all its units was strong and the sale of Organon BioSciences to Schering-Plough (SGP) is on track. (By Roberta B. Cowan) Aviva PLC (AV.LN), the U.K.s largest insurance group, said that total worldwide sales rose 18% in the first quarter, boosted by its acquisition of AmerUs in the U.S. (By Victoria Howley) Carphone Warehouse Group PLC (CPW.LN), the U.K. broadband and mobile phone provider, said it plans to attract 3.5 million broadband customers by March 2010, and unveiled U.S. retail expansion plans that will see it operating in up to 200 stores over the next 18 months. (By Daniel Thomas) Associated British Foods PLC (ABF.LN) posted a 5.1% rise in underlying first-half profit and said it expects further progress in the remainder of the year. (By Michael Carolan) Luxury goods maker Compagnie Financiere Richemont SA (CFR.VX) reported a 12% rise in full-year sales on strong demand for high-end watches. (By Martin Gelnar) Fortum (FUM1V.HE) reported a 3.8% increase in operating profit for the first quarter of 2007, as its hedging positions enabled it to offset lower Nordic spot electricity prices. (By Elizabeth Cowley) Shares in Yell Group PLC (YELL.LN), the U.K.-based directories publisher, plunged nearly 20% in early trading after the company sharply downgraded its organic growth forecasts for its U.S. unit. (By Jessica Hodgson) Pharmaceutical giant Elan Corp. PLC (ELN) posted a wider first-quarter net loss, but the number was skewed as it included retired debt and was set against substantial one-off gains in the first quarter of 2006. (By Quentin Fottrell) U.K. Chancellor of the Exchequer Gordon Brown has met most of his public finance targets for fiscal year 2006-7, despite worse-than-expected borrowing figures in March. (By Andrew Peaple)


 

The Annual General Meeting of Thin Film Electronics ASA will be held on Wednesday 9 May 2007 at 17:15 at Vika Atrium Conference Center, Munkedamsveien 45 in Oslo. The full notice is enclosed in pdf file. 24 April 2007 Thin Film Electronics ASA


 

KONE Corporation, Press Release, 24 April, 2007 KONE has signed its largest ever single contract for cruise ships. The contract was signed with Aker Yards for the supply of all elevators and escalators in two luxury 4,200 passenger cruise ships to be built for Norwegian Cruise Line. The ships will be built at the Aker Yards' shipyard in Saint Nazaire, France. The two ships will be delivered in 2009 and 2010 respectively. The contract also includes an option for delivery to additional identical ships. KONE will design, supply and install altogether 60 custom designed elevators and 12 escalators tailored for passenger and service use. The value of the contract is approximately EUR 15 million. "We are very pleased to work alongside Aker Yards once again. This is an excellent example that a first-rate product offering and good customer service continuously increases customer loyalty," says Heikki Leppänen, EVP, New Elevators and Escalators, KONE. "With this collaboration, KONE carries-on its long-term commitment to the marine industry and strengthens its market leader position as the elevator and escalator provider for the cruise ship segment." Norwegian Cruise Line is one of three major global cruise vacation companies, and the new series of ships will continue NCL's tradition of "Free-style Cruising". The new ships will be of 150,000 gross tons Post-Panama size, 325 meters long and 40 meters wide, each accommodating approximately 4,200 passengers. Sender: KONE Corporation Heikki Leppänen Executive Vice President, New Elevators and Escalators Minna Mars Senior Vice President, Corporate Communications & IR For further information, please contact: Minna Mars, SVP, Corporate Communications & IR, tel. +358 (0)50 384 9440 or +358 (0)204 75 4501 KONE is one of the world's leading elevator and escalator companies. It provides its customers with industry-leading elevators and escalators, with innovative solutions for their maintenance and modernization. KONE also provides maintenance of automatic building doors. In 2006, KONE had annual net sales of EUR 3.6 billion and approximately 29,000 employees. Its class B shares are listed on the Helsinki Stock Exchange in Finland. www.kone.com


 

Omniture Genesis, Discover 2, and TouchClarity Introduced at European Customer Summits Held in London, Paris, Munich and Copenhagen LONDON -- (MARKET WIRE) -- April 24, 2007 -- Omniture, Inc. (NASDAQ: OMTR), a leading provider of online business optimisation software, today announced the European launch of three products specifically designed to address the needs of marketers who are looking to better connect with customers and increase business success online: Online businesses can now optimise the performance of their Web site, by combining Web analytics and behavioural targeting; and integrating both with all their other online marketing applications (such as CRM, search and affiliate marketing). At a summit in London today, Omniture unveils three new products available in the UK, to help companies make their online operations profitable. The first of these, Omniture Genesis, is a groundbreaking application that integrates multiple online marketing systems to provide a complete view of a business's online marketing efforts. Omniture Genesis launches with over 30 partners on board, including Salesforce.com, Google, Responsys, Advertising.com, Mercado, DoubleClick, and YourAmigo, among others. This means that customers already using these applications can easily integrate them with Omniture's Web analytics platform, SiteCatalyst®, with just a simple drag and drop. It has been run in early 2007 by existing Omniture customers and is now fully available in the UK. Omniture is also launching Omniture TouchClarity, a behavioural targeting offering following the company's acquisition last month of TouchClarity. In a recent survey with marketing executives, Forrester Research ranked on-site behavioural targeting as the number one area of planned marketing technology investment for 2007. Omniture TouchClarity technology combines the most sophisticated advancements in real-time predictive modeling, data mining and machine learning via the on-demand, software-as-a-service model to deliver automatically the most relevant content and marketing offers to site visitors based on behaviour. The recently acquired TouchClarity technology expands the Omniture Online Business Optimisation Platform -- making the company the first to combine Web analytics and behavioural targeting to deliver automated revenue and profit uplift for customers. Finally, the company is announcing the launch of Omniture Discover 2, which allows customers to access, segment and sort customer data, looking at it from any angle. A key obstacle facing companies today is their inability to measure, segment and analyse customer data fast enough to take advantage of new market opportunities. Omniture Discover 2 provides direct access to granular data from any angle and at any level using business visualisations -- allowing companies to uncover new business opportunities, devise new customer acquisition strategies and drive more revenue from online marketing campaigns. Discover 2 is an integral component of the Omniture Online Business Optimisation platform and operates on a single data set with Omniture SiteCatalyst Web analytics, providing the industry's most complete, real-time analytics solution. The solution empowers all levels of business users -- from executives using dashboards to managers using operational reports to analysts performing free-form data exploration and segmentation -- to have an integrated view of data so they can make more accurate, timely and insightful decisions. Omniture's SVP and general manager EMEA, Neil Weston, believes that the future of Web analytics lies not so much in simply analysing data, but in using that data to inform all aspects of a company's online business, in order to make that business more profitable. "Omniture is driving the trend towards what we call online business optimisation," says Weston. "Our customers rely on us to help them be successful online. We do this by continuing to innovate and drive the market forward." About Omniture Omniture, Inc. is a leading provider of online business optimisation software, enabling customers to manage and enhance online, offline and multi-channel business initiatives. Omniture's software, which it hosts and delivers to its customers as an on-demand subscription service, enables customers to capture, store and analyse information generated by their Web sites and other sources and to gain critical business insights into the performance and efficiency of marketing and sales initiatives and other business processes. In addition, Omniture offers a range of professional services that complement its online services, including implementation, best practices, consulting, customer support and user training through Omniture University(TM). Omniture's more than 2,000 customers include ABN Amro, AOL, Center Parcs, eBay, Thomas Cook, Vodafone Group Services Limited, Waitrose and Yell.com. www.omniture.com. Note on Forward-Looking Statements Management believes that certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, including, but not limited to, statements regarding the anticipated benefits of our technology and services to our customer. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, with our ability to ensure that our solutions address the specific requirements of our customers, the continued adoption by customers of our services, the significant capital requirements of our business model, our ability to develop or acquire new services and enhance existing service offerings, errors, defects, disruptions or other performance problems with our services, our ability to hire, retain and motivate our employees, our ability to collect customer data, the adoption of laws or regulations relating to the Internet or our operations, or interpretations of existing law, which could adversely affect our business; and such other risks described in Omniture's annual report on Form 10-K for the year ended December 31, 2006 and from time to time in other reports filed by Omniture with the U.S. Securities Exchange Commission. These reports are available on the Investor Relations section of our website at http://www.omtr.com. Omniture undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations. Omniture Press Contacts Kate Hartley Malini Majithia Carrot Communications 020 7386 4860 Malini.majithia@carrotcomms.co.uk


 

Qualitative, forward-looking fund analysis identifies high standards of management and performance consistency Fortis Private Banking today announced it has signed an agreement to supply clients with market-leading qualitative fund research from Standard & Poor's Fund Services, the largest provider of fund research, analysis and ratings in Europe. This is the latest in a series of initiatives by Fortis that has seen it partner with external, specialist providers to harness the best products for its clients. It follows an agreement struck in September 2006 by Fortis Private Banking to provide clients with award-winning equity research on more than 500 global large-cap stocks from Standard & Poor's Equity Research. Under the new agreement, Fortis Private Banking clients will also gain access to detailed research on more than 2,200 mutual funds currently monitored by Standard & Poor's Fund Services across the equity, fixed income and alternative asset classes. Pim Mol, member of the Global Management Board of Fortis Private Banking comments : "Fortis Private Banking has expanded its 'best brains' concept, so we can concentrate even more on what we are best at: asset allocation, portfolio construction and product development, thereby bringing greater value to our clients. At the same time we have enlarged our offering in funds. Clients have a much broader choice as we now have a truly global scope, covering all regions and all market segments. We hope that by providing access to independent, qualitative-based research, clients and their advisors will be able to make more informed decisions about fund selection beyond what is achievable by reviewing historical risk and return figures alone. Thanks to our stringent selection process our clients know that they can choose from the best performing funds." Aidan O'Mahony, Head of Standard & Poor's Fund Services, said: "Past performance and a well-known fund name cannot be relied upon to form the basis for fund selection. The research carried out by Standard & Poor's Fund Services is used as a selection tool by many of the world's leading institutional and private client advisers and there are powerful reasons why: only the top 20% of funds within each sector are eligible for consideration, so investors and their advisers have the confidence that they are selecting quality funds that best meet their requirements." Press Office contacts: Fortis Press Office Brussels +32 (0) 2 565 35 84 Utrecht +31 (0)30 226 32 19 Matthew McAdam, S&P Communications, Tel. +44 (0) 207 176 3605 Matthew_McAdam@standardandpoors.com About Fortis Fortis is an international financial services provider engaged in banking and insurance. We offer our personal, business and institutional customers a comprehensive package of products and services through our own channels, in collaboration with intermediaries and through other distribution partners. With a market capitalisation of EUR 44.6 billion (31/03/2007), Fortis ranks among the twenty largest financial institutions in Europe. Our sound solvency position, our presence in 50 countries and our dedicated, professional workforce of 60,000 enable us to combine global strength with local flexibility and provide our clients with optimum support. More information is available on www.fortis.com About Standard & Poor's Standard & Poor's, a division of The McGraw-Hill Companies (NYSE:MHP), is the world's foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 7,500 employees, including wholly owned affiliates, located in 21 countries. Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.


 

Wärtsilä Corporation FINANCIAL CALENDAR 24.4.2007 at 11.10 am Wärtsilä Corporation will publish its Interim Report for the period January-March 2007 on Friday 4 May 2007 at 8.30 am Finnish time. The interim report will be available on the company website at www.wartsila.com after publishing. An analyst and press conference will be held on Friday 4 May 2007 starting at 10.45 a.m. Finnish time (8.45 am UK time) at the Wärtsilä headquarters in Helsinki, Finland. The combined web- and teleconference can be viewed on the Internet at the following address: http://194.100.179.98:80/wip/directlink.do?newbrowser=1&pid=1437901. To participate in the teleconference and have the possibility to ask questions, please call: +358 9 8248 6348 and enter the PIN-code 2160. To only listen to the teleconference call the same number and enter PIN-code 390911. An on-demand version of the conference will be available on the company website later the same day. www.wartsila.com


 

Oslo, Norway, April 24th 2007 Photocure ASA will present its results for 1st quarter 2007 at Shipping klubben, Haakon VIIs gate 1 (top floor), Oslo, Norway on Wednesday 25th of April 2007. The presentation will begin at 17:00h and and representatives from the company will be Kjetil Hestdal, President & CEO and Christian Fekete, CFO. Annual General meeting will begin at 18:00h Please register your attendance at Photocure ASA by Wednesday 25th of April at 15:00 h. Contact person: Ms. Grete Faye-Schjøll (mailto: gfs@photocure.no phone +47 22 06 22 10 or fax +47 22 06 22 18).


 

STOCKHOLM (Dow Jones)--Norwegian Air Shuttle Tuesday announces that they will acquire Finnairs Swedish subsidiary FlyNordic. The company said the acquisition will strengthen its position in the Nordic region as well as in the European market. Stockholm will as a consequence be its new base for its operations from Sweden. Norwegian Air Shuttle carried 5.1 million passengers in 2006 while FlyNordic carried 1.2 million. "Through this co-operation we will further strengthen our position in the traffic between Scandinavia and Asia" said Finnair President and CEO Jukka Hienonen. Finnair and Norwegian Air Shuttle have signed a memorandum of understanding regarding the sale of Finnairs subsidiary FlyNordic to Norwegian Air Shuttle within the second quarter of this year. The transaction is subject to regulatory clearance. As consideration Finnair will receive ordinary shares and stock options in Norwegian Air Shuttle. As a consequence of the agreed transaction structure Finnairs ownership in Norwegian Air Shuttle will initially exceed 5%. If Finnair decides to exercise all stock options, Finnairs share in Norwegian Air shuttle may increase to approximately 10% (based on current number of shares). The stock options can be exercised until the end of 2008 at an average strike price of NOK 115. Finnair and Norwegian Air Shuttle have also agreed to start a strong co-operation. Norwegian Air Shuttles Scandinavian network will be linked to Finnairs increasing Asian connections. This will, for instance, support the demand in Asia for travel to Scandinavia and central Europe. FlyNordic will remain as a brand and it will strengthen and develop its position in Sweden. The company said it will continue to have focus on low fares for both the business and the leisure market. In addition it will further develop its IT solutions with focus on the website, direct to gate and automated check-in and will also continue to focus on high efficiency in its operation. (END) Dow Jones Newswires


 

DJIA 12919.40 -42.58 -0.33% Nasdaq 2523.67 -2.72 -0.11% S&P 500 1480.93 -3.42 -0.23% FTSE 100 6479.70 -7.10 -0.11% Xetra DAX 7335.62 -6.92 -0.09% CAC40 5917.32 -21.58 -0.36% Above are closing prices Nikkei 225 17467.11 +11.74 +0.10% Hang Seng 20611.77 +55.20 +0.30% S&P/ASX 200 6174.50 -17.70 -0.30% Taiwan Index 8040.33 +29.87 +0.40% S.Korea Kospi 1549.64 +5.29 +0.30% Dow Future 12986.00 +12.00 +0.10% NASDAQ Future 1867.75 +4.75 +0.30% S&P Future 1489.25 +1.00 +0.10% Above are as of 0450 GMT USD/JPY 118.54-57 -0.08% Range 118.66 - 118.25 EUR/USD 1.3567-70 -0.06% Range 1.3584 - 1.3549 AUD/USD 0.8256-60 -0.79% Range 0.8339 - 0.8241 GBP/USD 1.9980-85 -0.08% Range 2.0013 - 1.9957 USD/CHF 1.2090-93 -0.06% Range 1.2098 - 1.2089 Above are as of 0450 GMT vs NY close USD/JPY Vol Option Contract 7.60%/7.90% EUR/USD Vol Option Contract 5.80%/6.20% AUD/USD Vol Option Contract 8.60%/8.75% GBP/USD Vol Option Contract 6.00%/6.20% USD/CHF Vol Option Contract 6.54%/6.76% Above are 1-Mo prices as of 0440 GMT 2Y Tsy 99 24/32 +1/32 4.63% -1.7 5Y Tsy 99 26/32 +4/32 4.54% -2.7 10Y Tsy 99 26/32 +6/32 4.65% -2.4 10Y JGB 1.6650% -0.0150 Closing Treasury prices vs prior NY close; JGB as of 0400 GMT Asian Spot Gold $687.35 -$2.35 -0.3% Comex Gold $691.20 -$3.00 -0.4% Brent Crude Oil $67.94 -$0.21 -0.3% Above are as of 0400 GMT vs NY close EUROPEAN OUTLOOK & US/ASIAN SUMMARIES: European stock markets are set to pause to consolidate before the next runup, while government bonds are poised for a mixed opening. The euro is lower, while gold and oil also are giving back some of their recent gains. STOCKS: European shares are tipped to open slightly lower on Tuesday, after hovering near six-and-a-half-year highs on Monday. Investors now are in the mood for a consolidation, pending more earnings reports, although Texas Instruments rally overnight might inspire tech buyers. UK spreadbettors Cantor Index are calling the FTSE down 8 at 6471, the DAX off 27 at 7308, the CAC dow 17 at 5900, and Eurostoxx 10 lower at 4310. "The markets are listless and looking for direction. We had a great week last week with markets hitting new highs and markets are taking a bit of a breather ahead of a big week for earnings," said Mike Lenhoff at Brewin Dolphin Securities. Lenhoff noted the fundamental picture for earnings is still very good and said theres every reason to think that markets will continue to do well. By the end of the week, around 60% of companies in the S&P 500 index will have reported earnings, while around 150 top European companies are due to report over the next two weeks. Wall Street stocks, whose futures are higher Tuesday, retreated from historically lofty levels Monday as rising oil prices chilled investor enthusiasm for strong earnings reports and new takeover activity. The Dow Jones industrials came within 17 points of 13,000 before Although the Dow passed 12,000 only last October, there appeared to be little of the kind of frenzy that drove the markets major indexes to record after record during the dot-com boom. "Anytime you approach a new milestone - especially 13,000, which is a psychological barrier - its not going to happen overnight. Its going to take some time," said Peter Cardillo, chief market economist at New York-based brokerage house Avalon Partners Inc. "The market has gone up on earnings, and the earnings story has already been factored in .... There are a lot of negative things out there that the market has been ignoring." Later this week, investors will see results from six more of the Dow component companies, as well as data on the housing market, durable goods, gross domestic product and consumer confidence. "We still have quite a bit of earnings news this week. Generally, thats going to be positive. As long as the economic data falls in line, we should still continue to push prices higher," said Jack Ablin, chief investment officer at Harris Private Bank. In late trading Monday, Texas Instruments Inc. shares jumped 10% after its sales forecast came in above analysts expectations, while shares of Amgen Inc. (AMGN) rose after the biotech giants quarterly earnings met Wall Streets estimate. In Japan, futures-led buying brought the Nikkei back into the plus column toward the close, with oil and miners leading the charge. But overall, investors remained reluctant to commit large amounts before upcoming earnings releases. In Australia, shares at first rallied on sharply slower inflation in the first quarter. The CPI rose just 0.1% on quarter, and 2.4% year to year. The news prompted hopes the central bank would avoid raising rates again. But later, the market backed off its session highs. Australian Treasurer Peter Costello Tuesday said the latest consumer price index data showed underlying inflation was within the Reserve Banks target band. FOREX: The euro is retreating against the dollar and yen, after traders decided to take profit off recent highs. Dealers put support at around $1.3540-50, a level defended only by small amounts of buy orders. According to some analysts, the dollar is due for a recovery after sinking to near record-level lows against the euro last week, thanks in part to an easing of central bank reserve diversification flows. But the U.S. economys slowdown could short-circuit a dollar rebound. "The array of U.S. data this week could further weigh on the U.S. dollar," Ashraf Laidi, chief currency analyst at CMC Markets, said, pointing specifically to the existing home sales report due Tuesday and Wednesdays new home sales data. BONDS: European government bond prices may open mixed Tuesday, with technicals pointing to tests of supports, amid hawkish ECB talk and lower stocks. "Outside of the U.S. Treasury market impact, price action this week in Europe will be dependent on the German Ifo Wednesday, German State CPIs and the euro," said Jason Simpson, a strategist at ABN AMRO. Risks to euro-zone price stability remain upward, European Central Bank Vice-President Lucas Papademos said Monday. He also reiterated the ECBs view that monetary policy remains "on the accommodative side," with interest rates that are "moderate." Money and credit growth remain vigorous, while euro-zone liquidity is abundant, he said. "Consequently, firm and timely action is warranted to ensure price stability over the medium term," he added. "The markets are running with the euro story, but that looks quite dangerous," said Simon Penn, a market analyst at UBS, given recent ECB members hawkish comments on the need for vigilance against inflation threats. Penn added, "If ECB President (Jean-Claude) Trichet plays down the benefit of the stronger euro at the next press conference, it leaves fixed income facing a correction." U.S. Treasury prices, trading slightly higher Tuesday in Asia, gained Monday as investors bet on weak U.S. economic data this week. Market participants are focusing on Tuesdays data on March existing-home sales and April consumer confidence figures - both of which are expected to be softer than previous figures - as well as the weeks most eagerly anticipated economic figure, the first-quarter advance gross domestic product report set for Friday. Expectations are for GDP to have gained 1.8% compared with the previous quarters expansion of 2.5%. "People are setting up for some weak data," said Carl Lantz, fixed income strategist at Credit Suisse. Lantz said the 10-year note could potentially drop to a 4.60% yield if the data do indeed come in soft. In Japan, investors switched to government bonds with stocks lower. Dealers had little worry that the sessions 20-year bond auction would draw sufficient interest to support the overall JGB market. ENERGY: Oil prices dropped slightly in Asia Tuesday, with sluggish trade weighed down by a lack of clear direction. June Nymex crude lost 19 cents to $65.70 a barrel. That followed Mondays jump of $1.78 to settle at $65.89 a barrel. "Traders are hesitant to buy crude after such a jump yesterday, as nobody knows whether the rise will continue today. But it is also difficult to sell, given the tight supply of oil products in the U.S. and Europe" due to seasonal refinery maintenance, said Ken Hasegawa of Tokyo brokerage Himawari CX. Traders were turning to the weekly U.S. petroleum inventory data due Wednesday for price direction, and to see if more refineries have come back on line ahead of the summer driving season, when gasoline demand peaks. The report is expected to show that crude oil inventories fell by 1.2 million barrels on average, according to a Dow Jones Newswires survey of analysts estimates. METALS: Spot gold was down $2.35 at $687.35, with the elusive $700 mark slipping away as the market continues its consolidation. LME 3-month copper was at $7,990/ton, down $19 from the PM kerb, while the market consolidated without any plain near-term direction. CALENDAR: Tuesday, April 24, 2007 GMT Expected Previous 0130 JPN 20-yr Govt Bond Auction 0730 ITA Apr Consumer Confidence Survey 0800 ITA Feb Retail Sales +0.3%MM -0.4%MM +0.7%YY 0.0%YY 0830 UK Mar Public Sector Net Borrowing +GBP7.0B +GBP1.9B 0830 UK Mar Public Sector Net Credit Requirement +EUR16.0B +EUR1.0B 0830 UK Apr BoE Monetary Policy Committee at Tsy Committee 0900 EU Feb Indus New Orders +1.2%MM -0.2%MM +8.5%YY +12.0%YY 0915 EU ECB allotment of main refi tender 0930 ITA 6-month T-Bill Auction 0930 ITA 24-month Zero Coupon Bonds Auction 1145 US Apr 21 ICSC-UBS Chain Store Sales -0.6% 1255 US Apr 21 Redbook Retail Sales Index -4.0% 1300 CAN Bank of Canadas rate decision 4.25% 4.25% 1300 EU Mar EuroCOIN indicator of euro-area economic activity 1330 UK Apr Quarterly Indus Trends Survey 1400 US Apr Richmond Fed Mfg Index -10 1400 US Apr Conference Board Consumer Confidence 105.0 107.2 Index 1400 US Mar Existing Home Sales -4.0% +3.9% 1530 US Tsy Secy Paulson speaks with small- business owners and finance providers in Mexico 2100 US Apr 13 ABC/Washington Post Consumer Confidence -5 Index 2350 JPN Mar Provisional Trade Statistics N/A UK Russian Economic Forum N/A GER German Chancellor Merkel meets UK PM Blair N/A UK Mar Producer Prices AB Foods (ABF.LN): 1H Earnings Average pretax pre-exceptional profit (DJ, four analysts): GBP266.5M (GBP255M) Note: Strong profit growth is expected at the Primark retail chain, while in sugar, a strong international performance will offset weak UK results. Analysts are looking for indications that organic sales at Primark are returning to growth. Any update on plans for Primark in Spain is also sought. Autonomy (AU.LN): 1Q Revenue Average revenue (Co, 13 analysts): $65M ($56.1M) Average pretax profit: $18M ($10.3M) Average adjusted EPS: $0.062 ($0.04)B) Note: Expected to report 1Q revenues up based on organic growth and acquisitions in the enterprise software market. Aviva (AV.LN): 1Q New Business Average EEV life and pensions new business sales (Co, 16 analysts): GBP7.52B PVNBP (GBP6.78B) Note: Reporting a rise in 1Q 07 EEV life and pensions new business sales reflecting the first time AmerUS has been incorporated in the numbers. Consensus is the average of 16 analyst estimates provided by the company. EEV new business contribution seen +11% at GBP261M from GBP235M. An analyst says that UK sales are likely to be stable, and that France will be an important bellwether for the group. Banco BPI SGPS (BPI.LB): 1Q Earnings Average net profit (DJ, 3 analysts): EUR77.2M (EUR74.2M) Average net interest income: EUR149.72M (EUR140.5M) Note: Expected after market close, to report a rise in net profit for the first quarter from a year earlier. Analysts say expansion costs are largely offset by lending growth, especially in Angola, where the bank recently started operating. Focus will be on any updates on EUR4.3B bid from Banco Comercial Portugues (BCP.LB), which runs until May 4. Banco Comercial Portugues (BCP.LB): 1Q Earnings Average net profit (DJ, 3 analysts): EUR187.4M (EUR165.6M) Average net interest income: EUR368M (EUR351.2M) Note: Expected after the market closes to report a rise in first quarter net profit from a year earlier. Analysts expect corporate portfolio to offset growing competition in the mortgage segment. Focus will be on any updates on the EUR4.3B bid for Banco BPI SGPS (BPI.LB), which runs until May 4. BP (BP): 1Q Earnings Average underlying profit (DJ, 4 analysts): $4B ($5.28B) Note: Profits will be lower because a year-on-year fall in oil prices will more than offset higher refining margins. The underlying profit strips out the impact of inventory gains and losses from the bottom line. Casino Guichard Perrachon et Cie (12558.FR): 1Q Revenue Average revenue (DJ, 5 analysts): EUR5.48B (EUR5.94B) Note: Result will be weighed down by the absence of sales from disposed assets in Taiwan, Poland and the US. Analysts will be looking closely at reissued figures that account for the contribution of disposed assets, and the companys French discount format Leader Price. Danone (DA): 1Q Revenue Average revenue (DJ, 6 analysts): EUR3.67B (EUR3.53B) Note: Analysts also see Danones 1Q organic growth at 9.3%. JP Morgan says Danone "could surprise again on the upside." Investors expect some comments on issues with Chinese partner Wahaha and potential consequences on the companys outlook for the full year. Elan (ELN): 1Q Earnings Average diluted loss per share (DJ, 5 analysts): $0.13 ($0.16) Average revenue: $175M (N/A) Note: Goodbody Stockbrokers sees $46.7M in global 1Q sales of MS drug Tysabri, of which $28.7M will be recorded as revenue by Elan under its agreement with its JV partner Biogen Idec (BIIB). Fortum Oyj (FUM1V.HE): 1Q Earnings Average operating profit (DJ, 5 analysts): EUR505M (EUR472M) Average EBITDA: EUR659M (EUR570M) Average EPS: EUR0.52 (EUR0.39) Note: The rise is pinned on higher realized electricity prices. Focus is expected on the companys electricity price hedging ratio for 08, which is the primary share price driver, and any comment on the Russian operating environment, analysts say. Kone (KNEBV.HE): 1Q Earnings Average underlying pretax profit (DJ, 3 analysts): EUR72M (EUR51M) Average underlying EBIT: EUR73.3M (EUR52M) Average sales: EUR813M (EUR735M) Note: Underlying EBIT is seen up helped by higher volumes. Lukoil (LKOH.RS): 4Q Earnings Average net profit (DJ, 6 analysts): $1.39B ($1.64B) Average EBITDA: $2.43B (N/A) Average revenue: $16.30B (N/A) Note: Expected to post a fall in net profit for the fourth quarter of 06, due to lower crude oil prices and higher export tariffs. "Due to the double negative effect of falling prices and rising duties, cost dynamics will mainly define financial performance," say Nadia Kazakova and Andrey Gromadin of MDM Bank. Luxottica (LUX): 1Q Earnings Average net profit (DJ, 4 analysts): EUR123.4M (EUR103.2M) Note: The companys expected to report continued strong demand for the luxury eyewear it makes for the likes of Chanel, Prada and Versace. But analysts will also be looking for comment on how Luxotticas coping with the weakness of the dollar given that the company has significant retail operations in the US and books nearly a quarter of its wholesale revenue there. Numbers due sometime after 1000 GMT. Michelin (12126.FR): 1Q Revenue Average revenue (Co, 13 analysts): EUR4.12B (EUR3.98B) Note: Analysts are looking for guidance on raw material costs, price increases, earnings outlook and possible comments on cost reduction program. Company reports at 1540 GMT Tuesday. Millicom (MICC): 1Q Earnings Average pretax profit (DJ, 4 analysts): $107M ($62M) Average revenue: $589M ($322M) Note: Revenues are seen rising as subscriber growth continues and a recent acquisition in Colombia is integrated. Year ago figures include Pakistani operations that have now been sold. Focus will be on progress with restructuring in Colombia and growth in African business. Modern Times Group (MTG-B.SK): 1Q Earnings Average pretax profit (DJ, 4 analysts): SEK508M (SEK440M) Average EBIT: SEK506M (SEK453M) Average sales: SEK2.71B (SEK2.38B) Note: The rise is seen driven largely by higher earnings at Russian CTC Media in which MTG has a 40% stake. Sales are seen rising by 14%, whilst EBIT is seen +12%. Focus will be on the performance of the companys Scandinavian free-to-air operations which performed below expectations in the fourth quarter. Oerlikon (OERL.VX): 1Q Revenue Average sales (DJ, 3 analysts): CHF1.25B (CHF376M) Note: Expected to post a substantial increase in first quarter sales, driven by the acquisition of Saurer in the fall of 06. Orders seen at CHF1.25B from CHF495M. Focus will be on guidance, and impact of the postponed Solar order. OMX (OMX.SK): 1Q Earnings Average net profit (DJ, 3 analysts): SEK252M (SEK243M) Average sales: SEK1.01B (SEK903M) Average costs: SEK669M (SEK580M) Note: Net profit seen up on stronger earnings generation but weighed down by higher costs. Eyes on any news about consolidation of the stock exchanges in Europe and on results in technology sector. Outokumpu (OUT1V.HE): 1Q Earnings Average net profit (DJ, 4 analysts): EUR275M (EUR56M) Average operating profit: EUR386M (EUR67M) Average revenue: EUR2.14B (EUR1.41B) Note: Expected to report more than a tripling in 1Q net profit boosted by strong steel prices. Eyes will be on any comments on the future price of stainless steel. Richemont (CFR.VX): FY Revenue Average sales (DJ, 5 analysts): EUR4.84B (EUR4.31B) Note: Strong growth expected across all divisions, with its luxury watch, writing instrument and jewellery businesses seen as the key drivers. Sales at Chloe also expected to have risen sharply. Geographically, Asia - with the exception of Japan - and the US are expected to have been particularly strong, while growth in Europe also expected to have been healthy. Sales likely to have been tempered by negative currency impact Saab (SAAB-B.SK): 1Q Earnings Average net profit (DJ, 3 analysts): SEK297.7M (SEK423M) Average EBIT: SEK441 (SEK533) Average revenue: SEK4.89B (SEK4.31B) Note: Expected to report a drop in 1Q net profit on the back of a one-time gain. Revenue is seen rising due to strong order intake. Eyes are on whether Saab will be able to maintain strong order growth going forward, including more small and medium size contracts. STMicroelectronics (STM): 1Q Revenue Average revenue (DJ, 8 analysts): $2.305B ($2.364B) Average EBIT: $109M ($140M) Note: 1Q EBIT is expected down as strong euro and low utilization levels have put pressure on margins. Deutsche Bank says any positive announcements on the future of the companys struggling Flash memory unit are already "factored in STM shares." Dresdner Kleinwort expects "those looking for evidence of a turnaround at STM to be disappointed." TeliaSonera (TLSN.SK): 1Q Earnings Average pretax profit (DJ, 4 analysts): SEK5.794B (SEK5.542B) Average revenue: SEK22.55B (SEK21.979B) Note: Focus will be on fixed-line business where revenue is falling rapidly, and investors will also be watching to see if recovery in Finland continues. Valeo (13033.FR): 1Q Earnings Average net profit (DJ, 5 analysts): EUR20.6M (EUR23M) Average operating profit: EUR58.6M (N/A) Average revenue: EUR2.61B (EUR2.70B) Note: Reporting a drop in 1Q net profit from in the first three months of 06, reflecting weak car production and pricing pressure. Revenue expected up giving an operating margin of 2.2%, unchanged from the year before. Analysts will be looking for comments on outlook for companys ownership as investment funds circle. Company reports after-market on April 24. CEO to comment on 1Q figures at a press conference pre-market April 25. Verbund (VER.VI): 1Q Earnings Average net profit (DJ, 4 analysts): EUR175.5M (EUR138.2M) Average EBIT: EUR239.2M (EUR213.9M) Average sales: EUR801.2M (EUR876.3M) Note: Earnings were helped by a hike hydropower production and higher front-year futures prices, while spot prices declined in 1Q, analysts say. Sales are seen down 8.6%, but comparison is distorted by the 2006 deconsolidation of subsidies for eco-electricity, which were almost EUR100M in 1Q 2005, but didnt affect earnings. An Erste Bank analyst sees wholesale prices increase and expects record 07 results. Says EBIT margin and ROE are way above peer average. Says the shares have upside potential of at least 20%. Whitbread (WTB.LN): FY Earnings Average pretax pre-execptional profit (DJ,3 analysts): GBP206.5M (GBP181.1M) Note: Revenue growth at Premier Travel Inn and Costa Coffee are seen as the main growth drivers. Analysts are looking for an update on the plans for David Lloyd Leisure, which may be sold, and any balance sheet restructuring or REIT conversions. OTHER SCHEDULED EVENTS: Acta Holding (ACTA.OS): Q1 Earnings Aedes (AE.MI): AGM AGFA (AGFB.BT): AGM Akzo Nobel (00913.AE): Q1 Earnings Alleanza Assicurazioni (AL.MI): AGM Amplifon (AMP.MI): AGM Anima SGR (ANM.MI): AGM APL (APL.OS): Q1 Earnings Arnoldo Mondadori Editore (MN.MI): AGM Arte (FMR.MI): AGM Assicurazioni Generali (G.MI): AGM & EGM Associated British Foods (ABF.LN): 1H Earnings ATOSS Software (AOF.XE): Q1 Earnings Autogrill (AGL.MI): AGM Azimut Holding (AZM.MI): AGM Baltika (BLT1T.ET): Q1 Earnings Banca Generali (BGN.MI): AGM Banco BPI (BPI.LB): Q1 Earnings Banco Comercial Portugues (BCP.LB): Q1 Earnings Bank Coop (BC.EB): AGM Banque Cantonale de Geneve (BCGE.EB): AGM Belships Co (BEL.OS): Q1 Earnings & AGM Benfield Group (BFD.LN): AGM Berkeley Group (BKG.LN): EGM BHP Billiton (BLT.LN): Trading Update Biofarm (BIO.RO): AGM & EGM BioGaia (BIOG-B.SK): Q1 Earnings & AGM Boiron (6112.FR): Q1 Revenue Boras Wafveri (WAFV-B.SK): Q1 Earnings & AGM Bradford & Bingley (BB.LN): AGM Brit Insurance Holdings (BRE.LN): AGM Bucher Industries (BUCN.EB): Q1 Revenue Bulgari (BUL.MI): AGM Campari (CPR.MI): AGM Carnegie & Co (CAR.SK): Q1 Earnings Carpetright (CPR.LN): FY Trading Update Carphone Warehouse (CPW.LN): Trading Update Casino (CASI.MP): Q1 Revenue Character Group (CCT.LN): 1H Earnings Cloetta Fazer (CFA-B.SK): Q1 Earnings & AGM Comdirect Bank (COM.XE): Q1 Earnings Componenta (CTH1V.HE): Q1 Earnings Computer Service Support (CSS.WA): Q1 Earnings Continental (CON.XE): AGM Conzzeta Holding (CZH.EB): AGM Cross Systems Company (416167.FR): FY Earnings Cybergun (CYB.FR): Q4 Revenue Dada (DA.MI): AGM Daetwyler Holding (DAE.EB): AGM DanTruck-Heden (DANTR.KO): AGM Danware (DANW.KO): AGM Datamonitor (DTM.LN): AGM DnB NOR Bank (10017.LH): AGM Effnet Holding (EFFN.SK): Q1 Earnings & AGM Egide (GID.FR): FY Earnings Egide (GID.FR): Q1 Revenue Elisa (ELI1V.HE): Q1 Earnings Exendis (EXNDS.AE): AGM Fagerhult (FAG.SK): Q1 Earnings Faiveley (LEY.FR): FY Revenue Fleury Michon (7475.FR): FY Earnings Fleury Michon (7475.FR): Q1 Revenue Formjet (FMJ.LN): FY Earnings F-Secure Corp (FSC1V.HE): Q1 Earnings FullSIX (FUL.MI): AGM Game Group (GMG.LN): FY Earnings Geodis (3828.FR): Q1 Revenue GoYellow Media (VRI.XE): Q1 Earnings Groupe Bruxelles Lambert (GBLB.BT): AGM & EGM Groupe Crit (CEN.FR): FY Earnings Groupe Gascogne (BI.FR): Q1 Revenue H Lundbeck (LUN.KO): AGM Hagemeyer (35547.AE): AGM Hanson (HNS.LN): AGM Hi Media (HYNS.LN): Q1 Revenue High Co (HCO.FR): Q1 Revenue Home Properties (HOPR.SK): Q1 Earnings Implenia (IMPN.EB): AGM Inbev (INB.BT): AGM Industrial and Financial (IIC.KW): Q1 Earnings ING Group (30360.FR): AGM Ingenico (IGO.YY): Q1 Revenue Inmobiliaria Urbis (GPA.LB): AGM & EGM Intrum Justitia (IJ.SK): Q1 Earnings IP Group (IPO.LN): AGM ITS Seevia Group (7384.FR): Q1 Revenue IVF Hartmann (VBSN.EB): AGM JPMorgan Fleming US Discovery (JPU.LN): AGM Jyske Bank (JYSK.KO): Q1 Earnings Karolin Machine Tool (KMT.SK): Q1 Earnings Klemurs (KMU.FR): Q1 Revenue La Gaiana (GAI.MI): Q1 Earnings LISI (5035.FR): Q1 Revenue LOreal (12032.FR): AGM Lonmin (LMI.LN): Trading Update Lottomatica (LTO.MI): AGM & EGM Lycos Europe (LCY.XE): Q1 Earnings Macintosh Retail Group (36798.AE): AGM Martela (MARAS.HE): Q1 Earnings Medivir (MVIR-B.SK): AGM Meliorbanca (MEL.MI): AGM Memscap (MEMS.FR): Q1 Earnings & Revenue Micronas Semiconductor (MASN.EB): Q1 Earnings Micropole Univers (7757.FR): FY Earnings Mikron Holding (MIKN.EB): Q1 Revenue Munters (MTRS.SK): Q1 Earnings & AGM MWB (MWB.XE): Q1 Earnings Neomarkka (NEMBV.HE): Q1 Earnings Nordnet (NN-B.SK): Q1 Earnings & AGM Northern Rock (NRK.LN): AGM Novestra (NOVE.SK): Q1 Earnings & AGM OEM International (OEM.LN): Q1 Earnings & AGM Oriola-KD Corp (OKDBV.HE): Q1 Earnings Panevezio Statybos Trestas (10144.LH): AGM Pharmexa (PHARMX.KO): AGM Phoenix Mecano (PM.EB): Q1 Earnings Plastic Omnium (12457.FR): Q1 Revenue & AGM plenum (PLE.XE): FY Earnings Polish Energy Partners (PEP.WA): Q1 Earnings Ponsse (PONV1.HE): Q1 Earnings Precise Biometrics (PREC.SK): Q1 Earnings & AGM Premuda (PR.MI): AGM Retelit (LIT.MI): AGM & EGM RoyalBlue Group (RYB.LN): AGM Sabaf (SAB.MI): AGM Sadi (SSI.MI): AGM Safilo Group (SFL.MI): AGM SalusAnsvar (SALA-B.SK): Q1 Earnings & AGM Sanitas (10617.LH): Q1 Earnings Sardus (SARD.SK): Q1 Earnings Schaumann Properties (SCHAUP-B.KO): AGM Schroders (SDR.LN): AGM SeLoger.com (SLG.FR): Q1 Revenue Sia Abrasives Holding (SIAN.EB): AGM Software (SOW.XE): Q1 Earnings Stefanel (STEF.MI): AGM Subsea 7 (SUB.OS): Q1 Earnings Swisscom (SCMN.VX): AGM Sydbank (SYDB.KO): Q1 Earnings Teleca (TELC-B.SK): Q1 Earnings & AGM Telelogic (TLOG.SK): Q1 Earnings Teleste Corporation (TLT1V.HE): Q1 Earnings Ticket Travel Group (TICK.SK): Q1 Earnings Tim (TIM.WA): Q1 Earnings TNT (TNT): FY 2006 Ex-Dividend Date Twentsche Kabel Holding: AGM UKProduct Group: FY Earnings UMS Schweizerische Metallwerke (UMS.EB): FY Earnings Unipol - Ord (UNI.MI): AGM & EGM UPM-Kymmene (UPM1V.HE): Q1 Earnings Vemer Siber Group (VEM.MI): AGM Verbund (VER.VI): Q1 Earnings Vianini Lavori (VLA.MI): AGM WMH Walter Meier Holding AG (WMHN.EB): AGM XRT (5458.FR): Q1 Revenue York Pharma (YRK.LN): FY Earnings Zardoya Otis (ZOT.MC): AGM Zhejiang Expressway (ZHEH.LN): FY Earnings Beijer Electronics (BELE.SK): FY 2006 Ex-Dividend Date BioMar Holding (BIOMAR.KO): FY 2006 Dividend Payment Date British Sky Broadcasting Group (BSY.LN): 1H 2007 Dividend Payment Date Catena (CATE.SK): FY 2006 Ex-Dividend Date D/S Torm (TORM.KO): FY 2006 Dividend Payment Date Dan-Ejendomme Holding (DEH.KO): FY 2006 Ex-Dividend Date Electrolux - A Shares (ELUX-B.SK): FY 2006 Dividend Payment Date Electrolux - B Shares (ELUX-B.SK): FY 2006 Dividend Payment Date Fagerhult (FAG.SK): FY 2006 Ex-Dividend Date Haynes Publishing (HYNS.LN): 1H 2006 Dividend Payment Date Holidaybreak (HBR.LN): FY 2006 Dividend Payment Date Huhtamaki (HUH1V.HE): FY 2006 Dividend Payment Date Lundbergforetagen (LUND-B.SK): FY 2006 Ex-Dividend Date Marimekko (MMO1V.HE): FY 2006 Dividend Payment Date Migatronic (MIGA-B.KO): FY 2006 Ex-Dividend Date Ponsse (PON1V.HE): FY 2006 Dividend Payment Date Sampo (SAMAS.HE): FY 2006 Dividend Payment Date Scanfil (SCF1V.HE): FY 2006 Dividend Payment Date Spar Nord Bank (SPNO.KO): FY 2006 Ex-Dividend Date Stavanger Aftenblad (STA.OS): FY 2006 Ex-Dividend Date Wolters Kluwer (WKL.AE): FY 2006 Ex-Dividend Date (END) Dow Jones Newswires


 

SAN JOSE, CA -- (MARKET WIRE) -- April 24, 2007 -- Cisco Systems, Inc. (NASDAQ: CSCO) today announced that it is extending its previously announced tender offer for all outstanding shares of WebEx Communications, Inc. (NASDAQ: WEBX), until 12:00 Midnight, New York City time, on Monday, May 7, 2007 (which is the end of the day on May 7, 2007). The tender offer has been extended because certain foreign regulatory approvals necessary for the consummation of the tender offer have not yet been received, as Cisco anticipated in the Offer to Purchase dated March 27, 2007. Cisco continues to expect to complete its tender offer in the fourth quarter of Cisco's fiscal year 2007. As announced previously, on March 27, 2007, Cisco, through its wholly-owned subsidiary Wonder Acquisition Corp., commenced a tender offer for all outstanding shares of WebEx at a price of $57.00 per share net to the seller in cash without interest, less brokerage fees and less any required withholding taxes, pursuant to the definitive merger agreement between Cisco and WebEx. The tender offer was previously set to expire at 12:00 Midnight, New York City time, on Monday, April 23, 2007. As of 5:00 p.m., New York City time, on Monday, April 23, 2007, an aggregate of approximately 38.1 million shares of WebEx common stock, or approximately 75.9% of WebEx's outstanding shares, had been tendered into, and not withdrawn from, the offer. Securities Law Disclosure This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities. The solicitation and the offer to buy shares of WebEx common stock will be made only pursuant to an offer to purchase and related materials that Cisco Systems, Inc. and Wonder Acquisition Corp. have filed with the SEC on Schedule TO on March 27, 2007, as amended. WebEx also has filed a solicitation/recommendation statement on Schedule 14D-9, as amended, with respect to the offer. WebEx stockholders and other investors should read these materials carefully because they contain important information, including the terms and conditions of the offer. WebEx stockholders and other investors may obtain copies of these materials without charge from the SEC through the SEC's website at www.sec.gov, from Georgeson Inc., the information agent for the offer, toll-free at (888) 264-7052 (banks and brokers call (212) 440-9800), from Cisco (with respect to documents filed by Cisco with the SEC) by going to Cisco's Investor Relations Website at http://www.cisco.com/go/investors, or from WebEx (with respect to documents filed by WebEx with the SEC) by going to WebEx's Investor Relations Website at www.WebEx.com. Stockholders and other investors are urged to read carefully those materials prior to making any decisions with respect to the offer. About Cisco Systems Cisco (NASDAQ: CSCO) is the worldwide leader in networking that transforms how people connect, communicate and collaborate. Information about Cisco can be found at http://www.cisco.com. For ongoing news, please go to http://newsroom.cisco.com Cisco, Cisco Systems, and the Cisco Systems logo are registered trademarks or trademarks of Cisco Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. This document is Cisco Public Information. For direct RSS Feeds of all Cisco news, please visit "News@Cisco" at the following link: http://newsroom.cisco.com/dlls/podcasts/rss.html Press Contact: John Noh 408 853-8445 jnoh@cisco.com Investor Relations Contact: Laura Graves 408 526-6521 lagraves@cisco.com


 

KYOTO, Japan, April 24, 2007 (PRIME NEWSWIRE) -- Nidec Corporation ("Nidec") (NYSE:NJ) announced today that it has completed its tender offer for Japan Servo Co., Ltd. ("Japan Servo") (Tokyo Stock Exchange Second Section: 6585). The tender offer, which commenced on Wednesday, March 14, 2007, expired on Monday, April 23, 2007, Japan time. Nidec received valid acceptances of 18,203,000 shares (or 51.77 percent) of common stock in Japan Servo for 260 yen per share (or 4,733 million yen). As a result, Japan Servo will become a consolidated subsidiary of Nidec on Friday, April 27, 2007. The Nidec Corporation logo is available at http://www.primezone.com/newsroom/prs/?pkgid=1734 CONTACT: Nidec Corporation Hiroshi Toriba, Senior General Manager, Investor Relations +81-75-935-6140 HIROSHI_TORIBA@notes.nidec.co.jp


 

Houston, Texas and Asker, Norway (24 April 2007) - On April 2nd, 2007 TGS-NOPEC Geophysical Company ("TGS") notified investors that it had signed a definitive agreement to acquire all shares of Parallel Data Systems, Inc ("PDS"), subject to U.S. regulatory approval. TGS wishes to inform investors that the necessary Hart-Scott-Rodino application has now been submitted to authorities. Initial review of the application should occur within the next 30 days. Due to unanticipated delays in submitting the application, TGS is now rescheduling its Capital Markets day from Thursday May 3rd in Houston to Thursday August 9th in Oslo. This will allow TGS to discuss in much greater detail its plans concerning PDS, the largest acquisition in the Company's history. TGS-NOPEC Geophysical Company (TGS) is a leading global provider of multi-client geoscientific data, associated products and services to the oil and gas industry. TGS specializes in the creation of non-exclusive seismic surveys worldwide. The Company provides advanced depth imaging solutions and software through its TGS Imaging division. Well log data is available for conversion, sourcing, management and immediate delivery through TGS subsidiary, A2D Technologies. Multi-client interpretive products and subsurface consulting services are provided through the Company's Aceca subsidiary. The TGS family of companies places a strong emphasis on providing high-quality data and the highest level of service to the industry. All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include TGS' reliance on a cyclical industry and principal customers, TGS' ability to continue to expand markets for licensing of data, and TGS' ability to acquire and process data products at costs commensurate with profitability. Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason. TGS-NOPEC Geophysical Company ASA is listed on the Oslo Stock Exchange (OSLO: TGS). For more information about this news release, please contact: Arne Helland Chief Financial Officer Tel: +47 66 76 99 31/+47 91 88 78 29 Email: arne.helland@tgsnopec.no John Adamick VP, Business Development Tel: 713 860 2100 Email: jada@tgsnopec.com --- End of Message --- TGS-NOPEC Baardsrudveien 2 Nærsnes Norway ISIN: NO0003078800; ;


 

Following the March 12 announcement regarding the intended sale of Organon BioSciences (OBS), the results for the company's Pharma activities will, in line with IFRS, be shown under Discontinued Operations until the closing of the transaction, foreseen in the second half of 2007. Financial highlights +-------------------------------------------------------------------+ | EUR mln | Q1 2007 | Q1 2006 | % change | |-----------------------------+----------+---------------+----------| | Revenues Coatings/Chemicals | 2,501 | 2,472 | 1 | |-----------------------------+----------+---------------+----------| | EBITDA* Coatings/Chemicals | 307 | 279 | 10 | |-----------------------------+----------+---------------+----------| | EBITDA margin*, in % | 12.3 | 11.3 | | |-----------------------------+----------+---------------+----------| | EBIT* Coatings/Chemicals | 219 | 185 | 18 | |-----------------------------+----------+---------------+----------| | Net income* | 133 | 113 | 18 | | Coatings/Chemicals | | | | |-----------------------------+----------+---------------+----------| | Net income* Organon | 111 | 102 | 9 | | BioSciences | | | | |-----------------------------+----------+---------------+----------| | Total net income | 246 | 249 | (1) | +-------------------------------------------------------------------+ * Before incidentals Highlights * Autonomous growth of Coatings/Chemicals 6% * EBITDA margin further improved to 12.3% * Operational results of Coatings/Chemicals 18% higher * Coatings - higher EBITDA margin on 8% revenue growth * Chemicals - strong EBITDA margin maintained on 4% autonomous growth * EUR 11 billion cash deal for Organon BioSciences announced * Good quarter for Organon and Intervet * EUR 1.6 billion share buyback to commence May 3, 2007 Arnhem, the Netherlands, April 24, 2007 - Akzo Nobel (Euronext Amsterdam: AKZ; Nasdaq: AKZOY) has reported a strong start to the year for the refocused company. The combined Coatings and Chemicals business posted autonomous growth of 6%, while operational results before incidentals were 18 percent higher than the corresponding period last year. The Pharma activities also performed well, with first quarter operating results jumping 8%. At EUR 2.5 billion, revenues for Coatings and Chemicals were 1% above the Q1 figure for 2006, with autonomous growth of 6% being largely offset by a negative currency impact. The refocused company posted EBITDA of EUR 307 million, an increase of 10% compared with last year. The operating result was up 18%. Incidentals only had a minor impact during the quarter, in contrast to Q1 2006, when the company booked significant positive incidentals. Excluding incidentals - but including the Pharma activities - total net income rose 13%, from EUR 215 million to EUR 244 million. Including incidentals, net income was virtually unchanged. Commenting on the company's first quarter results, CFO Rob Frohn said: "The operational performance during the first quarter was very positive. I'm pleased that strong autonomous growth and the effects of our margin improvement programs, both in Coatings and Chemicals, resulted in an operating income increase of 18 percent. In addition Intervet reported a record quarter." Coatings - higher EBITDA margin on 8% revenues growth Coatings turned in a strong quarter, with revenues up 8% on 2006. The European businesses improved, and emerging markets continued to drive growth. Before incidentals, EBITDA rose 11% to EUR 153 million. Autonomous growth was 8%, with 5% due to higher volumes and 3% higher prices. Acquisitions added 4%, while currencies had a negative impact of 4%. Decorative Coatings delivered a promising start to the year, with both volume growth and improved margins, while the company's Marine & Protective activities enjoyed double digit revenues growth, led by Aerospace and Protective Coatings. The Industrial activities delivered a healthy performance, although the slowdown in the U.S. housing industry affected some parts of the businesses. Car Refinishes continued to report improved EBIT margins on both cost control and growth in emerging markets. Chemicals - strong EBITDA margin on 4% autonomous growth Chemicals revenues increased by 1% to EUR 917 million, with volume growth of 1% and price increases of 3% being partially offset by a negative currency impact of 2%. Before incidentals, EBITDA amounted to EUR 164 million, in line with last year. The EBIT margin improvement was a result of the margin management programs in all units. Pulp & Paper Chemicals benefited from higher margins for bleaching products in Europe and the Americas. Base Chemicals delivered a strong operational performance, driven by strong demand for chlor-alkali products. Functional Chemicals achieved increased margins in Chelates, Sulfur Products and Cellulosic Specialties, and the production issues in Ethylene Amines at our Swedish plant were resolved. Despite headwinds from currencies and higher raw material prices, the EBIT of Surfactants improved due to price increases and improved operational efficiency. EBIT of Polymer Chemicals was well ahead of 2006 due to cost savings and benefits from the margin improvement program. Discontinued operation - Organon BioSciences First quarter revenues for Pharma amounted to EUR 920 million, equal to the same period in 2006. The EBIT of OBS before incidentals was up 4% to EUR 147 million. Organon's autonomous growth of 4% was more than offset by currency effects and the loss of Avinza® sales. NuvaRing® is continuing to do well. The EBIT was unchanged at EUR 84 million. Intervet reported a record quarter, driven by autonomous growth of 12%. The European region and products for companion animals were particularly strong contributors. The Intervet EBIT margin improved to 21.7%. The preparations of the transfer of Organon BioSciences are on track. Workforce Akzo Nobel's workforce in Coatings and Chemicals was 42,880 employees, up from 42,690 at year-end 2006. The number of employees at Organon BioSciences was 19,140. Strong financial position The company's strong financial position improved further due to a decrease of EUR 0.1 billion net interest-bearing borrowings to EUR 1.0 billion. Trading conditions Akzo Nobel is well positioned for profitable growth. Assuming no important change in the major economies of the world, the company believes that it is well placed to outgrow its markets and improve the financial returns in Coatings and Chemicals. The Report for the 1st quarter is attached and can be read on the company's corporate website: http://www.akzonobel.com/com/News/Reports.htm Note to editors Akzo Nobel is a Fortune Global 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the second quarter will be published on July 24, 2007. Internet: www.akzonobel.com Not for publication - for more information Akzo Nobel nv Corporate Media Relations, tel. +31 26 366 43 43 Contact: Tim van der Zanden


 

OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today that its CEO will present at the 7th Annual Fortis Bank Biotechnology Conference in London this week. Joost Holthuis, Chief Executive Officer, will present on Wednesday, 25 April at 2:45 PM BST. For further information, please contact: Rianne Roukema, Corporate Communications: +31 (71) 524 4044 About OctoPlus OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs. OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs. OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl. This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.


 

Quickborn/Frankfurt/Main, 24 April 2007. comdirect bank (www.comdirect.de) is continuing its successful path. The bank closed the first quarter of 2007 with a pre-tax profit of EUR 25.9m, exceeding the record result of the previous year's first quarter (EUR 25.2m). "Higher profits, further investment and continued growth: the first quarter was a strong start to the year," says Andre Carls, CEO of comdirect bank. In the first quarter of 2007, the bank achieved record total earnings of EUR 68.2m, 16.6% more than in the first quarter of the previous year. The main factor influencing this rise was net interest income before provisions, which increased by 50.2% to EUR 28.6m (previous year: EUR 19.0m). The main causes of this were the continued strong growth in customer deposits and higher market interest rates. At EUR 39.1m, net commission income in the first quarter of 2007 reached the remarkable level of the previous year (EUR 39.1m) amid lively stock market activity. According to Carls, "Our earnings structure has again made significant improvements in the first quarter because the portion of earnings that are independent of the development of trades has risen considerably." As part of the comvalue growth programme, comdirect bank has made additional investments in marketing, an improved service offering and the expansion of its infrastructure since the beginning of the year. The increases in earnings are therefore coupled with scheduled increases in administrative expenses, which rose by 27.2% from the previous year (EUR 33.3m) and amounted to EUR 42.4m. Other administrative expenses accounted for over 70% of this, amounting to EUR 31.2m (previous year: EUR 23.5m). Personnel costs grew by 18.8% to EUR 9.0m, mainly due to the increase in the number of employees. Depreciation remained low at EUR 2.2m (previous year: EUR 2.2m). comdirect bank pursued a stronger market presence in the first quarter, with intensive promotion of its two anchor products, the call money account Tagesgeld PLUS and the current account. The strong media presence paid off: Tagesgeld PLUS, introduced only last November, was already being used by 159,642 customers by the end of the first quarter. The number of current accounts rose by a further 15 thousand in the first three months of the year to 275,279. Deposit volume grew by around EUR 960m to EUR 5.6bn. comdirect bank maintains its increased growth targets for the end of 2009, which it announced last year. By this time, the bank aims to have over 1.3 million customers in total. The bank also intends to be managing around 650,000 custody accounts, 450,000 current accounts and 650,000 Tagesgeld PLUS accounts and providing 40,000 customers with individual advice on asset and provisioning issues from its offices. Up to EUR 150m will be invested by comdirect bank by 2009, of which more than EUR 30m will be invested during the current year alone. comdirect shareholders can look forward to a pleasing dividend next month. Subject to approval by the annual general meeting on 3 May 2007, EUR 1.40 per share will be distributed from the 2006 group earnings. Key figures +-------------------------------------------------------------------+ | EUR '000 | Q1/06 | Q4/06 | Q1/07 | Q1/07 vs. | | | | | | Q1/06 | |----------------------------+--------+--------+--------+-----------| | Net interest income before | 19,017 | 23,976 | 28,567 | 50.2 % | | provisions | | | | | |----------------------------+--------+--------+--------+-----------| | Provisions | -854 | -839 | -495 | -42.0 % | |----------------------------+--------+--------+--------+-----------| | Net commission income | 39,051 | 32,888 | 39,073 | 0.1 % | |----------------------------+--------+--------+--------+-----------| | Other income | 1,305 | 1,448 | 1,100 | -15.7 % | |----------------------------+--------+--------+--------+-----------| | Administrative expenses | 33,324 | 36,110 | 42,382 | 27.2 % | |----------------------------+--------+--------+--------+-----------| | Pre-tax profit | 25,195 | 21,363 | 25,863 | 2.7 % | |----------------------------+--------+--------+--------+-----------| | After-tax profit | 16,149 | 15,985 | 16,837 | 4.3 % | +-------------------------------------------------------------------+ Length: 3,121 characters incl. spaces, excl. table Press contact: Ullrike Hamer, comdirect bank AG, Tel. +49 (0)4106 704 1960, email: presse@comdirect.de. Press information: All press releases are available at www.comdirect.de/pr. Should you no longer wish to receive these press releases, please send an e-mail to presse@comdirect.de. --- End of Message --- comdirect bank AG Pascalkehre 15 Quickborn WKN: 542800; ISIN: DE0005428007; Index: CDAX, CLASSIC All Share, Prime All Share, SDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin Bremen, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;


 

On 23 April, the Board of Directors of Feintool International Holding decided on a structural change to its Group Management. With the departure of Serge Gafner as Head of Group Human Resources as of 1 May 2007, HR will come under the area of responsibility of CFO Jürg E. Wenger. Human Resources has been reorganized in such a way that the higher-level Group activities are properly coordinated and the HR units of the individual Group companies are appropriate to the complex tasks required of them. For further information, please contact: Joachim Kaufmann, Chief Executive Officer Jürg E. Wenger, Chief Financial Officer Phone +41 (0)32 387 51 11 Feintool is a leading technology and systems provider in fineblanking/forming and assembly automation. It is also a global supplier of metal and plastic components. Feintool operates throughout the world at the company's own facilities in Switzerland (head office in Lyss), Germany, France, Italy, Great Britain, the United States, Japan, China and Thailand, where around 1800 employees are committed to customer satisfaction. Feintool International Holding Industriering 8, CH-3250 Lyss Phone +41 (0)32 387 51 11 Fax +41 (0)32 387 57 81 feintool-fim@feintool.com www.feintool.com Corporate Communications Urs Feitknecht Phone +41 (0)32 387 51 63 Fax +41 (0)32 387 54 16 Mobile 079 204 41 13 urs.feitknecht@feintool.com The media release can be downloaded from the following link: --- End of Message --- Feintool International Holding Industriering 8 Lyss Schweiz WKN: 905428; ISIN: CH0009320091 ; Index: SPI, SPIEX, SSCI; Listed: Main Market in SWX Swiss Exchange;


 

Swedish Match shareholders approve dividend hike to 2.50 SEK Major items approved by today's Annual General Meeting include: - Dividend will increase from 2.10 SEK/share to 2.50 SEK - Election of Conny Karlsson as new Chairman of the Board - Election of Charles A. Blixt and John P. Bridendall to the Board - Mandate to repurchase up to 10 percent of all shares in the Company prolonged - 13 million shares repurchased by the Company are authorized to be withdrawn At the Annual General Meeting of Swedish Match on 23 April, it was resolved in accordance with the proposal of the Board of Directors to pay a dividend per share of 2.50 SEK. The record date for the dividend entitlement was set at 26 April, 2007. The dividend is expected to be distributed on 2 May, 2007, through VPC. Shareholders have re-elected Andrew Cripps, Sven Hindrikes, Arne Jurbrant, Conny Karlsson, Kersti Strandqvist and Meg Tivéus to the Board of Directors, and elected Charles A. Blixt and John P. Bridendall as new members to the Board of Directors. Conny Karlsson was elected new Chairman of the Board. Furthermore, the shareholders approved a mandate to repurchase up to 10 percent of all shares in the Company for a maximum amount of 3,000 MSEK. In addition, the shareholders also approved an authorization for a reduction of 13,000,000 previously repurchased shares, with a simultaneous capitalization issue in an amount corresponding to the number of cancelled shares or 18,084,644.37 SEK. The shareholders also approved that the reduction will be allocated to a fund for use in repurchasing the Company's own shares. In addition, shareholders approved all other proposals made by the Board of Directors and the Nominating Committee as outlined in the published notice of the Annual General Meeting for Swedish Match AB. ____________ Swedish Match is a global Group of companies with a broad assortment of market-leading brands in smokeless tobacco products, cigars, pipe tobacco and lights products. The Group's global operations generated sales of 12,911 MSEK for the twelve month period ending December 31, 2006. Swedish Match shares are listed on Stockholmsbörsen (SWMA). ____________ Swedish Match AB (publ), SE-118 85 Stockholm Visiting address: Rosenlundsgatan 36, Telephone: +46 8 658 02 00 Corporate Identity Number: 556015-0756 www.swedishmatch.com ____________ For further information, please contact: Sven Hindrikes, President and Chief Executive Officer Office +46 8 658 02 82, Mobile +46 70 567 41 76 Lars Dahlgren, Chief Financial Officer Office +46 8 658 04 41, Mobile +46 70 958 04 41 Fredrik Peyron, Senior Vice President Legal Affairs, Secretary and General Counsel Office +46 8 658 03 23, Mobile +46 70 548 23 23 Bo Aulin, Senior Executive Advisor & Senior Vice President Corp. Communications Office +46 8 658 03 64, Mobile +46 70 558 03 64 Emmett Harrison, Vice President, Investor Relations Office +46 8 658 01 73, Mobile +46 70 938 01 73 Richard Flaherty, COO OTP, North America Division, US Investor Relations contact Office +1 804 302 1774, Mobile +1 804 400 1774 The press release can be downloaded from the following link:


 

Vancouver, April 24, 2007 - On Monday April 23, 2007, World Hockey Association Corp. (PINKSHEETS: WHKA) issued comments in response to a press release issued by Global Developments Inc. (PINKSHEETS: GDVM) on the same day. All comments by the WHA were factually inaccurate. In their press release, the WHA made the following two statements: 3) Arrangements have been made to pay the City of Osoyoos in British Columbia for all past due bills. These arrangements have been made through the Parks and Recreation Board at the Mayor's offices. This is similar to the same arrangements which have been made to all the cities who are owed money by the WHA for ice time bills accumulated during the 2006-2007 hockey season. 4) The City of Osoyoos has invited the WHA back for the 2007-2008 hockey season. Any statement made to the contrary by The Briner Group and/or Global Developments, Inc. is false and misleading. Global Developments Inc. contacted the Honorable John Slater, Mayor of Osoyoos, by e-mail and asked him to confirm these statements. His response was as follows: The Town of Osoyoos wishes to clarify that as of 2:30 p.m. on Monday April 23, 2007 the Town has not received payment in full from the WHA. In addition, the team has not been formally invited back to play in the community. The Town requires payment in full from the WHA before Council would entertain a formal request to have a WHA team in our community. This would require a formal resolution from Council to either extend the invitation or not. Global Developments Inc. will address the remaining points in the WHA press release at the appropriate time. About Global Developments Inc. Global Developments, Inc. was formed to create a unique investment vehicle representing a growing portfolio of innovative and emerging growth-oriented companies. Global acquires its portfolio companies primarily as wholly or majority owned subsidiaries. As a result, Global maintains substantial management control, thereby giving it the ability to provide significant oversight and guidance in building value and creating liquidity events for its shareholders. Global invests in companies with solid management, operational excellence, and the potential to grow substantial revenue streams. Please visit http://www.globaldevelopmentsinc.com for more information. Forward-Looking Statements You should not place undue reliance on forward-looking statements in this press release. This press release contains forward-looking statements that involve risks and uncertainties. Words such as ``will,'' ``anticipates,'' ``believes,'' ``plans,'' ``goal,'' ``expects,'' ``future,'' ``intends,'' and similar expressions are used to identify these forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks we face as described in this press release. For further information about Global Developments, Inc. please refer to its Web site at http://www.globaldevelopmentsinc.com. Contact: Global Developments, Inc. 1-866-907-4237 info@globaldevelopmentsinc.com Source: GLOBAL DEVELOPMENTS, INC.


 

Vancouver, April 23, 2007 - Global Developments Inc. (PINKSHEETS: GDVM) announced today that the counter-claim filed in Nevada Federal Court by the World Hockey Association Corp. (PINKSHEETS: WHKA) is just one more example of WHA CEO Ricky Smith using a public forum to fabricate allegations against others to hide his own misdeeds. In a statement issued today, Global Development's Board of Directors stated, "Mr. Smith is an amazing storyteller. He takes a series of unrelated events and weaves them into fictional tales of intrigue and conspiracy which are short on facts and long on imagination. It's a classic technique of diverting attention away from the real culprit: Mr. Smith himself. " They added, "The evidence we have amassed against Mr. Smith and the rest of the defendants is incontrovertible. Mr. Smith would have you believe that others issued 100 million shares illegally. Yet we have treasury orders issued by Mr. Smith, letters signed by Mr. Smith, and e-mails sent by Mr. Smith directing the shares to be issued, discussing how much money he was making off the trades, and then joking about how sharply the share price was dropping. While he would have you believe he was an innocent bystander, the evidence is clear that he masterminded the whole affair." "But of course, anyone who has dealt with Mr. Smith and the WHA in the past will already know that this is just his normal way of conducting business. We know of at least 3 examples where Mr. Smith has reneged on his commitments: 1. K1 Sportswear Inc. vs. WHA - In September 2006, the WHA is ordered in Minnesota District Court to pay the Plaintiff, K1 Sportswear Inc., $45,875 for breach of a jersey merchandising contract; 2. Town of Osoyoos vs. WHA - In February 2007, Osoyoos Town Council passed Motion 14/07 effectively ending the WHA Junior West hockey in Osoyoos citing a "breach of contract", a result of unpaid bills in the amount of over $11,000.00 to the town, as the reason for the termination. For the full story visit www.desertconnections.ca/morgue/0206.20070208 3. Charter Bus Lines vs. WHA - In February 2007, Charter Bus Lines cancelled their charter agreement with the WHA for unpaid transportation costs of approximately $70,000. "In addition to unpaid bills for ice time and transportation, we know the WHA has failed to pay billeting fees for their players, traveling expenses for road trips, and salaries for their coaches. Global Developments Inc. is just one more creditor or financing partner who has been duped by Mr. Smith." Global Developments Inc.'s Board of Directors ended by stating, "Although we know it will be costly, we are looking forward to seeing Mr. Smith in court because it's about time someone exposed him for who he really is." About Global Developments, Inc. Global Developments, Inc. was formed to create a unique investment vehicle representing a growing portfolio of innovative and emerging growth-oriented companies. Global acquires its portfolio companies primarily as wholly or majority owned subsidiaries. As a result, Global maintains substantial management control, thereby giving it the ability to provide significant oversight and guidance in building value and creating liquidity events for its shareholders. Global invests in companies with solid management, operational excellence, and the potential to grow substantial revenue streams. Please visit http://www.globaldevelopmentsinc.com for more information. Forward-Looking Statements You should not place undue reliance on forward-looking statements in this press release. This press release contains forward-looking statements that involve risks and uncertainties. Words such as ``will,'' ``anticipates,'' ``believes,'' ``plans,'' ``goal,'' ``expects,'' ``future,'' ``intends,'' and similar expressions are used to identify these forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks we face as described in this press release. For further information about Global Developments, Inc. please refer to its Web site at http://www.globaldevelopmentsinc.com. Contact: Global Developments, Inc. Leighton Dean 1-866-907-4237 info@globaldevelopmentsinc.com Source: GLOBAL DEVELOPMENTS, INC.


 

Evox Rifa Group Oyj Stock Exchange Release on 23 April 2007 The Annual General Meeting of Evox Rifa Group Oyj has on 23 April 2007 made the following decisions: The Annual General Meeting of Evox Rifa Group Oyj decided in accordance with the Board's proposal that no dividend will be paid for the financial year 2006. The Financial Statements for the financial year 2006 were adopted and the Members of the Board of Directors and Company's President were discharged from liability for the financial year 2006. Mr. Per-Olof Lööf, Mr. David E. Gable, Mr. Marc Kotelon, Mr. Kirk D. Shockley and Mr. Michael W. Boone were elected as Members of the Board. The Board of Directors has today elected Per-Olof Lööf as Chairman for the Board of Directors. The Authorized Public Accounting Firm KPMG Oy was appointed auditor of the company with APA Lasse Holopainen as the responsible auditor. The Annual General Meeting decided to approve the proposal of the Board to amend the Articles of Association (The proposal of the Board has been summarized in the stock exchange release on 4 April 2007). The Articles of Association, as amended, have been attached to this stock exchange release as enclosure 1. For more information, please contact Ms. Tuula Ylhäinen, President of Evox Rifa Group Oyj at +358 9 5406 5001. EVOX RIFA GROUP OYJ Tuula Ylhäinen President & CEO Distribution: Helsinki Stock Exchange Principal press and media


 

Airline's fleet of Q400 aircraft will increase to 48 with this third order TORONTO, ONTARIO -- (MARKET WIRE) -- 04/23/07 -- Bombardier Aerospace announced today that Horizon Air of Seattle, Washington, has placed a firm order for 15 Bombardier Q400 airliners and has taken options on an additional 20 Q400 aircraft. With this order, Horizon Air continues to be the largest North American operator of the Q400 aircraft. The airline serves 49 cities in the Western U.S. and Western Canada. Based on the list price for the Q400 aircraft, the value of the contract for the 15 firm-ordered aircraft is approximately $393 million US. "Horizon Air has been a valued customer of Bombardier for over 20 years and they were the North American launch customer for the Q400 airliner," said Steven Ridolfi, President, Bombardier Regional Aircraft. "We are grateful for Horizon Air's continuing confidence in Bombardier, demonstrated by the airline's utilization of both our CRJ Series regional jets and Q-Series turboprop aircraft to meet its fleet requirements." "Our first-hand experience with the Q400 over more than six years has given us the confidence to invest further in the model," said Jeff Pinneo, President and Chief Executive Officer, Horizon Air. "We have a keen understanding of the aircraft's many advantages - its superior economics, how well it's accepted by customers, and its exceptional fit to our unique market requirements." Including the order announced today, Horizon Air has over the years ordered a total of 115 Bombardier aircraft, comprised of 21 Dash 8/Q100, 28 Q200 and 46 Q400 turboprop airliners, and 20 Bombardier CRJ700 regional jets. The airline also acquired two additional previously owned Q400 aircraft from Hainan Airlines. Making full use of the Q400 aircraft's technical capabilities, Horizon Air has obtained the first approval for Head-up Guidance System operations allowing approaches in Category III weather conditions. The airline is also the first Q400 operator to obtain approval for Required Navigation Performance (RNP) 0.3 operations with curved approaches using the FAA's "Special Aircraft and Aircrew Authorization Required" (SAAAR) rules. Bombardier has now recorded orders for a total of 230 Q400 aircraft. As of January 31, 2007, 143 of these aircraft had been delivered to operators in Africa, the Asia-Pacific region, Europe, the Middle East and North America. About Bombardier A world-leading manufacturer of innovative transportation solutions, from regional aircraft and business jets to rail transportation equipment, systems and services, Bombardier Inc. is a global corporation headquartered in Canada. Its revenues for the fiscal year ended Jan. 31, 2007, were $14.8 billion US, and its shares are traded on the Toronto Stock Exchange (BBD). News and information are available at www.bombardier.com. Bombardier, CRJ700, Dash 8-100, Q200 and Q400 are trademarks of Bombardier Inc. or its subsidiaries. About Horizon Air Named 2007 Regional Airline of the Year by Air Transport World magazine, Horizon serves 49 cities throughout California, Colorado, Oregon, Washington, Idaho, Montana, Nevada, and British Columbia and Alberta. Together, Horizon Air and Alaska Airlines serve 90 cities and are subsidiaries of Alaska Air Group, Inc. (NYSE: ALK). Notes to Editors Images of Horizon Air Q400 aircraft are available in our Multimedia Library at: www.aero.bombardier.com/htmen/F15.jsp Contacts: Bombardier Aerospace Marc Holloran 416-375-3030 www.bombardier.com


 


 

Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announces today that its Annual Shareholders' Meeting has approved the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for 2006, as well as the proposed appropriation of the results, use and creation of reserves. Shareholders also granted discharge to the members of the Board of Directors (Board) and Executive Management from liability. In addition, Santhera shareholders approved an amendment to the Company's Articles of Incorporation and elected Klaus Schollmeier, CEO of Santhera, as a new member of the Board. Michael Lytton, Martin Gertsch, Rudolf Gygax, George Nebgen, Timothy Rink and Bernd Seizinger were reelected as members of the Board. Finally, shareholders voted to reelect Ernst & Young as auditors and group auditor. The Annual Shareholders' Meeting was Santhera's first as a public company. A total of 56.75 % of the total share capital of the Company or 63.18 % of the shares entered into the Company's share register (with the right to vote) was represented at the shareholders meeting. Presentation to Shareholders In his presentation to shareholders, Michael Lytton, Chairman of the Board, outlined the considerable progress that Santhera has made in developing a late-stage clinical portfolio of neuromuscular drug candidates and securing funds from both private and public investors. With regard to 2006, he commented, "The results of last year reflect the progress that Santhera has made across all areas of its business, creating significant value for its shareholders. This success reflects both our sound strategy and the excellent execution by the company's management." The Company achieved some major milestones in 2006, in particular the very positive results from the collaborative study with the US National Institutes of Health for its lead program in Friedreich's Ataxia (FRDA), the start of the collaboration with Juvantia for the further clinical development of JP-1730 for Dyskinesia in Parkinson's Disease, and the successful listing on the SWX Swiss Exchange. Santhera's current pipeline continues to mature with two compounds in four Phase III and Phase II clinical development programs. The Company is preparing its first product registration filing for SNT-MC17 for FRDA in Europe for this summer. Mr Lytton added: "This milestone will mark a major step on our journey to achieving our vision of becoming a leading specialty pharmaceutical company offering therapies for a number of neuromuscular conditions with significant unmet medical need." Discharge and Board elections Santhera shareholders granted discharge to the members of the Board and to the members of the management from liability. The shareholders also approved the proposed amendment to the Company's Articles of Incorporation and elected Klaus Schollmeier, CEO of Santhera, as new member of the Board. Commenting on his election, he said: "I feel extremely honored by the shareholder's clear vote to appoint me to the Board and would like to extend them my sincere thanks for their confidence." It is not foreseen that Klaus Schollmeier will become Chairman of the Board or a member of any of its committees. Six Board members whose terms of office expired at the Shareholders' Meeting were reelected individually. In order to assure continuity in the Company's governance and experience, the shareholders accepted the introduction of staggered terms of office for Board members. As a result, Santhera's Board consists of Michael Lytton, Chairman (elected until the 2009 Shareholders' Meeting); Hans Peter Hasler, Vice-Chairman (until 2009); Martin Gertsch (until 2010); Rudolf Gygax (until 2008); Georg Nebgen (until 2008); Timothy Rink (until 2009); Klaus Schollmeier (until 2010); and Bernd Seizinger (until 2010). The Board members combine considerable experience in research, development, commercialization and financial management. These are the key skills that Santhera needs as it positions itself for the next stage of its corporate development. In its constituting meeting after the Shareholders' Meeting, the Board confirmed Michael Lytton as Chairman. The Board also decided that the memberships of its three committees remain unchanged; Martin Gertsch continues to chair the Audit Committee and Michael Lytton continues to chair the Nomination & Compensation Committee as well as the Financing Strategy & Transaction Committee. Appropriation of the results, use and creation of reserves Santhera shareholders approved to compensate the accumulated loss of CHF 12,836,478 with its capital reserves and share premium of CHF 119,088,589 and to transfer the amount of CHF 104,508,627 from capital reserves and share premium to the free reserves, resulting in net capital reserves and share premium of CHF 1,743,484. As a consequence of the transfer of CHF 104,508,627, the free reserves amount to CHF 146,000,000 as of January 1, 2007. Finally Ernst & Young was reelected as auditors and group auditors for the period of one year. * * * About Santhera Santhera Pharmaceuticals (SWX: SANN) is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of severe neuromuscular diseases. Santhera's vision is to become a leading specialty pharmaceutical company offering therapies for a number of indications in this area of high unmet medical need which includes many orphan indications with no current therapy. Santhera currently has four clinical-stage development programs, three of which are investigating its lead compound SNT-MC17 (INN: idebenone) in the treatment of Friedreich's Ataxia (FRDA), Duchenne Muscular Dystrophy (DMD) and Leber's Hereditary Optic Neuropathy (LHON). The fourth clinical program is investigating JP-1730 (INN: fipamezole) for the treatment of Dyskinesia in Parkinson's Disease (DPD) in cooperation with Juvantia, the compound's owner. The most advanced program, SNT-MC17 in FRDA, is currently in preparation for Marketing Authorization Approval (MAA) filing in Europe and in Phase III clinical development in the US while the other clinical programs are in Phase II. For further information, please visit www.santhera.com. For Further Information, Contact Santhera Pharmaceuticals Klaus Schollmeier, Chief Executive Officer phone: +41 (0)61 906 89 52 klaus.schollmeier@santhera.com Barbara Heller, Chief Financial Officer phone: +41 (0)61 906 89 54 barbara.heller@santhera.com Thomas Staffelbach, VP Public & Investor Relations phone: +41 (0)61 906 89 47 thomas.staffelbach@santhera.com Media Contacts: Citigate Dewe Rogerson David Dible phone: +44 207 638 95 71 david.dible@citigate.dr.co.uk Disclaimer/Forward-looking Statements This news release is not and under no circumstances is to be construed as a solicitation, offer, or recommendation, to buy or sell securities issued by Santhera. Santhera makes no representation (either express or implied) that the information and opinions expressed in this news release are accurate, complete or up to date. Santhera disclaims, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information contained in this news release. Forward-looking statements and other information contained in this release involve risks and uncertainties. Such statements reflect the current views, intentions and estimates of the Company. They are based on assumptions that may be inaccurate. Results could differ materially from those anticipated. Certain of these forward-looking statements can be identified by the use of forward-looking terminology such as "believe", "expect", "may", "are expected to", "will", "will continue", "should", "would be", "seek" or "anticipate" or by discussions of strategy, plans or intentions. Furthermore, the Company does not assume any obligation to update these forward-looking statements. --- End of Message --- Santhera Pharmaceuticals Holding AG Hammerstrasse 47 Liestal Switzerland WKN: A0LCUK; ISIN: CH0027148649; Index: SPI, SPIEX, SSCI; Listed: Main Market in SWX Swiss Exchange;


 
Ýmislegt
23. apríl 2007

Rule 8.3 - EMI LN

FORM 8.3 DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE (Rule 8.3 of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of person dealing (Note 1) | Tisbury Capital | | | Management LLP | |-------------------------------------------------+-----------------| | Company dealt in | EMI Group Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | 14p ordinary | | dealings being disclosed relate (Note 2) | | |-------------------------------------------------+-----------------| | Date of dealing | 20 April 2007 | +-------------------------------------------------------------------+ 2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) +-------------------------------------------------------------------+ | | Long | Short | | | | | |---------------------------+--------------------+------------------| | | Number | (%) | Number | (%) | | | | | | | |---------------------------+-----------+--------+---------+--------| | (1) Relevant securities | | | | | | | | | | | |---------------------------+-----------+--------+---------+--------| | (2) Derivatives (other | | | | | | than options) | 9 797 471 | 1.161 | | | | | | | | | |---------------------------+-----------+--------+---------+--------| | (3) Options and | | | | | | agreements to | 133 000 | 16.614 | 145 750 | 18.207 | | purchase/sell | 000 | | 000 | | | | | | | | |---------------------------+-----------+--------+---------+--------| | Total | 142 797 | 17.775 | 145 750 | 18.207 | | | 471 | | 000 | | +-------------------------------------------------------------------+ (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) +-------------------------------------------------------------------+ | Class of relevant security: | Long | Short | | | | | |-------------------------------------+--------------+--------------| | | Number | (%) | Number | (%) | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (1) Relevant securities | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (2) Derivatives (other than | | | | | | options) | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | (3) Options and agreements to | | | | | | purchase/sell | | | | | | | | | | | |-------------------------------------+--------+-----+--------+-----| | Total | | | | | | | | | | | +-------------------------------------------------------------------+ (c) Rights to subscribe (Note 3) +---------------------------------------+ | Class of relevant security: | Details | | | | |-----------------------------+---------| | | | +---------------------------------------+ 3. DEALINGS (Note 4) (a) Purchases and sales +----------------------------------------------------------------+ | Purchase/sale | Number of securities | Price per unit (Note 5) | | | | | |---------------+----------------------+-------------------------| | | | | |---------------+----------------------+-------------------------| | | | | +----------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product | Long/short | Number of securities | Price per | | name, | (Note 6) | (Note 7) | unit (Note 5) | | e.g. CFD | | | | |----------+------------+---------------------------+---------------| | CFD | Long | 500 000 | 234.7800 GBp | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------+ | Product |Writing, |Number of |Exercise|Type, e.g.|Expiry|Option money | | name, |selling, |securities to which|price |American, |date |paid/received | |e.g. call|purchasing, |the option relates | |European | |per unit (Note| | option |varying etc.|(Note 7) | |etc. | |5) | | | | | | | | | |---------+------------+-------------------+--------+----------+------+--------------| | | | | | | | | +------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit (Note 5) | | | | | |--------------------+----------------------+-----------------------| | | | | | | | | +-------------------------------------------------------------------+ (d) Other dealings (including new securities) (Note 4) +-------------------------------------------------------------------+ | Nature of transaction | Details | Price per unit (if applicable) | | (Note 8) | | (Note 5) | | | | | |-----------------------+---------+---------------------------------| | | | | | | | | +-------------------------------------------------------------------+ 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives +-------------------------------------------------------------------+ | Full details of any agreement, arrangement or understanding | | between the person disclosing and any other person relating to | | the voting rights of any relevant securities under any option | | referred to on this form or relating to the voting rights or | | future acquisition or disposal of any relevant securities to | | which any derivative referred to on this form is referenced. If | | none, this should be stated. | |-------------------------------------------------------------------| | | | None | | | +-------------------------------------------------------------------+ Is a Supplemental Form 8 attached? (Note 9) YES +-------------------------------------------------------------------+ | Date of disclosure | 23/04/2007 | |------------------------------------------------+------------------| | Contact name | Julien Naginski | |------------------------------------------------+------------------| | Telephone number | +44 20 7070 9642 | |------------------------------------------------+------------------| | If a connected EFM, name of offeree/offeror | | | with which connected | | |------------------------------------------------+------------------| | If a connected EFM, state nature of connection | | | (Note 10) | | +-------------------------------------------------------------------+ Notes The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk SUPPLEMENTAL FORM 8 DETAILS OF OPEN POSITIONS (This form should be attached to Form 8.1, Form 8.1(b)(ii) or Form 8.3, as appropriate) OPEN POSITIONS (Note 1) +----------------------------------------------------------------------+ |Product |Written or|Number of |Exercise|Type, e.g.|Expiry date| |name, |purchased |securities to |price |American, | | |e.g. call| |which the option |(Note 2)|European | | |option | |or derivative | |etc | | | | |relates | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 5 000 000 |240 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 5 000 000 |240 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 5 000 000 |240 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 10 000 000 |260 GBp | American |15/06/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 10 000 000 |260 GBp | American |15/06/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short put|Written | 7 000 000 |180 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short put|Written | 7 000 000 |190 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long put |Purchased | 21 000 000 |200 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long put |Purchased | 750 000 |200 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short put|Written | 20 000 000 |210 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long put |Purchased | 20 000 000 |220 GBp | American |15/06/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 8 000 000 |240 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 15 000 000 |240 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 5 000 000 |240 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 21 000 000 |240 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 15 000 000 |250 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Long call|Purchased | 20 000 000 |250 GBp | American |21/09/2007 | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 8 000 000 |260 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 15 000 000 |260 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 30 000 000 |260 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 15 000 000 |280 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | |---------+----------+-----------------+--------+----------+-----------| |Short |Written | 15 000 000 |300 GBp | American |21/09/2007 | |call | | | | | | |option | | | | | | +----------------------------------------------------------------------+ Notes 1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell should also be given on this form. 2. For all prices and other monetary amounts, the currency must be stated. For details of the Code's dealing disclosure requirements, see Rule 8 and its Notes which can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

* Lending increased by SEK 8bn (8) to SEK 489bn * Operating profit was SEK 1,097m (1,264) * Recoveries exceeded new loan losses during the period Earnings performance Stadshypotek's operating profit for the period was SEK 1,097m. The profit for the corresponding period in 2006 was SEK 1,264m. The change in profit is mainly due to decreased net interest income. During the first quarter, there has been great price pressure in the market, which has led to continued pressure on margins with a negative impact on net interest income. Stadshypotek's lending volume on the private market has continued its very positive development during the period. However, compared to the same period last year, it has not been possible to fully compensate the falling lending margins. Net interest income was also negatively impacted during the first quarter by effects relating to decisions concerning repurchase of bonds relating to the transition to IFRS. These effects will gradually decline until 2008. Compared to the fourth quarter of 2006, net interest income was SEK 36m higher during the first quarter of 2007. Low loan losses Recoveries exceeded new loan losses; the net amount recovered was SEK 29m (54), which corresponds to a loan loss ratio of -0.02% (-0.05) of lending. As at 31 March 2007, Stadshypotek's bad debts before deduction of the provision for probable loan losses were SEK 328m (528). SEK 35m (52) of the bad debts were non-performing loans and SEK 293m (476) were loans on which the borrowers pay interest and amortisation, but which are considered doubtful in view of the uncertainty as to the borrowers' repayment capacity and the value of the collateral. In addition, there were non-performing loans of SEK 221m (222) that are not assessed as being bad debts. After deduction of the provision for probable loan losses, the volume of bad debts was SEK 236m (400). Growth in lending Loans to the public were SEK 489bn - an increase of SEK 8bn for the period. The first quarter has continued to see a very favourable increase in Stadshypotek's share of net growth in the private market. Stadshypotek's overall share of mortgage institutions' lending on the private market was 26.5%. Stadshypotek has retained its position as a leading player on the Swedish corporate market, with a market share of 34.5%. Capital adequacy On 1 February 2007, new capital adequacy regulations were implemented - the Basel II rules. The new rules entail major changes in how the capital requirement is to be calculated and how a satisfactory capital base is to be ensured. The new rules will be gradually implemented since the transitional rules allow for an adaptation over three years. As at 31 March 2007, the capital ratio was 10.3% (8.6). As at 31 March 2007, the Tier 1 capital ratio was 7.3% (7.3). Further information about capital adequacy is available in the section Capital base and capital requirement. Rating Stadshypotek's rating was unchanged. Stadshypotek Long-term Short-term Moody's Aa1 P-1 Standard & Poor's AA- A-1+ Fitch AA- F1+ Covered bonds Moody's Aaa Accounting policies The accounts comply with the IASB accounting standards adopted by the EU. The regulations of the Annual Accounts Act for Credit Institutions and Securities Companies (ÅRKL) and the directives issued by the Swedish Financial Supervisory Authority are also applied. The interim report is also adapted to these. The same accounting policies and calculation methods have been applied in the interim report as in the latest annual report. Stockholm, 23 April 2007 Frank Vang-Jensen Chief executive This interim report has not been examined by the company's auditors The report can be downloaded from the following link:


 

The Board of Sealift Ltd ("Sealift" or the "Company") is currently in discussion with another industry party about a strategic transaction. Consummation of the transaction is likely to improve short and long term earnings and thereby the valuation of the Sealift shares. The transaction might also include contribution of new equity at an issue price significantly higher than current OTC price. The Board has in view of this investigated the possibility to suspend the trading of the Company's shares on the OTC market until final outcome of these discussions is expected later in the week. Since such a suspension has been difficult to achieve the Board feel that it is proper to inform the market that essential strategic discussions are taking place. However no assurance can be given that a transaction will be completed. The Board of Sealift Ltd 23rd April 2007


 

MICRON ENVIRO SYSTEMS, INC. ("Micron") 1205-789 West Pender Street Vancouver, BC Canada V6C 1H2 Tel: (604) 646-6903 April 23, 2007 MENV, MENVE:OTCBB USA NDDA:Frankfurt Stock Exchange Symbol A0J3PY:WKN # Frankfurt Stock Exchange Corporate Update Micron Enviro Systems, Inc.'s (OTCBB: MENV, MENVE) (Frankfurt Stock Exchange: NDDA --- WKN:A0J3PY---ISIN: US59510E2072) ("Micron" or the "Company") was not able to file the Company's Annual Report containing the year end audited financial statements on time. Therefore, the Company received an "E" on the end of its symbol to indicate to the public that NASDAQ did not have received the financials within the filing deadline. Micron will continue to have to trade under the "MENVE" symbol until one or two days after the Annual Report is filed, at which time the symbol will change back to "MENV". The financial statements were filed today, therefore the "E" will be removed from the Company's symbol on the market open on Tuesday or Wednesday. Bernie McDougall, Micron's president stated, "It is unfortunate that the filing was not submitted on time, however management wants to assure Micron's shareholders that our Annual Report has been completed and filed, and that fundamentally nothing has changed other than we temporarily did not have out Annual Report containing our audited financial statements filed by the required date. Management's goals have not changed and the board will carry on evaluating additional prospects primarily in the Alberta Oil Sands. Micron also plans to acquire additional leases in the future and move forward in developing the leases we currently have an interest in. Micron has added significant land holdings in the Alberta Oil Sands so far in 2007 and management is confident of acquiring additional leases in the future." Micron is an emerging oil and gas company that now has exposure to eight separate leases consisting of interests in 24.5 gross sections (15,500 acres) in the Oil Sands of Alberta, Canada, which is one of the largest oil producing regions in the world. Micron also has minor production from multiple conventional oil and gas wells throughout North America. Micron's goal is to become a junior oil and gas producer that focuses on the exploration, discovery and delivery of gas and oil to the North American marketplace. Micron continues to look for additional projects that would contribute to building Micron's market capitalization, including additional Oil Sands projects. At this time, Micron is one of, if not the smallest market capitalized company with multiple leases (eight) and now has positive operations underway in this world-class oil and gas producing region. This is quite an enviable position for a company of Micron's modest market capitalization, and therefore Micron offers tremendous leverage to one of the world's largest oil resources. Please visit our website for detailed maps of the locations of Micron's prospects at www.micronenviro.com. If you have any questions, please call Micron at (604) 646-6903. If you would like to be added to Micron's update email list, please send an email to info@micronenviro.com requesting to be added. This news release contains forward-looking statements. Forward-looking statements are statements which relate to future events. In some cases, you can identify forward-looking statements by terminology such as ``may,'' ``should,'' ``expects,'' ``plans,'' ``anticipates,'' ``believes,'' ``estimates,'' ``predicts,'' ``potential'' or ``continue'' or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results. Readers are referred to the sections entitled ``Risk Factors'' in the Company's periodic filings with the United States Securities and Exchange Commission, which can be viewed at <http://www.SEC.gov>. For all details regarding working interests in all of MENV's oil and gas prospects or any previous news releases go to the SEC website. You should independently investigate and fully understand all risks before making investment decisions. Contact Information: Bernard McDougall Micron Enviro Systems, Inc. ir@micronenviro.com TEL: (604) 646-6903 Fax: (604) 689-1733 www.micronenviro.com


 

Oslo, Norway, 23 April 2007 - Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announces the appointment of Roger Harrison, PhD, to the newly created position of Chief Business Officer, reporting to Thomas Ramdahl, PhD, President and Chief Executive Officer. Dr Harrison will be responsible for implementing and further developing Algeta's corporate business development and commercial strategy. Dr Harrison (53) has more than two decades of broad-based experience in the pharmaceutical and biotech industry. Prior to joining Algeta, Dr Harrison was Senior Vice President, Director of Corporate Development at BTG plc, the London-based drug development and licensing company. He joined BTG in 1989 and held several senior business and corporate development positions, including head of the global pharmaceutical licensing team. He was particularly responsible for building a portfolio of oncology and antibody therapeutics. From 1979 to 1989, Dr Harrison worked at Amersham International plc (now GE Healthcare) in the USA and UK. He received his BSc and PhD in Chemistry from the University of Manchester Institute of Science and Technology. "Algeta is very pleased to welcome Roger to the management team at Algeta, as he brings to the company his broad experience in business development particularly in the creation of world-class partnerships with leading pharmaceutical companies," said Dr Ramdahl. "Roger has an extensive record of achievement spanning pharmaceutical research and development, global product licensing and technology assessment, with a strong focus in oncology. This will prove to be very important as we increasingly leverage the partnering opportunities for our unique prostate cancer therapeutic Alpharadin, which is now entering Phase III clinical trials." Dr Harrison said, "I am excited to be joining Algeta at this critical juncture in the Company's growth. The new Phase II data on Alpharadin in hormone refractory prostate cancer are highly promising, highlighting the great potential of this product in treating this serious disease as well as other cancers. I look forward to playing a leading role in Algeta's business development initiatives when commercializing Alpharadin and its other cutting-edge technologies." ### For further information, please contact Dr Thomas Ramdahl, CEO +47 23 00 79 90 / +47 913 91 458 (mob) post@algeta.com Geir Christian Melen, CFO +47 23 00 79 84 / +47 913 02 965 (mob) post@algeta.com Dr Mark Swallow / Helena +44 (0)207 638 9571 Galilee mark.swallow@citigatedr.co.uk Citigate Dewe Rogerson About Algeta Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology. Algeta is developing new targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use. Algeta's lead product candidate, Alpharadin, is expected to enter Phase III clinical trials in hormone refractory prostate cancer based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers. Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA). Alpharadin and Algeta are trademarks of Algeta ASA. Forward-looking Statement This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products. ###


 

Precise Biometrics AB (publ), which develops and sells world-leading and user-friendly biometric security solutions based on fingerprints and smart cards, has won an important procurement contract for national ID cards in Portugal. The consortium is led by the digital security partner Gemalto. The new so called "Citizen Card" will replace several ID documents and will become the official ID document for all Portuguese citizens. The card will include functions for simple, fast and secure interaction with government administrations, civil identification, tax payment, social security, health, and in the future, elections. A first pilot phase has started in the Azores region. After the initial roll-out more than 2 million cards will be rolled out yearly. Precise Biometrics will supply 14 million licenses over a seven-year contract period. The project also includes delivery of the Precise 250 MC fingerprint readers. Precise Biometrics has won the procurement contract in a consortium led by the digital security leader Gemalto, with whom Precise Biometrics also won the procurement contract for national ID cards in Qatar in 2006. "This is our first national ID card project in Europe, and after our successes in Asia and the Middle East we are very pleased about this breakthrough on the European market. Additional applications are planned for the Portuguese national ID cards in the future, so this project has the potential to become even bigger", says Thomas Marschall, President and CEO of Precise Biometrics AB. Precise Biometrics' algorithm Precise BioMatch(TM) is made available on all Java(TM) cards and is the Match-on-Card technology with the best performance world-wide and the smart card security is enhanced. For further information, please contact Thomas Marschall, President & CEO, Precise Biometrics AB Telephone +46 46 31 11 10, or +46 734 35 11 10 E-mail thomas.marschall@precisebiometrics.com Ann-Sofi Höijenstam, Director, IR & Communications, Precise Biometrics AB Telephone +46 46 31 11 47 or +46 734 35 11 47 E-mail ann-sofi.hoijenstam@precisebiometrics.com Precise Biometrics AB (publ.) is an innovative security company that supplies world-leading systems for fingerprint and smart card-based authentication. The company's solutions replace keys, PIN codes and passwords and enhance the integrity of ID cards and passports. With its Precise Match-on-Card(TM) technology, the company is a market leader within smart ID cards. The product line includes systems for access control to buildings, computers and networks and for integration into ID cards and passports. The Precise Biometrics group has subsidiaries in Sweden, Great Britain, USA and a joint venture agreement in China. The group headquarters are in Lund, Sweden. Precise Biometrics is listed on the small cap list at the Nordic Exchange in Sweden (symbol: PREC). For more information, please visit http://www.precisebiometrics.com/ The press release can be downloaded from the following link:


 

TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): Sinclair Pharma Plc 2. Reason for the notification (please place an X inside the appropriate bracket/s): An acquisition or disposal of voting rights: ( X ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( ) Revised due to DTR rules - see Section 13 3. Full name of person(s) subject to the notification obligation (iii): Fidelity International Limited (FIL) 4. Full name of shareholder(s) (if different from 3.) (iv): 88,175 State Str Bk and Tr Co LNDN (FPM) 133,954 State Str Bk and Tr Co LNDN (FIL) 322,214 Northern Trust London (FPM) 233,000 JP Morgan Bournemouth (FPM) 2,506,738 JP Morgan Bournemouth (FISL) 317,264 JP Morgan Bournemouth (FIL) 272,661 Brown Brothers Harriman and Co (FIJ) 5,277,005 Brown Bros Harriman Ltd Lux (FIL) 182,376 Bank of New York Brussels (FPM) 5. Date of the transaction (and date on which the threshold is crossed or reached if different) (v): 12 April 2007 6. Date on which issuer notified: 16 April 2007 7. Threshold(s) that is/are crossed or reached: 10% 8. Notified details: ....... A: Voting rights attached to shares Class/type of shares if possible Situation previous to the Triggering using the ISIN CODE transaction (vi) Number of shares Number of voting Rights (viii) 9,352,556 9,352,556 Resulting situation after the triggering transaction (vii) Class/type of shares if Number of Number of voting % of voting rights possible using the ISIN shares rights (ix) CODE Direct Direct Indirect Direct Indirect (x) (xi) ISIN 9,333,387 9.99% GB0033856740 B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Exercise/Conversion Number of voting % of financial Date (xiii) Period/ Date (xiv) rights that may be voting instrument acquired if the rights instrument is exercised/ converted. Total (A+B) Number of voting rights % of voting rights 9,333,387 9.99% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): See attached schedule Proxy Voting: 10. Name of the proxy holder: Fidelity International Limited (FIL) 11. Number of voting rights proxy holder will cease to hold: 19,169 12. Date on which proxy holder will acquire to hold voting rights: 12 April 2007 13. Additional information: 14. Contact name: Teresa Garry, Fidelity Alan Olby (Company Secretary) / Zoe McDougall (Communications), Sinclair Pharma plc 15. Contact telephone number: fil-regulatoryreporting@uk.fid-intl.com investorrelations@sinclairpharma.com Annex to Notification Of Major Interests In Shares (xvi) A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities): Fidelity International Limited (FIL) Contact address (registered office for legal entities): Pembroke Hall, 42 Crow Lane, Pembroke, HM19 Bermuda Phone number: 01737 837092 Other useful information (at least legal representative for legal persons): Company Secretary B: Identity of the notifier, if applicable (xvii) Full name: Fidelity Investments International Contact address: Windmill Court XTW2B, Millfield Lane, Lower Kingswood, Tadworth, Surrey KT20 6RB Phone number: 01737 837092 Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation): Authorised to make this filing under power of attorney C: Additional information : Notes to the Forms (i) This form is to be sent to the issuer or underlying issuer and to be filed with the competent authority. (ii) Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate. (iii) This should be the full name of (a) the shareholder; (b) the person acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all the parties to the agreement referred to in DTR5.2.1 (a), or (d) the direct or indirect holder of financial instruments entitled to acquire shares already issued to which voting rights are attached, as appropriate. In relation to the transactions referred to in points DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned: - in the circumstances foreseen in DTR5.2.1 (b), the person that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights; - in the circumstances foreseen in DTR 5.2.1 (c), the person holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and person lodging the collateral under these conditions; - in the circumstances foreseen in DTR5.2.1(d), the person who has a life interest in shares if that person is entitled to exercise the voting rights attached to the shares and the person who is disposing of the voting rights when the life interest is created; - in the circumstances foreseen in DTR5.2.1 (e), the parent undertaking and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking; - in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion; - in the circumstances foreseen in DTR5.2.1 (g), the person that controls the voting rights; - in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion. (iv) Applicable in the cases provided for in DTR 5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in DTR5.2. (v) The date of the transaction should normally be, in the case of an on exchange transaction, the date on which the matching of orders occurs; in the case of an off exchange transaction, date of the entering into an agreement. The date on which threshold is crossed should normally be the date on which the acquisition, disposal or possibility to exercise voting rights takes effect (see DTR 5.1.1R (3)). For passive crossings, the date when the corporate event took effect. (vi) Please refer to the situation disclosed in the previous notification, In case the situation previous to the triggering transaction was below 3%, please state 'below 3%'. (vii) If the holding has fallen below the minimum threshold , the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is less than 3%. For the case provided for in DTR5.2.1(a), there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an Article 9 threshold. This applies upon entering into, introducing changes to or terminating an agreement. (viii) Direct and indirect (ix) In case of combined holdings of shares with voting rights attached 'direct holding' and voting rights 'indirect holdings', please split the voting rights number and percentage into the direct and indirect columns-if there is no combined holdings, please leave the relevant box blank. (x) Voting rights to shares in respect of which the notifying party is a direct shareholder (DTR 5.1) (xi) Voting rights held by the notifying party as an indirect shareholder (DTR 5.2.1) (xii) If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%. (xiii) date of maturity / expiration of the finical instrument i.e. the date when the right to acquire shares ends. (xiv) If the financial instrument has such a period-please specify the period- for example once every three months starting from the (date) (xv) The notification should include the name(s) of the controlled undertakings through which the voting rights are held. The notification should also include the amount of voting rights and the percentage held by each controlled undertaking, insofar as individually the controlled undertaking holds 5% or more, and insofar as the notification by the parent undertaking is intended to cover the notification obligations of the controlled undertaking. (xvi ) This annex is only to be filed with the competent authority. (xvii) Whenever another person makes the notification on behalf of the shareholder or the natural person/legal entity referred to in DTR5.2 and DTR5.3 Schedule FIL Issuer name: Sinclair Pharma plc Current ownership percentage: 10.1% Total Shares Held: 9,352,556 Issued Share Capital: 93,361,219 +-------------------------------------------------------------------+ | Shares held | Nominee | Management Company | |-------------+--------------------------------+--------------------| | 88,175 | STATE STR BK AND TR CO LNDN (S | FPM | |-------------+--------------------------------+--------------------| | 153,123 | STATE STR BK AND TR CO LNDN (S | FIL | |-------------+--------------------------------+--------------------| | 322,214 | NORTHERN TRUST LONDON | FPM | |-------------+--------------------------------+--------------------| | 233,000 | JP MORGAN, BOURNEMOUTH | FPM | |-------------+--------------------------------+--------------------| | 2,506,738 | JP MORGAN, BOURNEMOUTH | FISL | |-------------+--------------------------------+--------------------| | 317,264 | JP MORGAN, BOURNEMOUTH | FIL | |-------------+--------------------------------+--------------------| | 272,661 | BROWN BROTHERS HARRIMAN AND CO | FIJ | |-------------+--------------------------------+--------------------| | 5,277,005 | BROWN BROS HARRIMN LTD LUX | FIL | |-------------+--------------------------------+--------------------| | 182,376 | BANK OF NEW YORK BRUSSELS | FPM | +-------------------------------------------------------------------+ ---END OF MESSAGE---


 

LONDON -- (MARKET WIRE) -- April 23, 2007 -- At the click of a keyboard travel agents around the world can expand their UK portfolio with the fantastic BritRail range. Using the dedicated BritRail agents' website http://www.agentbritrail.com/ they can sell rail travel, and complementary touring products, for their Britain-bound clients. This booking system makes it possible for small and medium sized agencies to access and sell the full BritRail product range easily and cost-effectively. Not only that, but BritRail pays 5% commission on these sales - easy money for easy work. Plus! Any agent selling EUR 500 or more in the three months of the May, June and July sales periods will earn an extra 2% commission on total sales. Agents - including UK-based agents selling to the in-bound market - simply go to http://www.agentbritrail.com/ to complete a quick registration form and start enjoying the benefits of being a BritRail agent. Once the sale is agreed and processed, the agent pays BritRail by debit/credit card and BritRail carries out the fulfilment - it is as easy as that. BritRail Passes are the go-as-you-please train ticket designed for visitors from overseas. They come in a range of flexible options to meet every traveller's needs at very affordable prices. Once in Britain there's no need for your clients to queue for tickets, no need to reserve in advance - they just join the trains of choice for a trip to remember. BritRail (a division of ACP Rail International) has the exclusive franchise to sell the world-renowned range of BritRail Passes and single journey tickets in all global markets outside the UK. Its comprehensive range of Britain-related travel products mean agents can become a one-stop shop for their Britain-bound clients by providing not just BritRail Passes but London Visitor Travel Cards, CitySightseeing bus passes, London Pass, Great British Heritage Pass, Madame Tussauds and much, much more. In addition to these, agents also have direct access to the real-time seat reservation system and can reserve specific seats on specific trains to make their clients journey even more enjoyable. Forward looking agents take the direct route and go via the official BritRail Travel Agent website http://www.agentbritrail.com/ to save time, earn extra commission and access great products. BritRail - Rail Travel Which is Easy to Sell and Easy to Use Contacts: Public Relations Manager (UK) Richard Haste Tel/Fax +44 (0) 1347 878 034 e mail richardhaste@acprail.com


 

TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): Sinclair Pharma Plc 2. Reason for the notification (please place an X inside the appropriate bracket/s): An acquisition or disposal of voting rights: ( X ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( ) Revised due to DTR rules - see Section 13 3. Full name of person(s) subject to the notification obligation (iii): Fidelity International Limited (FIL) 4. Full name of shareholder(s) (if different from 3.) (iv): 88,175 State Str Bk and Tr Co LNDN (FPM) 133,954 State Str Bk and Tr Co LNDN (FIL) 322,214 Northern Trust London (FPM) 233,000 JP Morgan Bournemouth (FPM) 2,506,738 JP Morgan Bournemouth (FISL) 317,264 JP Morgan Bournemouth (FIL) 272,661 Brown Brothers Harriman and Co (FIJ) 5,277,005 Brown Bros Harriman Ltd Lux (FIL) 182,376 Bank of New York Brussels (FPM) 5,973 Brown Brothers Harriman and Co (FIL) 5. Date of the transaction (and date on which the threshold is crossed or reached if different) (v): 17 April 2007 6. Date on which issuer notified: 19 April 2007 7. Threshold(s) that is/are crossed or reached: 10% 8. Notified details: ....... A: Voting rights attached to shares Class/type of shares if possible Situation previous to the Triggering using the ISIN CODE transaction (vi) Number of shares Number of voting Rights (viii) 9,333,387 9,333,387 Resulting situation after the triggering transaction (vii) Class/type of shares if Number of Number of voting % of voting rights possible using the ISIN shares rights (ix) CODE Direct Direct Indirect Direct Indirect (x) (xi) ISIN 9,339,360 10.00% GB0033856740 B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Exercise/Conversion Number of voting % of financial Date (xiii) Period/ Date (xiv) rights that may be voting instrument acquired if the rights instrument is exercised/ converted. Total (A+B) Number of voting rights % of voting rights 9,339,360 10.00% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): See attached schedule Proxy Voting: 10. Name of the proxy holder: Fidelity International Limited (FIL) 11. Number of voting rights proxy holder will acquire to hold: 5,973 12. Date on which proxy holder will acquire to hold voting rights: 17 April 2007 13. Additional information: 14. Contact name: Teresa Garry, Fidelity Alan Olby (Company Secretary) / Zoe McDougall (Communications), Sinclair Pharma plc 15. Contact telephone number: fil-regulatoryreporting@uk.fid-intl.com investorrelations@sinclairpharma.com Annex to Notification Of Major Interests In Shares (xvi) A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities): Fidelity International Limited (FIL) Contact address (registered office for legal entities): Pembroke Hall, 42 Crow Lane, Pembroke, HM19 Bermuda Phone number: 01737 837092 Other useful information (at least legal representative for legal persons): Company Secretary B: Identity of the notifier, if applicable (xvii) Full name: Fidelity Investments International Contact address: Windmill Court XTW2B, Millfield Lane, Lower Kingswood, Tadworth, Surrey KT20 6RB Phone number: 01737 837092 Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation): Authorised to make this filing under power of attorney C: Additional information : Notes to the Forms (i) This form is to be sent to the issuer or underlying issuer and to be filed with the competent authority. (ii) Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate. (iii) This should be the full name of (a) the shareholder; (b) the person acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all the parties to the agreement referred to in DTR5.2.1 (a), or (d) the direct or indirect holder of financial instruments entitled to acquire shares already issued to which voting rights are attached, as appropriate. In relation to the transactions referred to in points DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned: - in the circumstances foreseen in DTR5.2.1 (b), the person that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights; - in the circumstances foreseen in DTR 5.2.1 (c), the person holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and person lodging the collateral under these conditions; - in the circumstances foreseen in DTR5.2.1(d), the person who has a life interest in shares if that person is entitled to exercise the voting rights attached to the shares and the person who is disposing of the voting rights when the life interest is created; - in the circumstances foreseen in DTR5.2.1 (e), the parent undertaking and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking; - in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion; - in the circumstances foreseen in DTR5.2.1 (g), the person that controls the voting rights; - in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion. (iv) Applicable in the cases provided for in DTR 5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in DTR5.2. (v) The date of the transaction should normally be, in the case of an on exchange transaction, the date on which the matching of orders occurs; in the case of an off exchange transaction, date of the entering into an agreement. The date on which threshold is crossed should normally be the date on which the acquisition, disposal or possibility to exercise voting rights takes effect (see DTR 5.1.1R (3)). For passive crossings, the date when the corporate event took effect. (vi) Please refer to the situation disclosed in the previous notification, In case the situation previous to the triggering transaction was below 3%, please state 'below 3%'. (vii) If the holding has fallen below the minimum threshold , the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is less than 3%. For the case provided for in DTR5.2.1(a), there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an Article 9 threshold. This applies upon entering into, introducing changes to or terminating an agreement. (viii) Direct and indirect (ix) In case of combined holdings of shares with voting rights attached 'direct holding' and voting rights 'indirect holdings', please split the voting rights number and percentage into the direct and indirect columns-if there is no combined holdings, please leave the relevant box blank. (x) Voting rights to shares in respect of which the notifying party is a direct shareholder (DTR 5.1) (xi) Voting rights held by the notifying party as an indirect shareholder (DTR 5.2.1) (xii) If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%. (xiii) date of maturity / expiration of the finical instrument i.e. the date when the right to acquire shares ends. (xiv) If the financial instrument has such a period-please specify the period- for example once every three months starting from the (date) (xv) The notification should include the name(s) of the controlled undertakings through which the voting rights are held. The notification should also include the amount of voting rights and the percentage held by each controlled undertaking, insofar as individually the controlled undertaking holds 5% or more, and insofar as the notification by the parent undertaking is intended to cover the notification obligations of the controlled undertaking. (xvi ) This annex is only to be filed with the competent authority. (xvii) Whenever another person makes the notification on behalf of the shareholder or the natural person/legal entity referred to in DTR5.2 and DTR5.3 Schedule FIL Issuer name: Sinclair Pharma plc Current ownership percentage: 10.1% Total Shares Held: 9,352,556 Issued Share Capital: 93,361,219 +-------------------------------------------------------------------+ | Shares held | Nominee | Management Company | |-------------+--------------------------------+--------------------| | 88,175 | STATE STR BK AND TR CO LNDN (S | FPM | |-------------+--------------------------------+--------------------| | 153,123 | STATE STR BK AND TR CO LNDN (S | FIL | |-------------+--------------------------------+--------------------| | 322,214 | NORTHERN TRUST LONDON | FPM | |-------------+--------------------------------+--------------------| | 233,000 | JP MORGAN, BOURNEMOUTH | FPM | |-------------+--------------------------------+--------------------| | 2,506,738 | JP MORGAN, BOURNEMOUTH | FISL | |-------------+--------------------------------+--------------------| | 317,264 | JP MORGAN, BOURNEMOUTH | FIL | |-------------+--------------------------------+--------------------| | 272,661 | BROWN BROTHERS HARRIMAN AND CO | FIJ | |-------------+--------------------------------+--------------------| | 5,277,005 | BROWN BROS HARRIMN LTD LUX | FIL | |-------------+--------------------------------+--------------------| | 182,376 | BANK OF NEW YORK BRUSSELS | FPM | +-------------------------------------------------------------------+ ---END OF MESSAGE---


 

KESKO CORPORATION STOCK EXCHANGE RELEASE 23.04.2007 AT 14.00 Kesko Food Ltd has decided to look into opportunities to sell its HoReCa wholesaling subsidiary, Kespro Ltd, and its sourcing operations. Kesko Food's aim is to concentrate more closely on consumer-customer trade in line with its strategy. Supporting Kesko Food's customer-driven quality, service and price programme, as well as facilitating market share growth will require a strong focus placed on the development of customer programmes, such as the K-Plussa Supercard announced last week. Kespro is the leading wholesaler in the Finnish HoReCa business. Its customers include hotels, restaurants, caterers, traffic stations, kiosks, bakeries, manufacturing industry and retail dealers. In 2006, Kespro's net sales were ¤688 million. Kespro employs 550 people. Further information President Terho Kalliokoski, Kesko Food Ltd, tel. +358 1053 22204 Kesko Corporation Paavo Moilanen Senior Vice President, Corporate Communications DISTRIBUTION Helsinki Stock Exchange Main news media


 

YIT CORPORATION STOCK EXCHANGE RELEASE April 23, 2007 13:30 1 (1) The Series F share options that YIT Corporation issued in 2004 and the Series K and L share options issued in 2006 were made available for trading on the Main List of Helsinki Stock Exchange as from April 2, 2007. The Series E share options issued in 2004 have been available for trading on the Main List of Helsinki Stock Exchange since April 3, 2006. From April 2 to April 20, 2007 a total of 19,972 YIT shares were subscribed for on the basis of the Series E share options and a total of 55,616 shares on the basis of the Series F share options. Each Series E and F share option entitles its bearer to subscribe for two YIT Corporation shares and each K and L share option for one YIT Corporation share. The subscription price with the Series E options is EUR 6.80 per share, with the Series F options EUR 6.15 per share and with Series K and L options EUR 20.53 per share. The increase in the share capital as a consequence of these share subscriptions, EUR 477,848, is to be entered in the Trade Register on April 30, 2007. YIT CORPORATION Veikko Myllyperkiö Vice President, Corporate Communications For additional information, contact: Marja Salo, Director of Administration, tel. +358 20 433 2470, marja.salo@yit.fi Jaakko Mäkynen, Vice President, Finance, tel. +358 20 433 2307, jaakko.makynen@yit.fi Distribution: Helsinki Stock Exchange, principal media, www.yit.fi


 
Ýmislegt
23. apríl 2007

EPT Disclosure

FORM 38.5(a) DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY (Rule 38.5(a) of the Takeover Code) 1. KEY INFORMATION +-------------------------------------------------------------------+ | Name of exempt principal trader | HSBC Bank Plc | |-------------------------------------------------+-----------------| | Company dealt in | Freeport Plc | |-------------------------------------------------+-----------------| | Class of relevant security to which the | Ordinary Shares | | dealings being disclosed relate (Note 1) | | |-------------------------------------------------+-----------------| | Date of dealing | 20th April 2007 | +-------------------------------------------------------------------+ 2. DEALINGS (Note 2) (a) Purchases and sales +-------------------------------------------------------------------+ | Total number of | Highest price paid | Lowest price | | securities | (Note 3) | paid | | purchased | | (Note 3) | |---------------------------+--------------------+------------------| | 53,507 | 401p | 401p | +-------------------------------------------------------------------+ +-------------------------------------------------------------------+ | Total number of | Highest price | Lowest price | | securities | received | received | | sold | (Note 3) | (Note 3) | |-------------------------+--------------------+--------------------| | 53,507 | 401p | 401p | +-------------------------------------------------------------------+ (b) Derivatives transactions (other than options) +-------------------------------------------------------------------+ | Product name, | Long/short | Number of | Price per | | e.g. CFD | (Note 4) | securities | unit | | | | (Note 5) | (Note 3) | |----------------+------------+---------------------+---------------| | | | | | +-------------------------------------------------------------------+ (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying +------------------------------------------------------------------------------------------+ |Product |Writing, |Number of securities to|Exercise|Type, e.g.|Expiry|Option | |name,e.g|selling, |which the option |price |American, |date |moneypaid/received| |call |purchasing,|relates (Note 5) | |European | |per unit (Note 3) | |option |varying etc| | |etc. | | | |--------+-----------+-----------------------+--------+----------+------+------------------| | | | | | | | | +------------------------------------------------------------------------------------------+ (ii) Exercising +-------------------------------------------------------------------+ | Product name, e.g. | Number of securities | Exercise price per | | call option | | unit | | | | (Note 3) | |-----------------------+----------------------+--------------------| | | | | +-------------------------------------------------------------------+ 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. .................................................. .................................................. +------------------------------------------------------------------+ | Date of disclosure | 23rd April 2007 | |----------------------------------------------+-------------------| | Contact name | Seema Soni | |----------------------------------------------+-------------------| | Telephone number | 0207 992 1565 | |----------------------------------------------+-------------------| | Name of offeree/offeror with which connected | Freeport Plc | |----------------------------------------------+-------------------| | Nature of connection (Note 6) | Connected Advisor | +------------------------------------------------------------------+ Notes The Notes on Form 38.5(a) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk ---END OF MESSAGE---


 

Hybrid Technologies Selects Warner Music Group (NYSE: WMG) to Bring Environmentally-Friendly Electric Lithium Vehicles to the Music Community Multi-Platinum Recording Artist, James Blunt, to Encourage Fans to Go Green by Driving Electric Mini Cooper Latest in WMG's Industry-Leading Environmental Efforts NEW YORK, NEW YORK -- (MARKET WIRE) -- April 23, 2007 -- Hybrid Technologies (OTCBB: HYBT), an emerging leader in the development and marketing of lithium battery powered products worldwide, has presented Warner Music Group (WMG) and multi-platinum Atlantic recording artist James Blunt with environmentally-friendly, all-electric cars. Lyor Cohen, Chairman and CEO of U.S. Recorded Music for WMG, and James Blunt are among the first private users of the advanced all- lithium cars produced by Hybrid Technologies under a Space Act partnership with NASA. Richard Griffiths, Director of Development for Hybrid Technologies, stated, "We chose Warner Music Group's Lyor Cohen to be one of our first recipients of a Smart Car because he is someone who represents a new generation of leaders working to address climate change. Under Lyor's leadership, Warner Music Group's U.S. record labels have lead the industry in their environmentally responsible efforts. Lyor has always been on the cutting edge; therefore, we are proud he is one of the first to have our cars." Griffiths added, "James Blunt is a great example of artists who are working to raise awareness about the importance of our environment. And with artists and executives willing to show fans everywhere the benefits of ecologically responsible behavior in their everyday lives, we believe over time we can encourage more and more consumers to drive Smart Cars and have a meaningful impact on the environment." Commenting on driving Hybrid Technology's Smart Car, Cohen said, "It's one thing to talk about the environment, it's another to incorporate ecologically friendly behavior in your everyday lives. I'm proud that Warner Music has led the industry in going green, from greening our company events to transforming our CD and DVD packaging as well as strengthening our company's recycling efforts. We're proud to work with Richard and the Smart Car team and look forward to encouraging more and more people to drive smart." Hybrid Technologies currently has pilot programs with NASA, Paratransit, the City of New York as well as the Canadian Federal Government. About Warner Music Group: www.wmg.com About Hybrid Technologies: www.hybridtechnologies.com Forward-Looking Statements This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company's current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Contacts: Hybrid Technologies, Inc. Media 1-888-HYBTECH (1-888-492-8324) Email: pr@hybridtechnologies.com Hybrid Technologies, Inc. Investor Relations 1-888-669-1808 Email: info@hybridtechnologies.com Website: www.hybridtechnologies.com


 

Summary January-March 2007 compared with January-March 2006 * Operating profit was SEK 3.9bn (5.0) * Return on equity was 17.1% (26.4) * Earnings per share were SEK 4.48 (6.32) * Income totalled SEK 6.9bn (8.2) * The C/I ratio was 45.2% (39.7) * Profits after tax were SEK 2.8bn (4.1) * The Bank's statutory capital requirement calculated according to the basic model for internal risk classification will be reduced by 41% when the Basel II rules are fully implemented Summary of first quarter 2007 compared with fourth quarter 2006 * Operating profit was SEK 3.9bn (5.0) * Net interest income rose by 3% * The profits from Swedish branch office operations increased by 8% to SEK 2.5bn (2.3) * Operating profit in the branch office operations outside Sweden increased by 22% to SEK 648m (533) * Branch office lending volumes outside Sweden increased by over 8% * The Bank repurchased 5.9 million shares The Group Q1 2007 compared with Q4 2006 Operating profit SEK 3.9bn The operating profit was SEK 3,859m (5,032). The overall profit from the Bank's branch operations, inside and outside Sweden, rose by SEK 301m or almost 11%. The decline in the Bank's operating profit was mainly due to the fact that the Bank realised value changes on assets available for sale in the previous quarter, and to a decreased profit in the insurance operations. Expenses were SEK 3,125m (3,260), a decrease of 4%. Return on equity was 17.1% (23.2). The C/I ratio was 45.2% (39.0). Earnings per share were SEK 4.48 (5.79). Net interest income increased Net interest income increased by 3% and totalled SEK 3,853m (3,726). Volume increases in lending compensated for poorer margins and in general both deposit margins and volumes continued to increase. In Sweden, the average volume of lending rose by 2.6% and in the branch operations outside Sweden, the increase was 8.3%. Net fee and commission income was SEK 2,213m (2,749), a decrease of SEK 536m or 19%. The Bank has never before had such high income in one quarter from brokerage and fund and custody operations. The decrease was mainly due to a lower yield split in the insurance operations. The yield split - the income which the Bank receives when the yield to the policyholders exceeds the guaranteed level - decreased by SEK 401m to SEK 117m. Net gains/losses on financial items at fair value were SEK 678m (1,607), a decrease of 58%. The decrease was partly due to a lower writeback for the deferred capital contribution in the insurance operations - SEK 216m - and also that in the previous quarter the Bank had income of SEK 733m from realised value changes on assets available for sale. Income totalled SEK 6,913m (8,347) a decrease of 17%. This was partly due to a decrease in the value change in the deferred capital contribution in SPP; that the Bank during the fourth quarter of 2006 realised value changes related to assets available for sale and also to a decrease in the yield split in the insurance operations. Expenses decreased Expenses decreased by 4% to SEK 3,125m (3,260). The decrease is mainly because staff costs were SEK 144m lower, which in turn was due to a lower provision for performance-related remuneration. The Bank made no provision to the Oktogonen profit-sharing foundation. Other administrative costs were SEK 1,281m (1,272). The costs for expansion were mainly unchanged. The number of employees rose to 10,500 (10,320). Recoveries exceeded loan losses Recoveries exceeded the period's gross loan losses and net recoveries totalled SEK 70m (-55). The loan loss ratio was SEK -0.02% (-0.01). Net bad debts were SEK 937m, an increase from SEK 876m. The proportion of bad debts was 0.07% (0.07) of lending. Q1 2007 compared with Q1 2006 Profits decreased by 23% to SEK 3,859m (5,016). This was entirely due to the fact that last year the Bank could write back the change in value of the previously underfunded insurance contracts, which reduced the deferred capital contribution. Expenses fell by 4% and totalled SEK 3,125m (3,252). Return on equity went down from 26.4% to 17.1%. The C/I ratio was 45.2% (39.7). Increased net interest income and lower expenses The comparison with the same period last year is similar to that between the quarters. Income fell by 16% and the whole decrease was because net gains/losses on items at fair value were lower. This was partly because the Bank realised assets available for sale at the beginning of last year for an amount of SEK 159m and also due to a change in the deferred capital contribution in SPP by SEK 1,105m. Net interest income went up by SEK 69m or 2%. The rate of increase was negatively impacted by SEK 98m due to the repurchases the Bank made in connection with the transition to IFRS. Excluding this the rate of increase would have been over 4%. In the Swedish branch operations, net interest income grew mainly due to significantly improved deposit margins and outside Sweden, the increase in volume boosted the net interest income. The average volume of lending in Sweden rose by 11%, while in the branch operations outside Sweden it increased by nearly 24%. Commissions fell by SEK 129m, which was mainly due to a lower yield split in the insurance operations. This was partly compensated for by higher fund and custody commissions. The yield split fell from SEK 284m to SEK 117m. Expenses decreased by 4% from SEK 3,252m. Staff costs fell by SEK 197m which also in this comparison was due to a fall in performance-related remuneration. Other administrative costs grew by 7% from SEK 1,068m to SEK 1,144m, mainly due to higher external IT costs. Recoveries exceeded the period's gross loan losses and net recoveries totalled SEK 70m (79). The loan loss ratio was -0.02% (-0.03). Bad debts fell from SEK 1,441m to SEK 937m. The proportion of bad debts fell from 0.13% of lending to 0.07%. Handelsbanken expands outside Sweden The Bank has decided to step up the pace of its organic growth outside Sweden. The aim is to open 30-40 branches this year in the branch operations outside Sweden. Three new branches were opened during the period: St Petersburg in Russia, and Mikkeli and Espoo Matinkylä in Finland. A total of 25% of the Bank's lending to the public is in the branch operations outside Sweden and almost 40% of the increase between the years has been outside Sweden. The corresponding increase between the quarters was 50%. Handelsbanken in Great Britain was noticed when the Bank came 11th in the Sunday Times' annual awards for Best Employer. A total of 650 companies participated in the group where the Bank was represented. This boosts the Bank's image in Great Britain and should make it even easier to recruit the best employees for its rapidly expanding operations. Higher business volumes Business volumes grew significantly in practically all parts of the Bank. In total the average volume of lending in the Group rose by 14% during the last 12 months. Outside Sweden, the increase was 23%. In local currency, lending in the non-Swedish regional banks rose by between 13% and 63%. The highest rate of increase was in Great Britain. The average mutual fund volume grew by 15% to SEK 221bn (193) and the assets managed at Handelsbanken Pensions & Insurance rose by 9% to SEK 176bn (162). Capital ratio Starting on 1 February 2007, the Bank reports the capital requirement and capital base in accordance with the Basel II rules. Calculated according to the transitional rules, the Bank's capital ratio was 10.2%, while the Tier 1 capital ratio was 7.0%. If no transitional rules had applied, the statutory capital requirement would have been reduced by 41% compared with the requirement in accordance with Basel I. However, the transitional rules stipulate that banks are only allowed to include 5% as a reduction in the first year. The main change in the capital requirement applies to credit risks. To calculate these, the Bank has elected to use an internal risk classification method called IRB, where there are two different approaches: a basic model and a more advanced model. Handelsbanken uses the advanced method for household exposures in Sweden and the basic method for corporate exposures in Sweden and Norway. However, the Bank intends to change over to the advanced IRB method for corporate exposures during 2010. It is expected that this will further reduce the statutory capital requirement. Buybacks and rating Since the 2006 AGM, the Bank has repurchased 20.7 million shares, of which 5.9 million during the quarter. The number of outstanding shares was subsequently 628.3 million. The board is proposing to the 2007 AGM to cancel the repurchased shares. At the AGM, there will also be a proposal from the board for a new repurchase programme for a maximum of 40 million shares. On condition that the board's proposal regarding dividend is accepted by the AGM, the Bank will have transferred 72% of the profit for 2006, or SEK 9.4bn, to the shareholders. Handelsbanken's rating was unchanged with all three rating agencies which rate the Bank. Moody's rating for the Bank was Aa1 and from Fitch and Standard & Poor's it was AA-. Pär Boman President and Group Chief Executive For further information please contact: Pär Boman, Group Chief Executive phone: +46 (0)8 - 22 92 20, pabo01@handelsbanken.se Ulf Riese, Head of Control and Accounting phone: +46 (0)8 - 701 1212, ulri02@handelsbanken.se Bengt Ragnå, Head of Investor Relations phone: +46 (0)8 - 701 1216, bera02@handelsbanken.se The full report including tables can be downloaded from the attached link.


 

Cargotec Corporation, Stock Exchange Release, April 23, 2007 at 12:00 p.m. Finnish time - Orders received during the first quarter were record high totaling EUR 915 (1-3/2006: 805) million. - The order book grew due to the strong order intake and on March 31, 2007 totaled EUR 1,811 (December 31, 2006: 1,621) million. - First quarter net sales grew by 13 percent and amounted to EUR 694 (1-3/2006: 614) million. - Operating profit improved to EUR 57.9 (1-3/2006: 50.9) million. - Cash flow from operating activities before financial items and taxes totaled EUR 52.1 (1-3/2006: 40.6) million. - Net income for the reporting period amounted to EUR 39.4 (1-3/2006: 33.9) million. - Earnings per share were EUR 0.62 (1-3/2006: 0.52). - General market activity is expected to remain healthy. Development of the services business will continue during the year in line with Cargotec's strategy. Following the record high order intake in the first quarter Cargotec's full year 2007 order intake is expected to surpass net sales. Net sales growth including acquisitions is expected to clearly exceed 10 percent. Cargotec's operating margin in 2007 is expected to be on the level of last year's operating margin from operations before on-going growth and efficiency related investments as well as purchase price allocation treatment of acquisitions. Cargotec's President and CEO Mikael Mäkinen: "The amount of orders received during the first quarter is an excellent achievement. The quarter profited from more big orders than we had anticipated. Year 2007 is an important investment year in order to achieve our strategic targets. During the beginning of the year we have realized a sizeable number of important acquisitions and, in line with our plans, initiated projects for the further development of our services business and strengthening of our knowledge base. These investments will affect operating profit in the short-term but their positive impact will start to materialize from next year." An analyst and press conference An analyst and press conference (in Finnish) will be arranged on Monday, April 23, 2007 at 2.00 p.m. Finnish time at Cargotec's head office, Sörnäisten rantatie 23, Helsinki. The interim report will be presented by Cargotec's Senior Executive Vice President and CFO Kari Heinistö. An international telephone conference for analysts and investors will be held at 4.00 p.m. Finnish time. The presentation material will be available on the Company's internet pages by 2.00 p.m. Finnish time. The conference call phone numbers are the following: +1 617 614 3946 (if calling from the U.S.) +44 20 7365 8426 (if calling from rest of world) Access code: Cargotec Corporation The telephone conference can also be viewed as a live audio webcast through the internet pages at www.cargotec.com starting at 4.00 p.m. Finnish time. The archived webcast will be available on the internet pages later the same day. Sender: Cargotec Corporation Kari Heinistö Senior Executive Vice President and CFO Eeva Mäkelä SVP, Investor Relations and Communications For further information, please contact: Kari Heinistö, Senior Executive Vice President and CFO, tel. +358 204 55 4256 Eeva Mäkelä, SVP, Investor Relations and Communications, tel. +358 204 55 4281 The whole report including tables can be downloaded from the link below Cargotec is the world's leading provider of cargo handling solutions whose products are used in the different stages of material flow in ships, ports, terminals, distribution centers and local transportation. Cargotec Corporation's brands, Hiab, Kalmar and MacGREGOR, are market leaders in their fields and well-known among customers all over the world. Cargotec's net sales are EUR 2.7 billion. The company employs approximately 9,000 people and operates in close to 160 countries. Cargotec's class B shares are quoted on the Helsinki Stock Exchange. www.cargotec.com


 

(Lysaker, 23 April 2007): NEAS ASA has concluded an option agreement with NCC Property Development to purchase the shares in Arnstein Arnebergsvei 12 AS. This is a property at Lysaker outside Oslo where NCC intends to build a 4 500-square-metre office building. At the same time, NEAS has received a binding offer from an investor who wants to take over the property, including a long-term lease to NEAS. Selling on the option will give NEAS a substantial gain. NEAS is expanding fast, both organically and through acquisitions, and wishes through these transactions to strengthen the company's position as a leading expertise house for property and property-related services. By relocating more than 200 of the company's employees in the same building, NEAS is one step closer to fulfilling this ambition. The present agreement will give the company access to an ultra-modern building which offers the space and flexibility it needs to continue developing its business. "We're expanding and need the space," says Tor Rønhovde, CEO of NEAS. "The building at Lysaker will be cost effective and will be very suitable for our purposes. At the same time, the transaction will provide a substantial gain which strengthens our financial position." As soon as possible, at the latest May 2nd 2007, the parties will sign all underlying agreements. The building is planned to be completed by January 1, 2009. Further information from Tor Rønhovde, CEO, NEAS ASA, tel: +47 67 40 10 00 Anders Bjerke, vice president, NEAS Consulting, tel: +47 67 40 10 00 or www.neas.no About NEAS NEAS is the leading Norwegian Facility Management company. The company is headquartered at Lysaker outside Oslo, and has offices in seven other cities in southern Norway. In 2006, NEAS generated revenues of about NOK 260 million and had by year-end approximately 270 employees.


 

Estonia, Latvia, Lithuania, Poland and Russia are among the fastest growing economies in the world. The Baltic economies are currently expanding even faster than during the previous boom year 1997. The expansion has been strong to the point of overheating and devaluation fears in Latvia. While we remain positive on the authorities' ability to control the situation, the risk is that the current very fast expansion will end in a hard landing. The real estate market is one important factor behind the expansion. Russia and Poland are seen to continue growing at a fast pace, with the former going into the election cycle. Despite the strong advances in recent years, the potential is far from exhausted yet. "We believe that the Baltic countries and Poland will continue growing faster than the EU on average in the coming years as well. Above-average growth in the Baltic Rim is also supported by the bright prospects in Russia, which has benefited a lot from the booming oil and gas prices," says Senior Analyst Mika Erkkilä, Nordea's economist responsible for the Baltic countries and Russia. Russia is now slowly but steadily regaining her status as a major power that has a say in the world affairs. In the run up to the election cycle, Russia has benefited from the high world market prices for its main exports, oil and other raw materials. The purchasing power of households, whose savings were largely wiped out after the rouble crisis in 1998, is increasing fast again. "The economy is more resilient to a possible oil price decline now," says Mika Erkkilä. "However, this is not to say that there aren't risks, either. There are concerns around the political development and the investment climate." Overheating risks in Latvia have increased as economic imbalances have aggravated. Double-digit growth has come at the expense of stubbornly high inflation, a very high current account deficit and growing indebtedness. Inflation has increased to the extent that the country has seen its EMU plans delayed. "There have been fears about a possible devaluation. Despite the risks, we think that ultimately the authorities will manage to steer the economy into calmer waters and avoid a hard landing of the Latvian economy," Mika Erkkilä points out. Estonia will probably escape a hard landing, as the economy is heading towards a cyclical slowdown. Credit growth has probably peaked and the real estate market is also likely to cool down. At the moment it seems that the risks of a hard landing have diminished. Although Lithuania has also experienced historically high growth rates, the country has not experienced the same lending and real estate boom, and indebtedness is also lower. The Polish economy is also performing strongly, although hardly as fast as in 2006. High growth and a tighter labour market should mean gradually higher interest rates, as the central bank is expected to act in order to avoid inflation accelerating too much. For further information: Mika Erkkilä, Senior Analyst, +358 50 56 88 294 Atte Palomäki, Chief Press Officer, Finland, +358 9 165 42325, +358 40 547 6390 Read the entire Baltic Rim Outlook.


 

Studsvik has secured a major decommissioning project at the Sellafield site in Cumbria. Studsvik has been awarded an early mobilisation contract to provide to design and build a new facility to manage waste associated with a Sellafield waste facility. The current contract is valued at GBP 2 million for the next three months pending main contract award. The overall expected contract value to Studsvik will exceed GBP 14 million over two years. Under the existing framework contract with Sellafield's Tier 1 contractor British Nuclear Group, Studsvik has received an initial contract to mobilise. The main contract will be finalised during May 2007, subject to formal signing at that time. The full contract will be undertaken under a target price arrangement with management fee and is valued at GBP 14 million, over two years. "This is a significant win for Studsvik in the emerging UK decommissioning market. It demonstrates the confidence which British Nuclear Group places in Studsvik to deliver this key project," comments Magnus Groth, CEO of Studsvik AB. "This project together with our other success in the UK market sees a significant growth in the size of our business in the UK" says Mark Lyons, President of Studsvik UK Limited. The facility was constructed in 1951, and has been used to house the interim storage of beta/gamma waste into eight shielded cells. The facility ceased to receive waste from 1996. Studsvik will build a new Waste Retrieval Facility over the eight cells. Waste will be retrieved from the cells and volume reduced before the waste is placed into liners for disposal as either ILW or LLW (Intermediate or Low Level Waste). British Nuclear Group is the Tier 1 Contractor responsible to the UK Nuclear Decommissioning Authority (NDA) for the operation, maintenance and clean-up of the Sellafield site. Current and previous activities on the site include nuclear power generation, spent fuel reprocessing, waste storage and treatment. For further information, please contact: Magnus Groth, President and CEO, Studsvik AB, tel: +46 155 22 10 86 or cell phone: +46 709 67 70 86 Mark Lyons, President, Studsvik UK Limited, tel: +44 191 482 7102 or cell phone: +44 7879 491 011 Facts about Studsvik Studsvik is a leading service supplier to the international nuclear industry. The company has almost a half century's experience of nuclear technology and radiological services. Studsvik addresses a market in strong growth with specialized services in four Strategic Business Areas: Waste Treatment, Decommissioning, Operating Efficiency and Service and Maintenance and. Studsvik has 1,200 employees in 7 countries and the company's shares are listed on the Nordic Stock Exchange, Stockholm, MidCap.


 

Aktiv Kapital ASA will present the financial results for the first quarter 2007 on Friday 27 April at 08.15. The presentation will be held by CEO Erik Øyno and CFO Scott Danielsen at Shippingklubben in Oslo. Breakfast will be served from 08:00. Please confirm your participation to May Engebretsen on tel. +47 22 91 57 00 or e-mail: may.engebretsen@aktivkapital.com Webcast The presentation will be broadcasted live on www.aktivkapital.com and www.oslobors.no/webcast


 

Ahlstrom Corporation STOCK EXCHANGE ANNOUNCEMENT 23.4.2007 Ahlstrom Corporation will publish its first quarter financial results 2007 on Friday, April 27, 2007 approximately at 8.30 a.m. Finnish time. A conference call for analysts and investors will be held on Friday, April 27, 2007 at 13.00 Finnish time. To participate in the teleconference, please dial +44 (0) 20 7162 0125 a few minutes before the call. Use the password: Ahlstrom. A replay number is available until May 4, 2007. The number for the replay is + 44 (0) 20 7031 4064, access code: 747430. The presentation material will be available at www.ahlstrom.com > Investors > IR presentations on April 27, 2007 after the interim report has been published. Ahlstrom Corporation Anne Pirilä Vice President, Corporate Communications and Investor Relations For further information, please contact: Anna Ahlberg Investor Relations Manager Tel: +358 10 888 4718 Distribution: Helsinki Stock Exchange Main media www. ahlstrom.com Ahlstrom in brief Ahlstrom is a global leader in the development, manufacture and marketing of high performance fiber-based materials. Nonwovens and specialty papers, made by Ahlstrom, are used in a large variety of everyday products, e.g. in filters, wipes, flooring, labels, and tapes. The company has a strong market position in several business areas in which it operates, built upon the company's unique fiber expertise and innovative approach. Ahlstrom's 5,700 employees serve customers via sales offices and production facilities in more than 20 countries on six continents. In 2006, Ahlstrom's net sales amounted to EUR 1.6 billion. Ahlstrom's share is listed on the Helsinki Stock Exchange. The company website is www.ahlstrom.com.


 

AMSTERDAM -- ABN Amro Holding NV (ABN) and Barclays PLC (BCS) said Monday that following several weeks of talks they have agreed to terms of a EUR67 billion. Barclays said it will offer 3.225 new Barclays shares for each ABN Amro share held, valuing its bid at EUR36.25 a share. The combination is expected to generate annual synergies of EUR3.5 billion by 2010, the banks said in a joint statement. The combined group will be based in Amsterdam and will be called Barclays PLC. Despite the agreement, ABN Amro Chairman Rijkman Groenink said he still plans to meet Royal Bank of Scotland Group PLC (RBS.LN) representatives Monday to discuss the U.K. banks possible consortium bid for the Dutch bank. RBS has said it is interested in possibly bidding for ABN Amro alongside Fortis NV (FORSY) and Santander Central Hispano SA (STD). RBS wasnt immediately reachable for comment. Groenink said he would study any alternative offers that emerged from the meeting. But he also expressed enthusiasm for the Barclays all-share merger offer. Barclays and ABN Amro said the merger is expected to be completed in the fourth quarter of 2007. ABN Amro shareholder The Childrens Investment Fund Management LLP, or TCI, which holds 2% of the banks shares and had called for it to be broken up as a way of maximizing returns to shareholders, said Monday it was studying the merger agreement and "may have additional comments in due course." A fund manager from Standard Life said Monday that the RBS-led consortium still has the edge over Barclays in spite of the agreed offer. David Cumming told the BBC, "I still think that RBS, Santander and Fortis have the better chance." He said shareholders would be reluctant to back Barclays in a bidding war with the consortium and that Barclays was "stretching its credibility with shareholders on the valuation of synergies from the deal. ABN Amro chairman Arthur Martinez will be the chairman of the new business, while Barclays Chief executive John Varley will be named CEO. Groenink will become non-executive director at Barclays. With the merger announcement ABN Amro said it also agreed to sell its Chicago-based bank LaSalle to Bank of America Corp. (BAC) For $21 billion. The completion of the LaSalle sale is a condition of the merger. The LaSalle sale is expected to completed in late 2007 but is still subject to regulatory approval and other customary closing conditions. The combined new bank will distribute EUR12 billion to shareholders after LaSalle has been sold, the banks said. The terms of the sale permit ABN Amro to accept a higher offer for LaSalle during a period of 14 calendar days from the date of the agreement. Bank of America also has an option to match a higher offer and provides for a termination fee of $200 million payable to the Bank of America if the agreement is terminated under certain circumstances, ABN Amro said. The U.K.s FSA will be the lead supervisor of the combined group. It is expected that the combination of Barclays and ABN Amro will result in a net reduction in staff of about 12,800. In addition, it is expected that 10,800 full-time equivalent positions will be moved offshore to low-cost locations. According to ABN Amro this will have an impact on a total of approximately 23,600 full-time equivalent positions of the combined work force of approximately 217,000. At 0746 GMT, Barclays shares were down 8 pence, or 1.3%, to 742 pence. ABN AMro shares were up EUR0.38, or 1.1%, to EUR36.67.


 

TietoEnator Corporation Press Release 23 April 2007 at 10.00 am EET TietoEnator has signed an agreement with Rautaruukki Corporation to provide full services for the information systems of Ruukki Production division. The agreement is an extension of long-term co-operation. With the agreement Ruukki is safeguarding the development and availability of the systems supporting its business operations and production. The agreement covers the information systems for the order-supply chain and for production and manufacturing control, in steel and hot rolling production in Raahe, in cold rolling and galvanizing production in Hämeenlinna, and in coating operations in Hämeenlinna and Kankaanpää. The total service provided by TietoEnator comprises application development and integration, server management, IT operations management, data security service, and customer support. The services will be produced by TietoEnator's Mill Competence Center, which functions in Raahe and Hämeenlinna and where the personnel have specialist knowhow in 24-hour service for the systems that are critical for the customer's business. Most of the personnel have participated in planning, building and developing Ruukki Production's present IT systems. About 90 people work at the Mill Competence Center. "The three million tonnes annual production of the Raahe Works passes through the systems covered by the agreement, and so do the 1.2 million tonnes of rolling and coating production at the Hämeenlinna Works. The agreement ensures that we have the resources and knowhow for the mainframe environments and means closer cooperation with TietoEnator in developing new business models," states Esko Ahola, business IT manager at Ruukki Production. "The agreement demonstrates the customer's confidence in the service we provide and in the knowhow of our personnel. The knowhow possessed by the Mill Competence Center is the result of persistent hard work that has demanded commitment from personnel, flexible service and continuous development in close cooperation with the customer. The development of the systems, their availability and performance, and the rapid management of incidents have met the special requirements set for the works environment," state Eeva Alasaarela and Arja Kuutila-Honka from the TietoEnator Raahe office. For further information, please contact Ari Järvelä, Senior Vice President, TietoEnator, Manufacturing tel. +358 3 235 9698, mobile +358 40 8400915, email: ari.jarvela@tietoenator.com Petri J. Ojala, Senior Vice President, TietoEnator, Processing & Network tel. +358 3 235 9842, mobile +358 40 546 3626, email: petri.j.ojala@tietoenator.com TIETOENATOR CORPORATION DISTRIBUTION Principal media TietoEnator is among the leading architects in building a more efficient information society and one of the largest IT services providers in Europe. TietoEnator specializes in consulting, developing and hosting its customers' business operations in the digital economy. The Group's services are based on a combination of deep industry-specific expertise and the latest information technology. TietoEnator has about 16 000 experts in close to 30 countries. www.tietoenator.com


 

Artumas Group Inc. calls for its Annual General Meeting to be held on 9th May 2007 at 16:30 hours at the Hotel Continental in Oslo, Norway. The Notice, including Management's Information Circular, Attendance Slip and Proxy, and Form of Proxy, is sent to shareholders according to a listing from the register of shareholders as of 19th April 2007. The Corporation's 2006 Annual Report, in conjunction with the attached Annual General Meeting materials, has also been sent to shareholders and posted with the Oslo Stock Exchange as of today's date.


 

Ericsson (NASDAQ:ERIC) has received favorable rulings from the relevant competition authorities to acquire all outstanding shares in Tandberg Television (OSE:TAT). Furthermore, no material adverse change has occurred. Consequently, all conditions in the terms and conditions set out in the offer document, dated February 26, 2007, have been met and Ericsson will complete the offer in accordance with the offer document. Settlement for the shares submitted in the voluntary public cash offer is expected to take place on or about April 25, 2007. As soon as possible following settlement, Ericsson will proceed with a mandatory offer for the remaining shares in Tandberg Television as required under chapter four of the Norwegian Securities Trading Act. In parallel, Ericsson plans to initiate a compulsory acquisition of the remaining shares in Tandberg Television in accordance with paragraph 4:25 of the Norwegian Public Limited Companies Act. Such compulsory acquisition of shares is expected to take effect soon after the announcement of the mandatory offer. In addition, Ericsson intends to arrange for a delisting of the Tandberg Television share from the Oslo Stock Exchange. Such delisting will likely take effect soon after settlement of the mandatory offer. Ericsson is shaping the future of Mobile and Broadband Internet communications through its continuous technology leadership. Providing innovative solutions in more than 140 countries, Ericsson is helping to create the most powerful communication companies in the world. Read more at: http://www.ericsson.com FOR FURTHER INFORMATION, PLEASE CONTACT Ericsson Media Relations Phone: +46 8 719 6992 E-mail: press.relations@ericsson.com Ericsson Investor Relations Phone: +46 8 719 4631 E-mail: investor.relations.se@ericsson.com


 

Revenues 4.3 mn euros (2005: 4 kEUR) EBIT 859 kEUR Net income 443 kEUR (2005: -4 kEUR) Frankfurt, April 23, 2007: IFM Immobilien AG, spezialized upon the development and revitalization of commercial real estate with a high potential for appreciation, announces its preliminary figures for the business year 2006. In the past year, the company generated revenues of 4.3 mn euros (2005: 4 kEUR), thereby showing an EBIT of 859 kEUR. Net income is 443 kEUR (2005: -4 kEUR). EPS is 0.05 euros. The equity ratio is 55 percent. "We feel very comfortable with the development in the business year 2006. Even in the setup year of the operational business, we achieved positive results. This does underline the know how of IFM Immobilien AG and stands for our valuable portfolio structure as well as for our clear corporate strategy. Additionally, we were able to strengthen our market position considerably. Most notably, this is of great importance for us when it goes about the tenancy of office space. The current development shows that, close to its completion, our office space meets the needs of renowned companies looking for offices to rent. Our tenant structure is composed of domestic and international companies which, to the bigger part, have signed long-term rental contracts. This positive development for our company and our investors gives reason to a hopeful outlook", Georg Glatzel, CEO of IFM Immobilien AG, stated. The business year 2006 took a very dynamic course for IFM Immobilien AG. "A part of the means raised in the course of the listing, enabled us to invest in utterly attractive and monetarily lucrative properties. Furthermore, we could gain an option on a parcel in the top location of Berlin. With the investments fulfilled, in the business year 2006 we generated revenues of 4.3 mn euros (2005: 4 kEUR), thereby showing an EBIT of 859 kEUR. The net income of 443kEUR resulting from that, relates to an EPS of 0.05 euros. As of December 31, 2006, cash and cash equivalents were 29.5 mn euros, the equity ratio is 55 percent. The throughoutly good financials reflect perfectly clear the development of our operational activities, Glatzel added. The annual report will be made public in May. The Board IFM IMMOBILIEN AG Karl-Ludwig-Straße 2 D-69117 Heidelberg T. +49 (0) 6221 434098-0 F. +49 (0) 6221 434098-66 info@ifm.ag www.ifm.ag Ulmenstraße 23-25 D-60325 Frankfurt T. +49 (0) 69 7040386-0 F. +49 (0) 69 7040386-25 For queries, please contact GFEI Gesellschaft für Effekteninformation mbH Beethovenstraße 60 D-60325 Frankfurt www.gfei.de T. +49 (0) 69 743037-00 F. +49 (0) 69 743037-06 About IFM Immobilien AG: IFM Immobilien AG is an investor and a project developer of commercial real estate focusing on office and retail utilization. Center of the business activities is the restructuring, the redevelopment and the asset management of commercial real estate as well as the development of appealing marketing respectively rental concepts. The objects being acquired by IFM Immobilien AG, in general show an attractive risk-reward-ratio, high potential for development as well as appreciation and an ever preferable location. With this strategy and its four core competencies, IFM Immobilien AG establishes a re-positioning of real estate thus creating lasting property values. For 20 years, the company's management has been involved in the real estate sector. Since May 19, 2006, IFM Immobilien AG is listed on the Entry Standard of the Frankfurt Stock Exchange.


 

ATLANTA, GA -- (MARKET WIRE) -- April 23, 2007 -- AtheroGenics, Inc. (NASDAQ: AGIX) today reported that AstraZeneca has notified the Company that it is ending their collaboration to develop and commercialize AGI-1067. As a result of this decision, AtheroGenics will reacquire all worldwide rights for AGI-1067 and will continue to develop the compound. AtheroGenics has been meeting with clinical and regulatory experts to discuss the various options for further development of the compound, and the Company expects to announce its strategy in May. As part of the termination provisions of the agreement, AstraZeneca is responsible for providing transition support to AtheroGenics. "Based on our analysis of the data and discussions we've had to date with clinical and regulatory experts, we remain committed to further developing AGI-1067," stated Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer of AtheroGenics. "AtheroGenics has the financial resources to continue the development of AGI-1067, and we look forward to providing more detailed plans in the coming weeks." About AGI-1067 Preliminary data from the ARISE Phase lll clinical study of AGI-1067 was recently presented at the American College of Cardiology 56th Annual Scientific Sessions. While AGI-1067 did not show a difference from placebo in the composite primary endpoint, the study achieved a number of other important predefined endpoints. These endpoints included a reduction in the composite of "hard" atherosclerotic clinical endpoints, composed of cardiovascular death, resuscitated cardiac arrest, myocardial infarction (heart attack) and stroke, as well as improvement in the key diabetes parameters of new onset diabetes and glycemic control. About AtheroGenics AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. In addition to AGI-1067, the Company has a clinical-stage development program studying AGI-1096, a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit http://www.atherogenics.com. Disclosure Regarding Forward-Looking Statements This press release contains forward-looking statements that involve significant risks and uncertainties, including summary statements relating to the potential efficacy and safety profile of AGI-1067. These and other statements contained in this press release that relate to events or developments that we expect or anticipate will occur in the future are deemed to be forward-looking statements, and can be identified by words such as "believes," "intends," "expects" and similar expressions. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. AtheroGenics cautions investors not to place undue reliance on the forward-looking statements contained in this release. Additional information relating to the safety, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. In addition, our forward-looking statements are subject to a number of factors that could cause actual outcomes to differ materially from those expressed or implied in our forward-looking statements, including that the Food and Drug Administration might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints, and, to the extent approved, additional clinical trial work may take a significant period of time to complete or require significant additional resources to complete. We cannot ensure that AGI-1067 will ever be approved or be proven safe and effective for use in humans. These and other risks are discussed in AtheroGenics' Securities and Exchange Commission filin